The development of S-trityl L-cysteine based inhibitors of Eg5 as anticancer chemotherapeutics. by Good, James Arthur Dudley
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Good, James Arthur Dudley (2012) The development of S-trityl L-cysteine 
based inhibitors of Eg5 as anticancer chemotherapeutics. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/3748/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
  
 
The development of S-trityl L-cysteine 
based inhibitors of Eg5 as anticancer 
chemotherapeutics.   
 
 
 
Submitted in fulfilment of the requirements for the degree of   
Doctor of Philosophy by  
 
 
James Arthur Dudley Good MSci. 
2012 
 
 
The Beatson Institute for Cancer Research, 
Faculty of Medicine, 
University of Glasgow. 
 2 
 
Author’s Declaration 
I declare that except where explicit reference is made to the contribution of others, this 
thesis is the result of my own work and has not been submitted for any other degree at the 
University of Glasgow, or any other institution.  
 
Signature: 
 
 
 
Printed name:       (James A.D. Good)  
 3 
Copyright Notice 
The following material is reproduced in part with permission from Wang, F.; Good, J. A. 
D.; Rath, O.; Kaan, H. Y. K.; Sutcliffe, O. B.; Mackay, S. P.; Kozielski, F. 
Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity. 
Journal of Medicinal Chemistry 2012, 55, 1511-1525.  Copyright 2012 American 
Chemical Society.  Sections 1.3.2, 3.2.1, 3.2.2, 3.2.4.1, 3.2.4.2, 5.1, 5.2, 5.3.1; Figures 13, 
14 and 20-22; Table 10, 11 and 13.  
The following material is reproduced in part with permission from Journal of Medicinal 
Chemistry, submitted for publication. Unpublished work copyright 2012 American 
Chemical Society. Sections 2.1.2, 2.3.1, 3.2.1.1, 3.2.1.2, 3.2.2.2, 3.2.3, 3.2.4.3, 3.2.5, 
3.2.6.1, 3.3.1, 3.3.2, 3.3.3, 3.4, 3.5, 5.1.3, 5.1.5; Figure 18, 24-26.  Scheme 6 and 13; Table 
10-12, 14-16, 18-20, 22 and 23.   
Sections 1.1.2.1 and 1.2.2.2 are reprinted from Seminars in Cell & Developmental 
Biology, Vol. 22, Good, J. A. D.; Skoufias, D. A.; Kozielski, F.,  Elucidating the 
functionality of kinesins: An overview of small molecule inhibitors., 935-945, Copyright 
(2012), with permission from Elsevier. 
  
 4 
Abstract 
The kinesins are a class of microtubule based motor proteins which have extensive 
involvement in the orchestration of the mechanics of mitosis.  The most studied of these is 
the kinesin spindle protein Eg5, which is crucially involved in the establishment of the 
bipolar spindle in prometaphase.  Inhibition of this protein results in monopolar mitotic 
spindles and subsequently mitotic arrest, which can lead to apoptosis in cancer cell lines.   
S-Trityl L-cysteine (STLC) was identified as a selective small molecule inhibitor of Eg5 
which binds to an allosteric pocket formed by the loop L5 of Eg5.  In this thesis, I present 
the structure based design and development and optimisation of the STLC scaffold to 
produce orally available potential drug candidates.  This was accomplished by optimising 
the lipophilic binding interactions of the trityl group, and investigating a number of 
hydrophilic optimisation vectors from the same moiety.  The L-cysteine tail was optimised 
to improve the potency and metabolic stability, and fluorination as a means of altering the 
lead candidates’ drug like properties investigated.  In order to improve efficacy in multi-
drug resistant (MDR) cell lines overexpressing the P-glycoprotein transporter, I also 
investigated a number of strategies related modifying to the terminal α-carboxylic acid.   
The optimised candidates display growth inhibition ≤ 50 nM across multiple tumour cell 
lines, and possess favourable metabolic, toxicological and physicochemical attributes.  
Evaluation in vivo confirms their anti tumour activity, and finally strategies for the further 
progression and development of the lead series in targeting haematological malignancies 
are discussed.   
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Chapter 1. Introduction 
1.1. An overview of anti-mitotic therapy 
1.1.1. Cancer 
1.1.1.1. Overview 
The war on cancer was formally declared in 1971.
2
  In the subsequent years, protracted 
efforts have yielded many improvements in cancer care and treatment.
3
  However, many 
manifestations of this complex and heterogeneous disease remain intractable to medicine’s 
best efforts.
4
  Cancer is a disease characterised by uncontrolled cell proliferation,
5
 and the 
targeting of cellular division represents a key strategy in its treatment.  Anti-mitotic 
chemotherapy formed the cornerstone of initial approaches to treat and suppress 
malignancies,
6
 and now the radical and elegant subsequent demarcation of mitosis into 
distinct mechanistic stages regulated by a complex symphony of proteins allows for the 
design of more specific and targeted therapies.  Our aim has been to design one such new 
therapy, through targeting a crucial protein to mitosis.   
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1.1.1.2. The hallmarks of cancer 
Cancer is an exceedingly complex and heterogeneous group of disease states.  Decades of 
endeavour however have yielded great progress in our understanding of cancer biology and 
tumourigenesis, summarised succinctly by Hanahan and Weinberg in 2000.
5
  In this 
seminal paper, they outlined the hallmarks of cancer: six acquired characteristics which 
collectively give rise to cancerous disease states (Figure 1).   
 
Figure 1 – The hallmarks of cancer.   
Six acquired characteristics proposed to form an underlying basis for the majority of cancerous 
disease states.  Reproduced with permission from reference 7.  Copyright 2011, Elsevier.   
These attributes, which may be acquired in parallel and in various orders, are proposed to 
provide an underlying basis for tumourigenesis.  Self-sufficiency in growth signals and 
insensitivity to anti-growth signals describes the ability of tumour cells to become 
independent of and insensitive to the body’s natural growth signals that regulate normal 
tissue proliferation.  Apoptosis causes significant attrition to cell populations as tumours 
develop, and the ability to evade programmed cell death forms a further stage in 
carcinogenesis.  Collectively, these three abilities involving deregulation from routine 
cellular growth mechanisms are not sufficient for tumour development, as normal cells are 
still replicatively limited.  To enable continued expansion, malignant cells develop 
unlimited replicative potential through maintenance of telomeres and evading senescence.  
Tumour cells require nutrition to fuel their growth, and to accomplish this acquire the 
ability to induce and sustain angiogenesis.  The invasion of surrounding tissues is 
ultimately the cause of lethality in 90% of cancer patients,
8
 and the ability to metastasise 
which is typically the final change in the progression of cancer.
5
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1.1.1.3. Emerging hallmarks 
In the subsequent years since the demarcation of the six initial hallmarks of cancer, four 
additional emerging or enabling characteristics have been recognised.
7
  The emerging 
hallmarks are the ability of cancer cells to adjust cellular energy metabolism to limit it 
principally to glycolysis, and the implicit ability for nascecent malignancies to evade 
detection or destruction by the immune system.  Of the enabling characteristics, while not a 
direct function of tumour cells, it is now recognised that the inflammatory response of the 
body to tumour cells actually can be counterproductive and may favour and accelerate 
tumour progression.  Finally, guard systems which ensure genomic integrity under normal 
circumstances operate efficiently to ensure mutation rates in cell populations are low.  
Cancer cells exhibit multiple mutations which suggests malfunction of these guardian 
pathways, leading to increased rates of mutation, thereby enabling the emergence of other 
hallmarks.  Strategies targeting all these traits are under investigation, with our focus on 
disrupting the unregulated growth of cells.   
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1.1.2. Cell division 
1.1.2.1. The stages of mitosis 
Mitosis is the process by which a single cell divides, through a coordinated and discrete 
series of mechanical events to produce two genetically identical daughter cells (Figure 2).
9-
11
  At the onset of mitosis in prophase, chromosome condensation commences and is 
accompanied with a change in the dynamics of cytoplasmic microtubules and the 
separation of the duplicated centrosomes.  These nucleate two asters of microtubules which 
will go on to form the poles of the nascent mitotic spindle.  At prometaphase, the nuclear 
envelope breaks down and the chromosomes begin attaching to the microtubules of the 
developed bipolar spindle.  This attachment is mediated by protein complexes termed 
kinetochores.  Metaphase is reached upon complete attachment to the spindle apparatus.  
The chromosomes then congress and align to the metaphase plate, at a point equidistant 
between the two centrosome poles, prior to the commencing anaphase.  This is achieved by 
a combination of microtubule dynamics and mitotic proteins.  During anaphase the sister 
chromatids separate.  Initially in anaphase A, each translocates to a spindle pole before 
spindle elongation in anaphase B.  The nuclear envelope reforms on each chromatin in 
telophase, before cytokinetic separation of the two daughter cells.   
 
Figure 2 – Schematic illustration of the phases of mitosis. 
Modified from reference 12. 
 26 
 
1.1.2.2. The mitotic spindle  
The mitotic spindle apparatus serves as the fundamental mechanical platform through 
which many of the processes described above occur.  It is a self-organising molecular 
machine whose primary role is separation of the duplicated set of chromosomes to 
disparate locations within the cell through transport to either end of its poles (Figure 3).
13
  
Half of a replicated chromosome must arrive at opposite spindle poles for accurate genetic 
partition in the formation of two healthy daughter cells.  Chromosomal segregation is 
achieved through two mechanisms, both of which are reliant on the microtubule scaffold of 
the spindle.  Microtubules are rigid and polar polymers formed from α- and β-tubulin 
heterodimers which exhibit complex polymerisation dynamics during which they rapidly 
polymerise and depolymerise.  The most prevalent expression of this behaviour in cells is 
termed dynamic instability.
14
  Associated with this activity is the hydrolysis of GTP by β-
tubulin subunits to produce energy for mechanical work.
13, 14
  The second way in which 
microtubules facilitate separation is by serving as tracks utilised by the mechanochemical 
proteins involved in mitosis (section 1.2.2.2).
15
   
 
Figure 3 – The organization of the mitotic spindle in vitro. 
A static immunofluorescence photograph of a mitotic spindle from a cell in tissue culture.  Key to 
immunostaining: microtubules appear in green; chromosomes in blue; TPX2 (a protein involved in 
spindle pole organization)
16
 in red; overlapping TPX2/microtubule regions are yellow.  Modified from 
reference 13. 
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1.1.3. Anti-mitotic drugs  
1.1.3.1. Targeting the mitotic spindle 
All present anti-mitotic drugs target the mitotic spindle and interfere with the dynamics of 
microtubule polymerisation.
14, 17
  They may be classed into three families based on 
chemical structure: vinca alkaloids, taxanes and epothilones (1-3, Figure 4).  While each 
binds to an independent site on the β-tubulin microtubule subunit, the principles underlying 
the mechanism of action are conserved for the three classes.  Rapid modulation of the 
dynamic equilibrium is required throughout all stages of mitosis, and interference from 
microtubule binding drugs has a profound knock-on effects on the mitotic spindle’s ability 
to accurately segregate chromosomes.
14
  Structural aberrations in the spindle are typically 
detected by the constitutive spindle assembly checkpoint,
18
 resulting in mitotic arrest 
which ultimately leads to programmed cell death.
19
  While this covers the overall 
fundamental behind microtubule binding drugs, the specific attributes and effects of each 
class are distinct and complex.
14, 17
  Vinca alkaloids depolymerise microtubules, whilst the 
taxanes and epothilones stabilise microtubules, resulting in extensive formation of α-
tubulin heterodimers.
14
  In the case of the taxanes, the nature of the effects on microtubule 
polymerisation is known to be dependent on drug concentration.
20, 21
  Taxanes have also 
been observed to be cytotoxic against cells in both mitosis and interphase, and are likely to 
induce cell death through multiple mechanisms.
22
  Epothilone A (3) has been demonstrated 
to occupy the same cavity on -tubulin as paclitaxel (1), however while the binding sites 
overlap, the two molecules bind in distinct conformations through discrete interactions and 
do not share a pharmacophore.
23
  While understanding the complexity exhibited by these 
cytotoxic drugs in relation to their effects on tumours remains a non-trivial affair, they 
possess  great clinical utility.
19, 24
  The taxane family members paclitaxel and docetaxel are 
used in therapy against two of the most prevalent forms of the disease in the United 
Kingdom, lung and breast cancer.
12, 25
  Clinical applications of vinca alkaloids include the 
treatment of lymphomas, acute leukaemias and testicular cancer.
12
  Another class of natural 
products known to interfere with microtubule dynamics is the epothilones.  Epothilone A 
(3) has recently been approved in the US in combination with capecitabin in treatment of 
locally advanced or metastatic breast cancer, including those resistant to previous 
therapies.
17
  Serious shortcomings however persist with microtubule binding treatments: 
namely toxicity and resistance.   
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Figure 4 – Structures of selected microtubule based anti-mitotic drugs. 
Members of the taxane, vinca alkaloid and epothilone families respectively: paclitaxel (1), vincristine 
(2) and epothilone A (3). 
1.1.3.2. Limitations of microtubule based anti-mitotic agents 
Taxanes and vinca alkaloids are highly cytotoxic agents and use in therapy gives rise to 
serious adverse effects.
12, 26
  As a key constituent of the cytoskeleton, microtubules possess 
a number of functional roles outside of mitosis, including in axonal transport in neurons.
27
  
Resultantly, peripheral neuropathy is a common and severe toxicity amongst microtubule 
targeting drugs.
28
  Myelosuppresion, resulting from the cytotoxicity of anti-mitotics 
towards rapidly proliferating bone marrow cells is another regularly encountered dose 
limiting toxicity (DLT).
12, 26, 29
   
The other major concern with these regimens is resistance, which may be either acquired 
or innate.  Certain cancers remain unresponsive to currently available anti-mitotic 
chemotherapies,
4
 and determining the factors that govern tumour chemosensitivity is one 
of the most profoundly important currently unresolved questions in cancer chemotherapy.5, 
19, 24  Acquired resistance can emerge through mutations affecting drug binding or by 
differing expression levels of β-tubulin isotypes.30  High levels of expression of the βIII 
tubulin isotype are associated with more aggressive tumours and increased resistance to 
chemotherapy.   Efficacy is also known to be reduced through increased expression of 
microtubule-associated proteins which regulate microtubule polymerisation dynamics, and 
can stabilise them against depolymerisation.  In leukaemia, evidence suggests other 
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cytoskeletal proteins can also affect chemosensitivity.30, 31  Another pathway for resistance 
aside from epigenetic factors involves transmembrane proteins.  The ATP-binding cassette 
(ABC) encoded family of cellular efflux pumps function to remove xenobiotics from the 
cellular environment, and their presence can reduce drug efficacy and lead to the 
emergence of multi drug resistance in tumour cells.32  Although the physiological relevance 
in human cancers remains to be entirely discerned, the vinca alkaloids and taxanes are both 
recognized substrates for the ABC-encoded P-glycoprotein (Pgp) pump.   
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1.1.4. The next generation of therapeutic agents 
1.1.4.1. Improvements to treatments and new cellular targets 
The broad clinical efficacy and commercial success of current microtubule binding drugs, 
and conversely their well defined limits have led to extensive investigations aimed at 
improving them.
12, 17, 33
  This has yielded some success with many novel and modified 
agents: the recently approved epothilone ixabepilone
®
 displays activity against the 
previously resilient βIII tubulin isotypes and is not subject to efflux by Pgp, whilst a new 
formulation  of paclitaxel with albumin affords reduced toxicity.
17, 34
  Focus has also turned 
to novel routes of intervention in mitosis that overcome the limitations relating to 
microtubule targeting drugs by acting on more specific targets.  The anti-tumour activity of 
the vinca alkaloids and taxanes were first discovered in the 1950s and 1970s 
respectively,
35, 36
 and since then the complex processes controlling mitosis have been 
elucidated in extraordinary detail and revealed a myriad of target proteins.  Principle 
amongst the potentially druggable targets are members of the kinase and kinesin 
families.
12, 33, 37
  Our group has been investigating the kinesin motor proteins involved in 
mitosis as potential targets in cancer chemotherapy (section 1.2.2.2).  As instigators of 
phosphotransfer cascades integral to signalling transduction, protein kinases have emerged 
as one of the most important classes of oncological drug targets of recent years.
38
  Kinases 
may contribute to cancer biology through occupying key roles in oncogenic signalling 
cascades, acting to aid tumour growth and development, or mutationally activated kinases 
which may themselves trigger oncogenic transformations, of which interference with the 
latter is a proven strategy for therapeutic intervention.
39
  Of the kinases involved in mitosis, 
the most intensively investigated as therapeutic targets are the polo-like kinase and Aurora 
kinase families.  For more detailed information on the involvement of kinases in the cell 
cycle and as oncology targets, the reader is referred to a number of excellent reviews.
38-40
  
1.1.4.2. Aurora kinases 
Three members of the Aurora family are known in humans, Aurora A, B and C, and their 
primary functions relate to the accurate alignment and segregation of chromosomes to 
ensure genomic integrity is maintained during mitosis.
10, 41
  Aurora A has a critical role in 
regulating the timing of entry into mitosis, centrosome maturation and is also involved in 
spindle assembly and centrosome separation through phosphorylation of the kinesin motor 
protein Eg5 (section 1.2.3).
41, 42
 Aurora B is critically involved in the early stages of 
mitosis through regulating proteins affecting spindle microtubule dynamics during spindle 
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formation, subsequently encouraging correctly aligned chromosomal kinetochore 
attachment to the developed spindle and regulation of the spindle checkpoint controlling 
further progression.
41
  In the latter stages of mitosis, Aurora B assists in spindle cleavage 
furrow formation which is required for the successful completion of cytokinesis.  The role 
of Aurora C is much less well delineated, although it may overlap with that of Aurora B.  
Interestingly, with the exception of in the testis, the expression of Aurora C is 
comparatively limited.
12
  Inhibitors with pan-Aurora specificity or selectivity for either 
Aurora A or Aurora B have reached clinical trials, with the most advanced in phase 2.
41, 43
  
However, it is not yet apparent which of the Aurora family members represents the best 
therapeutic target and the response to the first round of clinical candidates has been 
limited, with the best responses to date in leukaemic cancers.
44
 
1.1.4.3. Polo-like kinases 
The other heavily investigated family of mitotic kinases are the polo-like kinases (PLK), of 
which five members (PLK1, PLK2, PLK3, PLK4 and PLK5) are present in humans.
45
  
Only PLK1 is highly expressed in mitosis, with the roles of the other family members 
much less clearly understood.
12, 45
  PLK1 is pivotal to the regulation of multiple key events 
throughout cell division, including controlling entry into mitosis and centrosome 
maturation, enabling separation of replicated sister chromatids through phosphorylating a 
binding protein termed cohesion, and also in kinetochore dynamics initiating anaphase.
45
  
A number of roles for PLK1 are also apparent in cytokinesis and leading to mitotic exit, 
including regulating the kinesin motor protein MKLP2 in cytokinesis and phosphorylating 
enzyme complexes involved in cleavage furrow formation.  Elevated PLK1 expression is 
apparent in multiple cancers and corresponds to a poor prognosis, which may be linked to 
its ability to negatively regulate the important tumour suppressor p53.
45, 46
  As such a 
significant mitotic regulator, PLK1 has emerged as an important prognostic and therapeutic 
oncology target, with several inhibitors now in phase 2 clinical trials.
47
 Modest responses 
have been recorded for the inhibitors for which data is available, with the most promising 
indications in non-small cell lung cancers.
44, 47
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1.2. Molecular motors in cell division 
1.2.1. The kinesin superfamily 
1.2.1.1. Overview 
Eukaryotic cells possess a plethora of molecular machines that coordinate intracellular 
transport, and are fundamental in organising the cellular architecture.  They are categorised 
into three protein superfamilies: myosin, kinesin and dynein.
48-50
  All employ hydrolysis of 
adenosine triphosphate (ATP) to produce a directed force along microtubule (or actin for 
dynein tracks) in performing their multiple roles.  The kinesins comprise of a superfamily 
of at least 650 distinct microtubule dependent motor proteins, so far found only in 
eukaryotes.
51
  This superfamily is divided into fourteen families (kinesin-1 to kinesin-14) 
by phylogenetic analysis of their characteristic motor domains of 330-440 residues in 
size.
52
  Outwith their motor domains however, they are structurally divergent with very 
little sequence conservation.  The motor domain is situated at either the N-terminal (N-type 
kinesins), internally (Kin I/ M-type kinesins), or the C-terminal (C-type kinesins).
49
  N-
terminal motors move towards the plus-end of microtubules (β-tubulin), whereas C-type 
kinesins travel to the microtubule minus end (α-tubulin).  M-type kinesins (kinesin-13) 
diffuse rather than move along microtubules until the end where they show microtubule 
depolymerisation activity.
53
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1.2.1.2. Structure of N-type kinesins 
The first member of the kinesin family to be identified was conventional kinesin (Kif5s, 
Kif5B, KHC, kinesin-1 family),
54, 55
 which is ubiquitously present in the human body as a 
protein dimer consisting of identical heavy chains conjoined through a pair of light 
chains.
56
  A prototypical N-terminal kinesin, it consists structurally of three distinct 
domains (Figure 5).   
 
Figure 5 – Domain organisation of conventional kinesin, a typical N-type kinesin. 
Modified from references 42 and 57. 
The conserved motor domain contains the nucleotide binding pocket and microtubule 
interacting regions, followed by a neck/neck linker region.  This connects the motor 
domain to an internal α-helical region, thereby forming a coiled coil which is responsible 
for oligomerisation into dimers or higher oligomers.  Following the coiled-coil region is 
the C-terminal tail domain, where interactions with cargo occur either directly or 
indirectly.  This site affords kinesins their diverse functionalities across transport, meiosis 
and mitosis.
49, 51
   
  
 34 
 
1.2.2. Kinesin functions 
1.2.2.1. Intracellular transport 
Kinesins are extensively involved in intracellular transport.  In axonal transport, they are 
responsible for movement of mitochondria, synaptic membrane and vesicle precursors, 
while in dendritic transport their cargoes include vesicles and messenger RNA protein 
complexes.
51
  Outside these processes, their roles include transport from the Golgi 
apparatus and translocation of lysosomes and endosomes.  Microtubule dynamics depend 
heavily upon kinesins.
58
  As well as an indirect influence through transporting microtubule 
regulators, kinesins directly affect microtubule dynamics, and are extensively involved in 
mitosis.   
1.2.2.2. Kinesins in mitosis 
The mitotic spindle apparatus serves as a suitable substrate for kinesin based motility 
events that lead to the generation of forces necessary for bipolar spindle formation, 
chromosome congression to the metaphase plate and segregation during anaphase, as well 
as cytokinesis.
59
  The establishment of a bipolar spindle requires the separation of the 
duplicated centrosomes through the sliding of overlapping antiparallel microtubules, a 
process which requires the collaboration of different plus-end directed kinesins, such as 
Eg5 and Kif15/HKLP2, as well as the antagonistic action of minus-end directed motors 
including KifC1/HSET and dynein.
60
  Chromosomal dynamics are also controlled by 
members of the kinesin-4 and kinesin-10 families termed chromokinesins: these associate 
to chromosome arms during mitosis, and contribute to the generation of forces, named 
polar ejection forces, that push the chromosome arms away from the poles and counter 
forces that drive chromosomes towards the poles.
61
  This generates the oscillatory motion 
of chromosomes observed in vertebrate cells.
62
  Kif18A, a member of the kinesin-8 family, 
is also known to be involved in chromosome congression in prometaphase.
63, 64
  Kinesins 
such as CENP-E contribute to the process of chromosomal congression to the metaphase 
plate, and to the capture of microtubules by the kinetochores.
65, 66
  At the same time, 
kinetochore associated Kif18A dampens microtubule dynamics,
67
 while depolymerising 
kinesin-13 family members promote destabilisation of the microtubule-kinetochore 
interactions.
68
  Such kinesin driven microtubule depolymerisation contributes to 
kinetochore microtubule dynamics,
69
 and is involved in the mechanism through which 
kinetochores correct erroneous microtubule attachment states to ensure genomic stability.
70
  
During post-metaphase events, MKLP-2 is responsible for the relocation of the 
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chromosome passenger protein complex from the inner centromeres to the central spindle 
in anaphase.
71
  All kinesin-6 family members and Kif4 undertake roles in the translocation 
of the regulatory proteins to the spindle midbody, and are necessary for completion of 
cytokinesis.
71-74
 
1.2.2.3. Kinesin inhibitors for chemical biology and therapy 
Inhibitors of mitotic kinesins may act as biochemical tools through which the processes 
involved in mitosis may be understood further and to investigate potential pathways for 
treatment.
59, 75, 76
  The synergistic activity of multiple antagonistic and complementary 
motor proteins, such as the kinesins described, is responsible for controlling the dynamic 
balance witnessed during spindle morphogenesis and subsequent chromosome movements.  
Interference with RNAi has suggested that at least twelve human kinesins are essential for 
the successful completion of cell division.
63
  It therefore follows that inhibition of these 
kinesins with specific small molecule inhibitors can elucidate the mechanisms underlying 
mitosis and their key regulators, and significantly may be used to disrupt mitosis for 
therapeutic purposes.  While understanding the physiological relevance of many of the 
kinesins described above will take further investigations, kinesin-5 family member Eg5 
already represents an attractive target in cancer therapy.  
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1.2.3. Homo Sapiens Eg5 
1.2.3.1. Structure and regulation 
Human Eg5 (hsEg5, Kif11, KSP, kinesin spindle protein, KNSL1; kinesin-5 family) is a 
N-type kinesin involved in assembly of the bipolar spindle in the early prometaphase stage 
of mitosis.
77, 78
  The founding member of the kinesin-5 family, known as ―blocked in 
mitosis‖ (BimC) kinesin, was identified in Aspergillus nidulans in 1990.79  It is structurally 
distinct amongst kinesins as it forms a homotetramer consisting of two parallel 
homodimers arranged in antiparallel association.
80, 81
  Eg5 travels towards the plus-end of 
microtubule tracks,
80
 however it moves relatively slowly
63, 65
 when compared to 
conventional kinesin.
82
  Targeting of Eg5 to the spindle is proposed to occur through 
phosphorylation of a threonine in a consensus sequence (BimC box) in the C-terminal tail 
domain by Cyclin-dependent kinase-1 (Cdk1).
78
  TPX2 (targeting protein for XKLP2) has 
additionally been demonstrated to regulate Eg5 activity and localisation,
83
 while in 
Xenopus laevis the kinase Aurora A also regulates Eg5.
42
   
1.2.3.2. In mitosis 
Across a variety of fungal, insect and vertebrae cells kinesin-5 orthologs are critical in 
establishing spindle bipolarity through separating the duplicate spindle poles.
84
  The 
homotetrameric structures of kinesin-5 family members are proposed to help them achieve 
this through the crosslinking of antiparallel arrays of oppositely polarized microtubules, 
and sliding them apart through their processive movement (Figure 6).  This behaviour has 
been observed directly in vitro during assays which examined the motion of Xenopus Eg5 
along immobilised microtubule tracks while cross-linked to free bundles of microtubules.
85
  
Eg5 orthologs in non-mammalian species are required once spindle bipolarity has been 
established for maintaining the spindle.
84
  The evidence for this role in mammalian cells 
remains ambiguous;
84, 86 
other kinesins are known to facilitate this activity in humans, such 
as the depolymerising Kif2a (kinesin-13 family) and another plus-end directed N-type 
kinesin HKLP2 (kinesin-12 family), suggesting that the involvement of Eg5 is likely to be 
secondary.
49, 74, 75
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Figure 6 – Schematic depictions of the role of Eg5 in organising spindle bipolarity. 
In Figure 6a, the tetrameric Eg5 motors (red) have organised the microtubules (green) nucleated from 
the centrosomes (blue) to form a stable bipolar spindle.  Figure 6b illustrates Eg5 crosslinking the 
antiparallel microtubule arrays and consequently shifting both polewards.  Modified from reference 
82. 
  
 38 
 
1.2.3.3. Outwith mitosis 
The role of Eg5 outside mitosis remains much less investigated than in cell division, 
however a number of functions have been identified.  Most recently Eg5 was identified to 
be active during interphase in translation: the efficiency of polypeptide synthesis decreased 
when Eg5 was depleted by RNAi or small molecule inhibition in a mammalian cell line.
87
  
This study by Bartoli et al. was the first to detect Eg5 activity in interphase, so the specific 
attributes of its involvement remain to be explicitly deciphered.  Eg5 is also expressed in 
terminally post mitotic neurons and may have a role in neuronal development.
88
  Neurons 
form the backbone of the central nervous system, and neuronal growth enables the 
formation signalling pathways throughout the body.
89
  Each neuronal cell in vertebrates 
contains a single projecting axon and multiple branched dendrites whose cytoskeleton is 
comprised of microtubules.  As with the mitotic spindle, multiple microtubule-based 
motors are conceived to coordinate and manage their structural organisation and 
development.
88, 89
  Eg5 was initially identified as being present in terminally differentiated 
neurons in Mus musculus, and subsequently was recognised to regulate the microtubule 
growth of axons and dendrites.  Depletion or inhibition of Eg5 in axons results in a 
temporal rapid growth increase (Figure 7).
90, 91
   
 
Figure 7 – Eg5 controls the rate of axonal growth in rat sympathetic neurons.   
Cultures are immunostained for β-III tubulin.  Figure 7a: neurons without Eg5 inhibitor visualised 4 h 
after plating.  Figure 7b: neuronal growth after 4 h in the presence of the small molecule Eg5 inhibitor 
monastrol (4).  Reproduced with permission from reference 90.  Copyright 2004 John Wiley & Sons, 
Inc. 
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This ―growth cone‖ of projected microtubules however appears uncontrolled and unable to 
turn appropriately to reach the intended synapse.
92
  In dendrites, inhibition of Eg5 with the 
specific small molecule inhibitor monastrol (section 1.2.4.1) results instead in a prolonged, 
rather than temporal, increase in observed growth.
91
  Collectively, these studies suggest 
that Eg5 may serve to regulate the growth of these microtubule emanations through 
cooperation with cytoplasmic dynein.
91, 93, 94
  As a much slower motor than dynein,
80
 its 
effect may be to limit the rate at which the faster motor performs its work.
94
   The 
mechanics behind the manipulations of microtubules by the kinesin in these regions are yet 
to be completely elucidated, although antiparallel arrays of microtubules are known to be 
present towards the leading process of migratory neurons.
94
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1.2.4. Inhibition of Eg5 
1.2.4.1. Monastrol and the loop L5 allosteric site 
Interest in the mitotic kinesins as potential targets in cancer treatment began following the 
discovery of the first selective mitotic kinesin inhibitor, the 1,4-dihydropyrimidine-based 
compound monastrol (4, Figure 8a).
95
  This inhibitor weakly and selectively inhibits Eg5 in 
a reversible manner and was identified in a high throughput (HT) phenotype based screen 
targeted towards identifying novel anti-mitotic agents.  Exposure to cells produced a 
distinctive monoastral spindle phenotype in cells comparable to that observed with RNAi 
mediated depletion (Figure 8b).
63, 95
   
 
Figure 8 – a) Structure of monastrol (4); b) the “monoastral” monopolar inhibition phenotype.   
BS-C-1 cells were treated with 68 µM monastrol for 4 h and immunofluorescence stained.   α-Tubulin 
is green, chromatin appears in blue.  Modified from reference 95. 
This was the first example of a compound which disrupted the mitotic spindle apparatus 
selectively without affecting tubulin.  Biochemical characterisation revealed 4 as ATP 
uncompetitive and non-competitive towards microtubules, suggesting an allosteric mode of 
action.
96
  The crystal structure of the ternary monastrol·Eg5·ADP complex was solved and 
confirmed binding at an allosteric site formed by helix α2/loop L5 and helix α3, 
approximately 12 Å removed from the nucleotide (Figure 9).
97
  Amongst the kinesins, 
monastrol is specific for Eg5,
95, 98
 and remarkably is also specific within the kinesin-5 
family for only the vertebrae homologs.
99
  This specificity has been attributed to the length 
of the loop L5 which forms the induced fit site;
97
 Turner et al. found this loop to be longest 
in kinesin-5 orthologs from a panel of nine kinesins from three different families.
100
  That 
non-mammalian kinesin-5 orthologs such as A. nidulans BimC are not inhibited does 
suggest a deficit in our understanding. 
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Figure 9 – A comparison of the crystal structure of Eg5·ADP in the absence (green) and presence of 
monastrol (red). 
Note the translocation of the loop L5 with the terminal Trp 127.  Modified from reference 101.
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1.2.4.2. Eg5 as a cancer target 
After the discovery of monastrol and its biochemical elucidation, several more selective 
allosteric Eg5 inhibitors were identified that also induced mitotic arrest in vitro.
102-104
  The 
first to demonstrate anti-tumour activity in vivo was CK0106023 (5, Figure 10).
105
   
 
Figure 10 – Structure of the quinazoline derivative CK0106023.  
 
Exposure to 5 produced robust mitotic arrest in a number of cancer cell lines, including 
several subject to multidrug resistance (MDR).  During xenograft studies with nude mice 
bearing human ovarian carcinoma SKOV3 tumours, 5 exhibited comparable anti-tumour 
activity to paclitaxel.  Tumour growth was inhibited by treatment with CK0106023 by on 
average 71% at 25 mg/kg, with a single partial regression in a cohort of eight mice.  
Treatment with paclitaxel at its maximum tolerated dose (MTD) of 20 mg/kg afforded 73% 
average growth inhibition.  Characterisation of CK0106023 confirmed selectivity amongst 
kinesins for Eg5 and correlated with the biochemical mode of action displayed by 
monastrol.  Excised tumours displayed the phenotypical monopolar mitotic spindles seen 
in cell culture (Figure 8b), implying efficacy through the proposed mechanism of action.  
This triggered enormous interest in Eg5 as a new oncology target, subsequently leading to 
the development of numerous potent and selective inhibitors acting at the loop L5 
pocket.
76, 106, 107
  Inhibition of Eg5 is now validated as a potential route to disrupt mitosis in 
a broad spectrum of cell culture and tumour xenograft experiments.  These include in 
paclitaxel resistant tumour cells,
108
 and in a large scale nude mice xenograft experiments 
with the clinical candidate ispinesib (section 1.4.1), complete responses were recorded for 
a number of tumours of varying histological origins.
109
  Investigation into the role of Eg5 
in cancer has identified overexpression in a number of cancers, although this could simply 
be as a result of increased proliferation.
110-112
  In mice, overexpression has been shown to 
cause errors in chromosome segregation leading to aneuploidy; the physiological relevance 
of these findings however remains to be defined.
113
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1.2.4.3. Structural origins of inhibition 
The involvement of loop L5 provides the mechanical basis for the allosteric inhibition of 
Eg5.  Kinesin motility is controlled by a series of conformational changes cascading 
throughout the protein upon ATP binding, hydrolysis and subsequent ADP release, which 
in turn determines affinity towards microtubules.
114
  Amidst these processes, the conserved 
region known as the ―neck linker‖ switches upon ATP binding from a mobile free state to a 
rigid docked pose, and in doing so swings from a rearward facing position towards the 
plus-end of microtubule tracks.
115
  This swing of the neck linker drags the cargo attached 
to the COOH terminus, and also conveys the structural changes necessary for processivity 
in kinesin oligomers.
114
   Key to controlling these processes is the ɣ-phosphate sensing 
machinery, comprising of switch I and switch II, which through interacting with each other 
and forming H-bonds to the ɣ-phosphate of the bound nucleotide, conduct the 
conformational changes from the nucleotide site to the neck linker that realise docking, and 
consequently kinesin motility.   Although the loop L5 allosteric site on Eg5 is distal from 
the neck linker, local inhibition induces a ~ 6 Å shift in the main chain of switch I, and 
crucially, widens the gap between switch II helices α-4 and α-5 by ~ 6 Å (Figure 11).97  
This opens a space into which the neck linker docks into a stable rigidified conformation.  
Kinetic investigations into monastrol binding have found that during inhibition, the 
Eg5:ADP complex stabilises and the rate of ADP release is dramatically decreased.
116
  
Thus when the L5 allosteric pocket forms, the neck linker remains locked, and the Eg5 
motor is unable to process along microtubules to form the bipolar spindle.   
 44 
 
 
Figure 11 – Comparison of the conformation of switch I, switch II and the neck linker before (red) and 
after monastrol binding (green). 
The depicted region is the switch-2 region, which is located on the opposite side of the motor domain 
from the monastrol binding site.  Modified from reference 97. 
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1.2.4.4. Cell death mechanism 
How Eg5 inhibitors trigger cell death in vitro has been revealed in great detail.  After 
mitotic arrest, the spindle checkpoint is activated which eventually results in cell death in 
certain tumour cell lines. 
108, 117
  This occurs primarily via the intrinsic apoptotic pathway, 
with mediation by the proapoptotic protein Bax and subsequent caspase activation.
117, 118
  
A number of other cell fates may also take place (Figure 12).   
 
Figure 12 – Possible cell fates following mitotic arrest induced by Eg5 inhibition.  
Modified from reference 119. 
Cells may slip from mitotic arrest and re-enter the cell cycle; those which have not 
undergone proper chromosome segregation and cytokinesis after exiting arrest will exist as 
tetraploid cells.
104, 106
  These may in turn undergo cell death, remain in a quiescent state or 
continue proliferating by mechanisms unknown.
119
  No effects of Eg5 inhibitors have been 
observed on cells in interphase (section 1.2.3.3).
108
   
Allosteric loop L5 inhibition is reversible, and after transient Eg5 inhibition cells can 
continue proliferating.
95, 119
  This has important ramifications in drug design, since 
potential drug candidates should have the pharmacodynamics and pharmacokinetics 
necessary to induce robust mitotic arrest in the first instance.  Interestingly, a study by Orth 
et al. illustrated that the breast cancer cell line MCF7 was less robust at recovering after 
mitotic arrest than cells from normal tissue, thereby suggesting that Eg5 inhibitors could be 
preferentially cytotoxic against tumours.
119
    Rello-Verano et al. also demonstrated that 
tetraploid HCT116 cells are more susceptible to Eg5 inhibitors than their diploid 
precursors cells, typically undergoing an apoptotic-like cell fate.
120
  As with microtubule 
based anti-mitotic drugs, the cellular responses induced by Eg5 inhibition vary between 
cell lines and even intracellular differences are apparent.
24 121
  A clearer understanding of 
the biomarkers that differentiate between eventual possible cell fates would provide a great 
advantage in determining the most appropriate cancer treatment.  However, discriminating 
between these factors remains a complex and sometimes contradictory affair, complicated 
further by the histological heterogeneity evident in cancer.  One emerging factor is that 
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cells more susceptible to apoptosis are more responsive Eg5 inhibition.
121, 122
  In addition, 
the duration of mitotic arrest appears to have little bearing on the subsequent fate of the 
cell.
24, 119, 121
  While differences between cell lines may be partially attributed to epigenetic 
factors, this cannot be the case when genetically identical sister cells respond discretely.  
One theory of how this differentiation arises is that two competing networks of cellular 
responses are at play when a cell undergoes arrest in mitosis: one operates to generate cell 
death signals which initiate apoptosis, while opposing this the levels of cyclin B1 begin to 
degrade, which can allow the cell to slip from mitosis.
24
  Alternatively, Shi et al. have 
proposed that sensitivity to inducing apoptosis with anti-mitotic drugs is affected by the 
anti apoptotic protein XIAP.
121
  Clearly while progress is being made, further work needs 
to be done to further our understanding in this seminal field.   
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1.3. S-trityl L-cysteine  
1.3.1. Biological background 
1.3.1.1. History of discovery 
One of the first Eg5 inhibitors to be identified was S-trityl L-cysteine (STLC: 6, Figure 
13a), whose origins as an anticancer agent began over fifty years ago.  After the 
observation was made in 1954 that leukemic white blood cells incorporated radiolabelled 
cysteine, S-alkylated derivatives of cysteine were investigated as potential anticancer 
agents.
123, 124
  STLC was initially synthesized for this purpose in 1959,
125
 and demonstrated 
in vivo murine leukaemia anti-tumour activity through mechanisms unknown at the Cancer 
Chemotherapy National Service Center of the National Cancer Institute (NCI) from the 
1960s onwards.
126, 127
  It was not until 1992 that Paull et al. recognised STLC as a 
cytotoxic anti-mitotic agent which did not affect microtubules when examining compounds 
of known anti-tumour activity from the NCI.
128
  During a HT screening programme 
involving NCI libraries, our group finally identified STLC and several other compounds as 
Eg5 inhibitors in 2003.
104
  STLC is therefore a serendipitously discovered rationally 
designed anticancer agent.
125
   
 
Figure 13 – a) Structure of STLC (6); b) monopolar spindles in HeLa cells treated with STLC. 
Modified from reference 104. 
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1.3.1.2. Biological activity 
STLC is a tight binding allosteric inhibitor which inhibits the in vitro basal ATPase activity 
of Eg5 with Ki
app
 ≈ 150 nM.129, 130  It binds at the same loop L5 allosteric site formed for 
monastrol,
131, 132
 and induces the phenotypic monopolar spindle indicative of mitotic arrest 
through Eg5 inhibition in cell culture.
104, 129
  Across the NCI60 panel of cancer cell lines, 
STLC exhibits a mean GI50 = 1.31 µM.
104
  As with other Eg5 inhibitors, docetaxel resistant 
prostate cancer cell lines remain sensitive to STLC treatment,
133
 and anti-tumour activity in 
vivo has been demonstrated in various xenograft models.
126, 127
  Proteomic analysis of the 
fate of HeLa cells treated with STLC revealed death occurred primarily by activation of the 
spindle checkpoint and the intrinsic apopototic pathway.
134
  STLC is selective for Eg5; the 
other human mitotic kinesins which have been evaluated (MKLP-1, MKLP-2, CENP-E, 
Kif22, Kif2A, MCAK and KifC1) are not affected.
129
  Additionally, conventional kinesin 
(hsKif5B), Drosophila Ncd and the kinesin-5 ortholog A. nidulans BimC are not inhibited 
by STLC.
104
  Outwith the kinesins, constrained derivatives of STLC were recently reported 
as weak inhibitors of the hepatitis C virus NS5B polymerase.
135
  
  
 49 
 
1.3.2. Eg5–STLC crystal structure 
The crystal structure of STLC in complex with Eg5 has been solved, and allows 
description at the molecular level of the key interactions in the inhibitor-binding pocket 
(Figure 14).
132, 136
  The three phenyl rings of the trityl head group are situated in the 
predominantly hydrophobic core of the allosteric inhibitor binding-site, in three discrete 
pockets (P1-P3, Figure 15).
137, 138
  Several key interactions are observed contributing to the 
overall binding of the trityl head group: the phenyl ring in P1 forms an offset stacked π···π 
interaction with Tyr211, while in P2 the phenyl ring is locked into position by both an 
edge-face interaction with the phenyl ring of Trp127, and a C–H···π interaction with the 
pyrrolidine ring of the neighbouring Pro137 on its opposing face.
132
  In the P3 pocket, a C-
H···π interaction is evident between the isopropyl side chain of Leu 214 and the third 
phenyl ring’s π-electron cloud.  Co-workers in the Mackay group recently showed by 
molecular dynamic (MD) simulations that for the trityl head group the majority of the 
enthalpic contributions to the free energy of binding for STLC stem from short range 
hydrophobic interactions, although surprisingly several long range electrostatic interactions 
were also noted.
139
  In contrast to the predominantly hydrophobic binding environment of 
the trityl group, the cysteine tail extends towards the bulk solvent and the amino acid 
terminus forms several important hydrogen bonding interactions.
132, 136
  The primary amine 
exhibits H-bonding interactions with the main chain carbonyl of Glu117, a side chain 
oxygen from Glu116 and a structural water molecule, while the carboxylate forms an H-
bonding network with several structural water molecules and an NH group of the proximal 
Arg221 guanidinium.  The interactions of the primary amine are by far the most important 
contribution to the overall free energy of binding of STLC; MD simulations calculated this 
moiety contributes -10.3 kcal mol
-1
.
139
  The same study demonstrated that contrary to this 
the enthalpic contribution of the carboxylate to the free energy of binding appears to be 
repulsive overall.  The predominant factor behind this is a repulsive electrostatic 
interaction between the carboxylate and the anionic diphosphate of ADP.  In the Eg5–
STLC structure, the more distal changes relating to conformational changes in the neck 
linker and the ɣ-phosphate sensing machinery of switch I and II that were seen in other 
Eg5·inhibitor complexes were also present.
97, 140
  Interestingly, in the 2 Å structure solved 
by our group, while in three of four subunits in the asymmetric unit the final inhibitor 
bound state incorporating a docked neck linker was observed, in the remaining subunit the 
switch II cluster was only partially rotated and the neck linker undocked.
132
  This appears 
to be a trapped intermediate state, which provides a structural corroboration for the 
proposed mechanism of ɣ-phosphate cascade inhibition discussed in section 1.2.4.3.   
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Figure 14 – Molecular interactions of STLC with Eg5.   
The protein side chains are coloured by atom type: white (C), blue (N) and red (O).  The STLC ligand 
is coloured by atom type: green (C), yellow (S), blue (N) and red (O).  Hydrogen-bonding interactions 
appear as dashed lines.  Modified from reference 132. 
 
Figure 15 – Surface diagram with an STLC analogue containing a p-chlorophenyl ring in the inhibitor 
binding pocket.   
STLC is coloured by atom type: white (C), yellow (S), blue (N) and red (O).  Modified from reference 
138. 
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1.3.3. Structure activity relationship of STLC scaffold 
1.3.3.1. Trityl head group 
Initial structure activity relationship (SAR) studies on STLC were carried out prior to the 
elucidation of structural data on the Eg5·STLC complex.  In the first in depth study by 
DeBonis et al., a minimum pharmacophore for effective inhibition was established.
130
  
Incorporation of a small lipophilic para-substituent on one phenyl ring of the trityl moiety 
produced analogues exhibiting improved GI50 values of ~ 200 nM in HeLa cells c/f GI50  = 
700 nM for STLC (e.g. 10, Table 1).  The most active compound in a smaller study by Ogo 
et al. had a p-trifluoromethylphenyl ring in the trityl group.
141
  The crystal structure of the 
p-chlorophenyl analogue 7 has latterly been solved, and demonstrated the halogen 
substituent to be positioned in the P3 pocket (Figure 15).
137
  Bulkier substituents are also 
tolerated if correctly orientated; docking studies implied the β-napthyl bicycle in 11 was 
also most likely to bind in the P3 pocket.  However fused rings such as fluorene in place of 
two phenyl rings in the trityl moiety displayed at best weak activity.
130
  Replacement of 
one phenyl ring in the trityl moiety with linear or branched alkyl groups is also tolerated, 
however when n < 3, (where n = the number of carbons in the alkyl group), the activity is 
greatly diminished (e.g. 13 and 14 c/f 12).  This may be due to the entropic penalty 
incurred with less conformationally restrained lower linear alkyl derivatives.   The effect of 
replacing two phenyl rings with alkyl groups was not reported.   
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Table 1 – Selected SAR for trityl modifications.  
 
 
Cmpd R 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
HeLa cells 
GI50 (nM) 
6 Ph 50* 700 
7 4-Cl-Ph 200 510 
8 4-Br-Ph 250 310 
9 4-Me-Ph 100 210 
10 4-OMe-Ph 200 200 
11 β-napthyl 200 330 
12 Et 450 > 5,000 
13 n-Pr 175 1,400 
14 i-Pr 150 1,080 
Notes = 
* 
Estimates of the Ki
app
 values vary depending on the buffer and test conditions used, due to 
STLC and analogues’ tight binding nature.129, 130  Modified from reference 130. 
Table 2 – Selected SAR for cysteine modifications.  
 
 
Cmpd R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
HeLa cells 
GI50 (nM) 
15 CO2H H n.i. n.d. 
16 NH2 H 150 1008 
17 NHAc CO2H n.i. n.d. 
18 NHBoc CO2H n.i. n.d. 
19 OH H n.i. n.d. 
Notes: n.d. = not determined; n.i. = no inhibition.  Modified from reference 130. 
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1.3.3.2. Amino acid tail 
Although in the crystal structure the terminal carboxylate in the cysteine tail forms several 
H-bonding interactions with structural water molecules,
132
 it is not required for effective 
inhibition (15 c/f 16, Table 2).
130
  The interactions formed between the primary amine and 
the peptide backbone are however essential; replacement with bulky secondary or tertiary 
amines in general completely abolished enzyme inhibition (e.g. 17 and 18).  There is little 
spatial discrimination between STLC and the D-cysteine analogue STDC, with both 
exhibiting comparable activities in basal and cellular assays, although STLC is marginally 
more potent against Eg5.
129
  The chain length is also critical: extension of the ethanamine 
chain in 16 produced compounds which no longer inhibited.
130 
 Replacement of the 
primary amine with a hydroxyl resulted in an inactive compounds (19), demonstrating that 
the ability of 16 to form multiple hydrogen bonds with the peptide backbone and also the 
electrostatic interaction with nearby salt bridge between Glu116 and Arg221 are important.  
It would appear that the orientations of the H-bonding interactions emanating from the 
primary amine are crucial, since replacement with a hydroxyl group afforded the inactive 
compound 19.  In conjunction with the findings from modifying the trityl group, these 
findings allow a minimum pharmacophore for effective inhibition to be established for the 
STLC scaffold (Figure 16).
130, 137, 141
   
 
Figure 16 – Minimum pharmacophore of STLC for effective inhibition of Eg5. 
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1.3.4. Molecular recognition by PgP pump 
1.3.4.1. Structure and mechanism of efflux 
Previous investigations by our group have uncovered that STLC 6 and related analogues 
were substrates for the multidrug resistance cellular efflux pump Pgp.
137, 139
  This is a 170 
kDa membrane integrated transporter encoded by the ABCB1 (MDR1) gene.  Structurally 
it comprises of two pseudo-symmetrical halves that each comprise of six transmembrane 
domains and an ATP binding site.
142
  These domains span ~ 70 Å across the surface of the 
cell membrane, and extend from the extracellular environment through the lipid bilayer by 
~ 136 Å.  At the core is a ~ 6000 Å
3
 cavity, lined primarily with hydrophobic residues, 
which accommodates and binds substrates following capture from the lipid bilayer.  Pgp 
has a number of important endogenous roles in ADME, including intestinal absorption and 
transport across the blood brain barrier.  In addition to these, it serves to protect cells from 
xenobiotics by effluxing them as they reach the cell membrane.
143
  Following the partition 
of substrates into the lipid bilayer, drugs are taken up into the binding cavity of Pgp 
through two gateways accessible from the inner membrane leaflet.
142, 144
  Upon ATP 
binding and hydrolysis at the dual nucleotide binding domains, the protein is proposed to 
undergo a conformational change which results in release of bound substrates from the 
inner cavity to the extracellular environment, although the exact mechanisms behind this 
are unclear. 
1.3.4.2. Role in resistance in cancer and relationship to STLC 
Although resistance in cancer is a multifactorial problem, with more than one mechanism 
implicated, Pgp is expressed in a number of different cancers, and included amongst its 
known substrates are anti-mitotic drugs belonging to the taxane and vinca alkaloid 
families.
32
  Unravelling the impact of Pgp related ABC-encoded transporters involvement 
in mediating resistance and the full extent of their physiological relevance is ongoing.  
However, in vitro these drugs are rapidly effluxed by tumour cell lines that overexpress 
Pgp, and in vivo clear correlations between levels of Pgp expression and the overall 
efficacy of chemotherapy treatments have been found in breast cancer and certain 
leukaemias.
145
   Investigations into the relationship of STLC with Pgp have shown that the 
key determinant in affecting the MDR ratio for the STLC analogues is the carboxylate.
137, 
139
  Whilst STLC had an MDR ratio of ~ 30, the thioethanamine 16 without the carboxylate 
had an MDR ratio of 1, indicating the growth inhibition activity of 16 was not being 
affected in the Pgp overexpressing cell line L-MDR1.
137
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1.4. Clinical progress 
1.4.1. Clinical candidates 
1.4.1.1. Ispinesib and related candidates 
In total, nine Eg5 inhibitors have now progressed to clinical trials.  The first and to date 
most intensively investigated is ispinesib, a quinazoline based compound from the same 
medicinal chemistry programme that generated CK0106023 (21, Table 3).  Ispinesib has 
been investigated in monotherapy and in combination against a variety of solid tumours.  
The best responses have been seen in a group of patients with previously treated metastatic 
breast cancer, with partial responses observed in three of thirty three.
146
  Trials in other 
advanced cancers have been less successful, with disease stabilisation in a number of other 
phase 2 monotherapy studies, including head and neck carcinomas, prostate cancer and 
melanomas.
147-149
  Ispinesib has also been tried in combination with various traditional 
chemotherapies, including carboplatin and docetaxel, however no synergy was recorded 
with stabilisation again the best recorded response.
150, 151
  However, ispinesib is a moderate 
to significant inhibitor of the cytochrome P450 (CYP) metabolising enzyme CYP3A4, 
which would contraindicate combination with many chemotherapy agents currently in 
use.
147, 152
  DLTs experienced have typically been haematological related and typical of 
antiproliferative treatment, with the most prevalent being grade 3/4 neutropaenia.
147, 149
  
Neurotoxicity has not been observed.  Cytokinetics have developed a second generation 
analogue with GlaxoSmithKline, which incorporates a chromen-4-one heterocycle in place 
of the quinazoline ring system (SB-743921; 22).
153
  Phase 2 studies are ongoing against 
Non-Hodgkin’s and Hodgkin’s lymphomas, with four partial responses recorded so far 
from a group of thirty.
154
  In a phase 1 study against multiple advanced solid tumours, 
disease stabilisation was again the best response, however one partial response was noted 
in a patient with cholangiocarcinoma who had been heavily pretreated with exisiting 
chemotherapy agents.
155
  Neutropaenia was again the DLT in both studies.
154, 155
  As the 
first clinical inhibitor disclosed, ispinesib prompted great interest from the pharmaceutical 
industry, resulting in multiple patent applications on modified quinazoline derivatives.
106, 
107
  One such fast follow approach from Astra Zeneca led to AZD4877,
156
 which has been 
examined in phase 1 studies against various solid tumours and a combined phase 1/2 study 
in treatment of refractory acute myeloid leukaemia (23, Table 3).
157, 158
  Interestingly, 
AZD4877 was reported to not inhibit five common CYP isoforms, including 3A4.
156 
 
Disease stabilization and neutropaenia were the major findings against solid tumours, 
while in the leukaemia study the major adverse effects included hypokalemia and 
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stomatitis.
144, 145
  Both branches of study were terminated due to lack of clinical 
response.
157, 158
  A fourth inhibitor based on the ispinesib scaffold has also entered clinical 
evaluation, the quinazoline ARQ 621 (24, Table 3).
159
  Phase 1 studies have been 
completed in patients with solid tumours, and ARQ 621 is much better tolerated than the 
structurally related candidates 21-23.
160
  The MTD is a weekly dose of 280 mg/m
2
 c/f, 7 
mg/m
2
 and 30 mg/m
2
 each week for three weeks for ispinesib and AZD4877 respectively, 
and 4 mg/m
2
 every three weeks for SB-743921, in comparable solid tumour study 
groups.
155, 157, 161
  No bone marrow toxicity (i.e. neutropaenia was observed) at this dosage; 
disease stabilization was the best reported outcome.
160
   
1.4.1.2. Candidates based on other scaffolds 
Several structurally distinct scaffolds have also been developed (25-28, Table 4).  Merck 
KGaA have developed a hexahydro-2H-pyrano[3,2-c]quinoline based inhibitor which 
underwent phase 1 trials against various advanced solid tumours (EMD 534085, 25).
162
  
However, the best response recorded was disease stabilization in 30% of patients, and no 
further clinical investigations have been undertaken to date.
163
  Following an extensive 
medicinal chemistry programme incorporating HT screening, crystallography driven SAR 
optimisation and detailed drug metabolism and pharmacokinetic (DMPK) screening, 
Merck & Co. produced the dihydropyrrole candidate MK-0731 for clinical studies (26).
140
  
Phase 1 studies in advanced solid tumours produced only prolonged stable disease in some 
cases, and further investigations for this candidate are not envisaged.
107, 164
  Two 
candidates structurally related to MK-0731 have entered clinical investigations.  ARRY-
520 (27) includes a thiadiazole motif instead of the central dihydropyrrole heterocycle in 
26, and following preclinical in vivo studies demonstrating complete tumour regressions 
against a number of haematological malignancies, entered clinical trials in multiple 
myleoma and advanced myeloid leukaemia (AML).
165
  In the phase 1 AML study, a 2% 
partial response and 29% disease stabilisation rate was observed from thirty four patients, 
with continued investigation terminated due to lack of efficacy.
166
  However, following 
promising results in a small scale phase 1 study,
167
 an objective response rate of 19% was 
recorded in patients with relapsed or refractory multiple myeloma after escalation into 
phase 2 clinical trials, with further studies planned.
168
  The primary DLTs with this 
analogue were neutropaenia and mucositis. 
166, 167
  Interestingly, in the AML study Grade 1 
or 2 QTc prolongation was recorded in ~ 25% of patients,
166
 indicating a potential 
interaction with the human ether-a-go-go related gene (hERG) modulated cardiac 
potassium ion channel, which leads to cardiac arrhythmia.
169
  Eli Lilly are evaluating a 2,3-
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dihydro-[1,3,4]-thiadiazole based inhibitor, under license from Kyowa Hakko Kirin of 
Japan in multiple Phase 2 trials (litronesib aka LY2523355; 28).
170, 171
  A phase 1 study in 
combination with pegfilgrastim in advanced malignancies reported disease stabilization for 
several patients,
172
 however little else has been disclosed about the efficacy of this 
compound.
171
  The first orally bioavailable kinesin inhibitor has been developed by 4SC, 
which has entered phase 1 trials; however very little is currently known about 4SC-205.
173
  
One patent from the company implies this compound is based on the indolopyridine 
inhibitor scaffold discovered by Hotha et al. (e.g. 29, Figure 17).
102, 174
 
 
Figure 17 – Example of indolopyridine structure from Nycomed patent on Eg5 inhibitors.   
Nycomed was later acquired by 4SC AG.  Structure taken from reference 160.    
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Table 3 – Clinical Eg5 inhibitors based on the ispinesib scaffold.  
Clinical Candidate Structure Company Phase Investigational Cancers DLTs 
Ispinesib 
(SB-715992) 
(21) 
 
Cytokinetics 
(licensed to GlaxoSmithKline) 
2 
Multiple solid tumours, particularly 
metastatic breast cancer 
Neutropaenia and leucopenia 
SB-743921 
(22) 
 
Cytokinetics/ 
GlaxoSmithKline 
2 
Advanced solid tumours and 
lymphomas 
Neutropaenia; leucopenia 
thrombocytopenia 
AZD4877 
(23) 
 
Astra-Zeneca 
2 
(inactive) 
Advanced solid tumours and AML 
Neutropaenia; hypokalemia, 
hypophosphatemia and 
stomatitis 
ARQ 621 
(24) 
 
Arqule 1 Advanced solid tumours 
Fatigue, intravascular 
hemolysis and abdominal pain 
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Table 4 – Eg5 inhibitors in clinical development based on alternative scaffolds.   
Clinical Candidate Structure Company Phase Investigational Cancers DLTs 
EMD 534085 
(25) 
 
Merck KGaA 
1 
(inactive) 
Solid tumours and haematological 
malignancies 
Neutropaenia and 
cardiac events 
MK-0731 
(26) 
 
Merck & Co. 
1 
(inactive) 
Advanced solid tumours Neutropaenia 
ARRY-520 
(27) 
 
Array Biopharma 2 AML and multiple myeloma Mucositis, neutropaenia 
Litronespib 
(LY2523355) 
(28) 
 
Kyowa Hakko Kirin 
(under license to Eli Lilly 
outside Japan) 
2 
Multiple, including 
metastatic breast cancer. 
Neutropaenia 
4SC-205 n/a 4SC AG 1 Solid tumours n/a 
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1.4.2. Clinical efficacy 
Limited responses have been recorded in the majority of monotherapy trials involving Eg5 
inhibitors, which has led some to question the efficacy of targeting Eg5.
44
  However most 
of those conducted have involved groups of heavily pretreated patients, with advanced, 
refractory cancers.  It is perhaps unsurprising given that many had failed to respond to 
prior treatments that a new anti-mitotic therapy produced only partial responses or disease 
stabilisation.  Pharmacodynamic responses have been recorded for many of the clinical 
candidates for which data has been reported, indicating that tumour growth inhibition is 
occurring by the proposed mechanism of action.
157, 161, 166
  So what does the future hold for 
Eg5 based cancer chemotherapy? 
One possibility may lie in palliative therapy helping patients manage disease and prolong 
life, but a more intriguing prospect is the use of Eg5 inhibitors in combination with other 
treatments.  The reasonable responses for ARRY-520 in treating patients with intractable 
multiple myeloma are to be followed up by clinical trials in combination with existing 
therapies.
168
  Promisingly, this candidate has already exhibited synergy with the 
proteasome inhibitor bortezomib in in vivo xenograft models.
175
  Therefore, for effective 
combination therapies to be developed, it is imperative that Eg5 clinical candidates are 
well-tolerated, specific and efficacious inhibitors to maximise the potential for achieving 
useful synergistic effects.  Many of the current crop of clinical candidates are molecularly 
obese (MWt. > 400), and thus are more likely to induce peripheral toxicity and exhibit less 
desirable DMPK attributes;
176
 this effect is compounded by the structural homogeneity 
amongst known candidates (e.g. 21-24 and 27-28, Table 3 and Table 4).  STLC on the 
other hand is relatively small and structurally less complex, and with known anti-tumour 
activity in the unmodified scaffold,
126, 127
 represents a promising lead for further 
optimisation studies.  The aim of this project is to make STLC into a viable cancer therapy 
agent.  
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Chapter 2. Synthesis 
2.1. Synthesis of tertiary alcohols 
2.1.1. Grignard reagent and phenyl lithium mediated reductions 
Expedient access to a structurally diverse array of STLC derivatives was achieved by 
thioetherification of tertiary trityl based alcohols, which were prepared using a variety of 
organometallic mediated reductions.  Trityl alcohols 30-38 were synthesised from 
benzophenone derivatives by reaction with phenyl magnesium bromide (Scheme 1), in 
typically moderate to excellent yields (Table 5).  
Scheme 1 – Synthesis of tertiary alcohols by reduction of substituted benzophenone analogues. 
 
Reagents and conditions: (i) PhMgCl, THF, reflux, 20 h. 
 
Phenyl lithium was utilised to reduce methyl benzoates 39 and 40 to access the phenols 42 
and 43, while the m-methoxy analogue 44 was prepared via the same route, following a 
literature procedure to prepare the corresponding methyl ether 41 (Scheme 2a).
177
  The 
tetrahydronapthyl derivative 46 was also prepared by this methodology following 
esterification of the corresponding acid 45 (Scheme 2b).
178
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Table 5 – Tertiary alcohols prepared by reduction of benzophenone analogues with Grignard reagents. 
 
Cmpd R
1
 R
2
 R
3
 Yield (%) 
30
a,b
 2-Cl H H 58 
31 3-F H H 64 
32 3-Cl H H 69 
33 3-Br H H 46 
34 3-Me H H 59 
35 3-CF3 H H 42 
36 4-Et H H 87 
37
b
 3-Me 4-Me H 90 
38 4-Me H 4-Me 46 
Notes: 
a 
= synthesised using PhMgX with ZnCl2 by the method of Hatano et al.
179
 
b
 = prepared using PhMgBr. 
 
Scheme 2 – Reduction of methyl benzoates with phenyl lithium. 
 
Reagents and conditions: (i) NaH, DMF, 0 °C, 20 min; (ii) MeI, rt, 23 h, 64%; (iii) PhLi, THF, -78 °C, 1 
h then -78 °C to rt, 16h; (iv) cat. conc. H2SO4, MeOH, reflux, 16 h, 91%; (v) PhLi, Et2O, -84 °C, 1 h, 
then -84 °C to rt, 16 h, 56%. 
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2.1.2. Lithium mediated organometallic reductions 
2.1.2.1. Lithium halogen exchange with aryl bromides 
When suitable ketones or esters were not readily available, the preferred route to synthesise 
tertiary alcohols structurally related to the trityl group was by reducing benzophenone with 
lithiated aryl bromides (Scheme 3).   
Scheme 3 – General route for the synthesis of trityl alcohols by lithium bromine exchange   
 
Reagents and conditions: (i) n-BuLi, THF, -78 °C, 1 h; (ii) Ph2CO -78 °C, 6 h, then -78 °C to rt, 16 h. 
This provided synthetic access to a wide range of substituents and substitution patterns in 
the trityl head group, in typically moderate to good yields (47-68, Table 6).  Lithium 
halogen exchange was also suitable for synthesising trityl alcohols with substituents on two 
different phenyl rings, through employing substituted benzophenone derivatives such as 3-
hydroxybenzophenone or 4-methylbenzophenone as reagents (65-68).   For reactions 
involving bromobenzonitrile substrates, to avoid nitrile reduction and self-condensation or 
o-phenyl deprotonation a different approach was required.
180
  Reports in the literature 
suggested lithiated benzonitriles could be stably formed either by lowering the temperature 
to -94 °C,
181
 or at -78 °C by reversing the order of addition.
180
  The cyano-containing trityl 
alcohols 63-65 were synthesised in reasonable yields by combination of these approaches 
(Scheme 4).      
Scheme 4 – Synthesis of cyano-trityl alcohols 63-65 via lithiated benzonitriles.   
 
Reagents and conditions: (i) 3-bromobenzonitrile or 4-bromobenzonitrile, THF, -94 °C, 1 h; (ii) Ph2CO  
or ≤ -80 °C, 4 h, then -50 °C to rt, 20 h. 
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Table 6 – Tertiary alcohols prepared by lithiation/lithium halogen exchange. 
 
Cmpd R
1
 R
2
 R
3
 R
4
 
Yield 
(%) 
47 3-Et H H Ph 44 
48 3-i-Pr H H Ph 47 
49 3-n-Pr H H Ph 41 
50 3-(2-methyl-1,3-dioxolane) H H Ph 70 
51 3-OCF3 H H Ph 23 
52 3-SMe H H Ph 54 
53 4-Me H H Ph 43 
54 4-(2-methyl-1,3-dioxolane) H H Ph 65 
55 4-OEt H H Ph 64 
56 4-OCF3 H H Ph 38 
57 4-SMe H H Ph 76 
58 2-F 3-Me H Ph 80 
59 2-F 4-Me H Ph 67 
60 2-F 4-OMe H Ph 76 
61 3-F 4-OMe H Ph 60 
62 3-Et 4-Me H Ph 91 
63 3-CN H H Ph 81 
64 4-CN H H Ph 68 
rac-65 3-CN H 4-Me  Ph 67 
rac-66 3-OH H 3-Cl Ph 39 
rac-67 3-OH H 3-Et Ph 59 
rac-68 3-OH H 4-Me Ph 37 
69 H H H 3-Pyridyl 29 
70 H H H 2-(1,3)-Thiazole 41 
71 H H H 2-(1,3)-Oxazole 27 
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2.1.2.2. Synthesis of trityl alcohols with phenyl ring replacements 
A small selection of analogues replacing one phenyl ring of the trityl group was also 
prepared (69-71, Table 6).  Whilst the 3-pyridiyl and thiazole derivatives 69 and 70 were 
accessible in modest yields under standard lithium halogen exchange conditions as 
described (Scheme 3), a slightly different approach was needed for the 2-oxazole 
derivative 71.   Direct lithiation of unsubstituted oxazole at the most acidic 2-position
182
 
and subsequent reaction with benzophenone furnished the desired tertiary alcohol 71, albeit 
in poor yield.
183
  The reaction is complicated by the propensity for 2-lithiooxazole 73 to 
ring open and form valence bond tautomers (e.g. 74), which could lead to formation of 
adducts at the 4-position (Scheme 5).
183, 184
  The spectral data for 71 however was 
consistent with successful substitution at the 2-position.
182, 183
 
 
Scheme 5 – Mechanism of 2-lithiooxazole ring opening tautomerism.   
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2.1.2.3. Preparation of aryl bromides 
Whilst the majority of the prerequisite aryl bromides for lithium exchange reactions were 
available commercially, additional preparation was required for certain trityl substituents.  
Ketones 75 and 76 required protection as acetals with ethylene glycol prior to lithium 
halogen exchange, whilst the m-substituted n-propyl precursor aryl bromide 80 was 
prepared by a modified version of the Wolff-Kishner reduction with hydrazine hydrate 
(Scheme 6).
185, 186
    A more demanding strategy was required to produce the trityl tertiary 
alcohol intermediate 62, substituted with m-ethyl and p-methyl substituents on a single ring 
(Scheme 7).  Starting from the conveniently substituted 5-bromobenzoic acid 81, 
conversion to the Weinreb amide 82 allowed synthesis of ketone 83 to be performed in a 
controlled manner, thanks to the autoinhibition of further reaction with the Grignard 
nucleophile by the chelating effect of the N-methoxy group.
187, 188
  Wolff-Kishner 
reduction by the Huang Minlon modification furnished aryl bromide 84, before lithium 
bromine exchange and subsequent reaction with benzophenone as described afforded the 
desired tertiary alcohol 62.
185, 186
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Scheme 6 – Preparation of non-commercially available aryl bromides. 
 
Reagents and conditions: (i) cat. p-TSA, ethylene glycol, toluene, reflux, 4 h; (ii) hydrazine hydrate, 
KOH, ethylene glycol, reflux, 20 h, 68%. 
 
Scheme 7 – Synthesis of the m-Et, p-Me substituted trityl intermediate 62. 
 
Reagents and conditions: (i) Oxalyl chloride, cat. DMF, CH2Cl2, rt, 2 h; (ii) NHMeOMe.HCl, NEt3, 
CH2Cl2, 0 °C, 1 h, 70%;  (iii) MeMgBr, THF, 0 °C, 2 h, 90%; (iv) hydrazine hydrate, KOH, ethylene 
glycol, reflux, 4 h, 55%; (v) n-BuLi, THF, -78 °C, 1 h; (vi) Ph2CO -78 °C, 6 h, then -78 °C to rt, 16 h, 
91%. 
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2.1.3. Preparation of polar substituted trityl alcohols  
In order to investigate the binding interactions of the trityl head group further and modulate 
physicochemical properties, a range of trityl alcohols with polar, H-bond accepting or 
donating substituent on one phenyl ring were prepared.  The cyano-substituted 
intermediate trityl alcohols 63-65 provided convenient synthetic starting points for 
diversification (Scheme 8).  Hydrolysis of 63-65 afforded access to the primary amides 85-
87, whereas under harsher and prolonged reaction conditions, the carboxylic acid 88 was 
obtained.  The carboxylic acids 88 and 89 were derivatised to secondary and tertiary 
amides 91-94 with the amide coupling reagent T3P
®
, a propylphosphonic anhydride,
189
 or 
reduced with LiAlH4 to produce a CH2OH motif (90).
127
  Reduction of the nitriles 63 and 
64 afforded amines 95 and 96, which were acetylated to produce amides 97 and 98.  
Oxidation of the thioethers 52 and 57 with m-CPBA afforded the sulfones 99 and 100.   
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Scheme 8 – Derivatisation of cyano intermediate trityl alcohols 62-64. 
 
Reagents and conditions: (i) 30% aq. H2O2, 6 M aq. NaOH, EtOH, 60 °C, 3 h; (ii) KOH, EtOH/H2O, 
reflux, 24 h; (iii) LiAlH4, THF, rt, 22 h; (iv) NH2Me.HCl or NHMe2.HCl, T3P
®
, NEt3, THF, rt, 48 h; (v) 
LiAlH4, THF, 1 h, 65 °C then 21 h, rt; (vi) Ac2O, DMF, rt, 4 h.   
Scheme 9 – Oxidation of methyl sulfide analogues 51 and 55. 
  
Reagents and conditions: (i) m-CPBA, CH2Cl2, rt, 3 h. 
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2.2. Thioetherification 
2.2.1. BF3∙Et2O mediated thioetherification of trityl alcohols 
The thioetherification of tertiary alcohols was initially carried out by the method 
previously employed in the synthesis of STLC related analogues in acetic acid with 
BF3∙Et2O.
130
  
Scheme 10 – BF3∙Et2O mediated thioetherification 
 
Reagents and conditions: (i) L-cysteine, BF3∙Et2O, AcOH, rt, 3 h. 
The reaction proceeds through dehydration of the tertiary alcohol facilitated by the Lewis 
acid to form the trityl carbocation in an SN1 type mechanism.  However, in the hands of the 
author, the reaction gave unsatisfactory yields, so an alternative method was sought.  
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2.2.2. Thioetherification in trifluoroacetic acid  
Trifluoroacetic acid (TFA) proved suitable as a higher yielding alternative acidic medium 
for the dehydration of tertiary alcohols and their subsequent thioetherification with thiols 
(Scheme 11).
190
   
Scheme 11 – General route for thioetherification of tertiary alcohols in TFA. 
 
Reagents and conditions: (i) L-cysteine or cysteamine hydrochloride, TFA, rt, 3 h. 
Notes: R
1
 = refer to Table 7 and Table 8; R
2
 = H or (R)-CO2H. 
This approach provided a reliable means by which to synthesise a diverse array of STLC 
analogues in modest to good yields, with a wide range of functional groups tolerated 
despite the strongly acidic conditions (TFA pKa = 0.52; Table 7 and Table 8).
191
   In 
common with the thioetherification described previously in acetic acid with BF3∙Et2O, this 
reaction proceeds through protonation of the 3° alcohol, dehydration to form the stable 3° 
trityl carbocation intermediate 168, followed by nucleophilic attack by the thiol 169 to 
generate the thioether product 16 (Scheme 12).   
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Scheme 12 – Proposed mechanism for TFA mediated thioetherification. 
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Table 7 – STLC analogues with mono-substituted phenyl rings prepared by thioetherification of trityl 
alcohols in TFA. 
 
 
  
Cmpd R
1
 R
2
 
Yield 
(%) 
 Cmpd R
1
 R
2
 
Yield  
(%) 
16 H H 81  122 4-COMe H 95 
102 3-F H 24  125 3-OH H 77 
104 3-Cl H 65  126 3-CN H 94 
105 3-Br H 48  127 3-CH2NH2 H 72 
106 3-Me H 55  128 3-CH2NHCOMe H 82 
107 3-Et H 44  129 3-CO2H H 36 
108 3-i-Pr H 69  130 3-CONH2 (R)-CO2H 34 
109 3-n-Pr H 63  131 3-CONH2 H 28 
110 3-CF3 H 32  132 3-CONHMe H 78 
111 3-OMe H 81  133 3-CONMe2 H 86 
112 3-SMe H 77  134 3-SO2Me H 82 
113 3-OCF3 H 78  135 4-CN H 68 
114 3-COMe (R)-CO2H 72  136 4-CH2OH H 29 
115 3-COMe H 31  137 4-CH2NH2 H 72 
116 4-Me H 69  138 4-CH2NHCOMe H 73 
117 4-Et H 85  139 4-CONH2 H 70 
118 4-OMe H 18  140 4-CONHMe H 57 
119 4-OEt H 58  141 4-CONMe2 H 88 
120 4-OCF3 H 36  142 4-SO2Me H 62 
121 4-COMe (R)-CO2H 55      
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Table 8 – STLC analogues with more complex substituent patterns prepared by thioetherification of 
trityl alcohols in TFA. 
 
Cmpd R
1
 R
2
 R
3
 R
4
 R
5
 
Yield  
(%) 
143 3-Pyridyl H H H H 59 
144 2-(1,3)-Thiazole H H H H 30 
145 2-(1,3)-Oxazole H H H H 27 
146 Ph 4-Me 4-Me H H 79 
rac-147 Ph 3-OH 3-Cl H H 68 
rac-148 Ph 3-OH 3-Et H H 51 
rac-149 Ph 3-OH 4-Me H H 83 
rac-150 Ph 3-CN 4-Me H H 71 
rac-151 Ph 3-CONH2 4-Me H H 71 
152 Ph H 2-F 3-Me H 64 
153 Ph H 2-F 4-Me H 48 
154 Ph H 2-F 4-OMe (R)-CO2H 50 
155 Ph H 2-F 4-OMe H 76 
156 Ph H 3-F 4-OMe H 67 
157 Ph H Cl Cl H 47 
158 Ph H 3-Me 4-Me (R)-CO2H 68 
159 Ph H 3-Me 4-Me H 79 
160 Ph H 3-Et 4-Me (R)-CO2H 71 
161 Ph H 3-Et 4-Me H 72 
162 Ph H 3,4-(CH2)4 (R)-CO2H 29 
163 Ph H 3,4-(CH2)4 H 70 
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2.3. Synthesis of triphenylbutanamines 
2.3.1. Synthesis of 3,4-dimethyl tritylsubstituted analogue rac-176 
2.3.1.1. Choice of synthetic route  
A more complex synthetic strategy was required for analogues incorporating an isosteric 
methylene replacement for the thiol linker in STLC (CH2-trityl analogues).  The route 
devised previously by Wang et al. was employed, starting with allylation of the previously 
prepared trityl alcohol 37 to introduce the carbon scaffold (Scheme 13).
138
  Iron trichloride 
mediates carbon-oxygen bond cleavage in this unusual but efficient methodology 
developed by Kabalka et al.
192
  After deprotonation to form the lithium alkoxide 177 this 
reaction is proposed to proceed through the iron alkoxide complex 178 and then the trityl 
carbocation intermediate 179, which forms the new carbon-carbon bond with 
allyltrimethysilane to furnish alkene 171 (Scheme 14).  Hydroboration and consequent 
oxidation of the alkene 171 yielded the primary alcohol 172,
193
 which was subsequently 
oxidised to the aldehyde 173 with Dess-Martin periodinane (DMP).
194
  The racemic α-
aminonitrile 174 was then prepared in a variation of the classical Strecker synthesis, 
employing Montmorillonite KSF clay as a solid phase acidic catalyst.
195, 196
  After 
hydrolysis of the nitrile rac-174, hydrogenation of the benzylamine rac-175 in a mild 
ammonium formate based procedure afforded the target amino acid rac-176 in an overall 
yield of 6.4%.
197
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Scheme 13 – Synthesis of 3,4-dimethylphenyl triphenylbutanamine rac-176. 
 
 
 
Reagents and conditions: (i) n-BuLi, CH2Cl2, rt, 30 min; (ii) allyltrimethylsilane, FeCl3, rt, 6 h, 91%; 
(iii) BH3·THF, THF, rt, 19 h; (iv) 30% aq. H2O2, 3 M aq. NaOH, 58%; (v) DMP, CH2Cl2, rt, 4 h, 42%; 
(vi) Mont. KSF clay, benzylamine, TMSCN, CH2Cl2, rt, 2.5 h, 68%; (vii) conc. HCl, dioxane, reflux,     
2 d, 57%; (viii) HCOONH4, 10% Pd/C, MeOH, 60 °C, 2 h, 83%. 
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Scheme 14 – Proposed mechanism for the iron trichloride mediated allylation of triphenylmethanol 37.   
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2.3.1.2. Attempted resolution of rac-176 
Attempts to separate the enantiomers of rac-176 by chiral HPLC were not successful.  
While structurally analogous triphenylbutanamines containing meta and para-methyl 
substituents respectively were resolved previously by semi-preparative chiral HPLC with a 
ChiralPak IC column,
138
 upon application of the same method no compound elution was 
observed for rac-176.  Therefore the method was modified from an isocratic to a varied 
gradient to increase the proportion of ethanol in the mobile phase.  This overcame the 
elution problems encountered and appeared to afford the resolved enantiomers (Figure 18).  
However, it was not possible to purify the obtained materials of the TFA/NEt3 salts 
required in the mobile phase, even after addition of aqueous ammonia to neutralize the 
TFA, and flash chromatography to remove the triethylammonium cations.  Therefore, it 
proved impossible to verify whether successful resolution of the enantiomers had been 
achieved by this method.  Unfortunately, both TFA and NEt3 are required in the mobile 
phase for successful elution of the zwitterionic rac-176.  Therefore, a more salient strategy 
would be to resolve the enantiomers of rac-176 at an earlier stage in the synthesis when the 
zwitterion was not present, such as the α-aminonitrile rac-174.  Limitations on both time 
and material however prevented further investigation. 
  
Figure 18 – HPLC trace for attempted resolution of rac-176.  
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2.3.2. Fluorinated analogues 
2.3.2.1. Overview 
To investigate the effect of modulating the pKa of the primary amine in the lead 
triphenylbutanamines, we embarked on the synthesis of a series of β-fluorinated analogues 
of 181 (182-184, Figure 19).    
 
Figure 19 – Proposed and investigated -fluorinated primary amines.   
Figure 19a) Structures of lead 4-methoxy substituted triphenylbutanamine 180 and proposed β-
fluorinated analogues 182-184.  Figure 19b) Structure of the β-fluorinated dihydropyrazole based Eg5 
inhibitor 185.
198
  
One potential route to synthesise the mono β-fluorinated analogue 182 was through α-
fluorination of an oxazolidinone, followed by removal of the chiral auxiliary and 
subsequent functional group interconversions to the primary amine.
198, 199
  This route was 
employed by scientists at Merck during the synthesis of the β-fluorinated amine moiety in 
185, an Eg5 inhibitor produced in the lead optimization programme that ultimately 
produced the clinical candidate MK-0731.
198
  More recently, in the literature, several 
groups concurrently and independently reported varying approaches to accomplish the 
direct and enantioselective α-fluorination of aldehydes by enamine based 
organocatalysis.
200-203
  We envisaged this as a more direct methodology to procure access 
to the desired -fluoro derivative 181.  As overfluorination is a common problem with 
these types of procedure whenever reaction conditions are not succinctly controlled, this 
could also provide access to the β,β-difluorinated derivative 183.  
(Trifluoro)trimethylsilane (TMS-CF3) has been well established as a nucleophilic 
trifluoromethylating agent in the transformation of aldehydes and ketones into α-
trifluoromethyl alcohols.
204, 205
  Thus, using this reagent would allow synthetic efforts to be 
directed from a common aldehyde precursor.   
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2.3.2.2. Synthesis of β-fluorinated primary amine 182.   
The required aldehyde starting material 189 was prepared by the previously described 
route from commercially available p-methoxy trityl alcohol 186 (Scheme 15).  Introduction 
of the α-fluorine to the aldehyde was performed by the method of Beeson et al., with L-
proline as the amine organocatalyst and N-fluorobenzenesulfonimide (NFSI) providing an 
electrophilic source of fluorine.
202, 206
  The exact mechanism governing fluorine transfer in 
electrophilic N-F fluorinating agents such as NFSI has not been elucidated, with both 
nucleophilic and single electron transfer mechanisms proposed as the predominant 
pathway.
207-209
  After workup and quenching of the reaction, 
19
F NMR of the crude product 
mixture containing rac-190 and 191 exhibited resonances at δ = -194.2 and δ = -107.6 ppm 
respectively, in agreement with comparable α-fluorinated aldehydes reported in the 
literature.
199
  However this crude material was not separated, but instead reduced 
immediately because this type of species is reported to be less stable in comparison to the 
non-fluorinated aldehyde precursors and unstable on silica gel.
199, 201
  Overall, the reaction 
proceeded smoothly and the alcohols could be readily separated by flash chromatography 
to furnish the desired mono β-fluorinated rac-192 in 68% yield, and as the minor 
difluorinated product 193 in 17% yield.  Interestingly, although the enhanced acidity of the 
α-proton in the α-fluorinated aldehyde rac-190 means α,α-fluorination is not unexpected, 
Beeson et al. observed only monofluorinated substrates when utilising bulkier amine chiral 
auxiliaries under comparable reaction conditions.
202
   
Following condensation of L-proline 196 with the aldehyde 189, the enamine 198 forms 
and reacts with NFSI to form the fluorinated species 199: subsequent hydrolysis releases 
the desired α-fluoro aldehyde 190 (Scheme 16).  Marigo et al. have proposed that the 
unexpected stability of the α-fluorinated intermediate 190 towards epimerisation and α,α-
difluorination originates from the steric shielding of the remaining α-proton by the chiral 
substituent on the auxiliary, thus preventing abstraction and ensuing enamine formation for 
a second time.
201
  Thus, through employing the relatively small chiral auxiliary L-proline, 
this protection was compromised, allowing increased formation of the α,α-fluorinated 191 
under the chosen conditions.  β-Fluorination was primarily designed to examine the effect 
on pKa, lipophilicity and cellular uptake in the lead series, therefore rac-190 was not 
resolved, although theoretically L-proline imparted modest enantioselectivity for the (R)-
enantiomer.
202
  Bulkier chiral auxiliaries that provide better stereoselectivity and 
potentially reduced difluorination under these reaction conditions were not investigated.  
Transformation to the primary amine rac-182 was achieved by functional group 
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interconversion through tosylation (rac-194), introduction of the azide (rac-195) and 
subsequent reduction to furnish the target compound (Scheme 15b).   
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Scheme 15 – Synthesis of the β-fluorinated primary amine rac-182. 
 
 
Reagents and conditions: (i) n-BuLi, CH2Cl2, rt, 30 min; (ii) allyltrimethylsilane, FeCl3, rt, 6 h, 60%; 
(iii) NaBH4, conc. H2SO4 in Et2O, diglyme, rt, 18 h then 75 °C, 1 h; (iv) 30% aq. H2O2, 3 M aq. NaOH, 
rt, 5.5 h, 50%; (v) DMP, CH2Cl2, rt, 4 h, 83%; (vi) L-proline, NFSI, THF/EtOH, -10 °C, 2 h then rt, 22 
h.  (vii) NaBH4, CH2Cl2/EtOH, rt, 4 h, 68% (191) and 17% (192); (viii) TsCl, pyridine, CH2Cl2, rt 3 h, 
93%;  (ix) NaN3, DMSO, 40 °C, 18 h, 70%; (x) HCOONH4, 10% Pd/C, MeOH, 60 °C, 2 h, 65%. 
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Scheme 16 – Mechanism for the enamine catalysed direct asymmetric α-fluorination of aldehydes. 
 
Notes: Scheme 16a) Enamine organocatalytic cycle for α-fluorination of aldehydes; adapted from 
Marigo et al.
210
  Scheme 16b) Stereochemical basis for discrimination: adapted from Beeson et al.
202
  
The Si face is shielded electronically and sterically by the α-carboxylic acid of L-proline, thus forcing 
electrophilic fluorination via the Re face.   
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2.3.2.3. Synthesis of α-trifluoromethyl amine 184.   
Synthesis of α-trifluoromethyl amine 184 was achieved from the common intermediate 
aldehyde 189, with the key step being the trifluoromethylation of 189 with the TMS-CF3.  
This organosilicon reagent, known as the Ruppert-Prakash reagent, is a nucleophilic 
trifluoromethyl synthon with general utility for the trifluoromethylation of various 
electrophilic species including aldehydes, ketones, esters, acid chlorides and sulphur based 
electrophiles (reviewed by Prakash et al.).
205
  Reaction conditions were first optimised 
using the commercially available 200 (Scheme 17 and Table 9).  Modest improvements in 
yield were realised upon increasing the relative stoichiometry of the TMS-CF3 and TBAF 
reagents, and prolonging the duration of the reaction (Entries 1, 3 and 5, Table 9).   Upon 
application of the optimised method with aldehyde 189, the desired α-trifluoro alcohol rac-
202 was obtained in 77% yield (Scheme 18).  While the mechanism has not been 
completely verified, the reaction is proposed to proceed through a catalytic species 
mediated by a key alkoxide intermediate 206, with fluorination arbitrated by a putative 
hypercoordinated silicon species 207 (Scheme 19).
205
  At the onset of the reaction, TBAF 
provides an initiating source of fluoride by which to activate TMS-CF3, which transfers a 
CF3 group to the electrophile aldehyde 189.  This forms the alkoxide species 206, and as a 
volatile byproduct Me3SiF.  The high affinity of silicon for the negatively charged alkoxide 
oxygen in 206 dictates coordination of a second molecule of TMS-CF3, and thereby the 
proposed formation of the pentavalent silicon species 207.  This putative key intermediate 
transfers a CF3 moiety to another molecule of the aldehyde 189, which probably 
precoordinates with the hypercoordinate species 207, thus ensuring delivery of the CF3 
group is performed in an essentially intramolecular manner.  Regeneration of the 
autocatalytic alkoxide 206 allows continuation until completion, whilst hydrolysing the 
silylated alcohol 208 affords the desired α-trifluoromethylated alcohol rac-202.  Following 
formation of rac-202, synthesis of the α-trifluoroamine rac-184 was accomplished by 
functional group interconversion through the triflate (rac-203), introduction of the azide 
(rac-204) and subsequent reduction to furnish the target compound (Scheme 18).   
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Scheme 17 – Trifluoromethylation of phenylpropionaldehyde. 
 
Reagents and conditions: (i) TMS-CF3, F
-
 source (5 mol%), rt, 4 h. (ii) Hydrolysis method as indicated 
in Table 9, rt, 2 h.   
 
Table 9 – Optimisation of Ruppert-Prakash reaction with 3-phenylpropionaldehyde. 
Entry 
Scale 
(mmol) 
TMS-CF3 
equivalents 
F
-
 source 
(mol %) 
Time 
(h) 
Hydrolysis 
method 
Yield 
(%)
a
 
1 1 1.5 TBAF (5%) 1.5 
HCl  
(excess, 3 M aq.) 
40 
2 1 1.5 CsF (5%) 1.5 
HCl  
(excess, 3 M aq) 
20
b
 
3 1 1.5 TBAF (5%) 3.5 TBAF (1 equiv) 42 
4 1 2 TBAF (5%) 3.5 TBAF (1 equiv) 49 
5 2 2 TBAF (10%) 21 TBAF (1 equiv) 61 
6 2 2 CsF (10%) 21 TBAF (1 equiv) 53
b
 
Notes: 
a
 = isolated yield; 
b 
= impure for starting material and an unidentified impurity. 
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Scheme 18 – Synthesis of α-CF3 triphenylbutanamine rac-184. 
 
Reagents and conditions: (i) TMS-CF3, TBAF, THF, rt, 16 h, then TBAF, rt, 3 h, 77%; (ii) Tf2O, 
pyridine, CH2Cl2, -50 °C, 3 h, 78%; (iii) NaN3, DMSO, 40 °C, 16 h, 75% (iv) HCOONH4, 10% Pd/C, 
MeOH, 60 °C, 2 h, 91%. 
 
Scheme 19 – Proposed mechanism for trifluoromethylation of aldehyde 189 with TMS-CF3. 
 
Notes: adapted from Prakash et al. and Wiedemann et al.
205, 211
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2.4. Carboxylate isosteres 
The SAR role of the cysteine was examined in more detail with a small series of analogues 
incorporating isosteric replacements for the carboxylic acid (Scheme 20).  Primary amide 
210 was synthesised by treatment of propionic acid derivative 209 with oxalyl chloride to 
generate the acid chloride, followed by displacement with ammonia.  The propionic acid 
derivative 209 was prepared by thioetherification of trityl alcohol with 3-
mercaptopropionic acid under standard conditions (section 2.2.2).  Amide isosteres 216-
218 were synthesised from N-tert-butoxycarbonyl (t-BOC) protected STLC 224 with the 
T3P
®
 coupling reagent, followed by deprotection in TFA.
189
  The hydroxamic acid 
derivative 220 was prepared from the methyl ester of STLC 219 according to a procedure 
reported by Tegoni et al.
212
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Scheme 20 – Synthesis of carboxylate isosteres of STLC. 
 
Reagents and conditions: (i) 3-mercaptopropionic acid, TFA, rt, 2 h, 55%; (ii) oxalyl chloride, cat. DMF, CH2Cl2, rt, 1.5 h; (iii) NH3, dioxane, rt, 18 h, 56%; (iv) T3P
®
, NEt3, 
NR
1
R
2
.HCl, rt, 24 h.  (v) TFA, rt, 2 h; (vi) SOCl2, MeOH, rt, 16 h, 98% (vii) conc. aq. NH4OH, CHCl3, rt, 1 h; (viii) NH2OH, MeOH, rt, 24 h, then 5 °C, 24 h, 24%.
 89 
Chapter 3. Results & Discussion 
3.1. Overview 
3.1.1. SAR investigation strategies 
Examination of the preliminary SAR against the established pharmacophore allowed the 
potential areas of STLC for further structural modifications to be identified (Figure 20).  
The most potent STLC derivatives prepared thus far incorporated lipophilic substituents on 
one phenyl ring of the trityl head group;
130, 137, 141
  initial investigations focussed on the 
expansion of the SAR in this region (section 3.2.1).  In the development and optimisation 
of any lead compound, improvements to the potency must be balanced with ensuring 
prospective drugs have the necessary physicochemical and pharmacokinetic characteristics 
to ensure overall efficacy.
213
  Therefore while the trityl group occupied a primarily 
hydrophobic environment,
132, 139
 it was necessary to also maximise any potential 
hydrophilic vectors to achieve optimal drug-like properties.  These strategies are discussed 
in section 3.2.4.  In parallel with the optimisation of the hydrophobic and hydrophilic 
binding interactions of the trityl head group, the SAR of the amino acid tail were 
investigated.
138
  This work was primarily conducted by Dr. Fang Wang, and her key 
findings are reported in section 3.2.2.  Our further joint investigations on the influence of 
the amino acid tail on DMPK related attributes and its relationship to cellular efflux by the 
Pgp transporter are discussed in section 3.2.6.   
 
Figure 20 – Structural features of STLC. 
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3.1.2. Evaluation process for new compounds 
Newly synthesised compounds were first evaluated for inhibitory activity by measuring 
their effect on the basal ATPase activity of Eg5 in the pyruvate kinase/lactate 
dehydrogenase-linked assay.
214
  From these measurements an estimated Ki
app
 value was 
calculated; this parameter was measured rather than an IC50 value to account for the tight-
binding kinetics displayed by STLC and its analogues.
129, 215
  For each inhibitor, the ligand 
efficiency was calculated from the Ki
app
 to afford an additional means of comparison 
between structurally similar compounds of varying activities and size.
216
  This metric 
relates the ratio of the free energy of binding over the number of heavy atoms in a 
molecule: more efficient ligands tend to be smaller and thus provide better starting points 
for further optimisation.
217
  For all evaluated compounds, the physicochemical properties 
were calculated in silico, and where relevant this data is included in the discussion; the 
complete dataset is presented in appendix 1.   The majority of inhibitors were assessed for 
growth inhibition activity against the K562 human leukaemia cell line, and this work is 
reported in context with the basal inhibitory activity SAR discussions.   We subsequently 
evaluated particularly promising lead compounds across a panel of multiple tumour cell 
lines.  For the selected lead candidates, the physicochemical and ADMET properties were 
then evaluated, prior to progression into in vivo xenograft models of cancer.   
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3.2. Structure activity relationship studies 
3.2.1. Lipophilic modifications to the trityl head group 
3.2.1.1. Inhibition of basal Eg5 ATPase activity by thioethers with a hydrophobic 
trityl substituent 
STLC analogues incorporating a lipophilic para substituent on one ring in the trityl moiety 
had displayed increased potency against Eg5 in previous SAR studies.
130, 137, 141
  The 
structure of the p-chlorophenyl derivative 7 in complex with Eg5 has been solved, and 
provided a structural explanation for these observations.
137
  This established the p-
chlorophenyl was positioned in the P3 pocket, surrounded predominantly by hydrophobic 
residues (Figure 15).  To investigate this environment further, a series of analogues were 
prepared with a single hydrophobic substituent on one phenyl ring (101-122, Table 10).  
While the o-chloro substituent of 101 significantly reduced activity against Eg5 compared 
with STLC (6), a m-chloro (103) produced an approximately 2-fold improvement in Ki
app 
for
 
basal inhibition of Eg5.  To optimise this interaction, a series of meta substituted 
analogues of varying electronic and steric character was prepared (104-115, Table 10).  
Alkyl groups proved particularly beneficial for improving Eg5 inhibitory activity and the 
efficiency of inhibitors.  A stepwise improvement was evident in Ki
app
 from 106 (Me, Ki
app
 
= 80 ± 24 nM), 109 (n-Pr, Ki
app
 = 26.9 ± 11 nM), 108 (i-Pr, Ki
app
 = 10.3 ± 3.4 nM) to 107 
(Et, Ki
app
 = 5.9 ± 2.3 nM), which illustrates this region of the inhibitor binding site is 
sensitive to steric bulk, with the increase in activity most likely reflecting an interaction 
between the proximal lipophilic Leu214 side chain.  The electronic effects on the phenyl 
ring are also important: 110 with a m-CF3 group, which can be considered as sterically 
comparable to a methyl substituent but electron-withdrawing (-I), proved 4-fold less active 
than 106.  In all the crystal structures of STLC and its analogues with Eg5, a C−H···π 
interaction is observed in the P3 pocket with the adjacent isopropyl side chain of Leu 214 
(Figure 14).
132, 136, 137
  This interaction has been calculated to be the most important 
contribution to the free energy of binding from a single residue in the P3 pocket.
139
  As this 
interaction is mediated via the π-electron clouds of the phenyl ring, changes in its 
distribution will consequently affect the strength of interaction with local residues.   
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Table 10 – STLC analogues with one lipophilic trityl substituent 
 
Cmpd R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
6 (STLC) H (R)-CO2H 135.9 ± 20.5 0.36 1452  76 
16 H H 245.0 ± 1.8 0.39 2286  213 
101 2-Cl (R)-CO2H 1783.9 ± 384.0 0.29 n.d. 
102 3-F H 377.4 ± 38.4 0.36 n.d. 
103 3-Cl (R)-CO2H 89.9 ± 18.5 0.36 2404 222 
104 3-Cl H 297.8 ± 60.0 0.37 1045  42 
105 3-Br H 293.9 ± 61.8 0.37 n.d. 
106 3-Me H 80.0 ± 23.9 0.40 698  115 
107 3-Et H 5.9 ± 2.3 0.45 680  84 
108 3-i-Pr H 10.3 ± 3.4 0.42 581  68 
109 3-n-Pr H 29.6 ± 11.0 0.39 1760 ± 124 
110 3-CF3 H 352.7 ± 27.9 0.33 n.d. 
111 3-OMe H 149.8 ± 18.5 0.37 n.d. 
112 3-SMe H 520.4 ± 87.6 0.34 1474  330 
113 3-OCF3 H 27.8 ± 5.0 0.37 1518  164 
114 3-COMe (R)-CO2H 519.8 ± 102.0 0.30 964 ± 82 
115 3-COMe H 185.8 ± 30.4 0.35 706 ± 47 
116 4-Me H 27.4 ± 6.5 0.43 731 ± 36 
117 4-Et H 57.5 ± 9.0 0.39 871 ± 59 
10 (NSC123528) 4-OMe (R)-CO2H 15.7 ± 0.9 0.38 240 ± 17 
118 4-OMe H 21.5 ± 2.8 0.42 700 ± 27 
119 4-OEt H 17.3 ± 2.5 0.41 1901 ± 212 
120 4-OCF3 H 29.7 ± 3.8 0.37 2218 ± 198 
121 4-COMe (R)-CO2H 271.7 ± 36.6 0.31 4266 ± 274 
122 4-COMe H 51.0 ± 21.6 0.38 705 ± 77 
Note: n.d. = not determined; L.E. = ligand efficiency.  
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Several additional para substituted analogues were also prepared (116-122, Table 10).  
These results were in accord with the findings from the meta substituted series, with strong 
basal inhibition by both alkyl and ether substituted derivatives.   Interestingly in the para 
position, ether substituents 118 and 119 displayed superior inhibitory activity against Eg5 
to alkyl derivatives 116 and 117, in contrast with the meta substituted series (e.g. 106 c/f 
111).  However, the range of para substituted derivatives prepared was much narrower.  
Analysis of all results using a Craig plot
218
 substantiated the optimal substituents in the 
meta and para positions as both electron-donating (+I) and hydrophobic relative to 
hydrogen (Figure 21).   
 
Figure 21 – Craig Plot for aromatic substituents of  vs π. 
π is the substituent hydrophobicity constant, and  the Hammett substitution constant, a measure of 
the electronic influence of the substituent.  Values obtained from model systems from the following 
references.
218-220
  Modified from reference 138.   
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3.2.1.2. Evaluation of growth inhibition by thioethers with a hydrophobic trityl 
substituent 
From the panel of derivatives prepared, submicromolar activity was evident against the 
K562 cell line for alkyl (106-108 and 116-117), acetate (114, 115, 122), and p-methoxy 
substituted analogues (118; Table 10).  These in general yielded a ≥ 2-fold enhancement in 
potency c/f the benchmark compounds STLC (6) and its cysteamine analogue (16).  
Paradoxically, 109 and 119 with n-propyl and ethoxy substituents respectively both 
exhibited dramatic losses in cellular activity in comparison to their excellent basal 
inhibitory activity.  This probably can be attributed to their limited aqueous solubility at 
physiological pH (turbidimetric solubility at pH 7.4: 109 = 3.75 µM; 119: = 3.75 µM).  
Introduction of a carboxylic acid into the tail of 122 to produce 121 resulted in a 4-fold 
reduction in Eg5 activity, comparable to that seen with 115 and 114, but produced a much 
more pronounced reduction in activity in the K562 cell line.  This was a reversal of the 
pattern seen with STLC 6 and its cysteamine analogue 16 and the p-methoxy analogues 10 
and 118.  From the comparable inhibitors prepared, two pairs with modified trityl moieties 
had better activity in the Eg5 basal assay when prepared without the carboxylic acid (114 
and 115; 121 and 129), while all modified S-trityl analogues with the carboxylic acid 
moiety exhibited lower activity in the cellular assay than their corresponding counterparts 
without the carboxylate (103 and 104; 114 and 115; 121 and 122) apart from the p-
methoxy pair (10 and 118).  This demonstrates the SAR role of the carboxylic acid is 
complex and its influence on efficacy required more investigation.    
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3.2.1.3. Crystal structure of the Eg5–115 complex 
The crystal structure of the Eg5·115 complex was solved by Kristal Kaan to a resolution of 
2.75 Å, with the modified trityl group of 115 adopting the same overall conformation as 
STLC (Figure 22).
138
  This clearly demonstrated the m-acetate substituent binding in the 
hydrophobic P3 pocket: the ketone carbonyl appears to hydrogen bond with the main chain 
nitrogen in Ala218 and the side chain nitrogen (NH1) of Arg221.  Removal of the 
carboxylic acid appears to afford increased conformational flexibility to the ethanamine 
tail.  Although the hydrogen bonding interactions observed in the Eg5·STLC complex with 
the amide carbonyl and carboxylate of Glu117 and Glu116 respectively are maintained,
132
 
in one molecule in the unit cell the primary amine is positioned pointing towards Arg221 
instead.
138
  Interestingly in one of the seven Eg5 structures within the asymmetric unit cell, 
the neck linker remained undocked and the distal conformational adjustments at the switch 
II cluster were not fully propagated.  This apparent transition state was previously also 
observed in the one molecule of the unit cell in the Eg5·STLC complex.
132
  Together, these 
findings provide further support for the proposed biomechanical pathway of 
conformational changes that ultimately compromises Eg5 processivity (section 1.2.4.3).   
 
Figure 22 – Eg5-115 crystal structure showing 115 in the inhibitor-binding pocket.   
Protein side chains are coloured by atom type: white (C), blue (N) and red (O).  The ligand is coloured 
by atom type: turquoise (C), yellow (S), blue (N) and red (O).  The dashed lines indicate hydrogen 
bonding interactions.
 
 Modified from reference 138.   
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3.2.2. Triphenylbutanamines  
3.2.2.1. Introduction of the CH2-trityl linker 
In parallel to optimisation of the hydrophobic binding interactions of the trityl group in the 
P3 pocket, the effects of further SAR changes to the amino acid tail were examined by Dr. 
Fang Wang.
138
  A crucial discovery from these investigations was that a methylene could 
serve as a replacement for the S-trityl linker in STLC (Figure 20).
138
  Interestingly, 
although the activity of the CH2-trityl analogue rac-221 was lower against Eg5 c/f STLC 6, 
in the growth inhibition assay the activity improved (Table 11).  The (R)-221 enantiomer 
proved more active than the (S)-enantiomer across both assays, in a reversal of the trend 
observed between STLC and STDC.  Against Eg5, STLC is marginally more potent than 
its enantiomer STDC
129, 137
 and (R)-221 is in the opposite absolute configuration with 
respect to STLC.
138
  In another contrast to the S-trityl analogues 6 and 16, the CH2-trityl 
analogue 222 without the terminal α-carboxylic acid exhibited improved activity against 
both Eg5 and in the cellular assay over the zwitterionic rac-221.  Introduction of the CH2-
trityl bioisostere negated concerns regarding the possible susceptibility of the thioether to 
metabolism via S-oxidation.
221
  Additionally both STLC and its CH2-trityl analogue rac-
221 were demonstrated to be stable under acidic hydrolysis conditions comparable to those 
found in the stomach (pH = 1.0; t½ > 24 h).
138
  Drug candidates derived from either 
molecular skeleton could potentially therefore be administered orally.    
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Table 11 – Triphenylbutanamine analogues of STLC with one lipophilic trityl substituent 
 
 
Cmpd R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
rac-221 H CO2H 311.6 ± 53.9 0.34 865  131 
(S)-221 H (S)-CO2H 416.5 ± 64.2 0.33 2065 ± 168 
(R)-221 H (R)-CO2H 173.5 ± 24.5 0.35 776 ± 26 
222 H H 214.7 ± 30.1 0.40 577  61 
223 3-Cl H 120.6 ± 20.7 0.35 596  68 
rac-224 3-Me CO2H 12.2 ± 3.8 0.40 73 ± 3 
(S)-224 3-Me (S)-CO2H 11.1 ± 3.9 0.40 128 ± 15 
(R)-224 3-Me (R)-CO2H 6.4 ± 3.9 0.41 91 ± 9 
225 3-Me H 8.8 ± 1.8 0.46 200  16 
226 3-Et H 3.6 ± 0.5 0.45 253 ± 13 
227
a
 3-i-Pr H 6.7 ± 1.3 0.43 305 ± 30 
rac-228 4-Me CO2H 7.5 ± 1.7 0.41 95.5 ± 5 
(S)-228 4-Me (S)-CO2H 16.7 ± 3.0 0.39 149 ± 6 
(R)-228 4-Me (R)-CO2H 5.4 ± 1.7 0.42 82 ± 4 
229 4-Me H 16.4 ± 1.9 0.44 219  21 
230
a
 4-Et H 9.7 ± 3.2 0.44 750 ± 34 
rac-231 4-OMe CO2H 7.2 ± 2.2 0.40 94 ± 8 
181 4-OMe H 7.9 ± 3.4 0.44 83 ± 4 
Notes: All compounds prepared by Fang Wang and modified from references 138 and 222 unless 
noted; 
a 
=  prepared by Dawid Podgórski.
222
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3.2.2.2. Triphenylbutanamines containing a mono-substituted phenyl ring 
The optimal phenyl substituents in the meta or para position were introduced to the CH2-
trityl based analogues, and across both assays a systematic increase in potency was evident 
relative to the comparable thioether analogues (223-231, Table 11).
138, 222
  These analogues 
were prepared by Dr. Fang Wang and a visiting student under my supervision Dawid 
Podgórski.  Multiple inhibitors displayed estimated Ki
app
 values ≤ 10 nM in the Eg5 basal 
activity assay; 226 was comparable in activity to the Phase II clinical candidate ispinesib 
(Ki
app
 ≈ 2 nM).223  In the cell-based assay, a consistent improvement over the equivalent 
thioethers was found that ranged from ~ 2-fold (e.g. m-Cl: 104 and 223; m-i-Pr: 108 and 
227) to a pronounced 8-fold enhancement (e.g. m-OMe 118 and 232).  The exception was 
230, which was comparable in growth inhibition activity to the thioether analogue 117.  
However, 117 had exhibited poor aqueous solubility (turbidimetric solubility at pH 7.4 = 
37.5 µM), which may have also been a limiting factor in the cellular activity of 230.  The 
SAR findings generally corresponded with those described for the thioether series (section 
3.2.1.1): the most advantageous modifications in the meta position were small alkyl 
substituents, while in the para position a methyl or methoxy substituent was favoured.  The 
most potent compounds were the carboxylic acid containing rac-224, (R)-228 and rac-231, 
and the butan-1-amine 181.  (R)-Enantiomers consistently proved the more potent 
stereoisomer when racemates were resolved.  The m-methyl and p-methyl substituted 
amino acid containing analogues rac-224 and rac-228 were 2-fold more active in the K562 
assay than their comparable butan-1-amine analogues 225 and 229.  In contrast to this, the 
p-methoxyphenyl containing analogues rac-231 and 181 were equipotent against Eg5, but 
in the cell-based assay 181 without the carboxylate displayed marginally more growth 
inhibition activity.  However, in the majority of cases, translation of potent basal inhibition 
into cellular growth inhibition appeared to require the carboxylic acid.   
3.2.2.3. Crystal structure of the Eg5–224 complex 
The structure of the Eg5·rac-224 complex was solved by Kristal Kaan to a resolution of 
2.75 Å, and demonstrated the new CH2-trityl analogues bound to Eg5 in the same overall 
configuration as STLC (Figure 23).
138
  The three phenyl rings are situated in the same 
distinct hydrophobic regions described for STLC (P1-P3, Figure 15),
132
 with the m-tolyl 
ring positioned in the P3 pocket.
138
  As the racemate was employed for crystallisation, 
electron density was observed for both enantiomers.  The overall length of the amino acid 
tail was shortened by replacing the sulphur atom with a methylene (C−S−C bond = 4.5 Å; 
C−C−C bond = 3.9 Å);138 however the interactions observed between (S)-224 and Eg5 are 
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conserved  with respect to those found in the Eg5·STLC complex.
132, 136
  The primary 
amine in (S)-224 forms hydrogen bonds with the backbone carbonyl of Gly117 and the 
carboxylate side chain of Glu116, and additionally the carboxylic acid hydrogen bonds to a 
guanidinium side chain nitrogen of Arg221.
138
  Interestingly, the same interactions were 
not apparent in the more potent (R)-enantiomer: instead, the amino acid moiety appears to 
interact with the peptide backbone through a structural water molecule.  The reason for the 
improved activity of the CH2-trityl analogues c/f their S-trityl analogues is not evident, 
although recent MD calculations on the Eg5·STLC complex indicate the overall 
contribution to the free binding energy from the sulphur atom is positive and 
unfavourable.
139
   However the disparity in cellular activity between the two series 
illustrates that the influence of other factors additionally contribute, and probably in fact 
predominate over the enthalpic changes to the free energy of binding.   
 
Figure 23 – Eg5-224 crystal structure showing (S)-224 (pink) and (R)-224 (yellow) in the inhibitor-
binding pocket. 
Protein side chains and ligands are coloured by atom type: white (C), blue (N) and red (O).  The 
carbon atoms for (S)-224 are pink, whilst for (R)-224 enantiomer they are yellow.  The dashed lines 
indicate hydrogen bonding interactions.  Modified from reference 129.   
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3.2.3. Analogues containing a disubstituted phenyl ring 
3.2.3.1. Thioethers with a fluorine and another hydrophobic phenyl substituent.   
The data from our own SAR and previous studies suggested that further optimisation of the 
hydrophobic binding interactions in the P3 pocket was possible.  Impressive increases in 
affinity with Eg5 had been recorded by scientists at Merck during the optimisation of their 
clinical candidate MK-0731 by situating a 2,5-difluorophenyl ring into the P3 pocket.
224
  A 
m-fluoro substituent had proved detrimental to Eg5 affinity when present in the STLC 
scaffold (102, Table 10), however fluorine substituents in alternative positions in 
combination with the optimal m-alkyl or p-alkyl/methoxy substituents had not been 
investigated.  An o-fluorine substituent diminished inhibitory activity against Eg5 
substantially when combined with a methyl substituent in either the meta or para position 
(152 and 153, Table 12).  However, when combined with a p-methoxy substituent (154 and 
155), the o-fluorine modification afforded a ≥ 2-fold improvement in potency against Eg5 
c/f the mono p-methoxy substituted analogue 118 (Table 10).  Repositioning of the fluorine 
substituent in the meta position whilst retaining the p-methoxy substituent was not 
tolerated (156).  In the cellular assay, 152, 153, 156 and 157 all proved weak inhibitors, but 
the improvements in 155 translated to a modest improvement in growth inhibition c/f the p-
methoxyphenyl benchmark 111.  On incorporation of the carboxylic acid, a satisfying 3-
fold improvement in growth inhibitory activity was realised in 154, which demonstrated 
growth inhibition comparable to the lead triphenylbutanamine analogues prepared 
previously (GI50  75 nM; rac-224 and rac-228, Table 11).
138
  Improved multi-polar 
contacts from the o-fluorine substituent may be partially responsible for the enhanced 
binding of 154 and 155 to Eg5;
225
 the increases in cellular efficacy may additionally reflect 
a minor balancing of the physiochemical properties.   The small size of the fluorine 
substituent also meant that these modest improvements were achieved with limited penalty 
to the efficiency of the ligand (111, L.E. = 0.42; 155, L.E. = 0.42).  Interestingly, the o-
fluoro, p-methoxyphenyl analogue with a CH2-trityl linker 232 proved 2-fold less potent 
against Eg5 than its S-trityl equivalent 155, and this loss in activity was also evident in the 
cell-based assay.   
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Table 12 – STLC analogues containing a disubstituted phenyl trityl ring. 
 
Cmpd X R
1
 R
2
 R
3
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
152 S 2-F 3-Me H 293.6 ± 23.2 0.36 2547 ± 141 
153 S 2-F 4-Me H 201.3 ± 18.7 0.37 2084 ± 109 
154 S 2-F 4-OMe (R)-CO2H 10.4 ± 0.5 0.38 82 ± 3 
155 S 2-F 4-OMe H 11.6 ± 3.7 0.42 489 ± 26 
156 S 3-F 4-OMe H 162.2 ± 15.6 0.36 1892 ± 134 
157 S 3-Cl 4-Cl H 35.2 ± 4.9 0.41 1993  343 
158 S 3-Me 4-Me (R)-CO2H 1.2 ± 0.1 0.43 72 ± 8 
159 S 3-Me 4-Me H 25.7 ± 6.3 0.41 729 ± 43 
160 S 3-Et 4-Me (R)-CO2H 4.6 ± 1.7 0.39 34 ± 2 
161 S 3-Et 4-Me H 6.9 ± 3.6 0.43 1045 ± 42 
162 S 3,4-(CH2)4 (R)-CO2H 2.1 ± 0.5 0.40 56 ± 2 
163 S 3,4-(CH2)4 H 7.1 ± 2.6 0.41 934 ± 127 
232
a
 CH2 2-F 4-OMe H 37.9 ± 4.7 0.39 764 ± 42 
rac-176 CH2 3-Me 4-Me CO2H 12.4 ± 0.4 0.38 23.4 ± 1.8 
Notes:
 a 
= prepared by Dawid Podgórski.
222
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3.2.3.2. Thioethers with dialkyl phenyl substituents.   
Crystallographic and SAR data also implied that further expansion was possible into the P3 
pocket.  A β-napthyl derivative of STLC had demonstrated strong activity against both Eg5 
and HeLa cells, and docking studies had indicated the bicyclic ring was most likely to be 
situated in the P3 cavity (11, Table 1).
130
  This compound had suffered from poor aqueous 
solubility (turbimetric solubility = 37.5 µM) and in addition naphthalene is a known 
toxicophore.
226
  This observation correlated with the Ki
app
 estimates ≤ 30 nM displayed by 
thioethers substituted with m-(i-propyl) or p-ethoxy groups (108 and 119, Table 10); again 
however both these derivatives displayed weak cellular growth inhibition primarily due to 
poor aqueous solubility (section 3.2.1.2).  Thioethers 152-156 with dialkylphenyl 
substitutents were prepared to investigate whether further pharmacodynamic improvements 
could be achieved, whilst maintaining a physicochemical profile conducive to overall 
efficacy (Table 12).
176
  Excellent inhibitory activity was evident on combining m-ethyl and 
p-methyl substituents (161), and also in the tetralene analogue 163: both of which 
demonstrated Ki
app 
estimates
  ≤ 10 nM.  Substantial improvements were realised upon 
introduction of the terminal α-carboxylic acid, with an estimated Ki
app
  1 nM for the 
dimethylphenyl analogue 158 against Eg5.  In contrast to their potency in the Eg5 basal 
activity assay, the dialkylphenyl analogues 159, 161 and 163 without the carboxylate were 
disappointingly weak inhibitors of cellular growth.  Evaluation of the aqueous solubility of 
38 and 40 demonstrated both were poorly soluble, implying physicochemical limitations 
were the cause of their reduced cellular efficacy (turbidimetric solubility at pH 7.4: 38 = 
3.75 M; 40 = 3.75 M).  The presence of the carboxylic acid ameliorated this: in addition 
to low nanomolar activity against Eg5, the amino acid containing analogues 158, 160, and 
162 all exhibited GI50 values < 100 nM against the K562 cell line.  The most potent of 
these contained both a m-ethyl and p-methyl substituent on the phenyl ring (160): the GI50 
value reported (GI50= 34 nM) represents an impressive ~ 30-fold improvement over 161 
without the carboxylic acid, and is ~ 40-fold more active than STLC 6.  These are the most 
active S-trityl based inhibitors of Eg5 reported, thereby suggesting the optimal balance 
between lipophilicity and physicochemical properties has been achieved for this scaffold.  
The presence of the carboxylic acid is beneficial for both Eg5 inhibition and cellular 
activity in these examples: the main contribution of the carboxylate is apparently to 
enhance aqueous solubility.  However, S-alkylated derivatives of cysteine were first 
designed as anticancer agents following the observation that radiolabelled cysteine was 
incorporated by leukemic white blood cells.
123, 124
  Therefore the involvement of active 
transport cannot be discounted.   
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3.2.3.3. Triphenylbutanamines with dialkylphenyl substituents 
To investigate whether further gains in binding affinity were achievable, the optimal 
dialkyl phenyl modifications were combined with the triphenylbutanamine scaffold.  The 
poor aqueous solubility of tetralene analogue 162, even with the addition of the carboxylic 
acid precluded continuing with this modification (turbidimetric solubility at pH 7.4 = 20 
M).  While 160 was the most potent in the cellular assay, the superior physicochemical 
properties and exquisite enzymatic potency of 158 marked this as the optimal 
dialkylphenyl substitution pattern.  The zwitterionic triphenylbutanamine analogue rac-176 
was less potent in the enzymatic assay, but significantly a 3-fold improvement in the 
cellular assay was afforded over the S-trityl analogue 158, and the most active 
triphenylbutanamines previously reported (224 and 228, Table 11).
138
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3.2.4. Hydrophilic modifications to the trityl head group.   
3.2.4.1. Rationale 
All the modifications to the trityl group described so far increased its hydrophobicity, 
which in certain cases compromised cellular efficacy due to poor aqueous solubility 
(section 3.2.3).  In addition to this immediate drawback, excessively lipophilic (i.e. log 
P/log D7.4 > 3) compounds are more likely to possess unfavourable ADME properties, and 
bind more promiscuously, which is likely to result in greater side effects and general 
toxicity.
176
  Therefore it was important to investigate parameters which were not based 
solely on improving the lead analogues through lipophilicity, but also through increasing 
the hydrophilicity of the trityl head group.
227
   
3.2.4.2. Thioethers with hydrophilic phenyl substituents  
On examining the available crystallographic data, several potential hydrophilic vectors 
emanating from the trityl group presented themselves.  Crystallographic studies on STLC 
and related analogues had established that the phenyl ring in P1 π-stacked with the nearby 
phenol of Tyr 211, and that its leading edge both faced the nearby the acidic residue 
Glu215 and was exposed to the bulk solvent (Figure 14 and Figure 15).
132
  Furthermore, 
the crystal structures of other ligands bound to Eg5 had revealed small polar substituents 
like the m-hydroxy group in (S)-monastrol 4 hydrogen bonds with the amide main chain 
oxygen  of Glu118 in the P2 pocket.
97
  A series of thioethers was prepared containing 
hydrophilic phenyl substituents designed to target these interactions (123-142, Table 13).  
The only compound to improve upon basal Eg5 inhibitory activity over STLC was the m-
hydroxy STLC analogue 124, which suggested hydrogen bonding similar to that observed 
in the crystal structures for dihydropyrimidine-Eg5 ternary complexes was being 
achieved.
24, 25
  The direct analogue 125, which differed only by the absence of the 
carboxylic acid in the tail, while 4-fold less potent in the basal assay, was 5-fold more 
potent than 124 in the cellular assay.  This can be attributed to the difference in cell 
permeability resulting from the dual presence of the carboxylic acid and phenol.  
Evaluation of the passive in vitro cellular permeability by parallel artificial membrane 
permeability assays (PAMPA) demonstrated 125 to have higher permeability (Papp = 16.7 ± 
2.6 x 10
-6
 cm s
-1
), with no permeability recorded for 124.  All other compounds in this 
series displayed moderate inhibition of the basal activity of Eg5, but were generally similar 
in cellular activity to 16 which demonstrated a wide tolerance for polar substrates.  Not 
surprisingly, aside from 124 and 125, given the lower basal activities and relatively bulky 
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substituents all compounds were less efficient ligands than the comparative starting points 
6 and 16.  A modest ~ 2-fold improvement in K562 cellular activity was observed for the 
meta-primary and secondary amides 131 and 132 c/f STLC, although their Eg5 inhibitory 
activity was reduced 2-fold and 4-fold respectively.  Similarly, the p-CH2OH containing 
compound 136 had improved cellular activity, but reduced Eg5 inhibitory activity.  This 
could suggest their improved cellular activity is being expressed through an alternative 
mechanism to Eg5 inhibition.  The m-primary amide derivative 130, which has the 
carboxylic acid group in the tail had similar Eg5 inhibitory activity to 131, but significantly 
reduced cellular activity (32-fold less than 131 and 18-fold less than STLC), probably due 
to a very low log D (log D7.4 for 130 = 1.13; c/f log D7.4 for 131 = 1.41).  Measurement of 
the cell permeability by PAMPA assays found 131 to possess high permeability of (Papp = 
42.8 ± 15.0 x 10
-6
 cm s
-1
), while no membrane diffusion was detected for 130 when 
evaluated by this method.  Thus, the dual presence of the trityl amide modification and 
carboxylate is incompatible with effective cell penetration, similar to the observations 
made for the phenol and carboxylate.  In summary, although a penalty in basal activity and 
ligand efficiency is incurred, hydrophilic modifications to the trityl group such as m-
primary or secondary amide substituents can potentially act as alternatives to the terminal 
carboxylic acid.    
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Table 13 – STLC analogues with one hydrophilic trityl substituent 
 
Cmpd R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
123 2-OH (R)-CO2H 1978.5 ± 587.3 0.29 n.d. 
124 3-OH (R)-CO2H 48.8 ± 22.0 0.37 2559 ± 302 
125 3-OH H 200.3 ± 51.9 0.38 555  121 
126 3-CN H 450.6 ± 197.4 0.35 2128 ± 108 
127 3-CH2NH2 H 838.2 ± 164.1 0.33 2018 ± 244 
128 3-CH2NHCOMe H 829.2 ± 100.5 0.30 2133 ± 135 
129 3-CO2H H 990.6 ± 156.9 0.31 2138 ± 241 
130 3-CONH2 (R)-CO2H 329.9 ± 49.2 0.30 16749 ± 6112 
131 3-CONH2 H 419.7 ± 38.8 0.33 802 ± 51 
132 3-CONHMe H 887.8 ± 74.9 0.31 982 ± 72 
133 3-CONMe2 H 6055.6 ± 1123.0 0.25 2831 ± 171 
134 3-SO2Me H 2089.6 ± 246.6 0.29 2559 ± 180 
135 4-CN H 432.4 ± 91.2 0.35 2178 ± 149 
136 4-CH2OH H 311.2 ± 31.8 0.35 783 ± 50 
137 4-CH2NH2 H 2942.4 ± 782.8 0.30 2594 ± 191 
138 4-CH2NHCOMe H 1721.3 ± 294.5 0.28 2904 ± 150 
139 4-CONH2 H 3228.6 ± 447.4 0.29 4335 ± 341 
140 4-CONHMe H 2030.8 ± 671.6 0.29 3954 ± 293 
141 4-CONMe2 H 1526.7 ± 359.7 0.28 2911 ± 271 
142 4-SO2Me H 1212.1 ± 179.9 0.30 2735 ± 482 
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3.2.4.3. Heterocycles in the trityl group 
An alternate way to reduce lipophilicity was to replace a phenyl ring in the trityl group 
with small alkyl groups (12-14, Table 14).
130, 137
  The structure of one such analogue 
complexed with Eg5 was solved and depicted the sec-butyl replacement for the phenyl ring 
positioned in the solvent exposed P1 pocket.
137
  We postulated that a heterocyclic moiety 
situated in this region could undergo enthalpically favourable - -stacking with the 
proximal Tyr 211 phenol,
139
 whilst improving the physicochemical attributes of the trityl 
group by reducing the overall lipophilicity and potentially interacting with water in the 
solvent exposed pocket.  Unfortunately pyridyl, thiazole and oxazole derivatives prepared 
to investigate this premise were all weak inhibitors of Eg5 in the basal assay, and only 
modestly active in the cellular assay (143-145, Table 14).  This corroborated with the weak 
activity recorded for a 2-thienyl STLC derivative from the NCI library, and 4-pyridyl 
analogues of STLC recently reported by Abualhasan et al.
137, 139
  Collectively, these 
findings indicate that the tested heterocycles are not well tolerated in the Eg5 binding site 
when incorporated into the STLC scaffold.   
Table 14 – STLC analogues with heterocycles in the trityl group 
 
Cmpd R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
143 3-Pyridyl H 1460.7 ± 73.4 0.36 2442 ± 147 
144 2-(1,3)-Thiazole H 3584 ± 381.0 0.39 3750 ± 165 
145 2-(1,3)-Oxazole H 3013.3 ± 163.0 0.29 2312 ± 122 
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3.2.5. Analogues with two modified phenyl rings 
3.2.5.1. Basal Eg5 activity inhibition by analogues with two modified phenyl rings 
One potential explanation for the poor activity exhibited by the thioethers 123-142 with 
hydrophilic trityl substituents was that these analogues did not bind as proposed.  If the 
hydrophilic substituents were situated in the hydrophobic P3 pocket, rather than either the 
solvent exposed P1 area or the P2 pocket with the potential to form hydrogen bonding 
interactions, this could explain the diminished affinity with Eg5.  To investigate, a series of 
thioethers was prepared that incorporated a combination of the optimal hydrophobic and 
hydrophilic phenyl substituents onto discrete rings in the trityl group with the aim driving 
the more lipophilic phenyl into the P3 pocket (146-151, Table 15).  This would leave the 
more hydrophilic phenyl group to bind in either of the remaining pockets and therefore 
potentially produce a synergistic increase in inhibitory activity.  This was not the case for 
rac-147 containing both m-phenol and m-chlorophenyl modifications, which exhibited 
poor basal inhibition, whereas related m-phenol analogues rac-148 and rac-149 with 
discrete m-ethyl and p-methyl substituents were ~ 2-fold and 4-fold more potent inhibitors 
of basal Eg5 activity, in comparison to their respective analogues 107 and 116.  This 
implied a synergistic binding motif was being realised through hydrogen bonding 
interactions in P2 from the phenol and improved hydrophobic interactions in P3 by the 
more hydrophobic phenyl ring.  Improvements in Eg5 inhibitory activity were also seen 
when a p-tolyl was combined with a second phenyl containing either an m-cyano or m-
primary amide substitiuents (rac-150 and rac-151).  The more hydrophilic phenyl group 
for these two compounds is more likely to be positioned in the solvent exposed P1 region 
because the relatively large hydrophilic substituents would not be accommodated in the P2 
pocket, since this area is sterically restrained and can only accept a small hydroxyl 
group.
162, 224, 228
     
 
  
  
109 
 
Table 15 – STLC analogues with modifications to two phenyl rings. 
 
Cmpd X R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
125 S 3-OH H 200.3 ± 51.9 0.38 555  121 
126 S 3-CN H 450.6 ± 197.4 0.35 2128 ± 108 
130 S 3-CONH2 H 419.7 ± 38.8 0.33 802 ± 51 
102 S 3-Cl H 297.8 ± 60.0 0.37 1045  42 
107 S 3-Et H 5.9 ± 2.3 0.45 680  84 
116 S 4-Me H 27.4 ± 0.7 0.43 731 ± 36 
229 CH2 4-Me H 16.4 ± 1.9 0.44 219  21 
146 S 4-Me 4-Me 56.0 ± 5.0 0.40 2174 ± 119 
rac-147 S 3-OH 3-Cl 200.3 ± 35.3 0.37 1662 ± 77 
rac-148 S 3-OH 3-Et 3.7 ± 0.8 0.44 260 ± 19 
rac-149 S 3-OH 4-Me 7.1 ± 1.8 0.44 98 ± 6 
rac-150 S 3-CN 4-Me 64.2 ± 5.2 0.38 1186 ± 34 
rac-151 S 3-CONH2 4-Me 55.6 ± 8.0 0.37 308 ± 16 
rac-233
a
 CH2 3-OH 4-Me 33.6 ± 6.4 0.41 232 ± 24 
Notes:
 a 
= prepared by Fang Wang.
222
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3.2.5.2. Cellular growth inhibition by analogues with two modified phenyl rings 
Reflective of its poor Eg5 inhibition, the m-chlorophenyl/m-phenol analogue rac-147 was 
weakly active in the cellular assay (Table 15).  However all analogues with modifications 
on two phenyl rings that exhibited improved basal inhibition over their comparable 
benchmarks were also more efficacious in the K562 assay.  The m-phenol/m-ethylphenyl 
and m-phenol/p-tolyl analogues rac-148 and rac-149 improved ≥ 2-fold and ≥ 5-fold 
respectively over their comparable mono substituted counterparts 107, 116 and 125.  With 
GI50  100 nM, rac-149 is the most potent thioethanamine analogue not including the 
terminal carboxylic acid in the cellular assay, and is ~ 15-fold more active than STLC 6 
against the K562 cell line.  Interestingly, the comparable CH2-trityl analogue (rac-233) 
was less active against both Eg5 and the K562 cell line than either rac-149 or the 
structurally related triphenylbutanamine 229.  These compounds (147-151) were prepared 
as racemic mixtures which suggested further gains in affinity were possible.  However, the 
m-phenol modification was not pursued after concerns were raised over its metabolic 
stability.  The high clearance
229
 of rac-149 c/f other lead candidates (section 3.4.1.2) was 
confirmed in an in vitro human hepatocyte assay (Clint  = 50.1 ± 4.2 L/min/million cells; 
t½ = 27.7 min).  The cyano-substituted rac-150 demonstrated a 2-fold improvement over 
the comparable mono-substituted derivative 126, but was still only active in the 
micromolar range.  A similar improvement was also displayed by m-primary amide 
substituted rac-151 over its mono-substituted counterparts 116 and 130.  The synergistic 
increases in activity support the proposed binding mode with the p-tolyl occupying the P3 
pocket and the m-amide situated in the P1 region for rac-151, and confirm this amide 
substituent as a potential alternative hydrophilic modification to the terminal α-carboxylate 
in STLC.   
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3.2.5.3. Crystal structure of the Eg5 – rac-148 complex 
The crystal structure of rac-148 complexed to Eg5 was solved to a resolution of 2.65 Å by 
Kristal Kaan, and provided structural confirmation for the proposed binding mode (Figure 
24).
222
  The inhibitor adopts the same overall conformation seen in STLC and related 
analogues, with the three phenyl rings occupying the defined P1-P3 pockets.
132, 137, 138
  
Interestingly, although the racemic mixture of 148 was employed, electron density was 
only observed for the (R)-enantiomer, implying this is more stable.   The two phenyl 
substituents could be easily identified, and a structural rationale provided for the increased 
potency of rac-148.  In the P2 pocket, the m-hydroxy substituted phenol forms a hydrogen 
bond with the main chain carbonyl of Glu118, in an identical manner to that observed in 
the structures of monastrol (4) and structurally related dihydropyrimidines.
97, 230
   The m-
ethyl substituent is situated into the P3 pocket bounded by Leu160, Gly217, Ala218, 
Arg221, with the terminal CH3 occupying previously unutilised space between the methyl 
of Ala218 and the aliphatic chain of Arg221.  These improved hydrophobic contacts may 
explain the improved activity against Eg5 by ligands incorporating this substituent (e.g. 
107 and 160).  In the thioethanamine chain, the primary amine maintains the crucial 
hydrogen bonds exhibited in all STLC analogues with the carboxylate of Glu116 and the 
main chain amide carbonyl of Gly117.
132, 136
  In summary, this crystal structure provides a 
valuable structural validation for the rationale beneath the SAR improvements 
implemented.   
  
112 
 
 
Figure 24 – Eg5-rac-148 crystal structure showing (R)-148 in the inhibitor-binding pocket. 
The protein side chains are coloured by atom type: white (C), blue (N) and red (O).  The (R)-148 ligand 
is coloured by atom type: turquoise (C), blue (N), red (O) and yellow (S).  Hydrogen bond interactions 
between the protein and inhibitor are represented by dashed lines.  Modified from reference 222.   
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3.2.6. Modifications to the amino acid tail  
3.2.6.1. β-Fluorination to modulate amine basicity 
The p-methoxy triphenylbutanamine analogue 181 without the carboxylic acid had 
exhibited excellent potency in both the basal and cellular assays (Table 11), and was a 
potential backup candidate to the lead dialkylphenyl analogues (Table 12).  However, 
profiling of the comparable m-methylphenyl analogue 225 revealed several potentially 
significant toxicological interactions in analogues without the carboxylic acid, such as 
hERG and inhibition of common CYP isoforms.
138
  Therefore, we examined whether in the 
DMPK profile for this analogue could be improved by modulating the basicity of the 
primary amine through -fluorination.231, 232  Although a common strategy to overcome 
hERG liabilities is alkylation of a primary amine, the necessity of the primary amine in the 
STLC scaffold to form three hydrogen bonds had already been demonstrated.
137
  -
Fluorination represented a more subtle approach, and 182-184 were prepared as tool 
compounds to investigate this strategy (Table 16).  While good inhibitory activity was 
retained in the basal assay for the mono-fluorinated analogue 182, a > 10-fold reduction 
was recorded for the difluorinated 183 and activity abolished to micromolar levels for the 
α-trifluoro containing 184.  Evaluation in the cellular assay revealed an ~ 8-fold drop in 
activity for the mono-fluorinated 182 c/f the benchmark 181, with micromolar activity for 
the difluorinated 183 and no apparent inhibition by 184.  Measurement of the pKa values of 
181-184 revealed a variation of over 5 log units as the number of fluorine atoms in the -
position increased.  While these results reinforced the importance of the protonation state 
of the amine, and its subsequent ability to form three hydrogen bonds, the pKa of the NH2 
group in the zwitterionic amino acid moiety of 158 is equivalent to that in the -
difluorinated primary amine 183 (section 3.4.1.1.).  This indicates that additional factors 
contributed to the reduced cellular efficacy.  However, as useful efficacy was not 
demonstrated by these analogues, this was not investigated further.     
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Table 16 – -Fluorinated analogues of 4-(4-methoxyphenyl)-4,4-diphenylbutan-1-amine 181. 
 
Cmpd R
1
 R
2
 pKa 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
181
a
 H H 9.86 ± 0.05 7.9 ± 3.4 0.44 83 ± 4 
rac-182 F H 7.86 ± 0.07 27.3 ± 1.2 0.40 652 ± 61 
183
a
 F2 H 7.11 ± 0.05 88.4 ± 1.9 0.36 2624 ± 379 
rac-184 H CF3 4.63 ± 0.10 2268 ± 39.1 0.27 >100000 
Notes: 
a 
= prepared by Fang Wang.
222
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3.2.6.2. Bioisosteric replacements for the carboxylic acid to overcome Pgp efflux 
At the onset of lead optimisation, a known liability of STLC and related analogues was 
their efflux by the MDR related Pgp transporter.
137, 139
   The physiological relevance of Pgp 
efflux to cancer therapy has yet to be fully deciphered, and it is not as likely to play as 
important a role in drug efficacy as intrinsic activity and advantageous DMPK 
characteristics (section 1.3.4.2).
32, 145
  However, it is a pathway of resistance known to 
affect several classes of existing chemotherapy drugs and for Eg5 inhibitors to provide 
therapeutic benefits over existing treatments, it was therefore desirable to develop 
strategies to circumvent or reduce efflux by the Pgp transporter.  The carboxylic acid had 
been identified in preceding investigations as the critical structural feature in STLC for 
determining whether uptake and efflux by Pgp would occur.
137, 139
  A direct approach to 
ameliorating extracellular Pgp-mediated efflux was therefore to replace the carboxylic acid 
with a suitable bioisostere.  In the crystal structure of STLC, the carboxylate forms a 
hydrogen bonding interactions with the Arg221 guanadinium and to the bulk solvent.
132, 136
  
MD calculations had contrastingly demonstrated that the enthalpy from binding with Eg5 
was unfavourable for the carboxylate because of repulsion from the anionic diphosphate of 
the neighbouring nucleotide.
139
  In combination with the SAR established for the most 
active ligands (section 3.2.3), this supported the hypothesis that the principle contribution 
of the carboxylic acid to enhancing efficacy is by improving physiochemical parameters.  
To investigate whether improved interactions with Eg5 could be achieved through 
optimising interactions in this region, a number of analogues incorporating amide 
replacements for the carboxylic acid were prepared (Table 17).  Replacement of the entire 
amino acid zwitterion with a primary amide in 210 resulted in an abolition of inhibitory 
activity, reinforcing the prerequisite of the amine moiety to form three hydrogen bonds.
132, 
137
  The primary amide replacements for the carboxylate (215) proved equivalent to STLC 
in the basal assay, and improved in the cellular assay.  This result agrees with the findings 
of Ogo et al. who evaluated this isostere against Hela cells and found 215 more active than 
STLC.
141
  This perhaps surprising result suggests a primary amide replacement for the 
carboxylate can function as a bioisostere in the Eg5 binding site.  Other bulkier secondary, 
tertiary and Weinreb amide replacements for the carboxylate (216-218) were less active 
against Eg5 than STLC, and whilst a reduction in intrinsic affinity was tolerable if 
improved activity was accomplished in Pgp overexpressing systems, these analogues were 
also disappointingly weak in the cellular assay.  A number of conventional isosteres for a 
carboxylic acid were also tested.
233
  Whilst the hydroxamic acid derivative 220 displayed 
reasonable basal Eg5 inhibition, only weak activity in the cellular assay was apparent.  The 
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tetrazole CH2-trityl based analogue rac-235 demonstrated reasonable inhibition in the 
enzymatic assay; again however this did not translate into the cellular assay, with an 8-fold 
decrease in potency when compared to the amino acid rac-231.  Similar levels of basal 
inhibition to rac-231 were displayed by the amino alcohol rac-234.  Satisfyingly, rac-234 
did maintain reasonable levels of growth inhibition in the cellular assay, in agreement with 
recent findings for cysteinol based STLC derivatives reported by Rodriguez et al.
234
 
 
Table 17 – STLC analogues incorporating carboxylate isosteres. 
 
Cmpd X R
1
 R
2
 
Inhibition of basal 
ATPase activity 
Ki
app
 (nM) 
L.E. 
K562 cells 
GI50 (nM) 
6 (STLC) S H (R)-COOH 135.9 ± 20.5 0.36 1452  76 
rac-231 C 4-OMe (R)-COOH 7.2 ± 2.2 0.35 94 ± 8 
210 S H 
 
n.i. n/a >100,000 
215 S H (R)-CONH2 133.2 ± 1.6 0.36 1064 ± 48 
216 S H (R)-CONHMe 359.2 ± 26.6 0.33 5012 ± 218 
217 S H (R)-CONMe2 249.3 ± 7.2 0.32 5916 ± 319 
218 S H (R)-CONMeOMe 429.3 ± 27.2 0.30 6918 ± 601 
220 S H (R)-CONHOH 298.2 ± 19.3 0.30 13152 ± 575 
rac-234
a
 CH2 4-OMe CH2OH 4.5 ± 2.9 0.42 192 ± 18 
rac-235
a
 CH2 4-OMe Tetrazole 20.6 ± 3.1 0.35 826 ± 55 
Notes: n.i. = no inhibition; n/a = not applicable; 
 a 
= prepared by Fang Wang.
222
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3.3. Further in vitro characterization 
3.3.1. Inhibition of microtubule stimulated Eg5 ATPase activity 
A selection of the most active compounds were evaluated for their inhibition of the 
microtubule-stimulated (MT-stimulated) ATPase activity of Eg5 (Table 18).  This assay 
provides a more accurate estimate of the Ki
app
, since the activity of Eg5 is increased in the 
presence of microtubules which allows lower concentrations of Eg5 to be employed than in 
the basal assay (~ 5 nM c/f ~ 80 nM).
235
   Differences were apparent for the 
dimethylphenyl thioethanamine analogue 158, which was much less potent than was 
observed in the basal assay (MT-stimulated Ki
app  50 nM c/f basal Ki
app 1 nM).  In 
general however, the results are in good agreement with the strong inhibitory activity 
demonstrated in the basal assay, with the most potent analogue 160 (Ki
app
 2.4 ± 0.4).   
Table 18 – Evaluation of MT-stimulated inhibitory activity of lead inhibitors.   
 
 
Cmpd X R
1
 R
2
 R
3
 
Inhibition  
of basal  
ATPase activity 
Ki
app
 (nM) 
Inhibition of  
MT-stimulated  
ATPase activity 
Ki
app
 (nM) 
6 (STLC) S H H (R)-COOH 135.9 ± 20.5 143.8 ± 21.6 
154 S 2-F, 4-OMe H (R)-COOH 10.4 ± 0.5 28.8 ± 1.0 
158 S 3-Me, 4-Me H (R)-COOH 1.2 ± 0.1 49.9 ± 2.6 
160 S 3-Et, 4-Me H (R)-COOH 4.6 ± 1.7 2.4 ± 0.4 
162 S 3,4-(CH2)4 H (R)-COOH 2.1 ± 0.5 13.9 ± 1.3 
rac-176 CH2 3-Me, 4-Me H COOH 12.4 ± 0.4 7.3 ± 0.9 
rac-149 S 4-Me 3-OH H 7.1 ± 1.8 9.7 ± 1.8 
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3.3.2. Specificity of rac-176 amongst kinesins 
To evaluate the specificity of the new analogues amongst human kinesins, one of the most 
active, the triphenylbutanamine rac-176 which incorporated a dimethylphenyl, was 
examined against a panel involved in both mitosis and intracellular transport (Table 19).
51, 
59
  Significant inhibition was not recorded of any of the kinesins examined at the 
concentrations tested, in agreement with the reported selectivity by STLC for Eg5 (section 
Table 19).
104, 129
    
Table 19 – Effect of rac-176 on the activity of other human kinesins.   
Kinesin 
Kinesin 
family 
Inhibition of basal 
ATPase activity 
Ki
app
 (M) [MIA (%)] 
Inhibition of MT-stimulated 
ATPase activity 
Ki
app
 (M) [MIA (%)] 
Kif5A
a
 Kinesin 1 n.i. (10) n.i. (10) 
Kif5B
b
 Kinesin 1 n.i. (5) n.i. (5) 
Kif3B Kinesin 2 n.i. (5) n.i. (20) 
MKLP-2
c
 Kinesin 6 n.i. (5) n.i. (10) 
MPP1
d
 Kinesin 6 n.i. (10) n.i. (15) 
Kif7 Kinesin 7 n.i. (5) n.i. (5) 
Kif9 Kinesin 9 n.i. (5) n.i. (20) 
Notes: MIA = maximum inhibitory activity observed.  n.i. = no inhibition.  
a
 = a.k.a. neuronal kinesin 
heavy chain; 
b
 = a.k.a. conventional kinesin, kinesin heavy chain; 
c
 = a.k.a. Kif20A, RabK6; 
d
 = Kif20B, 
MPHOSPH1, KRMP1.    
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3.3.3. Evaluation of lead analogues across multiple cell lines 
The most promising lead compounds were evaluated in a panel of five additional tumour 
cell lines derived from colon, breast, pancreatic and prostate cancers (Table 20).  STLC 
was included as a control, and selected triphenylbutanamines from the study by Wang et 
al,
138
 whilst to benchmark against external controls the Phase II clinical candidate ispinesib 
(21) and its second generation analogue SB-743921 (22) were evaluated.   The activity of 
the CH2-trityl linker was broadly comparable to STLC, apart from in the K562 cell line, 
reinforcing the observation that the most significant gains in potency were realised on 
incorporation of lipophilic trityl substituents (e.g. (R)-228 c/f 6).  The most potent 
triphenylbutanamine analogue (R)-228 with a p-methyl substituent was ~ 10 fold more 
active across comparable cell lines than the unsubstituted 6.  The S-trityl analogues 158, 
160 and 162 containing a dialkylphenyl displayed excellent potency across all cell lines: 
the m-ethyl, p-methylphenyl analogue 160 was the most potent STLC analogue in the 
pancreatic and LNCap prostate cancer derived cell lines.  Its activity was only surpassed by 
the CH2-trityl dimethylphenyl rac-176, which was more active in the HCT116, K562 and 
PC3 cell lines.   Between them, 160 and rac-176 bettered or matched the activity of the 
Phase II clinical candidates 21 and 22 in all of the cell lines, except HCT116.   The m-
phenol containing rac-149 also displayed good potency across most cell lines 
demonstrating that increases in activity were achievable through discrete modifications to 
the trityl group.   
 
 120 
Table 20 – Testing of selected analogues for growth inhibition of colon (HCT116), human leukaemia (K562), lung (NCI-H1299), pancreas (BxPC3) and prostate (LNCap and 
PC3) tumour cell lines. 
Cmpd 
HCT116 
GI50 (nM) 
K562 
GI50 (nM) 
NCI-H1299 
GI50 (nM) 
BxPC3 
GI50 (nM) 
LNCap 
GI50 (nM) 
PC3 
GI50 (nM) 
1 (STLC) 553 ± 57 1452  76 1549 ± 111 1563 ± 155 811 ± 116 1371 ± 96 
(R)-221
a
 472 ± 20 776 ± 26 1324 ± 55 1119 ± 138 n.d. n.d. 
(R)-228 40 ± 2 82 ± 4 111 ± 6 85 ± 12 32 ± 2 58 ± 4 
181 33 ± 2 83 ± 4 158 ± 10 168 ± 12 60 ± 6 158 ± 11 
154 114 ± 8 82 ± 3 325 ± 45 77 ± 15 93 ± 8 94 ± 10 
158 63 ± 9 72 ± 8 111 ± 10 124 ± 29 34 ± 6 73 ± 8 
160 34 ± 3 34 ± 2 39 ± 2 26 ± 6 9.2 ± 1.2 27.3 ± 2.3 
162 39 ± 2 56 ± 2 101 ± 9 53 ± 5 31 ± 2 43 ± 5 
rac-176 28 ± 2 23.4 ± 1.8 41 ± 3 44 ± 10 11.4 ± 0.8 21 ± 1 
rac-149 91 ± 10 98 ± 6 221 ± 16 427 ± 85 97 ± 10 258 ± 24 
21 (Ispinesib)
a
 25 ± 3 48 ± 4 82 ± 10 80 ± 15 22 ± 4 50 ± 5 
22 (SB743921) 9.7 ± 0.8 24 ± 1 35 ± 7 25 ± 4 15 ± 3.5 21.2 ± 2.4 
Notes: n.d. = not determined;
 a 
= from reference 138.  All other data modified from reference 222. 
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3.3.4. Evaluation of the MDR ratio for selected new inhibitors 
3.3.4.1. The effect of the CH2-trityl linker 
The MDR ratios of a representative panel of inhibitors were evaluated to compile an SAR 
portfolio for Pgp efflux (Table 21).  As a positive control, the known Pgp substrate 
vinblastine was included, and STLC and the thioethanamine analogue 16 were included as 
internal control compounds.  In agreement with previous results obtained from LLC-PK1 
and MDCKII and matched Pgp overexpressing cell lines L-MDR1 and MDCKII-MDR1, 
STLC had an MDR ratio of 42, whereas 16 without the carboxylic acid had an MDR ratio 
of 1.1.
137
  The CH2-trityl modification proved detrimental to activity in the Pgp 
overexpressing KB-V1 cell line: the zwitterionic rac-221, rac-224 and rac-228 exhibited 
2-fold worse MDR ratios than STLC, both displaying decreases in activity from < 100 nM 
in the parental cell line to > 5 μM in the Pgp overexpressing cell line.  The higher ratios 
evident for CH2-trityl versus S-trityl analogues may reflect the increase in the respective 
strengths of the acid and amine moieties.
138
  The increase in the ionised population would 
decrease the passive membrane diffusion, which may allow for the efficiency of Pgp 
mediated efflux to be increased resulting in a greater MDR ratio for these analogues.
144
  
Whilst Pgp is not intrinsically stereospecific,
142, 144
 selectivity was evident in the 
triphenylbutanamine series, with the (S)-enantiomers exhibiting greater decreases in 
activity in the KB-V1 assay than their (R)-enantiomers [e.g. (R)-228, MDR ratio = 92; (S)-
228, MDR ratio = 69], in agreement with prior observations made for STLC and STDC.
137
  
Removal of the α-carboxylic acid from the amino acid tail in the CH2-trityl series restored 
activity in the KB-V1 cell line, with submicromolar activity evident for 181 and 225.  This 
data illustrates that whilst the CH2-trityl linker contributes to the MDR ratio, it is not 
intrinsically incompatible with avoiding efflux.  The presence of the carboxylate remains 
the decisive factor in determining the overall rate efficacy of Pgp efflux in the 
overexpressing KB-V1 cell line.   
3.3.4.2. Modifications to the trityl group  
While the S-trityl analogue 160 displayed a comparable MDR ratio to STLC, the other 
dialkylphenyl substituted analogues 158 and 160 with the carboxylic acid had improved 
MDR ratios.  Thus the increased lipophilicity of 158 and 160 c/f 6 appeared to reduce their 
uptake through increased passive diffusion through the cell membrane, although why the 
same did not apply to 160 is not clear.  Interestingly, the excellent potency of the m-ethyl, 
p-methylphenyl analogue 160 meant that even with > 35 fold reduced activity, it still 
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registered ~ 1 M growth inhibition activity against the KB-V1 cell line.  This indicates 
that even small reductions in the MDR ratio for the most potent compounds would restore 
activity to acceptable levels and render Pgp efflux less of an issue for STLC based 
inhibitors.  The CH2-trityl dimethylphenyl analogue rac-176 exhibited the highest 
measured MDR ratio of all, confirming the CH2 modification as detrimental.  Although 
alkyl trityl substituents had a limited effect on the MDR ratio, the p-methoxy trityl 
substituent appeared to substantially increase the MDR ratio: e.g. 181 has an MDR ratio ~ 
3-fold worse than the comparable m-methyl substituted 225.  This agrees with prior SAR 
studies on Pgp which highlighted ethers as a common motif in accentuating recognition 
and transport.
144
  This may relate to increased aqueous solubility through the increased 
polar surface area slowing passive membrane diffusion and allowing increased uptake by 
Pgp.  The meta-primary amide analogue 131, which had been investigated as a potential 
replacement for the terminal α-terminal acid, had a greater MDR ratio than STLC.  Phenol 
containing analogues rac-148 and rac-149 proved moderate substrates, with MDR ratios of 
9.1 and 12.0 respectively.   
3.3.4.3. Modifications to the amino acid tail 
The strategies designed to modulate the properties of the amino acid tail proved generally 
successful at ameliorating Pgp efflux.  -Fluorinated amine analogue 182 displayed 
comparable potency across both the parental KB-3-1 and overexpressing KB-V1 cell lines.  
This confirmed proximal fluorination of the primary amine in STLC as a valid strategy to 
modulate DMPK properties, and one which could be employed to reduce Pgp efflux.  For 
the carboxylate isosteres and replacements, the activity of the tetrazole rac-234 was 
abolished, and the -amino alcohol analogue rac-135 similarly was subject to a high MDR 
ratio.   The weakly active amide analogues 216-218 were not subject to Pgp efflux, but 
their weak activity precluded their further use.  Most notably, the primary amide isostere 
215 displayed a low MDR ratio of 4.  Whilst still only weakly active in the KB-V1 cell line 
(~ 2 M), this represents a 10-fold improvement in activity on its direct analogue STLC.  
Thus, a primary amide represents a viable bioisosteric replacement for the carboxylic acid 
to alleviate Pgp-mediated efflux.     
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Table 21 – Determination of MDR ratios of STLC analogues with modifications to the trityl group. 
Cmpd 
KB-3-1` 
EC50 (nM) 
KB-3-1+Z 
EC50 (nM) 
KB-V1 
EC50 (nM) 
KB-V1+Z 
EC50 (nM) 
MDR ratio 
6 1094 ± 212 1002 ± 195 36982 ± 5200 922 ± 62 42 
16 1910 ± 364 1932 ± 537 2037 ± 516 1268 ± 296 1.1 
rac-221  1202 ± 47 1117 ± 102 > 50000 1109 ± 163 > 40 
(R)-221  748 ± 40 736 ± 94 > 50000 708 ± 124 > 65 
(S)-221  2213 ± 359 2009 ± 255 > 50000 2223 ± 600 > 25 
222 561 ± 92 587 ± 164 1972 ± 388 373 ± 29 3.5 
rac-224  81 ± 8 73 ± 6 6471 ± 808 46 ± 4 80 
(R)-224  70 ± 6 74 ± 5 5768 ± 748 69 ± 12 82 
(S)-224  207 ± 29 200 ± 21 12474 ± 1202 161 ± 39 60 
225 257 ± 42 208 ± 37 927 ± 186 188 ± 27 3.6 
rac-228 86 ± 5 78 ± 13 7145 ± 1482 71 ± 9 83 
(R)-228  73 ± 4 62 ± 5 6683 ± 998 68 ± 13 92 
(S)-228  161 ± 32 153 ± 15 11117 ± 1726 117 ± 26 69 
rac-231  105 ± 5 99 ± 9 12853 ± 2030 107 ± 16 122 
181 79 ± 5 72 ± 11 767 ± 73 71 ± 11 9.7 
154 108 ± 5 105 ± 5 8511 ± 997 96 ± 6 79 
158 245 ± 14 213 ± 16 3899 ± 376 100 ± 11 15.9 
160 28 ± 4 29 ± 4 1028 ± 66 27 ± 2 36.7 
162 92 ± 9 95 ± 14 2148 ± 233 70 ± 10 23.3 
rac-176 19.0 ± 2.2 23.0 ± 0.6 3304 ± 125 29 ± 2 174 
rac-148 229 ± 60 195 ± 24 2074 ± 327 188 ± 30 9.1 
rac-149 152 ± 13 160 ± 29 1820 ± 405 117 ± 21 12.0 
131 1138 ± 88 1010 ± 87 > 50000 740 ± 97 > 45 
182 670 ± 94 685 ± 116 855 ± 71 661 ± 248 1.3 
215 2028 ± 157 2344 ± 169 8279 ± 1166 1019 ± 332 4 
216 13677 ± 1283 12106 ± 852 9705 ± 757 4539 ± 841 n.d. 
217 5861 ± 812 6053 ± 891 5916 ± 672 5715 ± 894 1.0 
218 6516 ± 635 9120 ± 557 7709 ± 1604 5395 ± 661 1.2 
rac-234 1426 ± 153 1132 ± 86 >50000 587 ± 97 > 40 
rac-235 171 ± 41 163 ± 38 3311 ± 213 69 ± 6 19.4 
Vinblastine 12.6 ± 2.0 12.4 ± 1.8 2037 ± 135 13.0 ± 0.7 163 
Notes: MDR ratios were determined by dividing the GI50 value obtained in the Pgp over-expressing 
cell line KB-V1, with the GI50 determined in isogenic parental KB-3-1 cells.  A further control 
experiment was conducted in the presence of the specific Pgp inhibitor Zosuquidar trihydrochloride 
(Z).   
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3.4. Profiling of lead inhibitors 
3.4.1.1. Physicochemical properties 
The lead dialkylphenyl S-trityl analogues 158 and 160 and the CH2-trityl based rac-176 
were profiled to ascertain their drug-like properties in a series of in vitro and in vivo 
assays.  The physicochemical properties of S-trityl analogues 158 and 160 were at the 
upper limit of the typically described range for achieving optimal drug-like properties.
236
  
With molecular weights ~ 400, 158 and 160 were partially soluble, with a non-optimal 
LogP for 160.
176
  In contrast, the smaller CH2-trityl based analogue demonstrated good 
aqueous solubility (> 100 M) and an optimal Log P.176  The Log D at pH 7.4 for all three 
candidates was around 3 and favourable, although the inaccuracy associated with these 
readings diminishes their relative utility.   Interestingly, one significant difference evident 
between all three was the relative strengths of the acid/base moieties as reflected by their 
pKa, with the S-trityl analogues 158 and 160 much weaker acids/bases than the CH2-trityl 
analogue rac-176.   
3.4.1.2. ADME assays 
In mouse microsomal stability assays, both 160 and rac-176 were stable over the time 
course of the experiment, while 158 was cleared at a moderate rate (t½  80 min); all three 
were stable in human microsomes.  In human hepatocytes, 158 and rac-176 exhibited low 
clearance, while a moderate rate of clearance was observed for 160 (t½  60 min).  Another 
factor which is an important influence on distribution, clearance and overall 
pharmacological efficacy is the proportion bound to plasma protein: while both 158 and 
rac-176 had a comparable fraction unbound (fu  5.0%), a higher proportion of the more 
lipophilic analogue 160 was bound (fu  1.6%).  This compound was also demonstrated to 
possess good oral bioavailability of 62%, higher than the value reported for ispinesib, with 
a rapid onset of peak concentration (tmax = 0.5 h, Table 23).
138
  However, 160 is more 
rapidly cleared from the systemic circulation than ispinesib.   
3.4.1.3. Toxicology 
An important safety consideration which has emerged in recent years for drugs is the 
potential for interactions with hERG potassium channels which are involved in modulating 
electrical activity in the heart, as their disruption can cause cardiac arrhythmia.
169
  None of 
the lead inhibitors demonstrated interactions at the maximum concentration examined.  
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Screening was also performed against CYP isoforms from the five main families.
237
  
Metabolism by CYP enzymes accounts for the majority of degradation pathways 
encountered by known drugs in the body, and their inhibition can lead to adverse reactions 
resulting from drug-drug interactions.
238, 239
  This is therefore an important consideration 
for Eg5 inhibitors given the likelihood that they would be administered in combination 
chemotherapies.  The dimethyl S-trityl analogue 158 moderately inhibited the CYP2C19 
isoform, whilst 160 weakly interacted with the CYP2C9 isoform, whose activities account 
for 12% and 16% respectively of the overall CYP-mediated metabolism of drugs.
237
  No 
inhibition of the isoforms from the five main families was evident for the dimethyl CH2-
trityl analogue rac-176. 
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Table 22 – DMPK profiles of lead analogues 158, and 160 and rac-176.  
Assay / Compounds 158 160 rac-176 
Molecular Weight (Da) 391.53 405.55 373.49 
Turbidimetric Solubility 
[pH 2.0, 6.0, 7.4 (M)] 
 
65, 65, 65 
 
> 100, 65, 65 
 
>100, >100, >100 
Log P 2.94 ± 0.03 4.13 ± 0.03 1.955 ± 0.51 
pKa 
pKa 1: 8.21 ± 0.09 
pKa 2: 2.51 ± 0.11 
pKa 1: 7.10 ± 0.10 
pKa 2: 3.28 ± 0.07 
pKa 1: 9.36 ± 0.05 
pKa 2: 1.69 ± 0.46 
Log D7.4 3.17 ± 0.20 3.08 ± 0.15 3.28 ± 0.367 
Microsomal Stability    
[Clint (L/min/mg protein)]    
Human stable stable stable 
t½ (min) -- -- -- 
Mice 17.8 ± 3.67 stable stable 
t½ (min) 77.8 -- -- 
Human Hepatocytes 
   
(L/min/million cells) 7.9 ± 3.4 24.4 ± 4.7 5.91 ± 1.89 
t½ (min) 176 56.9 235 
Human Plasma 
Protein Binding (%) 95.5 98.4 94.9 
[fu(%)]  (4.5 ± 1.1)  (1.6 ± 1.1) (5.1 ± 1.2) 
Recovery (%) 79.6 70.7 78.9 
CYP450 Inhibition (M)    
1A2 > 25 > 25 > 25 
2C9 > 25 14.0 ± 4.9 > 25 
2C19 7.9 ± 1.3 > 25 > 25 
2D6 > 25 > 25 > 25 
3A4 > 25 > 25 > 25 
hERG (M) > 25 > 25 > 25 
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Table 23 – Bioavailability and pharmacokinetics of 160 compared to ispinesib 
 
Cmpd F 
(%) 
Oral Dosing (PO) Intravenous Dosing (iv) Comments 
Cmax 
(g/mL) 
tmax 
(h) 
AUClast 
[g/(mL x h)] 
C(0) 
(g/mL) 
t1/2 
(h) 
VD 
(L/kg) 
Cl 
(mL/min/kg) 
AUClast 
[g/(mL x h)] 
Ispinesib 45 0.25 2.7 1.50 2.15 4.14 2.53 20.49 3.11 Moderate clearance, good PO levels 
160 63 1.25 0.5 4.43 13.55 2.06 0.37 11.38 7.07 High clearance, good PO levels 
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3.5. Xenograft Studies 
3.5.1. Anti-tumour efficacy of 158, 160 and rac-176 
On the basis of these profiles we advanced 158, 160 and rac-176 into in vivo experiments 
with lung cancer patient explants (LXFS 538) passaged as subcutaneous xenografts in nude 
mice.  Explanted xenograft models provide a better model for predicting clinical outcomes 
over solid tumours derived from in vitro cell lines as the transplanted tumours retain the 
histological complexity from the patient and reflect prior treatment.   Earlier studies have 
shown that explants correctly replicate the response of the donor patient to standard 
anticancer drugs in > 90% of the cases, and they were also shown to be more accurate 
predictors of clinical outcome for the Eg5 drug candidate ARRY-520.
240, 241
  For 160 weak 
tumour growth inhibition was observed with T/C = 44% on day 32, corresponding to 
reduced tumour growth rate (Figure 25).  Two key factors may have contributed to this.  
The relatively short plasma t½ of 160 may have meant that maintenance of sufficient 
concentration of the drug to induce a pharmacodynamic response was not achieved with 
the employed dosing schedule (Table 23).  More pertinently, evaluation of the phase 2 
clearance of 160 in mice hepatocytes revealed high rates of clearance (Clint  = 58.7 ± 5.64 
L/min/million cells; t½ = 23.6 min).  For 158, no tumour growth inhibition activity was 
recorded, and a similar explanation applied for the lack of activity (Figure 26).  Although 
158 was stable or showed low clearance in human microsomes and hepatocytes 
respectively, in mice medium clearance was evident in microsomes (17.8 ± 3.7 L/min/mg 
protein) and extremely quick clearance in hepatocytes (170 ± 9.4 L/min/million cells; t½ 
= 8.2 min).  Mice xenografts therefore may not have been the most appropriate in vivo 
model for assessing the potential of 158 and 160, and in the future alternative models such 
as nude rats will have to be employed.  In contrast to the reduced efficacy of 
thioethanamines 158 and 160, the strong activity of the most potent butanamine rac-176 
translated into the xenograft model (Figure 26).  Total tumour regression was achieved by 
day 21 on a dosage of 15 mg/kg every 3-4 days administered intraperitoneally.   
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Figure 25 – Anticancer efficacy of 160 in a subcutaneous tumour xenograft model with LXFS 538. 
The 160 treatment group (■) received 15 mg/kg on days 0, 2, and 4; 17 mg/kg on days 7, 18, 21 and 23; 
14 mg/kg on days 11, 14 and 16; 20 mg/kg on days 25 and 28; 22.5 mg/kg on days 30 and 32.  The 
control group (●) received vehicle only on the same days.  The data are plotted as the mean of the RTV 
± standard deviation.  The difference between the treated group and vehicle is statistically significant 
(p = 0.0124). 
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Figure 26 – Differing responses of tumour xenografts to 158 and rac-176. 
Treatment with rac-176 in a subcutaneous tumour xenograft model with lung cancer patient explants 
(LXFS 538) resulted in complete tumour regression within 21 days (T/C = 0% on day 21), but no 
response was recorded for 158.  The rac-176 treatment group (■) received 15 mg/kg on days 0, 3, 7, 10 
and 14, while  the 158 treatment group (▲) received 15 mg/kg 34 on days 0, 3, 7, 10 and 14 and up to 
30 mg/kg during later treatment, without indications of toxicity at this dose.  The control group (●) 
received only vehicle on the same days.  Data are plotted as the mean of the RTV ± standard deviation.  
The difference between the treated group (rac-176, ■) and vehicle is statistically significant (p = 
0.0003).   
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Chapter 4. Conclusions 
4.1. Key conclusions 
The optimisation of STLC based inhibitors by rational, structure based drug design has 
been reported.  A number of modifications have been identified to dramatically increase in 
vitro efficacy, primarily focussed on substituents to the trityl group which were 
hydrophobic and electron-donating.  In the most active compounds, the role of the 
carboxylate was delineated to be balancing the physicochemical attributes of the lipophilic 
trityl head by enhancing the aqueous solubility of the amino acid tail.  Metabolic stability 
and potency was increased further by replacement of the S-trityl linker with a methylene 
group, whilst a number of effective hydrophilic vectors from the trityl group were also 
investigated.  Strategies to alleviate and eliminate the potential for Pgp efflux from certain 
resistant tumours were also considered, and produced two modifications which may prove 
effective in the future: proximal fluorination of the primary amine aliphatic chain and 
bioisosteric replacement of the carboxylate with a primary amide.  The activity of the 
optimised inhibitors has transferred to in vivo models.  While thioethanamine based 
analogues 158 and 160 evaluated displayed poor metabolic stability and limited efficacy in 
the chosen mouse model, the butanamine rac-176 induced tumour regression.  This lead 
compound displays strong drug-like properties conducive to further investigation, and 
represents an excellent candidate for cancer chemotherapy as either monotherapy or in 
combination.    
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4.2. Future Work 
4.2.1. Separation of rac-176 and improvements to synthesis. 
Limitations of time and material prevented further attempts at resolving the racemate of the 
most active compound prepared rac-176.  The problems encountered with separation 
(section 2.3.1.2) could readily be circumvented through resolving at an earlier stage in the 
synthesis, such as the α-aminonitrile rac-174.  Additionally, although effective, the linear 
nature of the synthesis of zwitterionic triphenylbutanamines such as rac-176 analogues 
precludes rapid generation of analogues.  A more convergent synthetic approach or 
employment of asymmetric syntheses such as the Schöllkopf method
242
 would therefore be 
welcome improvements.   
4.2.2. Identification of optimal substituent pattern 
Excellent in vitro potency has been achieved with the developed lead analogues.  To 
successfully translate this into strong in vivo efficacy will require a more detailed 
understanding of the metabolism and pharmacokinetics of the lead compounds.  A 
selection of combinations of substituents which can effectively increase in vitro potency 
have been developed; further ADMET and pharmacokinetic profiling will reveal which is 
optimal.  Additionally, only one triphenylbutanamine analogue of the most efficacious 
trityl modifications has been prepared so far (rac-176).   
 
 
Figure 27 – Selected optimal lipophilic trityl modifications and proposed further modification (236).   
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4.2.3. Development of Pgp-efflux resistant candidates 
4.2.3.1. Primary amide analogues 
The terminal carboxylic acid provides physicochemical balance to the scaffold, and can 
contribute to Eg5 affinity.  However, given the propensity for the carboxylate moiety to 
induce efflux by the Pgp transporter, it may be desirable to replace this feature, particularly 
given the likelihood of Eg5 therapy being given in combination with existing treatments.  
One bioisosteric alternative which emerged to the carboxylate was a primary amide 
(section 3.2.6.2).  To fully examine the potential of this modification, it would be 
interesting to combine it with the triphenylbutanamine scaffold (Figure 28).   
 
 
Figure 28 – Proposed terminal primary amide triphenylbutanamine rac-237  
 
The improved activity of the amide suggests we do not fully understand the electronic 
influences of the carboxylate with the Eg5 backbone; thus further structural modifications 
and investigation of isosteres
233
 may reveal more potent alternatives to the carboxylate 
which are not subject to Pgp efflux.   
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4.2.3.2. Use of proximal fluorination 
Another strategy which emerged was the use of -fluorination of a primary amine to 
attenuate Pgp-mediated efflux (sections 3.2.6.1 and 3.3.4.3).  Although the efficacy of the 
prepared examples was compromised, the effect of proximal fluorination on the MDR ratio 
of a zwitterionic candidate is intriguing (Figure 29).  However, diastereoselectively 
preparing the enantiomers of 238 is synthetically complex and makes this prospect 
unlikely.   
 
Figure 29 – Proposed -fluorinated amino acid 238 
 
 
4.2.4. Investigation into uptake mechanisms of lead candidates 
The initial observations that radiolabelled L-cysteine was incorporated into leukemic white 
blood cells, which led to the synthesis of STLC strongly suggest that active transport 
mechanisms are involved in the uptake of the lead amino acid based compounds.  When 
combined with the observations of dramatic increases in cellular efficacy on incorporation 
of the amino acid moiety in the lead series (section 3.2.3.2), that the natural amino acid 
enantiomers were more potent (section 3.2.2.1), and the excellent bioavailability of 160 
(section 3.4.1.2), it is clear further investigation is necessary.  A variety of in vitro assays 
are available to determine the level of involvement of membrane transporters and which 
specifically are involved.
243, 244
  As a first step, a Caco-2 assay to investigate intestinal 
absorption in comparison to the expected rates achieved by passive diffusion could be 
performed.  Alternatively, comparisons of the rate of passive diffusion into cells as 
measured by a PAMPA assay contrasted with the observed rate of uptake in cells could 
also provide compelling evidence for the involvement or lack of active transport.   
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4.2.5. Investigation of combination therapy in haematological malignancies 
The data from multiple clinical trials has indicated only limited efficacy when Eg5 
inhibitors are administered as a monotherapy (section 1.4).  One of the postulated reasons 
for this is that the in vivo preclinical models have artificially high cell division rates, not 
reflective of tumour growth rates found in patients.
44
  Therefore more selective novel anti-
mitotic therapies, such as Eg5 inhibitors are actually likely to be more effective against 
more rapidly dividing cancers.  There has been some corroboration of this hypothesis in 
the successes recorded for SB-743921and ARRY-520 in clinical studies focused on 
lymphomas and multiple myeloma.
154, 168
  Therefore, an intriguing prospect for the lead 
STLC-based exemplars would be to test these in haematological related xenograft models, 
and perform in vitro combination screening to identify potential synergy with existing 
therapeutic agents for haematological malignancies. 
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Chapter 5. Experimental 
5.1. Biology 
5.1.1. General 
Eg5 protein was expressed and purified by Dr. Kristal Kaan and Sandeep Talapatra.  The 
evaluation of the basal inhibition of Eg5 ATPase activity with new compounds was 
performed by Prof. Frank Kozielski and Sandeep Talapatra.  All cellular assays were 
conducted by Dr. Oliver Rath.  ADME and toxicology related assays were conducted by 
Cyprotex (Macclesfield, UK).  Tumour xenografts were carried out by Oncotest GmbH 
(Freiburg, Germany).   
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5.1.2. Measurement of the inhibition of the basal and MT-stimulated Eg5 ATPase 
activities. 
Eg51-368 was cloned, expressed and purified for use in ATPase assays as previously 
described.
132
  The inhibition of the basal Eg5 ATPase activity was determined as 
previously described.
137, 235
  In brief, ATPase rates were recorded using the pyruvate 
kinase/lactate dehydrogenase-linked assay.
214
  This assay couples the ADP turnover of Eg5 
with NADH oxidation, whose fluorescence can be monitored to allow measurement of the 
steady state ATPase rate.  These measurements were performed at 25 °C in 96-well μclear 
plates using a 96-well Tecan Sunrise photometer to monitor fluorescence at 340 nm.  
ATPase rate assays were conducted utilising a salt concentration of 150 mM NaCl for the 
inhibition of the basal ATPase activity.  No salt was employed in the measurement of the 
MT-stimulated ATPase activity.  It is noteworthy that the Ki
app
 estimates can vary 
dependent on the ionic strength of the buffer for this Eg5 construct.
223
  The Eg5 
concentration was ∼ 80 nM and ~ 5 nM in the basal and MT-stimulated assays 
respectively.  All data were measured at least in triplicate.  Estimates for the Ki
app
 values 
were calculated by fitting data to the Morrison equation.
245
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whereby vi/v0 is the fractional activity, vmax is the uninhibited protein activity, vmin is the 
remaining activity at the highest inhibitor concentration used, [E] and [I] represent the 
enzyme and inhibitor concentrations used in the assays respectively, and Ki
app
 is the 
determined apparent Ki value.    
5.1.3. Measurement of the inhibition of the basal and MT-stimulated ATPase 
activities of other human kinesins. 
Assays were performed as described in section 5.1.2 with rac-176 by Sandeep Talapatra 
with human kinesin constructs expressed and purified by Dr. Kristal Kaan and Sandeep 
Talapatra.  The salt concentrations were optimised for each kinesin.
223
  The highest 
concentration of rac-176 used against each kinesin was 200 M.   
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5.1.4. Cellular assays 
5.1.4.1. Tissue culture 
Tissue culture was performed as described previously by Dr. Oliver Rath.
138
  In brief,   
HCT116 (ATCC CCL-247) cells were cultured in DMEM, supplemented with 10% fetal 
bovine serum.  K562 (ATCC CCL-243), LNCaP (ATCC CRL-1740) and NCI-H1299 
(CRL-5803) cells were cultured in RPMI, supplemented with 10% fetal bovine serum.  
BxPC-3 (ATCC CRL-1687) cells were cultured in RPMI, supplemented with 1% non-
essential amino acids, 1% sodium pyruvate, 1% glutamine and 10% fetal bovine serum.  
All cells were maintained at 37 °C, 95% humidity and 5% carbon dioxide in a humidified 
incubator and used for experiments for 6-8 weeks, before being replaced with fresh stocks 
that had been stored in liquid nitrogen. 
5.1.4.2. Proliferation assays 
Cell proliferation assays were conducted  as described previously by Dr. Oliver Rath.
138
  
Cells were seeded in triplicates in 96-well assay plates at 1.250 cells (BxPC-3, HCT116), 
2.500 cells (hTERT-HME1, NCI-H1299), or 5.000 cells (K562) per well in 100 µL of the 
respective growth medium.  Medium blanks and cell blanks for every cell line were also 
prepared.  The following day, inhibitors were added with a starting concentration of 100 
µM in a 3-fold serial dilution series. 72 h post inhibitor addition, 10% Alamar Blue was 
added and depending on the cell line, 2-12 h later the absorbance was measured at 570 nm 
and 600 nm.  All values were corrected for the absorbance of the medium blank and the 
corrected cell blanks were set to 100%.  Calculations for determining the relative 
proliferation were performed using equations described in the manufacturer’s manual.  
Finally, the GI50 values were determined using a sigmoidal dose-response fitting (variable 
slope) with GraphPad Prism 5.03 for Windows (GraphPad Software, San Diego, USA). 
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5.1.5. Tumour xenografts 
5.1.5.1. Protocols 
Tumour xenograft experiments were performed as described previously at Oncotest GmbH 
with female NMRI nu/nu mice (Charles River, Sulzfeld, Germany).
138
  Tumour fragments 
were obtained from xenografts in serial passage in nude mice.  After removal from donor 
mice, tumours were cut into fragments (4-5 mm diameter) and placed in PBS until 
subcutaneous implantation.  The recipient mice were anaesthetized by inhalation of 
isoflurane, a small incision was made and one tumour fragment per animal was 
transplanted with tweezers.  The approximate age at implantation was 5-7 weeks.  At 10-12 
weeks, mice were randomized to the various groups and dosing started when the required 
number of mice carried a tumour of 50-250 mm
3
 volume, preferably 80-200 mm³.  The 
vehicle for all compounds was a solution of DMSO (8%), Tween 80 (2%), distilled water 
(pH 5).  All treatments were given intraperitoneally.   
Experiment 1: Vehicle control mice (group 1) were treated with 10 ml/kg vehicle on days 
0, 2, 4, 7, 11, 14, 16, 18, 21, 23, 25, 28, 30 and 32.  The 160 treatment group (group 2) 
received 15 mg/kg on days 0, 2, and 4; 17 mg/kg on days 7, 18, 21 and 23; 14 mg/kg on 
days 11, 14 and 16; 20 mg/kg on days 25 and 28; 22.5 mg/kg on days 30 and 32.  The 
experiment was terminated on day 34 and tumour samples were collected.  
Experiment 2: Vehicle control mice (group 1) were treated with 10 mL/kg vehicle on days 
0, 3, 7, 10 and 14.  The rac-176 treatment group (group 2) received 15 mg/kg rac-176 on 
days 0, 3, 7, 10 and 14.  The 158 treatment group (group 3) received 15 mg/kg 158 on days 
0, 3, 7, 10 and 14 and up to 30 mg/kg during later treatment, without indications of toxicity 
at this dose. 
Mortality checks were conducted at least daily during routine monitoring.  Body weight 
was used as means of determining toxicity, with mice weighed twice a week.  The tumour 
volume was determined by two-dimensional measurement with a calliper on the day of 
randomization (day 0) and then twice weekly (i.e. on the same days on which mice were 
weighed).  Tumour volumes were calculated according to the formula (a x b
2
) x 0.5, where 
a represents the largest and b the perpendicular tumour diameter.  
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5.1.5.2. Interpretation of data 
Tumour inhibition for a particular day (T/C in %) was calculated from the ratio of the 
median RTV values of test versus control groups multiplied by 100%, as illustrated by the 
following equation:   
 
T/Cx [%] = 
median RTVx treated group 
x 100 
median RTVx control group 
 
For the evaluation of the statistical significance of tumour inhibition, the Mann-Whitney 
U-Test was performed.  Individual RTVs were compared on days on which the minimum 
T/C value was achieved, as long as sufficient animals were left for statistical analysis or 
otherwise on days as indicated.  By convention, p-values ≤ 0.05 indicate significance of 
tumour inhibition.  Statistical calculations were performed using GraphPad Prism 5.01 
(GraphPad Software, San Diego, USA).   
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5.1.6. ADME profiling 
All ADME and toxicology related profiling was carried out by Cyprotex (Macclesfield, 
UK) as described previously.
138
   
5.1.6.1. Microsomal stability 
Human and mouse microsomal stability was measured at a compound concentration of 3 
M and a microsome concentration of 0.5 mg/ml at time points of 0.5,15,30 and 45 min. 
The final DMSO concentration was 0.25%.  NADPH was included as a cofactor to initiate 
the reaction.  Dextromethorphan and verapamil and diazepam and diphenydramine were 
included as controls for human and mouse microsomes, respectively.  The disappearance 
of compounds was monitored using LC-MS/MS.  The stability is expressed as the intrinsic 
clearance (Clint) ± its standard error and the half-life (t½).  Compounds with Clint values < 
8.6 (mouse: 8.8) or > 47.0 (mouse 48.0) were classified as showing low and high 
clearance, respectively.
229
 Compounds with negative values are considered stable in 
microsomal stability assays.   
5.1.6.2. Hepatocyte stability 
Human hepatocyte stability was measured at a compound concentration of 3 M using 
cryopreserved hepatocytes.  Incubation time was 0, 5, 10, 20, 40 and 60 min.  The final 
DMSO concentration was 0.25%.  Compounds with known activity were included as 
controls.  Data were analyzed using LC-MS/MS.  The stability is expressed as the intrinsic 
clearance ± its standard error and the half-life. 
5.1.6.3. Plasma binding  
The extent of binding to human plasma was determined by equilibrium dialysis at 50% 
plasma at compound concentrations of 5 M.  The experiments were performed as 
duplicates.  Quantifications were performed in each compartment by LC-MS/MS 
equilibration at 37 C.  Plasma protein binding is expressed as fraction unbound (fu100%) in 
100% plasma and the recovery (%Recovery) is given.  
5.1.6.4. hERG inhibition 
Inhibition of hERG was investigated using the Ionworks HT system (Molecular Devices).  
CHO-hERG cells were used with amphotericin B as the perforating agent. The compound 
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concentrations for the calculation of the IC50 values were 0.008, 0.04, 0.2, 1, 5, and 25 M 
(4 replicates).  The final DMSO concentration was 0.25%.  Quinidine was used as a 
positive control.  
5.1.6.5. Cytochrome P450 inhibition 
To assess whether the compounds inhibit one of the main cytochrome P450 isoforms 
CYP1A, CYP2C9, CYP2C19, CYP2D6 or CYP3A4, which might lead to adverse drug 
reactions or toxicity, cytochrome P450 inhibition assays were performed.  Assays were 
performed at a range of compound concentrations (0, 0.1, 0.25, 1, 2.5, 10, 25 M) in the 
presence of isoform-specific substrates.  Known isoform-specific inhibitors (-
naphthoflavone, sulphaphenazole, tranylcypromine, quinidine, and ketoconazole) were 
used as controls.  The formation of metabolites was monitored using LC-MS/MS and IC50 
values and their standard errors were calculated.  
5.1.6.6. Bioavailability 
To determine bioavailability, the compounds are administered by intravenous and by oral 
routes to mice at 5 mg/kg.  The vehicle used was 17.5-21.3 mM sodium citrate, pH 5.0, 
15% DMSO, 0.5-1.0% Tween 80 and either 160 or ispinesib.  Up to eight blood samples 
were taken over a period of up to 8 h.  The compound concentrations were quantified using 
LC-MS/MS.  Pharmacokinetic parameters were extracted for oral (Cmax, tmax, AUClast) and 
intravenous (C(0), AUClast, t½, VD, and Cl) dosing.   
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5.2. Chemistry 
5.2.1. General 
5.2.1.1. Materials and methods 
All reagents and solvents were of commercial quality and used without further purification.  
STLC (6), the primary acid isostere 215 and SB-743921 were purchased from Nova 
Biochem, Sigma Aldrich and Selleck Chemicals respectively and used without further 
purification.  The following compounds were prepared by Dr. Fang Wang as described 
previously:  181, 183, 221-226, 228-229, 231, and 233-235.
138, 222
  Compounds 227, 230 
and 232 were prepared by Dawid Podgórski.
222
  Compound 10 (NSC123528) was obtained 
from the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov) of the National 
Cancer Institute.  All other tested compounds were synthesised as described by myself.  
Anhydrous reactions were carried out in oven dried glassware under a nitrogen atmosphere 
unless otherwise noted.  Thin-layer chromatography (TLC) was carried out on aluminium 
backed SiO2 plates (silica gel 60, F254), and visualized using ultraviolet light (254 nm), and 
by staining with phosphomolybdic acid (alcohols) or ninhydrin (amines).  Flash column 
chromatography was performed on silica gel [SNAP KP-Sil, 60 Å, 40−63 μm cartridges] 
using a Biotage SP4 automated chromatography system (detection wavelength, 254 nm; 
monitoring, 280 nm).  
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5.2.1.2. Analysis and characterisation 
Melting points were determined using a Stuart Scientific SMP1 melting point apparatus 
and are uncorrected.  
1
H and 
13
C NMR spectra were recorded on a JEOL ECX-400 (400 
MHz), Avance DPX400 (400 MHz), or Avance DPX500 (500 MHz) spectrometer.  
19
F 
NMR spectra were recorded on an Avance AV400 (400 MHz) instrument equipped with a 
multinuclear probe.  
1H chemical shifts (δ) are reported in ppm relative to the residual 
signal of the deuterated solvent [7.26 in CDCl3, 3.31 in CD3OD (denoted as MeOD), and 
2.50 in DMSO-d6].  Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q 
(quartet), p (pentet), m (unresolved multiplet), and br (broad).  
13C chemical shifts (δ) are 
reported in ppm relative to the carbon resonance of the deuterated solvent (77.16 in CDCl3, 
49.00 in CD3OD, and 39.52 in DMSO-d6).  
19
F spectra are referenced relative to CFCl3.  
High resolution mass spectra were recorded on a Thermo Electron LTQ ORBITRAP mass 
spectrometer using electrospray ionisation.  Gas chromatography mass spectra (GC-MS) 
using electron ionisation (EI) were recorded on a Thermo Scientific Focus GC with DSQ2 
single quadrupole mass spectrometer.  GC-MS using chemical ionisation (CI) were 
recorded on an Agilent Technologies 7890A GC system and an Agilent 5975C Inert XL 
EI/CI MSD with DSQ2 single quadrupole mass spectrometer, equipped with an Agilent 
Technologies DB5-MS column (30 m x 0.25 mm x 0.25 μm).  Helium was the carrier gas 
(flow rate = 1 mL/min
-1
).  Elemental analysis was performed on a Perkin-Elmer 2400 
series 2 CHN analyzer.  LC−MS analyses were performed with an Agilent Quaternary 
1200 series pump and an Agilent 6130 dual source mass spectrometer with UV detection at 
254 nM.  Retention times (tR) were in minutes, and purity was calculated as percentage of 
total area.  The method for determining purity consisted of the following: Zorbax Eclipse 
XDB-C18 reverse phase column (15 cm x 4.3 m, particle size 5 m); column temperature 
40 °C; solvent A: H2O (5 mM ammonium acetate); solvent B: MeCN (5 mM ammonium 
acetate); gradient of A:B, 95:5 (0 – 3 min), A:B, 95:5  B, 100% (3 – 17 min), B, 100% 
(17- 27 min), B, 100%  A:B, 95:5 (27-33 min), A:B, 95:5 (33 – 36 min); flow rate 1 ml 
min
-1.  All assayed compounds were ≥ 95% pure by either elemental analysis or LC-MS.  
New compounds are named according to IUPAC nomenclature using ACD ChemSketch 
12.01 (Windows, Advanced Chemistry Development, Toronto, Canada).   
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5.2.2. Measurement of physicochemical properties 
Physicochemical measurements were made by Cyprotex (turbidimetric solubility and Log 
D7.4; Macclesfield, UK) and Sai Advantium (Log P and pKa ; Pune, India).   
5.2.2.1. Turbidimetric Solubility 
To determine turbidimetric solubility, compounds were measured at 1 M, 3 M, 10 M, 
30 M and 100 M at a final DMSO concentration of 1% in 10 mM phosphate buffered 
saline at pH 7.4, and optionally at pH 2.0 and 6.0.  Pyrene and Nicardipine were used as 
controls.  The temperature was 37 C with an incubation time of 2 h, and the turbidimetry 
was measured at a wavelength of 620 nm.  The number of replicates was n = 7.  
5.2.2.2. Log P and pKa  
The acid dissociation constant (pKa) and the partition coefficient (log P) were determined 
using the potentiometric method on a Sirius GL-pKa under standard conditions. 
5.2.2.3. Log D7.4 
Log D (distribution coefficient) is used as a measure of lipophilicity. The log D7.4 was 
measured using the miniaturized shake flask method. The partition solvent was n-octanol 
with ratios of buffer:octanol of 50:1, 5:1 and 1:2 (v/v).  Acetobutolol and ketoconazole 
were used as positive controls.  LC-MS/MS was used to quantify the samples. 
5.2.3. Enantiomeric separation of rac-176 
Attempts to separate rac-176 were performed on a Dionex P680 HPLC system using a 10 
mm × 250 mm ChiralPack IC column containing cellulose tris(3,5-
dichlorophenylcarbamate) immobilized on 5 m silica gel as the chiral stationary phase 
with UV detection at 254 nM.  The method consisted of the following: solvent A: n-
heptane (0.1% triethylamine/0.1% TFA v/v); solvent B: ethanol; gradient of A:B 95:5  
A:B 85:15 (0 – 30 min), A:B 85:15  A:B 80:20 (30 – 40 min), A:B 80:20 (40 – 47 min), 
A:B 80:20  A:B 95:5 (47 – 47.1 min), A:B 95:5 (47.1 min – 55 min); flow rate 4 ml  
min
-1
.   
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5.2.4. General procedures 
5.2.4.1. General procedure (i): Preparation of trityl alcohols by Grignard mediated 
reduction of substituted benzophenones. 
Intermediate trityl alcohols 31-38 were synthesised by the reaction of commercially 
available substituted benzophenones with phenylmagnesium bromide.  A representative 
procedure is provided for the synthesis of 31 (Scheme 21).   
 
Scheme 21 – Reduction of (3-fluorophenyl)(phenyl)methanone with PhMgBr.   
 
5.2.4.2. (3-Fluorophenyl)(diphenyl)methanol (31) 
To a solution of (3-fluorophenyl)(phenyl)methanone (2.00 g,  10 mmol) in anhydrous THF 
(5 mL) was added PhMgCl (2.0 M in THF, 12.5 ml, 25 mmol) and stirred at reflux for 20.5 
h.  The reaction was quenched with saturated aqueous NH4Cl solution (15 mL) and 
extracted with EtOAc (3 x 25 mL).  The organic extracts were washed with brine (75 mL), 
dried (MgSO4) and concentrated in vacuo.  Purification of the crude residue by flash 
chromatography [SiO2; 0-18% EtOAc in hexane] afforded the trityl alcohol 31 as a white 
solid (1.79 g, 64%).  Mpt. 112-113 °C (lit.
246
 117 °C). 
1
H NMR (500 MHz, CDCl3) δ = 
2.80 (s, 1H, OH), 6.96-7.00 (m, 1H), 7.05-7.10 (m, 1H), 7.26-7.36 (m, 11H).  
13
C NMR 
(125 MHz, CDCl3) δ = 81.86, 114.26 (d, J = 21.9 Hz), 115.24 (d, J = 22.7 Hz), 123.77, 
127.68, 127.98, 128.23, 129.47 (d, J = 8.7 Hz), 146.49, 149.60 (d, J = 6.0 Hz), 162.71 (d, J 
= 245.7 Hz).  HRMS (ESI+) calcd. for C19H14F [M-OH]
+
: 261.10741; found: 261.10742.  
Anal. Calcd. for C19H15FO: C, 81.99; H, 5.43.  Found: C, 82.06; H, 5.45.   
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5.2.4.3. General procedure (ii): Preparation of trityl alcohols by reduction of 
benzophenone with lithiated aryl bromides.   
Intermediate trityl alcohols 47-70 were synthesised by the reaction benzophenone with 
lithiated aryl bromides incorporating a variety of substituents.  A representative procedure 
is provided for the synthesis of 53 (Scheme 22).   
 
Scheme 22 – Synthesis of 4-methylphenyl)(diphenyl)methanol via lithium bromine exchange.  
  
5.2.4.4. (4-Methylphenyl)(diphenyl)methanol (53). 
n-Butyllithium (2.5 M in hexane, 2.4 mL, 6.00 mmol) was added by slow dropwise 
addition over 2 min to a cooled (-78 °C) solution of 1-bromo-4-methylbenzene (855 mg, 
5.00 mmol) in anhydrous THF (5 mL) and stirred for 30 min at ≤ -70 °C.  A solution of 
benzophenone (1.05 g, 5.75 mmol) in anhydrous THF (5.75 mL) was added by slow 
dropwise addition over 5 min, and the reaction mixture stirred with the temperature 
maintained ≤ -70 °C for 6 h, before allowing the reaction to warm to room temperature and 
stirring for a further 17 h.  The reaction was quenched with saturated aqueous NH4Cl 
solution (10 mL) and extracted with EtOAc (3 x 10 mL).  The combined organic layers 
were then washed successively with H2O and brine (30 mL each), dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-9% EtOAc in 
hexane] afforded the trityl alcohol 53 as a white solid (707 mg, 43%).  Mpt. 65-66 °C 
(lit.
247
 68-69 °C).  
1
H NMR (400 MHz, CDCl3) δ = 2.34 (s, 3H, CH3), 2.75 (s, 1H, OH), 
7.10-7.17 (m, 4H), 7.24-7.34 (m, 10H).  
13
C NMR (100 MHz, CDCl3) δ = 21.17, 82.03, 
127.32, 128.00, 128.03, 128.78, 137.09, 144.19, 147.15.  HRMS (ESI+) calcd. for C20H17 
= [M-OH]
+
: 257.1317; found: 257.1325.  Anal. calcd. for C20H18O: C, 87.56; H, 6.61.  
Found: C, 87.32; H, 6.72. 
  
  
148 
 
5.2.4.5. General procedure (iii): Thioetherification of trityl alcohols  
Thioethers were prepared from trityl alcohols by dehydration in trifluoroacetic acid and 
subsequent thioetherification with L-cysteine or cysteamine hydrochloride unless otherwise 
noted, in an adaptation of the procedure reported by Maltese et al.
190
  A representative 
procedure is provided for the synthesis of 126. 
 
Scheme 23 – Thioetherification of 3-(hydroxy(diphenyl)methyl)benzonitrile with cysteamine 
hydrochloride.   
 
5.2.4.6. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzonitrile (126).   
A solution of the tertiary alcohol 63 (1.0 mmol) with cysteamine hydrochloride (125 mg, 
1.1 mmol) in trifluoroacetic acid (1.0 mL) was stirred for 3 h at room temperature.  The 
volatiles were removed in vacuo, and the residue basified (circa. pH 10) with saturated 
aqueous sodium carbonate solution.  The aqueous mixture was extracted with CH2Cl2 (3 x 
10 mL) and the organic layer dried (MgSO4) and concentrated in vacuo.  Purification by 
flash chromatography [SiO2; 0-20% MeOH in CH2Cl2] afforded thioether 126 as a 
colorless oil (324 mg, 94%).  
1H NMR (400 MHz, MeOD) δ = 2.33 (t, J = 6.9 Hz, 2H, 
CH2), 2.46 (t, J = 6.9 Hz, 2H, CH2), 7.24-7.29 (m, 2H), 7.30-7.36 (m, 4H), 7.38-7.43 (m, 
4H), 7.46-7.51 (m, 1H), 7.59-7.62 (m, 1H), 7.73-7.78 (m, 2H).  
13
C NMR (100 MHz, 
MeOD) δ = 35.97, 41.46, 67.16, 82.00, 113.12, 119.57, 128.31, 129.30, 130.23, 130.60, 
131.65, 133.86, 145.23, 148.32.  HRMS (ESI+) calcd. for C22H21N2S [M+H]
+
: 345.1420; 
found: 345.1417.  Anal. calcd. for C22H20N2S·⅕CH2Cl2: C, 73.77; H, 5.69; N, 7.75.  
Found: C, 74.01; H, 5.63; N, 7.45. 
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5.2.5. Characterisation and synthetic procedures for all other compounds 
5.2.5.1. (2-Chlorophenyl)(diphenyl)methanol (30) 
 
The tertiary trityl alcohol 30 was prepared using an adaptation of the method reported by 
Hatano et al.
179
  Zinc chloride (284 mg, 2.1 mmol) was added to a solution of PhMgBr (1.0 
M in THF, 45 mL, 45 mmol) and the mixture stirred at room temperature for 1 h.  A 
solution of (2-chlorophenyl)(phenyl)methanone (4.33g, 20 mmol) in anhydrous THF (8 
mL) was added, and the reaction heated at reflux for 120 h.  The reaction was quenched 
with saturated aqueous NH4Cl solution (30 mL) and extracted with EtOAc (4 x 30 mL).  
The organic extracts were washed with brine (2 x 100 mL), dried (MgSO4) and 
concentrated in vacuo.  The crude product was purified by flash chromatography [SiO2; 0-
10% EtOAc in hexane] to afford trityl alcohol 30 as a white solid (3.432g, 58%).  Mpt. 83 
°C (lit.
248
 89-91 °C).  
1
H NMR (500 MHz, CDCl3) δ = 4.42 (s, 1H, OH), 6.71 (dd, J = 1.6, 
7.9 Hz, 1H), 7.09-7.13 (m, 1H), 7.23-7.35 (m, 11H), 7.40 (dd, J = 1.2, 7.9 Hz, 1H).
 
 
13
C 
NMR (125 MHz, CDCl3) δ = 82.73, 126.54, 127.52, 127.91, 128.14, 129.24, 131.50, 
131.64, 133.38, 143.88, 145.69.  HRMS (ESI+) calcd. for C19H14Cl [M-OH]
+
: 277.07785; 
found: 277.07770.  Anal. calcd. for C19H15ClO: C, 77.42; H, 5.13.  Found: C, 77.86; H, 
5.21.   
5.2.5.2.  (3-Chlorophenyl)(diphenyl)methanol (32) 
 
The title compound was prepared using an adaptation of the method described for 30 with 
(3-chlorophenyl)(phenyl)methanone (4.33 g, 20 mmol), zinc chloride (284 mg, 2.1 mmol) 
and PhMgCl (2.0 M in THF, 25 mL, 50 mmol) and 22 h at reflux.  Aqueous workup and 
purification by flash chromatography [SiO2; 0-15% EtOAc in hexane] afforded the trityl 
alcohol 32 a white solid (4.05 g, 69%).  Mpt. 42 °C (lit.
246
  53-55 °C). 
1
H NMR (500 MHz, 
CDCl3) δ = 2.80 (s, 1H, OH), 7.16-7.18 (m, 1H), 7.23-7.38 (m, 13H).  
13
C NMR (125 
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MHz, CDCl3) δ = 81.86, 126.37, 127.55, 127.72, 127.99, 128.16, 128.27, 129.62, 134.19, 
146.41, 149.01.  HRMS (ESI+) calcd. for C19H14Cl [M-OH]
+
: 277.07785; found: 
277.07764.  Anal. calcd. for C19H15ClO: C, 77.42; H, 5.13.  Found: C, 77.08; H, 4.98.   
5.2.5.3.  (3-Bromophenyl)(diphenyl)methanol (33). 
 
The title compound was prepared using general procedure (i) with (3-
bromophenyl)(phenyl)methanone (2.61 g, 10 mmol) and PhMgCl (2.0 M in THF, 12.5 ml, 
25 mmol) in anhydrous THF (5 mL).  Purification by flash chromatography [SiO2; 0-15% 
EtOAc in hexane] afforded the tertiary alcohol 33 as a colorless oil (1.55 g, 46%).  
1
H 
NMR (500 MHz, DMSO-d6) δ = 6.61-6.66 (m, 1H), 7.10-7.16 (m, 1H), 7.18-7.36 (m, 
10H), 7.41-7.50 (m, 2H).  
13
C NMR (125 MHz, DMSO-d6) δ = 810.25, 21.22, 126.92, 
127.00, 127.67, 127.70, 129.57, 129.74, 130.22, 147.00, 150.55.  HRMS (ESI+) calcd. for 
C19H14
79
Br [M-OH]
+
: 321.02734; found: 321.02750.  Anal. calcd. for C19H15BrO: C, 
67.27; H, 4.46.  Found: C, 68.65; H, 4.32.   
5.2.5.4. (3-Methylphenyl)(diphenyl)methanol (34). 
 
The title compound was prepared using general procedure (i) with (3-
methylphenyl)(phenyl)methanone (1.84 mL, 10 mmol) and PhMgCl (2.0 M in THF, 12.5 
ml, 25 mmol) in anhydrous THF (5 mL).  Purification by flash chromatography [SiO2; 0-
15% EtOAc in petroleum ether (40/60)] afforded the tertiary alcohol 34 as a white solid 
(1.61 g, 59%).  Mpt. 58 °C (lit.
249
 62-63 °C).  
1
H NMR (500 MHz, CDCl3) δ = 2.33 (s, 3H, 
CH3), 2.80 (s, 1H, OH), 7.03 (d, J = 7.8 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H), 7.16 (s, 1H), 
7.20 (t, J = 7.7 Hz, 1H), 7.28-7.35 (m, 10H).  
13
C NMR (125 MHz, CDCl3) δ = 21.74, 
82.15, 125.32, 127.35, 127.89, 128.04, 128.08, 128.18, 128.61, 137.13, 146.98, 147.09.  
HRMS (ESI+) calcd. for C20H17 [M-OH]
+
: 257.13248; found: 257.13235.  Anal. calcd. for 
C20H18O: C, 87.56; H, 6.61.  Found: C, 87.91; H, 6.51.   
  
151 
 
5.2.5.5. Diphenyl(3-(trifluoromethyl)phenyl)methanol (35).  
 
The title compound was prepared using general procedure (i) with phenyl-(3-
(trifluoromethyl)phenyl)methanone (2.50 g, 10 mmol) and PhMgCl (2.0 M in THF, 12.5 
ml, 25 mmol) in anhydrous THF (5 mL).  Purification by flash chromatography [SiO2; 0-
15% EtOAc in petroleum ether (40/60)] afforded the tertiary alcohol 35 as a pale yellow 
oil (1.38 g, 42%).  
1
H NMR (500 MHz, CDCl3) δ = 2.83 (s, 1H, OH), 7.25-7.27 (m, 4H), 
7.32-7.37 (m, 6H), 7.41-7.49 (m, 2H), 7.55-7.57 (m, 1H), 7.70-7.71 (m, 1H).  
13
C NMR 
(125 MHz, CDCl3) δ = 81.92, 124.24 (q, JCF = 3.5 Hz), 124.30 (q, JCF = 272.8 Hz), 124.57 
(q, JCF = 3.6Hz), 127.84, 127.97, 128.36, 128.42, 130.51 (q, JCF = 31.9 Hz), 131.58, 
146.35, 147.89.  HRMS (ESI+) calcd. for C20H14F3 [M-OH]
+
: 257.13248; found: 
257.13235.  Anal. calcd. for  C20H15F3O·½EtOAc: C, 70.96; H, 5.14.  Found: C, 70.21; H, 
4.40.   
5.2.5.6. (4-Ethylphenyl)(diphenyl)methanol (36). 
 
The title compound was prepared using general procedure (i) with (4-
ethylphenyl)(phenyl)methanone (1.18 ml, 6.0 mmol) and PhMgCl (2.0 M in THF, 7.50 ml, 
15.0 mmol) in anhydrous THF (10 mL).  Purification by flash chromatography [SiO2; 0-
10% EtOAc in hexane] afforded the tertiary alcohol 36 as a white solid (1.51 g, 87%).  
Mpt. 58-60 °C.  
1
H NMR (400 MHz, CDCl3) 1.24 (t, 3H, J = 7.6 Hz, CH3), 2.65 (q, 2H, J 
= 7.7 Hz, CH2), 2.78 (s, 1H, OH), 7.12-7.20 (m, 4H), 7.25-7.35 (m, 10H).  
13
C NMR (125 
MHz, CDCl3) δ = 15.54, 28.55, 82.06, 127.30, 127.56, 128.02, 128.05, 143.40, 144.39, 
147.18.  HRMS (ESI+) calcd. for C21H19 [M-OH]
+
: 271.1481; found: 271.1475.  Anal. 
calcd. for C21H20O: C, 87.46; H, 6.99.  Found: C, 87.48; H, 7.03. 
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5.2.5.7.  (3,4-Dimethylphenyl)(diphenyl)methanol (37). 
 
The title compound was prepared using general procedure (i) with 3,4-
dimethylbenzophenone (3.15 g,  15.0 mmol) and PhMgBr (1.0 M in THF, 22.5 ml, 22.5 
mmol)  in anhydrous THF (5 mL).  Purification by flash chromatography [SiO2; 0-8% 
EtOAc in hexane] afforded the trityl alcohol 37 as a colourless oil (3.90 g, 90%).  
1
H NMR 
(500 MHz, CDCl3) δ = 2.21 (s, 3H, CH3), 2.25(s, 3H, CH3), 2.75 (s, 1H, OH), 6.92 (dd, J = 
2.0, 7.9 Hz, 1H), 7.04-7.09 (m, 2H), 7.24-7.32 (m, 10H).  
13
C NMR (125 MHz, CDCl3): 
19.51, 20.12, 82.03, 125.64, 127.27, 128.00, 128.05, 129.16, 129.25, 135.77, 136.30, 
144.61, 147.22.  HRMS (ESI+) calcd. for C21H19 [M-OH]
+
: 271.1481; found: 271.1478.  
Anal. calcd. for C21H20O: C, 87.46; H, 6.99.  Found: C, 87.01; H, 6.86. 
5.2.5.8. Bis(4-methylphenyl)(phenyl)methanol (38). 
 
The title compound was prepared using general procedure (i) with bis(4-
methylphenyl)methanone (2.10 g, 10 mmol) and PhMgCl (2.0 M in THF, 12.5 ml, 25 
mmol) in anhydrous THF (10 mL), with the following modifications.  The reaction was 
stirred for 1 h at 0 °C, and then for a further 74 h at room temperature.  After aqueous 
workup, purification by flash chromatography [SiO2; 0-10% EtOAc in pet. ether (60/80)] 
afforded the trityl alcohol 38 as a white solid (1.33 g, 46%).  Mpt. 70-71 (lit.
250
 75.5-76.4 
o
C).  
1
H NMR (CDCl3, 500 MHz) δ 2.35 (s, 6H, 2 x CH3), 7.10-7.13 (m, 4H), 7.15-7.18 
(m, 4H), 7.46-7.33 (m, 5H).  
13
C NMR (CDCl3, 125 MHz) δ 21.16, 81.90, 127.23, 127.98, 
128.74, 136.98, 144.34, 147.31.  HRMS (ESI+) calcd. for C21H19 [M-OH]
+
: 271.1481; 
found: 271.1479.  Anal. calcd. for C21H20O: C, 87.46; H, 6.99; Found: C, 87.40; H, 7.06.   
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5.2.5.9. Methyl 3-methoxybenzoate (41). 
 
The title compound was prepared using a modification of the procedure reported by Ulrik 
et al.
177
  Methyl 3-hydroxybenzoate (3.80 g, 25 mmol), NaH (60% in mineral oil, 660 mg, 
27.5 mmol) in anhydrous DMF (41 mL) and subsequent treatment with iodomethane (1.71 
mL, 27.5 mmol) after stirring for 22.5 h at room temperature, aqueous workup and 
purification by flash chromatography [SiO2; 0-16% EtOAc in hexane] afforded 41 as a 
colorless oil (2.60 g, 63%).  
1
H NMR (400 MHz, CDCl3) δ = 3.85 (s, 3H), 3.91 (s, 3H), 
7.08-7.11 (m, 1H), 7.32-7.36 (m, 1H), 7.55-7.56 (m, 1H), 7.62-7.64 (m, 1H).  
13
C NMR 
(125 MHz, CDCl3) δ = 52.29, 55.56, 114.11, 119.65, 122.13, 129.52, 131.60, 159.71, 
167.13.  HRMS (ESI+) calcd. for C19H11O3 [M+H]
+
: 167.07027; found: 167.07028.  Anal. 
calcd. for C9H10O3: C, 65.05; H, 6.07.  Found: C, 64.75; H, 6.06.    
5.2.5.10. 2-(Hydroxy(diphenyl)methyl)phenol (42).   
 
Phenyllithium (1.8 M in Et2O, 17.7 mL, 32 mmol) was added to a solution of methyl 2-
hydroxybenzoate (699 μL, 8 mmol) in anhydrous THF (12 mL) at -78 °C, and stirred for 1 
h, whilst maintaining the temperature below -70 °C.  The reaction mixture was allowed to 
warm to room temperature, stirred for 2 h, then quenched with saturated aqueous NH4Cl 
solution (25 mL) and extracted EtOAc (2 x 30 mL).  The combined organic extracts were 
washed with brine (25 mL), dried (MgSO4) and concentrated in vacuo.  Purification by 
flash chromatography [SiO2; 5-20% EtOAc in hexane] yielded the trityl alcohol 42 as an 
off-white solid (1.26 g, 57%).  Mpt. 133-134 °C (lit.
251
 135.5-138.5 °C).  
1
H NMR (500 
MHz, CDCl3) δ = 3.68 (br s, 1H, OH), 6.53 (dd, J = 1.6, 7.8 Hz, 1H), 6.73-6.76 (m, 1H), 
6.90 (dd, J = 1.0, 8.1 Hz, 1H), 7.20-7.24 (m, 5H), 7.32-7.36 (m, 6H), 8.09 (br s, 1H, OH).  
13
C NMR (125 MHz, CDCl3) δ = 84.61, 117.76, 119.22, 125.97, 127.91, 128.10, 128.35, 
129.74, 130.15, 145.01, 156.02.  HRMS (ESI-) calcd. for C19H15O [M-H]
-
: 275.10775; 
found: 275.10791.  Anal. calcd. for  C19H16O2: C, 82.58; H, 5.84.  Found: C, 82.65; H, 
5.94.   
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5.2.5.11. 3-(Hydroxy(diphenyl)methyl)phenol (43).   
 
The title compound was prepared using an adaptation of the procedure for 42 using methyl 
3-hydroxybenzoate (1.52g, 10 mmol) and phenyllithium (1.8 M in Et2O, 22.2 mL, 40 
mmol) in anhydrous THF (16.6 mL) with the following modifications.  The reaction 
mixture was allowed to stir for 4.5 h after warming to room temperature.  Purification by 
flash chromatography [SiO2; 0-20% EtOAc in hexane] afforded the tertiary alcohol 43 as 
an off-white powder (1.55g, 56%).  Mpt. 139-142 °C (lit.
252
 148 °C from benzene). 
1
H 
NMR (500 MHz, CDCl3) δ = 2.85 (s, 1H, OH), 4.94 (br s, 1H, OH), 6.73-6.77 (m, 2H), 
6.81 (dd, J = 0.8, 7.9 Hz, 1H), 7.17 (t, J = 7.9 Hz, 1H), 7.26-7.32 (m, 10H).  
13
C NMR (125 
MHz, CDCl3) δ = 82.07, 114.42, 115.24, 120.72, 127.49, 128.05, 128.10, 129.33, 146.73, 
148.66, 155.37.  HRMS (ESI-) calcd. for C19H15O [M-H]
-
: 275.10775; found: 275.10793.  
Anal. calcd. for  C19H16O2: C, 82.58; H, 5.84.  Found: C, 82.46; H, 5.89.  
5.2.5.12. (3-Methoxyphenyl)(diphenyl)methanol (44).   
 
Phenyllithium (1.8 M in Et2O, 22.2 mL, 40 mmol) was added to a solution of methyl 3-
methoxybenzoate 41 (1.52g, 10 mmol) in anhydrous THF (16.6 mL) at -78 °C, and stirred 
for 1 h whilst maintaining the temperature below -70 °C.  The reaction mixture was 
allowed to warm to room temperature and stirred for 20 h, then quenched with saturated 
aqueous NH4Cl solution (25 mL) and extracted EtOAc (2 x 30 mL).  The combined 
organic extracts were washed with brine (2 x 50 mL), dried (MgSO4) and concentrated in 
vacuo.  Purification of the crude material by flash chromatography [SiO2; 0-20% EtOAc in 
hexane] afforded the tertiary alcohol 44 as a pale yellow solid (3.52 g, 84%).  Mpt. 80-81 
°C (lit.
253
 88-89
  
°C from Et2O).  
1
H NMR (500 MHz, CDCl3) δ = 2.81 (s, 1H, OH), 3.75 
(s, 3H, CH3), 6.82-6.84 (m, 2H), 6.89-6.90 (m, 1H), 7.21-7.25 (m, 1H), 7.27-7.33 (m, 
10H).  
13
C NMR (125 MHz, CDCl3) δ = 55.12, 82.13, 112.61, 114.13, 120.70, 127.43, 
128.06, 129.01, 146.89, 148.66, 159.44.  HRMS (ESI+) calcd. for C19H17O [M-OH]
+
: 
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273.12739; found: 273.12738.  Anal. calcd. for  C20H18O2: C, 82.73; H, 6.25.  Found: C, 
82.75; H, 6.23.   
5.2.5.13. Methyl 5,6,7,8-tetrahydronaphthalene-2-carboxylate (239).   
  
A solution of 5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (3.52 g, 20 mmol) and conc. 
sulphuric acid (1 mL) in anhydrous MeOH (20 mL) was refluxed for 17 h.  After cooling 
to room temperature, the reaction mixture was concentrated in vacuo, the crude residue 
dissolved in EtOAc (50 mL), and washed successively with saturated aqueous NaHCO3, 
water, brine (50 mL each), dried (MgSO4) and concentrated in vacuo to yield the crude 
product 236  as a colourless oil (3.45 g, 91%), which was used without further purification.  
1
H NMR (CDCl3, 400 MHz) δ 1.79-1.83 (m, 4H, 2 x CH2), 2.78-2.82 (m, 4H, 2 x CH2), 
3.89 (s, 3H, CH3), 7.11 (d, J = 7.6 Hz, 1H), 7.72-7.75 (m, 2H).  
13
C NMR (CDCl3, 100 
MHz) δ 22.98, 23.08, 29.40, 29.73, 52.01, 126.63, 127.44, 129.27, 130.53, 137.40, 142.94, 
167.54.  HRMS (ESI+) calcd. for C12H15O2  [M+H]
+
: 191.10666; found: 191.10661.  Anal. 
calcd. for C12H14O2·⅓H2O: C, 73.47; H, 7.53.  Found: C, 73.31; H, 7.39.   
5.2.5.14. Diphenyl(5,6,7,8-tetrahydronaphthalen-2-yl)methanol (46). 
 
Phenyllithium solution (1.8 M in Et2O, 13.8 mL, 25 mmol) was added to a solution of 239 
(1.90 g, 10 mmol) in anhydrous Et2O (3.5 ml) at -84 °C, and stirred for 1 h whilst 
maintaining the temperature below -70 °C.  The reaction mixture was allowed to warm to 
room temperature and stirred for 20 h, then quenched with saturated aqueous NH4Cl 
solution (25 mL) and extracted EtOAc (3 x 20 mL).  The combined organic extracts were 
washed successively with H2O and brine (50 mL each), dried (MgSO4) and concentrated in 
vacuo.  Purification of the crude material by flash chromatography [SiO2; 0-16% EtOAc in 
hexane] afforded the tertiary alcohol 46 as a white solid (1.76 g, 56%).  Mpt. 101-103 °C.  
1
H NMR (CDCl3, 500 MHz) δ 1.77-1.82 (m, 4H, 2 x CH2), 2.69-2.72 (m, 2H, CH2), 2.74-
2.78 (m, 3H), 6.92 (dd, J = 1.9, 8.0 Hz, 1H), 7.00 (d, J = 8.1 Hz, 1H), 7.26-7.34 (m, 10H).  
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13
C NMR (CDCl3, 125 MHz) 23.33, 29.19, 29.71, 82.02, 125.39, 127.24, 127.98, 128.05, 
128.52, 128.74, 136.35, 136.84, 144.19, 147.22.  HRMS (ESI+) calcd. for C23H21 [M-
OH]
+
: 297.16378; found: 297.16373.  Anal. calcd. for C23H22O·¼H2O: C, 86.62; H, 7.11.  
Found: C, 86.62; H, 7.23.   
5.2.5.15.  (3-Ethylphenyl)(diphenyl)methanol (47). 
 
The title compound was prepared using an adaptation of general procedure (ii) with 1-
bromo-3-ethylbenzene (1.11 g, 6 mmol) and n-butyllithium (2.5 M in hexane, 2.90 mL, 7.2 
mmol) in anhydrous THF:toluene (1:4, 11.4 mL) and subsequently benzophenone (1.33 g, 
7.30 mmol) in anhydrous toluene (7.2 mL).
254
  The reaction was maintained at ≤ -70 °C for 
1 h after addition of n-butyllithium, and for 4 h after the addition of benzophenone.  
Purification by flash chromatography [SiO2; 0-12% EtOAc in petroleum ether (60/80)] 
afforded the trityl alcohol 47 as a colorless oil (0.86 g, 50%).  
1
H NMR (500 MHz, CDCl3) 
δ = 1.20 (t, J = 7.6 Hz, 3H, CH3), 2.62 (q, J = 7.6 Hz, 2H, CH3), 2.80 (s, 1H, OH), 7.02-
7.04 (m, 1H), 7.13-7.14 (m, 1H), 7.18-7.19 (m, 1H), 7.23 (t, J = 7.7 Hz, 1H), 7.27-7.34 (m, 
10H).
 
 
13
C NMR (125 MHz, CDCl3) δ = 15.70, 29.07, 125.60, 126.90, 127.33, 127.55, 
127.94, 128.02, 128.08, 144.11, 146.99, 147.13.   HRMS (ESI+) calcd. for C22H19  
[M+H]
+
: 271.14813; found: 271.14758.  Anal. calcd. for  C21H20O: C, 87.46; H, 6.99.  
Found: C, 87.41; H, 6.99. 
5.2.5.16. Diphenyl(3-(propan-2-yl)phenyl)methanol (48).   
 
The title compound was prepared using an adaptation of the procedures described by 
Zhang et al. and Deshpande et al.
254, 255
 n-Butyllithium (2.5 M in hexane, 4.8 mL, 12.2 
mmol) was added to a cooled (-78 °C) solution of 1-bromo-3-(propan-2-yl)benzene (1.55 
mL, 10 mmol) in anhydrous THF (10 mL).  The reaction mixture was stirred for 1 h at -78 
°C, treated with a solution of benzophenone (2.10 g, 11.5 mmol) in anhydrous THF (10 
  
157 
 
mL) and stirred for a further 3 h at ≤ -70 °C. The mixture was allowed to warm to room 
temperature, stirred for 17 h, quenched with saturated aqueous NH4Cl solution (10 mL) 
and extracted with EtOAc (3 x 10 mL).  The combined organic layers were then washed 
successively with H2O and brine (75 mL each), dried (MgSO4) and concentrated in vacuo.  
Purification by flash chromatography [SiO2; 0-12% EtOAc in petroleum ether (40/60)] 
afforded the trityl alcohol 48 as a white solid (1.41 g, 47%).  Mpt. 51-54 °C.  
1
H NMR 
(500 MHz, CDCl3) δ = 1.22 (d, J = 7.0 Hz, 6H, 2 x CH3), 2.83-2.92 (m, 2H), 7.03-7.05 (m, 
1H), 7.17-7.19 (m, 1H), 7.22-7.26 (m, 2H), 7.29-7.35 (m, 10H).  
13
C NMR (125 MHz, 
CDCl3) δ = 24.11, 34.29, 82.28, 125.29, 125.76, 126.36, 127.30, 127.90, 128.00, 128.08, 
146.90, 147.17, 148.73.  HRMS (ESI+) calcd. for C22H21 [M-OH]
+
: 285.16378; found: 
285.16408.  Anal. calcd. for C22H22O·½H2O: C, 84.85; H, 7.44 Found: C, 85.02; H, 7.24.   
5.2.5.17. Diphenyl(3-propylphenyl)methanol (49).   
 
The title compound was prepared using an adaptation of the procedure for 48 using 1-
bromo-3-propylbenzene 80 (1.78 g, 8.92 mmol) and n-butyllithium (2.5 M in hexane, 4.28 
mL, 10.71 mmol) in anhydrous THF (8.92 mL), and subsequently benzophenone (1.79 g, 
9.81 mmol) in anhydrous THF (9.81 mL), with the following modifications.  The reaction 
was maintained at ≤ -70 °C for 2 h after the addition of benzophenone.  Purification by 
flash chromatography [SiO2; 0-15% EtOAc in hexane] afforded the trityl alcohol 49 as a 
white solid (1.12 g, 41%).  Mpt 42-43 °C.  
1
H NMR (CDCl3, 500 MHz) δ = 0.90 (t, J = 7.4 
Hz, 3H, CH3), 1.59 (p, J = 7.5 Hz, 2H, CH2), 2.55 (t, J = 7.6 Hz, 2H, CH2), 2.78 (s, 1H, 
OH), 7.02-7.04 (m, 1H), 7.10-7.11 (m, 1H), 7.13-7.14 (m, 1H), 7.21 (t, J = 7.6 Hz, 1H), 
7.27-7.34 (m, 10H).  
13
C NMR (CDCl3, 125 MHz) δ 13.92, 24.69, 38.25, 82.20, 125.56, 
127.32, 127.54, 127.87, 128.02, 128.08, 128.18, 142.56, 146.90, 147.14.  HRMS (ESI+) 
calcd. for C22H21 [M-OH]
+
: 285.16378; found: 285.16354.  Anal. calcd. for C22H22O: C, 
87.38; H, 7.33.  Found: C, 87.05; H, 7.60.   
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5.2.5.18. (3-(2-Methyl-1,3-dioxolan-2-yl)phenyl)(diphenyl)methanol (50). 
 
The title compound was prepared using general procedure (ii) with dioxolane 77 (1.82 g, 
7.50 mmol) and n-butyllithium (2.5 M in hexane, 3.60 mL, 9.00 mmol) in anhydrous THF 
(7.5 mL), and subsequently benzophenone (1.57 g, 8.63 mmol) in anhydrous THF (8.63 
mL), with the following modifications.  The reaction was maintained at ≤ -70 °C for 1 h 
after addition of n-butyllithium, and for 5 h after the addition of benzophenone.  
Purification by flash chromatography [SiO2; 0-30% EtOAc in hexane with 1% NH4OH] 
afforded the trityl alcohol 50 as a white solid (1.82 g, 70%).  Mpt. 104-105 °C.  
1
H NMR 
(400 MHz, CDCl3) δ = 1.62 (s, 3H, CH3), 2.82 (s, 1H, OH), 3.69-3.73 (m, 2H, CH2), 3.97-
4.01 (m, 2H, CH2), 7.15-7.18 (m, 1H), 7.25-7.34 (m, 11H), 7.39-7.43 (m, 1H), 7.49 (t, J = 
1.8 Hz, 1H).  
13
C NMR (100 MHz, CDCl3) δ = 27.58, 64.53, 82.16, 108.95, 124.45, 
124.81, 127.42, 127.66, 127.89, 128.04, 128.07, 143.08, 147.02.  HRMS (ESI+) calcd. for 
C23H23O3S [M+H]
+
: 347.1642; found: 363.1639.  Anal. calcd. for C22H22O3: C, 79.74; H, 
6.40.  Found: C, 79.55; H, 6.15.   
5.2.5.19. Diphenyl(3-(trifluoromethoxy)phenyl)methanol (51).   
 
The title compound was prepared using an adaptation of the procedure for 48 using 1-
bromo-3-(trifluoromethoxy)benzene (1.49 mL, 10 mmol) and n-butyllithium (2.5 M in 
hexane, 4.80 mL, 12.2 mmol) in anhydrous THF (10 mL), and subsequently benzophenone 
(2.10 g, 11.5 mmol) in anhydrous THF (10 mL).  Purification by flash chromatography 
[SiO2; 0-12% EtOAc in petroleum ether (40/60)] afforded the trityl alcohol 51 as a 
colourless oil (0.80 g, 23%).  
1
H NMR (500 MHz, CDCl3) δ = 2.85 (s, 1H, OH), 7.13-7.15 
(m, 1H), 7.21-7.35 (m, 13H).  
13
C NMR (125 MHz, CDCl3) δ = 81.82, 119.61, 120.61 (q, 
JCF = 257.8 Hz), 120.81, 121.64, 126.51, 127.77, 127.96, 128.29, 129.27, 146.37, 149.17, 
149.37.  
19
F NMR (376.5MHz, DMSO-d6) δ = -57.75.  HRMS (ESI+) calcd. for C20H14OF3  
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[M-OH]
+
: 327.09913; found: 327.09950.  Anal. calcd. for C20H15F3O2·¼H2O: C, 68.86; H, 
4.48.  Found: C, 68.90; H, 4.53.   
5.2.5.20.  (3-(Methylsulfanyl)phenyl)(diphenyl)methanol (52). 
 
The title compound was prepared using an adaptation of the procedure for 48 using (3-
bromophenyl)(methyl)sulfane (1.35 mL, 10 mmol) and n-butyllithium (2.5 M in hexane, 
4.80 mL, 12.2 mmol) in anhydrous THF (10 mL), and subsequently benzophenone (2.10 g, 
11.5 mmol) in anhydrous THF (10 mL).  Purification by flash chromatography [SiO2; 0-
15% EtOAc in petroleum ether (40/60)] afforded the tertiary alcohol 52 as a colorless oil 
(1.67 g, 54%).  
1
H NMR (500 MHz, CDCl3) δ = 2.40 (s, 3H, CH3), 2.83 (s, 1H, OH), 7.01-
7.03 (m, 1H), 7.16-7.18 (m, 1H), 7.21-7.33 (m, 12H).  
13
C NMR (125 MHz, CDCl3) δ = 
15.81, 82.08, 125.05, 125.34, 126.01, 127.51, 128.03, 128.12, 128.42, 138.37, 146.72, 
147.65. HRMS (ESI+) calcd. for C20H17S [M-OH]
+
: 289.10455; found: 289.104581.  Anal. 
calcd. for C20H18O2S: C, 78.39; H, 5.92. Found: C, 77.42; H, 5.87.   
5.2.5.21.  (4-(2-Methyl-1,3-dioxolan-2-yl)phenyl)(diphenyl)methanol (54). 
 
The title compound was prepared using general procedure (ii) with dioxolane 78 (1.46 g, 
6.0 mmol) and n-butyllithium (2.5 M in hexane, 2.52 mL, 6.3 mmol) in anhydrous THF (6 
mL), and subsequently benzophenone (1.20 g, 6.6 mmol in anhydrous THF (6 mL) with 
the following modifications.  The reaction was cooled initially to -84 °C, and following n-
butyllithium addition maintained at ≤ -70 °C for 1 h.  After addition of benzophenone, the 
reaction was stirred at ≤ -70 °C for 2 h.  Purification by flash chromatography [SiO2; 
EtOAc/Hexane with 1% NH4OH; 0-30%] afforded the tertiary alcohol 54 as a white solid 
(1.01 g, 49%).  Mpt. 129-130 °C (lit.
256
 128 °C). 
1
H NMR (400 MHz, CDCl3) δ = 1.65 (s, 
3H, CH3), 2.76 (s, 1H, OH), 3.75-3.84 (m, 2H, CH2), 3.99-4.07 (m, 2H, CH2), 7.22-7.33 
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(m, 12H), 7.39-7.43 (m, 2H).  
13
C NMR (100 MHz, CDCl3) δ = 27.65, 64.64, 108.89, 
125.00, 127.42, 127.93, 128.02, 128.08, 142.40, 146.54, 146.92.  HRMS (ESI+) calcd. for 
C23H23O3 [M+H]
+
: 347.1642; found: 347.1639.  Anal. calcd. for C23H22O3: C, 79.74; H, 
6.40.  Found: C, 79.63; H, 6.34.   
5.2.5.22.  (4-Ethoxyphenyl)(diphenyl)methanol (55). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-4-
ethoxybenzene (715 L, 5.00 mmol) and n-butyllithium (2.5 M in hexane, 2.40 mL, 6.00 
mmol) in anhydrous THF (5.00 mL), and subsequently benzophenone (1.050 g, 5.75 
mmol) in anhydrous THF (5.75 mL).  Purification by flash chromatography [SiO2; 0-14% 
EtOAc in hexane] afforded the trityl alcohol 55 as a white solid (0.967 g, 64%).  Mpt. 69-
71 °C.  
1
H NMR (400 MHz, CDCl3) δ = 1.40 (t, J = 7.0 Hz, 3H, CH3), 2.75 (s, 1H, OH), 
4.02 (q, J = 7.0 Hz, 2H, CH2), 6.80-6.84 (m, 2H), 7.13-7.17 (m, 2H), 7.24-7.33 (m, 10H).  
13
C NMR (100 MHz, CDCl3) δ = 14.98, 63.56, 81.89, 113.91, 127.29, 128.01, 129.36, 
139.23, 147.29, 158.26.  HRMS (ESI+) calcd. for C21H19O [M-OH]
+
: 287.14304; found: 
287.14252.  Anal. calcd. for C20H20O2: C, 82.86; H, 6.62.  Found: C, 81.38; H, 6.70. 
5.2.5.23. Diphenyl(4-(trifluoromethoxy)phenyl)methanol (56). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-4-
(trifluoromethoxy)benzene (743 μL, 5.00 mmol) and n-butyllithium (2.5 M in hexane, 2.40 
mL, 6.00 mmol) in anhydrous THF (5.00 mL), and subsequently benzophenone (1.050 g, 
5.75 mmol) in anhydrous THF (5.75 mL).  Purification by flash chromatography [SiO2; 0-
15% EtOAc in hexane] afforded the trityl alcohol 56 as a white solid (655 mg, 38%).  Mpt. 
38-39 °C.  
1
H NMR (400 MHz, CDCl3) δ = 2.78 (s, 1H, OH), 7.12-7.17 (m, 2H), 7.23-7.36 
(m, 12H).  
19
F NMR (376.5 MHz, CDCl3) δ = -57.77.  
13
C NMR (100 MHz, CDCl3) δ = 
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81.78, 120.33, 120.61 (q, JCF = 257.3 Hz), 127.70, 127.94, 128.27, 129.58, 145.53, 146.56, 
148.42 (q, JCF = 1.6 Hz).  HRMS (ESI+) calcd. for C20H14F3O [M-OH]
+
: 327.09913; 
found: 327.09848.  Anal. calcd. for C20H15F3O2: C, 69.76; H, 4.39.  Found: C, 69.63; H, 
4.44. 
5.2.5.24. (4-(Methylsulfanyl)phenyl)(diphenyl)methanol (57). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-4-
(methylsulfanyl)benzene (1.625 g, 8.0 mmol)  and n-butyllithium (2.5 M in hexane, 3.84 
mL, 9.6 mmol)) in anhydrous THF (8.00 mL), and subsequently benzophenone (1.676 g, 
9.2 mmol) in anhydrous THF (9.20 mL) with the following modifications.  The reaction 
was maintained at ≤ -70 °C for 1 h following addition of n-butyllithium, and 2 h after the 
addition of benzophenone.  Purification by flash chromatography [SiO2; 0-25% EtOAc in 
hexane;] afforded the tertiary alcohol 57 as an opaque white oil (1.860 g, 76%).  
1
H NMR 
(400 MHz, CDCl3) δ = 2.47 (s, 3H, CH3), 2.75 (s, 1H, OH), 7.16-7.21 (m, 4H), 7.24-7.34 
(m, 10H).  
13
C NMR (100 MHz, CDCl3) δ = 15.80, 81.92, 126.04, 127.47, 128.01, 128.12, 
128.58, 137.65, 143.91, 146.89.  HRMS (ESI+) calcd. for C20H17S [M-OH]
+
: 289.1045; 
found: 289.1043.  Anal. calcd. for C20H18OS: C, 78.39; H, 5.92.  Found: C, 78.05; H, 5.69.   
5.2.5.25. (2-Fluoro-3-methylphenyl)(diphenyl)methanol (58). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-2-fluoro-3-
methylbenzene (1.70 g, 9.0 mmol) and n-butyllithium (2.5 M in hexane, 3.96 mL, 9.9 
mmol) in anhydrous THF (15.0 mL), and subsequently benzophenone (1.37 g, 7.5 mmol) 
in anhydrous THF (7.5 mL) with the following modifications.  The reaction was 
maintained at ≤ -70 °C for 1 h following addition of n-butyllithium, and 2 h after the 
addition of benzophenone.  Purification by flash chromatography [SiO2; 0-10% EtOAc in 
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hexane] afforded the trityl alcohol 58 as a white solid (1.74 g, 80%).  Mpt. 64-67 °C.  
1
H 
NMR (400 MHz, CDCl3) δ = 2.26 (m, 3H, CH3), 3.61-3.66 (m, 1H, OH), 6.53-6.58 (m, 
1H), 6.88-6.92 (m, 1H), 7.14-7.19 (m, 1H), 7.27-7.39 (m, 10H).  
19
F NMR (376.5 MHz, 
CDCl3) δ = -114.90.  
13C NMR (400 MHz, MeOD) δ = 14.60 (d, JCF = 5.6 Hz), 81.27, 
123.19 (d, JCF = 3.6 Hz), 125.74 (d, JCF = 18.4 Hz), 127.59, 127.73, 128.09, 131.49 (d, JCF 
= 5.3 Hz), 134.11(d, JCF = 11.0 Hz), 145.85, 159.68 (d, JCF = 250.3 Hz).  HRMS (ESI+) 
calcd. for C20H16F [M-OH]
+
: 275.1231; found: 275.1229.  Anal. calcd. for C20H17FO: C, 
82.17; H, 5.86.  Found: C, 81.55; H, 5.81.   
5.2.5.26. (2-Fluoro-4-methylphenyl)(diphenyl)methanol (59). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-2-fluoro-4-
methylbenzene (1.14 mL, 9.0 mmol) and n-butyllithium (2.5 M in hexane, 3.96 mL, 9.9 
mmol) in anhydrous THF (15.0 mL), and subsequently benzophenone (1.37 g, 7.5 mmol) 
in anhydrous THF (7.5 mL) with the following modifications.  The reaction was 
maintained at ≤ -70 °C for 2.5 h after the addition of benzophenone.  Purification by flash 
chromatography [SiO2; 0-10% EtOAc in hexane] afforded the trityl alcohol 59 as a 
colourless oil (1.47 g, 67%).  
1
H NMR (400 MHz, CDCl3) δ = 2.34 (s, 3H, CH3), 3.54 (d, J 
= 10.0 Hz, 1H), 6.62 (t, J = 8.4 Hz, 1H), 6.80-6.84 (m, 1H), 6.90 (dd, J = 0.9, 13.0 Hz, 
1H), 7.25-7.36 (m, 10H).  
19
F NMR (376.5 MHz, CDCl3) δ = -111.20.  
13
C NMR (100 
MHz, CDCl3) δ = 21.03, 81.01, 116.92 (d, JCF = 29.3 Hz) 124.4 (d, JCF = 2.7 Hz), 127.59, 
127.72, 128.09, 130.2 (d, JCF = 3.4 Hz), 131.4 (d, JCF = 9.7 Hz), 140.4 (d, JCF = 8.7 Hz), 
145.80, 160.96 (d, JCF = 243.4 Hz).  HRMS (ESI+) calcd. for C20H16F [M-OH]
+
: 275.1231; 
found: 275.1228.  Anal. calcd. for C20H17FO: C, 82.17; H, 5.86.  Found: C, 82.27; H, 5.78. 
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5.2.5.27. (2-Fluoro-4-methoxyphenyl)(diphenyl)methanol (60). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-2-fluoro-4-
methoxybenzene (645 μL, 5.00 mmol) and n-butyllithium (2.5 M in hexane, 2.40 mL, 6.00 
mmol) in anhydrous THF (5.00 mL), and subsequently benzophenone (1.048 g, 5.75 
mmol) in anhydrous THF (5.75 mL).  Purification by flash chromatography [SiO2; 0-20% 
EtOAc in hexane] afforded the trityl alcohol 60 as a white solid (1.165 g, 76%).  Mpt. 84-
87 °C.  
1
H NMR (400 MHz, CDCl3) δ = 2.74 (s, 1H, OH), 3.87 (s, 3H, CH3), 6.85-6.90 (m, 
1H), 6.94-6.97 (m, 1H), 7.02-7.07 (m, 1H), 7.23-7.34 (m, 10H).  
19
F NMR (376.5 MHz, 
CDCl3) δ = -107.90.  
13
C NMR (100 MHz, CDCl3) δ = 56.38, 81.61 (d, JCF = 1.5 Hz), 
112.62, (d, JCF = 2.4 Hz), 116.22 (d, JCF = 19.7 Hz), 123.84 (d, JCF = 3.6 Hz), 127.59, 
127.91, 128.18, 140.17 (d, JCF = 5.1 Hz), 146.70, 146.81 (d, JCF = 10.8 Hz), 151.90 (d, JCF 
= 245.4 Hz).  HRMS (ESI+) calcd. for C20H16FO [M-OH]
+
: 290.11797; found: 290.11737.  
Anal. calcd. for  C20H17FO2·⅓H2O: C, 76.43; H, 5.66.  Found: C, 76.21; H, 5.44. 
5.2.5.28. (3-Fluoro-4-methoxyphenyl)(diphenyl)methanol (61). 
 
The title compound was prepared using general procedure (ii) with 4-bromo-2-fluoro-1-
methoxybenzene (1.03 g, 5.00 mmol) and n-butyllithium (2.5 M in hexane, 2.40 mL, 6.00 
mmol) in anhydrous THF (5.00 mL), and subsequently benzophenone (1.05 g, 5.75 mmol) 
in anhydrous THF (5.75 mL).  Purification by flash chromatography [SiO2; 0-20% EtOAc 
in hexane] afforded the trityl alcohol 61 as an off-white solid (0.93 g, 60%).  Mpt. 54-55 
°C.  
1
H NMR (400 MHz, CDCl3) δ = 3.43-3.48 (m, 1H), 3.78 (s, 3H, CH3), 6.52-6.55 (m, 
1H), 6.60-6.67 (m, 2H), 7.24-7.35 (m, 10H).  
19
F NMR (376.5 MHz, CDCl3) δ = -134.90.  
13
C NMR (100 MHz, CDCl3) δ = 55.73, 80.85, 102.78 (d, JCF = 26.5 Hz), 108.81 (d, JCF = 
2.6 Hz), 126.60 (d, JCF = 10.7 Hz), 127.58, 127.69, 128.10, 130.90 (d, JCF = 5.1 Hz), 
160.70 (d, JCF = 11.7 Hz), 161.60 (d, JCF = 245.6 Hz).  HRMS (ESI+) calcd. for C20H16FO 
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[M-OH]
+
: 290.11797; found: 290.11758.  Anal. calcd. for C20H17FO2·¼H2O: C, 76.78; H, 
5.64.  Found: C, 76.94; H, 5.72. 
5.2.5.29. (3-Ethyl-4-methylphenyl)(diphenyl)methanol (62). 
 
The title compound was prepared using general procedure (ii) with 4-bromo-2-ethyl-1-
methylbenzene 84 (918 mg, 4.61 mmol) and n-butyllithium (2.5 M in hexane, 2.21 mL, 
5.53 mmol) in anhydrous THF (4.61 mL), and subsequently benzophenone (966 mg, 5.30 
mmol) in anhydrous THF (5.30 mL) with the following modifications.  The reaction was 
maintained at ≤ -70 °C for 1 h after addition of n-butyllithium, and for 5 h after the 
addition of benzophenone.  Purification by flash chromatography [SiO2; 0-10% EtOAc in 
hexane] afforded the trityl alcohol 62 as a yellow oil (1.263 g, 91%).  
1
H NMR (CDCl3, 
500 MHz) 1.14 (t, J = 7.6 Hz, 3H, CH3), 2.31 (s, 3H, CH3), 2.59 (q, J = 7.6 Hz, 2H, CH2), 
2.77 (s, 1H, OH), 6.93 (dd, J = 2.0, 7.9 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 1.9 
Hz, 1H), 7.26-7.32 (m, 10H).  
13
C NMR (CDCl3, 125 MHz) δ 14.60, 18.92, 82.11, 125.60, 
127.24, 127.66, 127.98, 128.06, 129.67, 134.96, 142.11, 144.77, 147.26.  HRMS (ESI
+
) 
calcd. for C21H21 [M-OH]
+
: 285.16378; found: 285.16348.  Anal. calcd. for C22H22O: C, 
87.38; H, 7.33.  Found: C, 87.23; H, 6.81. 
5.2.5.30. 3-(Hydroxy(diphenyl)methyl)benzonitrile (63). 
 
The title compound was prepared using an adaptation of the reverse addition method 
developed by Luli ski et al. and the procedure reported by Neumann et al.180, 181  A 
solution of 3-bromobenzonitrile (1.82 g, 10.0 mmol) in anhydrous THF (10 mL) was added 
by slow dropwise addition over 5 min to a solution of n-butyllithium (2.5 M in hexane, 4.2 
mL, 10.5 mmol) at -94 °C, and stirred for 1 h maintaining the temperature ≤ -80 °C.  After 
cooling again to -94 °C, a solution of benzophenone (2.00 g, 11.0 mmol) in anhydrous 
THF was added by slow dropwise addition over 6 min and stirred with the temperature 
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maintained ≤ -50 °C for 4 h.  The reaction mixture was allowed to warm to room 
temperature and stirred for a further 19 h, then quenched with saturated aqueous NH4Cl 
solution (25 mL) and extracted with EtOAc (3 x 25 mL).  The combined organic layers 
were washed successively with H2O and brine (75 mL each), dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-25% EtOAc in 
hexane;] afforded the trityl alcohol 63 as a white solid (2.30 g, 81%).  Mpt. 90-92 °C 
(lit.
257
 96.5-97 °C). 
1
H NMR (400 MHz, CDCl3) δ = 2.85 (s, 1H, OH), 7.20-7.25 (m, 4H), 
7.30-7.38 (m, 6H), 7.42 (t, J = 7.8 Hz, 1H), 7.55-7.62 (m, 2H), 7.65 (s, 1H).   
13
C NMR 
(100 MHz, CDCl3) δ = 81.70, 112.18, 119.05, 127.90, 128.03, 128.47, 128.86, 131.02, 
131.60, 132.48, 145.91, 148.41.  HRMS (ESI+) calcd. for C20H16NO [M+H]
+
: 286.1226; 
found: 286.1224.  Anal. calcd. for C20H15NO: C, 84.19; H, 5.30; N, 4.91.  Found: C, 83.71; 
H, 5.13; N, 4.80.   
5.2.5.31. 4-(Hydroxy(diphenyl)methyl)benzonitrile (64). 
 
The title compound was prepared using an adaptation of the reverse addition method 
developed by Luli ski et al. and the procedure reported by Neumann et al.180, 181  A 
solution of 4-bromobenzonitrile (3.64 g, 20 mmol) in anhydrous THF (20 mL) was added 
by slow dropwise addition over 5 min to a solution of n-butyllithium (2.5 M in hexane, 
8.40 mL, 21 mmol) at -94 °C and stirred for 30 min, maintaining the temperature ≤ -85 °C.  
After cooling again to -94 °C, a solution of benzophenone (4.01g, 22 mmol) in anhydrous 
THF (17 mL) was added by slow dropwise addition over 15 min and stirred for 5 h with 
the temperature maintained ≤ -80 °C.  The mixture was allowed to warm to room 
temperature and stirred for a further 23 h, then quenched with saturated aqueous NH4Cl 
solution (40 mL) and extracted with EtOAc (3 x 40 mL).  The combined organic layers 
were washed successively with H2O (100 mL) and brine (100 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-30% EtOAc in 
hexane] afforded the tertiary alcohol 64 as an off-white solid (3.86 g, 68%).  Mpt. 85-87 
°C (lit.
257
 92-93.5 °C).  
1
H NMR (500 MHz, CDCl3) δ = 2.85 (s, 1H, OH), 7.22-7.25 (m, 
4H), 7.30-7.36 (m, 6H), 7.46-7.49 (m, 2H), 7.59-7.61 (m, 2H).  
13
C NMR (125 MHz, 
CDCl3) δ = 81.92, 111.19, 118.92, 127.93, 128.00, 128.44, 128.72, 131.89, 145.90, 152.00.  
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HRMS (ESI+) calcd. for C20H16NO [M+H]
+
: 286.1226; found: 286.1226.  Anal. calcd. For 
C20H15NO: C, 84.19; H, 6.30; N, 4.91.  Found: C, 83.91; H, 5.35; N, 4.81.   
5.2.5.32. 3-(Hydroxy(4-methylphenyl)phenylmethyl)benzonitrile (rac-65). 
 
The title compound was prepared using an adaptation of the reverse addition method 
developed by Luli ski et al. and the procedure reported by Neumann et al.180, 181  A 
solution of 3-bromobenzonitrile (1.18g, 6.50 mmol) in anhydrous THF (6.5 mL) was added 
by slow dropwise addition over 18 min to a solution of n-butyllithium (2.5 M in hexane, 
2.73 mL, 6.80 mmol) at -94 °C, and stirred for 1 h whilst maintaining the temperature ≤ -
90°C.  After cooling to -94 °C, a solution of (4-methylphenyl)(phenyl)methanone (1.40 g, 
7.15 mmol) in anhydrous THF was added by slow dropwise addition over 10 min, and the 
reaction mixture stirred with the temperature maintained ≤ -75 °C for 5 h.  The reaction 
was allowed to warm to room temperature and stirred for a further 16 h, then with 
saturated aqueous NH4Cl solution (15 mL) and extracted with EtOAc (3 x 15 mL).  The 
combined organic layers were washed successively with H2O and brine (50 mL each), 
dried (MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-
18% EtOAc in hexane] afforded the trityl alcohol rac-65 as a colourless oil (1.31 g, 67%).  
1
H NMR (500 MHz, CDCl3) δ = 2.36 (s, 3H, CH3), 2.81 (s, 1H, OH), 7.08-7.11 (m, 2H), 
7.13-7.16 (m, 2H), 7.22-7.24 (m, 2H), 7.29-7.36 (m, 3H), 7.39-7.43 (m, 1H), 7.54-7.57 (m, 
1H), 7.59-7.61 (m, 1H), 7.64-7.65 (m, 1H).  
13
C NMR (125 MHz, CDCl3) δ = 21.16, 81.56, 
112.13, 119.09, 127.84, 127.88, 127.92, 128.38, 128.41, 128.81, 129.16, 130.94, 131.60, 
132.46, 137.84, 143.10, 146.08, 148.60.  HRMS (ESI+) calcd. for C21H16N [M-OH]
+
: 
282.1277; found: 282.1276.  Anal. calcd. for C21H17NO: C, 84.25; H, 5.72; N 4.68.  Found: 
C, 82.52; H, 5.33; N, 5.32. 
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5.2.5.33. 3-((3-Chlorophenyl)(hydroxy)phenylmethyl)phenol (rac-66). 
 
The title compound was prepared using an adaptation of the procedure for 48 using 1-
bromo-3-chlorobenzene (2.11 mL, 18.00 mmol) and n-butyllithium (2.5 M in hexane, 8.42 
mL, 21.05 mmol) in anhydrous THF (9 mL), and subsequently (3-
hydroxyphenyl)(phenyl)methanone (1.19 g, 6.00 mmol) in anhydrous THF (6 mL), with 
the following modifications.  The reaction was maintained at ≤ -70 °C for 2 h after addition 
of (3-hydroxyphenyl)(phenyl)methanone.  Purification by flash chromatography [SiO2; 0-
25% EtOAc in pet. ether (40/60)] afforded the racemic trityl alcohol rac-66 as a pale 
yellow solid (0.73 g, 39%).  Mpt 95-96 °C.  
1
H NMR (500 MHz, CDCl3) δ = 2.77 (s, 1H, 
OH), 4.81 (br s, 1H, OH), 6.74-6.75 (m, 1H), 6.77 (ddd, J = 0.9, 2.5, 8.0 Hz, 1H), 6.79-
6.82 (m, 1H), 7.15-7.27 (m, 5H), 7.30-7.35 (m, 5H).  
13
C NMR (125 MHz, CDCl3) δ = 
81.71, 114.71, 115.16, 120.61, 126.33, 127.64, 127.80, 127.96, 128.12, 128.29, 129.29, 
129.54, 134.19, 146.15, 148.28, 148.75, 155.46.  HRMS (ESI-) calcd. for C19H14ClO2 [M-
H]
-
: 309.06878; found: 309.06894.  Anal. calcd. for C19H15ClO2: C, 73.43; H, 4.86. Found: 
C, 73.55; H, 5.03.    
5.2.5.34. 3-((3-Ethylphenyl)(hydroxy)phenylmethyl)phenol (rac-67). 
 
The title compound was prepared using general procedure (ii) with 1-bromo-3-
ethylbenzene (2.08 ml, 15 mmol) and n-butyllithium (2.5 M in hexane, 6.20 mL, 15.6 
mmol) in anhydrous THF (15.6 mL), and subsequently (3-
hydroxyphenyl)(phenyl)methanone (1.19 g, 6 mmol) in anhydrous THF (6.0 mL) with the 
following modifications.  The reaction was performed at at -84 °C and maintained at the 
same temperature for 1 h after addition of n-butyllithium, and after addition of (3-
hydroxyphenyl)(phenyl)methanone for 5 h at ≤ -70 °C.  Purification by flash 
chromatography [SiO2; 0-20% EtOAc in hexane] afforded the racemic trityl alcohol rac-67 
as a yellow oil (1.09 g, 59 %).  
1
H NMR (CDCl3, 500 MHz) δ 1.19 (t, J = 7.6 Hz, 3H, 
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CH3), 2.61 (q, J = 7.6 Hz, 2H, CH2), 2.81 (s, 1H, OH), 4.80 (s, 1H, OH), 6.73-6.75 (m, 
1H), 6.77-6.78 (m, 1H), 6.81-6.83 (m, 1H), 7.01-7.03 (m, 1H), 7.11-7.13 (m, 1H), 7.16-
7.23 (m, 2H), 7.27-7.33 (m, 5H).  
13C NMR (MeOD, 125 MHz) δ 15.69, 29.06, 82.09, 
114.33, 115.24, 120.76, 125.57, 126.99, 127.42, 127.51, 127.97, 128.05, 129.28, 144.15, 
146.72, 146.85, 149.01, 155.30.  HRMS (ESI+) calcd. for C21H19O [M-OH]
+
: 287.14304; 
found: 287.14307.  Anal. calcd. for C21H20O2: C, 82.86; H, 6.62.  Found: C, 82.14; H, 6.69.  
5.2.5.35. 3-(Hydroxy(4-methylphenyl)phenylmethyl)phenol (rac-68).   
 
The title compound was prepared using an adaptation of the procedure for 48 using 1-
bromo-4-methylbenzene (3.08 g, 18 mmol) and n-butyllithium (2.5 M in hexane, 8.42 mL, 
21.6 mmol) in anhydrous THF (10 mL), and subsequently (3-
hydroxyphenyl)(phenyl)methanone (1.19 g, 6 mmol) in anhydrous THF (6 mL), with the 
following modifications.  The reaction was maintained at ≤ -70 °C for 2 h after addition of 
(3-hydroxyphenyl)(phenyl)methanone.  Purification by flash chromatography [SiO2; 0-
28% EtOAc in pet. ether (60/80)] afforded the racemic trityl alcohol rac-68 as a white 
solid (0.65 g, 37%).  Mpt. 119-122 °C.  
1
H NMR (500 MHz, CDCl3) δ = 2.35 (s, 3H, CH3), 
2.85 (s, 1H, OH), 5.05 (br s, 1H, OH), 6.73-6.75 (m, 1H), 6.78-6.79 (m, 1H), 6.80-6.82 (m, 
1H), 7.11-7.19 (m, 5H), 7.27-7.33 (m, 5H).  
13
C NMR (125 MHz, CDCl3) δ = 21.15, 81.95, 
114.34, 115.20, 120.67, 127.40, 127.97, 128.01, 128.04, 128.79, 129.27, 137.18, 143.89, 
146.87, 148.97, 155.36.  HRMS (ESI-) calcd. for C20H17O2 [M-H]
-
: 289.12350; found: 
289.12340.  Anal. calcd. for C20H18O2: C, 82.73; H, 6.25.  Found: C, 82.09; H, 6.21.   
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5.2.5.36. Diphenyl(pyridin-3-yl)methanol (69). 
 
n-Butyllithium (2.5 M in hexane, 3.96 mL, 9.96 mmol) was added by slow dropwise 
addition over 8 min to a cooled (-94 °C) solution of 3-bromopyridine (722 μL, 7.5 mmol) 
in anhydrous THF (15 mL) stirred for 1 h at ≤ -70 °C.  A solution of benzophenone (1.50 
g, 8.25 mmol) in anhydrous THF (8.25 mL) was then added by slow dropwise addition 
over 10 min, and the reaction mixture stirred with the temperature maintained ≤ -85 °C for 
3 h, before allowing the reaction to warm slowly to room temperature and stirring for a 
further 15 h.  The reaction was quenched with aqueous HCl (1.0 M, 15 mL) and washed 
with Et2O (50 mL).  The organic washings were extracted with aqueous HCl (1.0 M, 3 x 20 
mL), and the combined aqueous layers basified (circa. pH 9) with saturated aqueous 
sodium carbonate solution, and extracted with Et2O (3 x 100 mL).  These organic extracts 
were washed with brine (100 mL), dried (MgSO4) and concentrated in vacuo.  Purification 
by flash chromatography [SiO2; 20-60% EtOAc in hexane] afforded the tertiary alcohol 69 
as a white solid (565 mg, 29%).  Mpt. 105-107 °C (lit.
258
 115-116 °C from EtOAc).  
1
H 
NMR (400 MHz, CDCl3) δ = 3.62 (br s, 1H, OH), 7.17-7.35 (m, 11H), 7.62-7.66 (m, 1H), 
8.39-8.48 (m, 2H).  
13
C NMR (400 MHz, CDCl3) δ = 80.79, 122.89, 127.77, 127.94, 
128.33, 135.62, 142.56, 146.20, 148.27, 149.47.  HRMS (ESI+) calcd. for C18H16NO 
[M+H]
+
: 262.1226; found: 262.1224.  Anal. calcd. for C18H15NO: C, 82.73; H, 5.79; N, 
5.36.  Found: C, 82.54; H, 5.47; N, 5.12.   
5.2.5.37. Diphenyl(1,3-thiazol-2-yl)methanol (70). 
 
The title compound was prepared using general procedure (ii) with 2-bromo-1,3-thiazole 
(676 μL, 7.50 mmol) and n-butyllithium (2.5 M in hexane, 3.15 mL, 7.88 mmol) in 
anhydrous THF (30 mL), and subsequently benzophenone (1.05 g, 5.75 mmol) in 
anhydrous THF (5.75 mL) with the following modifications.  The reaction was maintained 
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at ≤ -70 °C for 1 h after addition of n-butyllithium, and for 2 h after the addition of 
benzophenone.  Purification by flash chromatography [SiO2; 0-20% EtOAc in hexane] 
afforded the trityl alcohol 70 as a pale brown solid (825 mg, 41%).  Mpt. 107-108 °C 
(lit.
259
 114-115 °C from pet. ether).  
1
H NMR (400 MHz, CDCl3) δ = 4.20 (s, 1H, OH), 
7.29-7.37 (m, 6H), 7.38-7.44 (m, 4H), 7.81 (d, J = 3.3 Hz, 1H).  
13
C NMR (400 MHz, 
CDCl3) δ = 80.84, 120.19, 127.58, 128.12, 128.28, 142.81, 145.46, 177.39.  HRMS (ESI+) 
calcd. for C16H12NS [M-OH]
+
: 250.0685; found: 250.0683.  Anal. calcd. for C16H13NOS: 
C, 71.88; H, 4.90; N, 5.24.  Found: C, 70.85; H, 4.48; N, 5.06. 
5.2.5.38.  1,3-Oxazol-2-yl)(diphenyl)methanol (71). 
 
n-Butyllithium (2.5 M in hexane, 3.96 mL, 9.96 mmol) was added by slow dropwise 
addition over 15 min to a cooled (-94 °C) solution of oxazole (0.59 mL, 9 mmol) in 
anhydrous THF (25 mL) stirred for 30 min.  A solution of benzophenone (1.37 g, 7.50 
mmol) in anhydrous THF (7.5 mL) was then added by slow dropwise addition, and the 
reaction mixture stirred with the temperature maintained ≤ -85 °C for 1.5 h, before 
allowing the reaction to warm slowly to room temperature and stirring for a further 16 h.  
The reaction was quenched with saturated aqueous NH4Cl solution (15 mL) and extracted 
with Et2O (3 x 40 mL).  The combined organic layers were washed with aqueous HCl (1.0 
M, 3 x 10 mL), dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-15% EtOAc in hexane] afforded the tertiary alcohol 71 as a 
white solid (507 mg, 27%).  Mpt. 97.5-98.5 °C (lit.
183
 100-102 °C).  
1
H NMR (400 MHz, 
CDCl3) δ = 4.59 (br s, 1H, OH), 7.05 (d, J = 0.8 Hz, 1H).  7.31-7.36 (m, 10H), 7.65 (d, J = 
0.8 Hz, 1H).  
13
C NMR (400 MHz, CDCl3) δ = 78.43, 126.91, 127.32, 128.19, 128.28, 
139.78, 143.67, 166.94.  HRMS (ESI+) calcd. for C16H12NO [M+H]
+
: 234.0913; found: 
234.0909.  Anal. calcd. for C16H13NO2: C, 76.48; H, 5.21; N 5.57.  Found: C, 76.64; H, 
4.95; N, 5.34. 
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5.2.5.39. 2-(3-Bromophenyl)-2-methyl-1,3-dioxolane (77). 
 
Anhydrous ethylene glycol (2.31 mL, 42.0 mmol) and a catalytic amount of p-
toluenesulfonic acid monohydrate (114 mg, 0.6 mmol) were added to a solution of 1-(4-
bromophenyl)ethanone (1.59 mL, 12.0 mmol) in anhydrous toluene (80 mL) and the 
reaction mixture refluxed, using a Dean-Stark trap, for 20 h.  The reaction was cooled to 
room temperature, washed with brine (40 mL) and concentrated in vacuo to give the crude 
acetal 77 as a colourless oil, which was taken to the next step without further purification 
(2.64 g, 90%).  
1
H NMR (400 MHz, CDCl3) δ = 1.63 (s, 3H, CH3), 3.73-3.81 (m, 2H, 
CH2), 4.00-4.08 (m, 2H, CH2), 7.21-7.37 (t, J = 7.9 Hz, 1H), 7.39-7.44 (m, 2H), 7.63-7.65 
(m, 1H).  
13C NMR (100 MHz, CDCl) δ = 27.70, 64.68, 108.30, 124.14, 128.68, 130.04, 
131.07, 145.98. 
5.2.5.40. 2-(4-Bromophenyl)-2-methyl-1,3-dioxolane (78). 
 
Anhydrous ethylene glycol (1.32 mL, 24.0 mmol) and a catalytic amount of p-
toluenesulfonic acid monohydrate (114 mg, 0.6 mmol) were added to a solution of 1-(4-
bromophenyl)ethanone (2.39 g, 12.0 mmol) in anhydrous toluene (80 mL) and the reaction 
mixture refluxed, using a Dean-Stark trap, for 20 h.  The reaction was cooled to room 
temperature, washed with brine (40 mL) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-12% EtOAc in hexane with 1% NH4OH] yielded acetal 78 as a 
white solid (1.88 g, 65% yield), which was used directly in the next reaction.  
1
H NMR 
(400 MHz, CDCl3) δ = 1.64 (s, 3H, CH3), 3.73-3.77 (m, 2H, CH2), 4.01-4.05 (m, 2H, 
CH2), 7.33-7.37 (m, 2H), 7.4 3-7.49 (m, 2H).  
13C NMR (100 MHz, CDCl) δ = 27.74, 
64.70, 108.67, 122.10, 127.39, 131.55, 142.67.   
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5.2.5.41. 1-Bromo-3-propylbenzene (80).   
 
The title compound was prepared using an adaptation of the procedure reported by 
Chackal-Catoen et al.
260
  Hydrazine hydrate monohydrate
 
(2.18 mL, 45 mmol) was added 
to a solution of 1-(3-bromophenyl)propan-1-one (3.20 g, 15 mmol) and powdered KOH 
(2.53 g, 45 mmol) in anhydrous ethylene glycol (18.6 mL) and refluxed for 4 h.  After 
cooling to room temperature, the reaction was quenched was aqueous HCl (1.0 M, 70 mL) 
and extracted with CH2Cl2 (3 x 50 mL).  The organics were washed successively with 
water and brine (100 mL each), dried (MgSO4) and concentrated in vacuo and the residue 
purified by flash chromatography [SiO2; hexane] to afford the alkane 80 as a colorless oil 
(2.03 g, 68%).  
1
H NMR (CDCl3, 400 MHz) δ = 0.94 (t, J = 7.5 Hz, 3H, CH3), 1.63 (p, J = 
7.5 Hz, 2H, CH2), 2.56 (t, 2H, J = 7.5 Hz, 2H, CH2), 7.09-7.16 (m, 2H), 7.30-7.34 (m, 2H).  
13
C NMR (CDCl3, 125 MHz) δ 13.85, 24.47, 37.81, 122.46, 127.28, 128.88, 129.92, 
131.66, 145.17.  GC-MS (EI, 70 eV) tR = 4.72 min (m/z = 197.9, [M
+
]).   
5.2.5.42. 5-Bromo-N-methoxy-N,2-dimethylbenzamide (82).   
 
Oxalyl chloride (3.43 ml, 40 mmol) was added to a solution of 5-bromo-2-methylbenzoic 
acid (4.30 g, 20 mmol) in anhydrous CH2Cl2 (20 ml), with a catalytic amount of DMF (1 
drop), and stirred at room temperature for 2 h.  The reaction mixture was concentrated in 
vacuo, and the residual oil added by slow dropwise addition over 5 min to a cooled (0 °C) 
solution of N,O-dimethylhydroxylamine hydrochloride (2.24 g, 23 mmol) and 
triethylamine (3.67 mL, 50 mmol) in anhydrous CH2Cl2 (20 ml).  After stirring for 1 h, the 
reaction mixture was warmed to room temperature, stirred for 20.5 h, then quenched with 
water followed by aqueous HCl (0.5 M, 25 mL), and extracted with CH2Cl2 (3 x 25 mL).  
The combined organic extracts were dried (MgSO4), concentrated in vacuo, and purified 
by flash chromatography [SiO2; 0-50% EtOAc in hexane] to afford amide 82 as a 
colourless oil (3.63 g, 70%).  
1
H NMR (CDCl3, 500 MHz) δ 2.26 (s, 3H, CH3), 3.30 (br s, 
3H, CH3), 3.48 (br s, 3H, CH3), 7.07 (d, J = 8.6 Hz, 2H), 7.38-7.40 (m, 2H).  
13
C NMR 
(CDCl3, 125 MHz) δ 18.77, 61.33, 118.95, 129.13, 131.95, 132.23, 134.06, 137.20.  
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HRMS (ESI+) calcd. for C10H13BrNO2 [M+H]
+
: 258.01242; found: 258.01244.  Anal. 
calcd. for C10H12BrNO2: C, 46.53; H, 4.69; N, 5.43.  Found: C, 45.03; H, 4.78; N, 5.60.   
5.2.5.43. 1-(5-Bromo-2-methylphenyl)ethanone (83).   
 
The title compound was prepared using an adaptation of the procedure reported by 
Hirashima et al.
261
  MeMgCl (3.0 M in THF, 8.27 mL, 24.8 mmol) was added by slow 
dropwise addition over 10 min to a cooled (0 °C) solution of Weinreb amide 82 (3.27 g, 
12.4 mmol) in THF (12.4 mL) and stirred for 2 h.  The reaction mixture was warmed to 
room temperature, stirred for 2 h, before quenching with saturated aqueous NH4Cl solution 
(20 mL) and extracting with EtOAc (3 x 25 mL).  The organics were washed successively 
with water and brine (75 ml each), dried (MgSO4) and concentrated in vacuo to afford 
ketone 83 as a clear pale brown oil (2.40 g, 91%), which was used without further 
purification.  
1
H NMR (CDCl3, 500 MHz) δ 2.45 (s, 3H, CH3), 2.56 (s, 3H, CH3), 7.11 (d, 
J = 8.2 Hz, 1H), 7.48 (dd, J = 2.1, 8.2 Hz, 1H), 7.77 (d, J = 2.1 Hz, 1H).  
13
C NMR 
(CDCl3, 125 MHz) δ 22.10, 29.62, 119.24, 132.11, 133.77, 134.39, 137.29, 139.46.  GC-
MS (EI, 70 eV) tR = 4.68 min (m/z = 211.9, [M
+]).  Anal. calcd. for C9H9BrO C, 50.73; H, 
4.26.  Found: C, 50.44; H, 4.30.   
5.2.5.44. 4-Bromo-2-ethyl-1-methylbenzene (84).   
 
The title compound was prepared using an adaptation of the method described for 80.  
Ketone 83 (2.13 g, 10 mmol) in anhydrous ethylene glycol (10 ml) afforded after refluxing 
for 4 h, aqueous workup and purification by flash chromatography [SiO2; hexane] afforded 
alkane 84 as a colourless oil (1.10 g, 55 %).  
1
H NMR (CDCl3, 400 MHz) δ 1.20 (t, J = 7.5 
Hz, 3H, CH3), 2.24 (s, 3H, CH3), 2.59 (q, J = 7.5 Hz, 2H, CH2), 7.00 (d, J = 8.0 Hz, 1H), 
7.22 (dd, J = 2.0, 8.0 Hz, 1H), 7.28 (d, J = 1.9 Hz, 1H).  
13
C NMR (CDCl3, 100 MHz) δ 
14.21, 18.84, 26.18, 119.63, 128.72, 130.80, 131.71, 134.83, 144.68.  GC-MS (EI, 70 eV) 
tR = 4.90 min (m/z = 199.8, [M
+
]). 
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5.2.5.45. 3-(Hydroxy(diphenyl)methyl)benzamide (85). 
 
This hydrolysis protocol is a modification of the literature procedure reported by Iso et 
al.
262
  Hydrogen peroxide (30% in H2O, 536 µl, 5.25 mmol) and aqueous NaOH (6.0 M, 
350 µL, 2.1 mmol) were added to a solution of benzonitrile 63 (494 mg, 1.75 mmol) in 
EtOH (7.69 mL) and stirred at 60 °C for 4 h.  After cooling to room temperature, the 
reaction mixture was partitioned between CH2Cl2 (75 mL) and aqueous HCl (0.25 M, 
25mL).  The organic layer was washed successively with H2O (and brine (75 mL each), 
dried (MgSO4) and concentrated in vacuo.  Purification of the crude by flash 
chromatography [SiO2; 40-100% EtOAc in hexane] afforded the amide 85 as a white solid 
(440 mg, 83%).    Mpt. 168-169 °C.  
1H NMR (400 MHz, MeOD) δ = 7.23-7.32 (m, 10H), 
7.35-7.43 (m, 2H), 7.73-7.76 (m, 1H), 7.88-7.90 (m, 1H).  
13C NMR (100 MHz, MeOD) δ 
= 82.70, 127.06, 128.15, 128.46, 128.79, 129.26, 132.78, 134.57, 148.46, 149.61, 172.52.  
HRMS (ESI+) calcd. for C22H23N2OS [M+H]
+
: 363.1526; found: 363.1522.  Anal. calcd. 
for C20H17NO2: C, 79.19; H, 5.65; N, 4.62.  Found: C, 78.99; H, 5.57; N, 4.49.   
5.2.5.46. 4-(Hydroxy(diphenyl)methyl)benzamide (86). 
 
The title compound was prepared using an adaptation of the procedure for 85 with 
benzonitrile 64 (571 mg, 2.0 mmol), hydrogen peroxide (30% in H2O, 612 µl, 6.0 mmol) 
and aqueous NaOH (6.0 M, 400 µL, 2.4 mmol) in EtOH (15 mL) at 60 °C for 3 h.  
Purification by flash chromatography [SiO2; 50-90% EtOAc in hexane] afforded amide 86 
as a white solid (502 mg, 83%).    Mpt. 176-179 °C (lit.
263
 188 °C from MeOH). 
1
H NMR 
(500 MHz, MeOD) δ = 7.23-7.32 (m, 10H), 7.35-7.39 (m, 2H), 7.89-7.92 (m, 2H).  13C 
NMR (125 MHz, MeOD) δ = 82.68, 128.03, 128.20, 128.79, 128.79, 129.23, 129.33, 
133.48, 148.35, 152.91, 172.18.  HRMS (ESI+) calcd. for C20H18NO2 [M+H]
+
: 304.1332; 
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found: 304.1330.  Anal. calcd. for C20H17NO2: C, 79.19; H, 5.65; N, 4.62.  Found: C, 
79.01; H, 5.60; N, 4.56.   
5.2.5.47. 3-(Hydroxy(4-methylphenyl)phenylmethyl)benzamide (rac-87) 
 
The title compound was prepared using an adaptation of the procedure for 85 with 
benzonitrile rac-65 (400 mg, 1.34 mmol), hydrogen peroxide (30% in H2O, 409 µl, 4.01 
mmol) and aqueous NaOH (6.0 M, 400 µL, 2.4 mmol) in EtOH (10 mL).  Purification by 
flash chromatography [SiO2; 0-27% MeOH in CH2Cl2] afforded amide rac-87 as a white 
solid (262 mg, 62%).  Mpt. 77-80 °C.  
1H NMR (500 MHz, MeOD) δ = 2.32 (s, 3H, CH3), 
4.57 (s, 1H, OH), 7.09-7.12 (m, 4H), 7.22-7.31 (m, 5H), 7.34-7.42 (m, 2H), 7.72-7.75 (m, 
1H), 7.86-7.88 (m, 1H), 7.61-7.64 (m, 1H), 7.74-7.79 (m, 2H).  
13
C NMR (125 MHz, 
MeOD) δ = 21.02, 82.61, 127.01, 128.10, 128.42, 128.75, 129.22, 129.38, 129.41, 132.77, 
134.50, 137.95, 145.50, 148.56, 149.74, 172.57.  HRMS (ESI+) calcd. for C21H18NO [M-
OH]
+
: 300.1383; found: 300.1380.  Anal. calcd. for C21H19NO2·⅓H2O: C, 78.01; H, 6.13; 
N 4.33.  Found: C, 77.70; H, 5.90; N, 4.21. 
5.2.5.48. 3-(Hydroxy(diphenyl)methyl)benzoic acid (88). 
 
A solution of benzonitrile 63 (1.25 g, 4.37 mmol) and potassium hydroxide (2.728 g, 48.60 
mmol) was refluxed in an EtOH/H2O mixture (1:1, 49 mL) for 24 h.  After cooling to room 
temperature, the EtOH was removed under reduced pressure, the solution washed with 
Et2O (30 mL), acidified (circa pH 1) with aqueous HCl (1.0 M) and extracted with CH2Cl2 
(3 x 50 mL).  The organic extracts were dried (MgSO4) and concentrated in vacuo to yield 
as a white solid 88, which was used without further purification (1.25 g, 94%).  Mpt. 166-
168 °C.  
1
H NMR (400 MHz, DMSO-d6) δ = 6.60 (s, 1H, OH), 7.19-7.22 (m, 4H), 7.24-
7.28 (m, 2H), 7.29-7.34 (m, 4H), 7.41-7.44 (m, 2H), 7.81-7.85 (m, 1H), 7.86-7.88 (m, 1H), 
12.82 (br s, 1H, COOH).  
13
C NMR (100 MHz, DMSO-d6) δ = 80.40, 126.82, 127.69, 
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127.58, 130.20, 132.19, 147.33, 148.29, 167.40.  HRMS (ESI-) calcd. for C20H15O3 [M-H]
-
: 303.1027; found: 303.1028.  Anal. calcd. for C20H16O3∙⅓CH2Cl2: C, 73.42; H, 5.05.  
Found: C, 73.48; H, 5.06.   
5.2.5.49. (4-(Hydroxymethyl)phenyl)(diphenyl)methanol (90). 
 
The title compound was prepared using a modification of the procedure reported by Zee-
Cheng et al.
127
  A solution of 4-(hydroxy(diphenyl)methyl)benzoic acid (304 mg, 1.0 
mmol) in anhydrous THF (4 mL) was added by slow dropwise addition over 3 min to a 
cooled (0 °C) solution of lithium aluminium hydride (1.0 M in THF, 4.5 mL, 4.5 mmol).  
The reaction mixture was allowed to warm to room temperature and stirred for 20.5 h, then 
heated at 65 °C for 1 h.  The reaction was cooled to 0 °C, and quenched with EtOAc (5 
mL), H2O (0.17 mL), aqueous NaOH (15% w/v, 0.17 mL) and H2O (3 x 0.17 mL) and 
stirred for 45 min at room temperature.  After filtering and washing the precipitate with 
EtOAc, the filtrate was washed successively with saturated aqueous NaHCO3 solution, 
H2O and brine (50 mL each), dried (MgSO4) and concentrated in vacuo.  Purification by 
flash chromatography [SiO2; 0-40% EtOAc in hexane] yielded 90 as a white solid (182 
mg, 63%).  Mpt. 112-115 °C (lit.
127
 115-117 °C).  
1
H NMR (400 MHz, CDCl3) δ = 4.67 (s, 
2H, CH2), 7.25-7.33 (m, 14H).  
13
C NMR (100 MHz, CDCl3) δ = 65.23, 82.11, 126.80, 
127.52, 128.11, 128.18, 128.36, 140.01, 146.59, 147.02.  HRMS (ESI+) calcd. for C20H17O 
[M-OH]
+
: 273.1274; found: 273.1272.  Anal. calcd. for C20H18O2: C, 82.73; H, 6.25.  
Found: C, 82.17; H, 6.23.   
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5.2.5.50. 3-(Hydroxy(diphenyl)methyl)-N-methylbenzamide (91). 
 
Methanamine hydrochloride (203 mg, 3.0 mmol), followed by triethylamine (1.26 mL, 9.0 
mmol) and T3P
®
 (50% in DMF, 876 µL, 1.5 mmol) were added to a cooled (0 °C) solution 
of 88 (304 mg, 1.0 mmol) in anhydrous THF (2 mL), and stirred at room temperature for 
44 h.  The reaction was quenched with saturated aqueous NaHCO3 (10 mL) and stirred for 
45 min.  The volatiles were removed in vacuo and the pH was adjusted (circa. pH 7) with 
aqueous HCl (1.0 M) and extracted with CH2Cl2 (3 x 30 mL).  The organic extracts were 
washed successively with H2O and brine (75 mL each), dried (MgSO4), then concentrated 
in vacuo to afford 3-(hydroxy(diphenyl)methyl)-N-methylbenzamide 91 as a white solid, 
which was taken to the next step without further purification (248 mg, 78%).  Mpt. 137-
138 °C.  
1
H NMR (400 MHz, CDCl3) δ = 2.90 (d, J = 4.9 Hz, 3H, CH3), 3.15 (br s, OH), 
6.18 (br s, NH), 7.22-7.36 (m, 12H), 7.67-7.70 (m, 1H), 7.78-7.80 (m, 1H).  
13
C NMR (100 
MHz, CDCl3) δ = 26.90, 82.03, 125.88, 126.25, 127.65, 128.03, 128.24, 131.17, 134.58, 
146.59, 147.45, 168.32.  HRMS (ESI+) calcd. for C21H20NO2 [M+H]
+
: 318.1487; found: 
318.1489.  Anal. calcd. for C21H19NO2: C, 79.47; H, 6.03; N, 4.41.  Found: C, 78.44; H, 
6.07; N, 5.12.   
5.2.5.51. 3-(Hydroxy(diphenyl)methyl)-N,N-dimethylbenzamide (92).   
 
N-methylmethanamine hydrochloride (245 mg, 3.0 mmol), followed by triethylamine (1.25 
mL, 9.0 mmol) and T3P
®
 (50% in DMF, 876 µL, 1.5 mmol) were added to a cooled (0 °C) 
solution of 88 (304 mg, 1.0 mmol) in anhydrous THF (2 mL) and stirred at room 
temperature for 44 h.  The reaction was quenched with saturated aqueous NaHCO3 (10 
mL) and stirred for 1.5 h.  The volatiles were removed in vacuo, and the mixture extracted 
with CH2Cl2 (3 x 30 mL).  The organic extracts were washed successively with H2O and 
brine (75 mL each), dried (MgSO4), then concentrated in vacuo to the amide 92 as a white 
solid, which was taken to the next step without further purification (259 mg, 78%).  Mpt. 
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165-167 °C.  
1
H NMR (500 MHz, CDCl3) δ = 2.87 (s, 3H, CH3), 3.05 (s, 3H, CH3), 7.26-
7.37 (m, 14H).  
13
C NMR (125 MHz, CDCl3) δ = 35.48, 39.65, 82.00, 126.34, 126.75, 
127.58, 128.03, 128.18,   128.28, 129.23, 135.96, 146.65, 147.10, 171.60.  HRMS (ESI+) 
alcd. for C22H22NO2 [M+H]
+
: 332.1645; found: 332.1643.  Anal. calcd. for 
C22H21NO2·⅕H2O: C, 78.58; H, 6.09; N, 4.36.  Found: C, 78.87; H, 6.39; N, 4.57.   
5.2.5.52. 4-(Hydroxy(diphenyl)methyl)-N-methylbenzamide (93).   
 
Methanamine hydrochloride (203 mg, 3.0 mmol), followed by triethylamine (1.26 mL, 9.0 
mmol) and T3P
®
 (50%  in DMF, 876 µL, 1.5 mmol) were added to a cooled (0 °C) 
solution of 4-(hydroxy(diphenyl)methyl)benzoic acid (304 mg, 1.0 mmol) in anhydrous 
THF (2 mL) and stirred at room temperature for 44 h.  The reaction was quenched with 
saturated aqueous NaHCO3 (10 mL) and stirred for 45 min.  The volatiles were removed in 
vacuo and the pH was adjusted (circa. pH 7) with aqueous HCl (1.0 M) and extracted with 
CH2Cl2 (3 x 30 mL).  The organic extracts were washed successively with H2O and brine 
(75 mL each) then concentrated in vacuo.  Purification by flash chromatography [SiO2; 25-
90% EtOAc in hexane] afforded amide 93 as an off-white solid (181 mg, 57%).  Mpt. 62-
64 °C.  
1
H NMR (400 MHz, CDCl3) δ = 2.97 (d, J = 4.9 Hz, 3H, CH3), 3.01 (s, 1H, OH), 
6.17 (br s, 1H, NH), 7.22-7.33 (m, 10H), 7.36-7.38 (m, 2H), 7.65-7.68 (m, 2H).  
13
C NMR 
(100 MHz, CDCl3) δ = 26.96, 81.97, 126.59, 127.65, 128.01, 128.21, 128.23, 133.60, 
146.53, 150.28, 168.15.  HRMS (ESI+) calcd. for C21H20NO2 [M+H]
+
: 318.1489; found: 
318.1487.  Anal. calcd. for C21H19NO2: C, 79.47; H, 6.03; N, 4.41.  Found: C, 79.27; H, 
5.99; N, 4.33.   
5.2.5.53. 4-(Hydroxy(diphenyl)methyl)-N,N-dimethylbenzamide (94).   
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N-Methylmethanamine hydrochloride (245 mg, 3.0 mmol), followed by triethylamine 
(1.25 mL, 9.0 mmol) and T3P
®
 (50%  in DMF, 876 µL, 1.5 mmol) were added to a cooled 
(0 °C) solution of 4-(hydroxy(diphenyl)methyl)benzoic acid (304 mg, 1.0 mmol) in 
anhydrous THF (2.5 mL) and stirred at room temperature for 45 h.  The volatiles were 
removed in vacuo and the residue suspended in saturated aqueous NaHCO3 (10 mL) and 
stirred for 1 h at room temperature.  The pH was adjusted (circa. pH 7) with aqueous HCl 
(1.0 M) and extracted with EtOAc (3 x 30 mL).  The organic extracts were washed 
successively with H2O and brine (75 mL each) then concentrated in vacuo to afford tertiary 
amide 94 as a white solid, which was used without further purification (246 mg, 74%).  
Mpt. 142-143 °C.  
1H NMR (500 MHz, MeOD) δ = 3.00 (s, 3H, CH3), 3.09 (s, 3H, CH3), 
7.23-7.32 (m, 10H), 7.34-7.38 (m, 4H).  
13C NMR (125 MHz, MeOD) δ = 35.64, 40.06, 
82.64, 127.48, 128.17, 128.78, 129.23, 129.38, 135.81, 148.42, 150.91, 173.70.  HRMS 
(ESI+) calcd. for C22H22NO2 [M+H]
+
: 332.1645; found: 332.1642.  Anal. calcd. for 
C22H21NO2: C, 79.73; H, 6.39; N, 4.23.  Found: C, 79.25; H, 6.27; N, 4.02.   
5.2.5.54. (3-(Aminomethyl)phenyl)(diphenyl)methanol (95). 
 
A solution of lithium aluminium hydride (1.0 M in THF, 7.87 mL, 7.87 mmol) was added 
by slow dropwise addition over 8 min to a cooled solution (0 °C) of benzonitrile  63 (936 
mg, 3.28 mmol) in anhydrous THF (10.90 mL).  The reaction mixture was allowed to 
warm to room temperature and stirred for 22 h, and then cooled to 0 °C and quenched by 
slow dropwise addition of H2O (10 mL), followed by aqueous NaOH solution (15% w/v, 5 
mL) and H2O (15 mL).  The suspension was filtered and the precipitate washed with 
CH2Cl2, and the filtrate washed successively with H2O and brine (50 mL each), dried 
(MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-18% 
MeOH in CH2Cl2 with 1% NH4OH] afforded the tertiary alcohol 95 as a white solid (643 
mg, 68%).  Mpt. 136-138 °C.  
1
H NMR (500 MHz, DMSO-d6) δ = 3.66 (s, 2H, CH2), 6.38 
(br s, 1H, OH), 6.97-6.99 (m, 1H), 7.19-7.34 (m, 13H).  
13
C NMR (125 MHz, DMSO-d6) δ 
= 45.72, 80.58, 125.35, 125.87, 126.35, 126.55, 127.17, 127.46, 127.78, 143.19, 147.55, 
147.87.  HRMS (ESI+) calcd. for C20H20NO [M+H]
+
: 290.1539; found: 290.1537.  Anal. 
calcd. for C20H19NO: C, 83.01; H, 6.62; N, 4.84.  Found: C, 82.23; H, 6.43; N, 4.29.    
  
180 
 
5.2.5.55. (4-(Aminomethyl)phenyl)(diphenyl)methanol (96). 
 
A solution of lithium aluminium hydride (1.0 M in THF, 19.2 mL, 19.2 mmol) was added 
by slow dropwise addition over 10 min to a solution of benzonitrile 64 (2.28  g, 8.0 mmol) 
in anhydrous THF (25 mL) at 0 °C.  The reaction mixture was allowed to warm to room 
temperature stirred for 22 h.  It was then cooled to 0 °C and quenched by slow dropwise 
addition of H2O (40 mL), followed by aqueous NaOH solution (15% w/v, 20 mL) and H2O 
(20 mL).  As this failed to break up the aluminium salt emulsion, saturated aqueous 
Na2SO4 solution (250 mL) was added and the mixture stirred for 30 min at room 
temperature.  The mixture was filtered, the precipitate washed with CH2Cl2  and MeOH, 
and the filtrate concentrated to ~50 mL in vacuo, diluted with saturated aqueous Na2SO4 
solution (50 mL) and extracted with CH2Cl2 (3 x 50 mL).  The organic extracts were 
washed with brine (100 mL), dried (MgSO4) and and concentrated in vacuo.  Purification 
by flash chromatography [SiO2; 0-22% MeOH in CH2Cl2 with 1% NH4OH] afforded the 
title compound 96 as an off-white solid (1.34 g, 59%).  Mpt. 138-140 °C.  
1
H NMR (500 
MHz, DMSO-d6) δ = 3.68 (s, 2H, CH2), 6.36 (br s, 1H, OH), 7.11-7.14 (m, 2H), 7.19-7.25 
(m, 8H), 7.27-7.31 (m, 4H).  
13
C NMR (125 MHz, DMSO-d6) δ = 45.29, 80.43, 126.13, 
126.55, 127.45, 127.52, 127.75, 142.49, 145.69, 147.92.  HRMS (ESI+) calcd. for 
C20H20NO [M+H]
+
: 290.1539; found: 290.1536.  Anal. calcd. for C20H19NO: C, 83.01; H, 
6.62; N, 4.84.  Found: C, 82.54; H, 6.52; N, 4.66.   
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5.2.5.56. N-(3-(Hydroxy(diphenyl)methyl)benzyl)acetamide (97). 
 
Acetic anhydride (97 µL, 1.02 mmol) was added to a solution of 95 (270 mg, 0.93 mmol) 
in anhydrous DMF (1.17 mL) and stirred at room temperature for 4 h.  The reaction 
mixture was diluted with aqueous HCl (0.25 M, 5 mL) and extracted with CH2Cl2 (3 x 10 
mL).  The organic extracts were washed successively with saturated aqueous NaHCO3 
solution (20 mL), H2O (2 x 20 mL) and brine (20 mL), dried (MgSO4), and concentrated 
in vacuo to afford amide 97 as a white solid (290 mg, 88%), which was used in the next 
step without further purification.  Mpt. 170-172 °C.  
1
H NMR (500 MHz, DMSO-d6) δ = 
1.81 (s, 3H, CH3), 4.19 (d, J = 6.0 Hz, 2H, CH2), 6.42 (s, 1H, OH), 7.01-7.03 (m, 1H), 
7.11-7.13 (m, 1H), 7.17-7.32 (m, 12H), 8.29 (t, J = 6.0 Hz, 1H, NH).  
13
C NMR (125 MHz, 
DMSO-d6) δ = 22.48, 42.14, 80.51, 125.50, 126.36, 126.43, 126.61, 127.35, 127.48, 
127.77, 147.75, 168.89.  HRMS (ESI+) calcd. for C22H20NO [M-OH]
+
: 314.1539; found: 
314.1538.  Anal. calcd. for C22H21NO2·¼H2O: C, 78.66; H, 6.45; N, 4.17.  Found: C, 
78.72; H, 6.23; N, 3.98.   
5.2.5.57. N-(4-(Hydroxy(diphenyl)methyl)benzyl)acetamide (98). 
 
Acetic anhydride (104 µL, 1.1 mmol) was added to a solution of 96 (289 mg, 1.0 mmol) in 
anhydrous DMF (1.25 mL) and stirred at room temperature for 3 h.  The reaction mixture 
was diluted with aqueous HCl (0.25 M, 10 mL) and extracted with CH2Cl2 (3 x 10 mL).  
The organic extracts were washed successively with saturated aqueous NaHCO3 solution 
(30 mL), H2O (2 x 30 mL) and brine (30 mL), dried (MgSO4), and concentrated in vacuo 
to afford amide 98 as a white solid (286 mg, 86%), which was taken to the next step 
without further purification.  Mpt. 166-168.5 °C.  
1
H NMR (500 MHz, DMSO-d6) δ = 1.85 
(s, 3H, CH3), 4.22 (d, J = 6.0 Hz, 2H, CH2), 6.39 (s, 1H, OH), 7.13-7.25 (m, 10H), 7.27-
7.31 (m, 4H), 7.17-7.32 (m, 12H), 8.29 (t, J = 6.0 Hz, 1H, NH).  
13
C NMR (125 MHz, 
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DMSO-d6) δ = 22.53, 41.78, 80.39, 126.48, 126.61, 127.49, 127.68, 127.74, 137.82, 
146.34, 147.78, 169.05.  HRMS (ESI+) calcd. for C22H22NO2 [M+H]
+
: 332.1645; found: 
332.1643.  Anal. calcd. for C22H21NO2·½H2O: C, 77.62; H, 6.51; N, 4.11.  Found: C, 
77.66; H, 6.42; N, 3.87.   
5.2.5.58.  (3-(Methylsulfonyl)phenyl)(diphenyl)methanol (99). 
 
Intermediate sulfone 99 was prepared by adaptation of the procedure reported by Yeon 
Hwang et al.
264
   m-CPBA (68% pure, 620 mg, 3.59 mmol) was added to a cooled (0 °C) 
solution of 52 (500 mg, 1.63 mmol) in anhydrous CH2Cl2 (4.26 mL) and stirred at the same 
temperature for 3 h.  The reaction was poured into H2O (10 mL) and extracted with CH2Cl2 
(3 x 10 mL).  The organic extracts were washed successively with saturated aqueous 
NaHCO3 solution (3 x 30 mL), brine (30 mL), dried (MgSO4), and concentrated in vacuo.  
Purification by flash chromatography [SiO2; 10-75% EtOAc in hexane] afforded the 
sulfone 99 as a white solid (445 mg, 81%).  Mpt. 143-146 °C.  
1
H NMR (500 MHz, 
CDCl3) δ = 3.02 (s, 3H, CH3), 7.20-7.37 (m, 10H), 7.51 (t, J = 7.8 Hz, 1H), 7.58 (ddd, J = 
1.2, 1.8, 7.8 Hz, 1H), 7.87 (ddd, J = 1.2, 1.8, 7.7 Hz, 1H), 8.06-8.07 (m, 1H).  
13
C NMR 
(125 MHz, CDCl3) δ = 44.58, 81.93, 126.27, 126.49, 128.01, 128.06, 128.52, 129.04, 
133.51, 140.64, 146.14, 148.96.  HRMS (ESI+) calcd. for C20H17O2S [M-OH]
+
: 322.0944; 
found: 322.0941.   
5.2.5.59. (4-(Methylsulfonyl)phenyl)(diphenyl)methanol (100). 
 
The title compound was prepared using an adaptation of the procedure for 99 with 57 (759 
mg, 2.50 mmol) and m-CPBA (68% pure, 1.12 g, 4.41 mmol) in anhydrous CH2Cl2 (8 mL) 
for 7 h.    Purification by flash chromatography [SiO2; 10-100% EtOAc in hexane] 
afforded sulfone 100 as a white solid (395 mg, 58%).  Mpt. 179-180 °C.  
1
H NMR (500 
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MHz, DMSO-d6) δ = 3.20 (s, 3H, CH3), 6.72 (s, 1H, OH), 7.20-7.24 (m, 4H), 7.25-7.36 
(m, 6H), 7.49-7.53 (m, 2H), 7.86-7.89 (m, 2H).  
13
C NMR (125 MHz, DMSO-d6) δ = 
43.52, 80.41, 126.41, 127.02, 127.73, 127.79, 128.53, 139.14, 146.82, 153.37.  HRMS 
(ESI+) calcd. for C20H17O2S [M-OH]
+
: 322.0944; found: 322.0941.  Anal. calcd. for 
C20H18O3S: C, 70.98; H, 5.36.  Found: C, 70.35; H, 5.39. 
5.2.5.60. 2-(Tritylsulfanyl)ethanamine (16). 
 
The title compound was prepared following general procedure (iii) with triphenylmethanol 
(1.95 g, 7.5 mmol) and cysteamine hydrochloride (937 mg, 8.25 mmol) in trifluoroacetic 
acid (7.5 mL).  Purification by flash chromatography [SiO2; 0-16% MeOH in CH2Cl2 with 
1% NH4OH] afforded the thioether 16 as a white solid (1.94 g, 81%).  Mpt. 87-90 °C [lit 
90-93°C from petroleum ether (40/60)].
265
  
1
H NMR (500 MHz, MeOD) δ = 2.32-2.36 (m, 
2H, CH2), 2.41-2.45 (m, 2H, CH2), 7.19-7.24 (m, 3H), 7.25-7.31 (m, 6H), 7.39-7.41 (m, 
6H).  
13C NMR (125 MHz, MeOD) δ = 36.11, 41.56, 67.77, 127.79, 128.89, 130.78, 
146.34.  HRMS (ESI+) calcd. for C21H22NS [M+H]
+
: 320.1467; found: 320.1466.  Anal. 
calcd. for C21H21NS: C, 78.95; H, 6.63; N, 4.38.  Found: C, 78.96; H, 6.63; N, 4.20.   
5.2.5.61. (2R)-2-Amino-3-(((2-chloroxyphenyl)(diphenyl)methyl)sulfanyl)propanoic 
acid (101). 
 
The title compound was then prepared by an adaptation of the procedure reported by 
DeBonis et al.
130
  To a solution of 30 (325 mg, 1.1 mmol) and L-cysteine (121 mg, 1 
mmol) in AcOH (1 mL) was added BF3∙Et2O solution (214 μL, 1.70 mmol) and stirred for 
3 h at room temperature.  A solution of aqueous NaOAc (10% w/v, 3 mL) was added, 
followed by H2O (3 mL), and the solution extracted with EtOAc (3 x 10 mL).  The 
combined organic extracts were dried (MgSO4), concentrated in vacuo and the crude 
residue purified by flash chromatography [SiO2; 10-20% MeOH in (CH2Cl2 with 1% 
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NH4OH)] to give 101 as a white solid (117 mg, 29%).  Mpt. 159-161 °C.  
1
H NMR (500 
MHz, DMSO-d6) δ = 2.24-2.29 (dd, J = 8.8, 12.4 Hz, 1H, CH2), 2.24-2.29 (dd, J = 4.5, 
12.4 Hz, CH2), 2.37-2.41 (dd, J = 4.5, 8.7 Hz,  1H, CH2), 2.91-2.94 (m, 1H, CH), 7.21-7.26 
(m, 2H), 7.30-7.39 (m, 10H), 7.47-7.50 (m, 1H), 8.12-8.13 (m, 1H).  
13
C NMR (125 MHz, 
DMSO-d6) δ = 34.51, 53.18, 66.60, 126.73, 126.75, 127.30, 127.72, 127.80, 129.26, 
129.40, 131.81, 131.99, 134.26, 140.00, 140.83, 141.32, 168.74.  HRMS (ESI+) calcd. for 
C22H21ClNO2S [M+H]
+
: 398.09761; found: 398.09760.  Anal. calcd. for 
C22H20ClNO2S·H2O: C, 63.53; H, 5.33; N, 3.37.  Found: C, 63.24; H, 5.28; N, 3.60.   
5.2.5.62. 2-(((3-Fluorophenyl)(diphenyl)methyl)sulfanyl)ethanamine (102). 
 
The title compound was prepared using general procedure (iii) with 31 (278 mg, 1 mmol) 
and cysteamine hydrochloride (114 mg, 1 mmol) in trifluoroacetic acid (1 mL) with the 
following modifications.  Basification of the crude residue (circa pH 9) was performed 
with aqueous NaOH (1.0 M) and EtOAc was used for extraction of the aqueous mixture (3 
x 10mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the amine 102 as a white solid (79 mg, 24%).  Mpt. 62-63 °C.  
1
H NMR 
(500 MHz, DMSO-d6) δ = 2.14-2.18 (m, 2H, CH2), 2.42-2.46 (m, 2H, CH2), 7.06-7.17 (m, 
3H), 7.24-7.29 (m, 2H), 7.31-7.41 (m, 9H). 
13
C NMR (125 MHz, DMSO-d6) δ = 35.65, 
40.78, 65.35, 113.57 (d, J = 20.6 Hz), 115.78 (d, J = 23.0 Hz), 125.37, 126.85, 128.09, 
129.00, 129.91 (d, J = 8.3 Hz), 144.12, 147.66 (d, J = 6.4 Hz), 161.7 (d, J = 242.7 Hz).  
HRMS (ESI+) calcd. for C21H21NFS [M+H]
+
: 338.13733; found: 338.13739.  Anal. calcd. 
for C21H20FNS: C, 74.74; H, 5.97; N 4.15.  Found: C, 74.29; H, 5.92; N, 4.15.   
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5.2.5.63. (2R)-2-Amino-3-(((3-chloroxyphenyl)(diphenyl)methyl)sulfanyl)propanoic 
acid (103).   
 
In a procedure analogous to 101, the trityl alcohol 32 (325 mg, 1.1 mmol) and L-cysteine 
(121 mg, 1 mmol) in AcOH (1 mL) was treated with BF3·Et2O (214 μl, 1.70 mmol).  After 
stirring for 1 h a further portion of BF3.Et2O (214 μl, 1.70 mmol) was added and the 
mixture stirred for a further 1.5 h.  Aqueous workup and purification by flash 
chromatography [SiO2; 8-20% MeOH in CH2Cl2 with 1% NH4OH] afforded 103 as an off-
white solid (74 mg, 19%).  Mpt. 160-163 °C.  
1
H NMR (500 MHz, DMSO-d6) δ = 2.43 
(dd, J = 8.6, 12.4 Hz, 1H, CH2), 2.56 (dd, J = 4.6, 12.4 Hz, 1H, CH2), 3.01 (dd, J = 4.7, 
8.6 Hz, 1H, CH), 7.26-7.40 (m, 14H).  
13
C NMR (125 MHz, DMSO-d6) δ = 34.41, 53.25, 
65.62, 126.91, 127.04, 127.93, 128.27, 128.67, 129.03, 130.01, 132.78, 143.52, 143.55, 
146.87, 168.37.  HRMS (ESI+) calcd. for C22H21ClNO2S [M+H]
+
: 398.09761; found: 
398.09827.  Anal. calcd. for C22H20ClNO2S·⅓CH2Cl2: C, 62.97; H, 4.89; N, 3.29.  Found: 
C, 62.87; H, 4.80; N, 3.31.    
5.2.5.64. 2-(((3-Chlorophenyl)(diphenyl)methyl)sulfanyl)ethanamine (104).   
 
The title compound was prepared using general procedure (iii) with 32 (295 mg, 1 mmol) 
and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) with the 
following modifications.  Basification of the crude residue (circa pH 9) was performed 
with aqueous NaOH (1.0 M) and EtOAc was used for extraction of the aqueous mixture (3 
x 10mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the amine 104 as a colorless oil (231 mg, 65%).  
1
H NMR (MeOD, 500 
MHz) 2.33-2.36 (m, 2H, CH2), 2.45-2.48 (m, 2H, CH2), 7.23-7.36 (m, 3H), 7.28-7.36 (m, 
6H), 7.39-7.41 (m, 5H).  
13C NMR (MeOD, 125 MHz) δ 36.00, 41.50, 67.35, 127.91, 
128.10, 129.11, 129.19, 130.44, 130.63, 130.67, 134.93, 145.64, 148.84.  HRMS (ESI+) 
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calcd. for C21H21ClNS [M+H]
+
: 354.10777; found: 354.10754.  Anal. calcd. for  
C21H20ClNS·⅕H2O: C, 70.09; H, 5.79; N, 3.89.  Found: C, 70.39; H, 5.86; N, 3.51.   
5.2.5.65. 2-(((3-Bromophenyl)(diphenyl)methyl)sulfanyl)ethanamine (105).   
 
The title compound was prepared using general procedure (iii) with 33 (339 mg, 1 mmol) 
and cysteamine hydrochloride (136 mg, 1.2 mmol) in trifluoroacetic acid (1 mL) with the 
following modifications.  Basification of the crude residue (circa pH 9) was performed 
with aqueous NaOH (1.0 M) and EtOAc was used for extraction of the aqueous mixture (3 
x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the amine 105 as a colorless oil which solidified on standing to a white 
solid (192 mg, 48%).  Mpt. 59-61 °C.  
1
H NMR (500 MHz, DMSO-d6) δ = 2.16 (t, J = 7.0 
Hz, 2H, CH2), 2.45 (t, J = 7.1 Hz, 2H, CH2), 7.24-7.37 (m, 12H), 7.45-7.47 (m, 2H).
 
 
13
C 
NMR (125 MHz, DMSO-d6) δ = 35.64, 40.78, 65.33, 121.29, 126.89, 128.14, 128.31, 
128.98, 129.62, 130.17, 131.50, 143.98, 147.50.  HRMS (ESI+) calcd. for C21H21BrNS 
[M+H]
+
: 398.05726; found: 398.05716.  Anal. calcd. for C21H20BrNS: C, 63.32; H, 5.06; 
N, 3.52.  Found: C, 63.36; H, 4.96; N, 3.44. 
5.2.5.66. 2-(((3-Methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (106).  
 
The title compound was prepared following general procedure (iii) 34 (275 mg, 1 mmol) 
and cysteamine hydrochloride (136 mg, 1.2 mmol) in trifluoroacetic acid (1 mL) with the 
following modifications.  Basification of the crude residue (circa pH 9) was performed 
with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  Purification 
by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] afforded the 
amine 106 as a colorless oil (184 mg, 55%).  
1
H NMR (500 MHz, DMSO-d6) δ = 2.15 (t, J 
= 7.2 Hz, 2H, CH2), 2.25 (s, 3H, CH3), 2.43 (t, J = 7.1 Hz, 2H, CH2), 7.04-7.06 (m, 1H), 
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7.09-7.11 (m, 1H), 7.17-7.25 (m, 4H), 7.31-7.34 (m, 8H).  
13
C NMR (125 MHz, DMSO-
d6) δ = 21.24, 35.62, 40.82, 65.74, 126.27, 126.56, 127.28, 127.80, 127.89, 129.13, 129.51, 
136.94, 144.69, 144. 76. HRMS (ESI+) calcd. for C22H24NS [M+H]
+
: 334.16240; found: 
334.16226.  Anal. calcd. for C22H23NS·⅕H2O: C, 78.39; H, 7.00; N, 4.16.  Found: C, 
78.38; H, 6.65; N, 3.95.   
5.2.5.67. 2-(((3-Ethylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (107).  
 
The title compound was prepared following general procedure (iii) with 47 (298 mg, 1 
mmol) and cysteamine hydrochloride (129 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  The reaction time was 2 h, basification of the crude 
residue (circa pH 9) was performed with aqueous NaOH (1.0 M) and EtOAc was used for 
extraction (3 x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the amine 107 a colorless oil (157 mg, 44%).  
1
H NMR 
(500 MHz, DMSO-d6) δ = 1.11 (t, J = 7.5 Hz, 3H, CH3), 2.16 (t, J = 7.1 Hz, 2H, CH2), 
2.42 (t, J = 7.1 Hz, 2H, CH2), 2.54 (q, J = 7.5 Hz, 2H, CH2), 7.07-7.10 (m, 2H), 7.21-7.25 
(m, 4H), 7.30-7.34 (m, 8H). 
13
C NMR (125 MHz, DMSO-d6) δ = 15.52, 28.23, 35.66, 
40.85, 65.83, 126.02, 126.57, 127.88, 128.48, 129.12, 143.23, 144.68, 144.75. HRMS 
(ESI+) calcd. for C23H26NS [M+H]
+
: 348.17805; found: 348.17786.  Anal. calcd. for 
C23H25NS·⅕H2O: C, 78.73; H, 7.35; N, 3.96.  Found: C, 78.90; H, 7.10; N, 3.70.  
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5.2.5.68. 2-(((3-(Propan-2-yl)phenyl)diphenylmethyl)sulfanyl)ethanamine (108).   
 
The title compound was prepared following general procedure (iii) with 48 (302 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  The reaction time was 2 h, basification of the crude 
residue (circa pH 9) was performed with aqueous NaOH (1.0 M) and EtOAc was used for 
extraction (3 x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the amine 108 as a colorless oil (249 mg, 69%).  
1
H 
NMR (500 MHz, DMSO-d6) δ = 1.13 (d, J =  6.9 Hz, 6H, 2 x CH3), 2.17 (t, J = 7.0 Hz, 
2H, CH2), 2.42 (t, J = 7.0 Hz, 2H, CH2), 2.81 (p,  J = 6.9 Hz, 1H, CH), 7.06-7.08 (m, 1H), 
7.11-7.12 (m, 1H), 7.21-7.26 (m, 4H), 7.31-7.33 (m, 8H).  
13
C NMR (125 MHz, DMSO-
d6) δ = 23.78, 33.36, 35.68, 40.87, 65.92, 124.44, 126.57, 126.74, 127.26, 127.82, 127.88, 
129.09, 144.48, 144.82.  HRMS (ESI+) calcd. for C22H28NS [M+H]
+
: 362.19370; found: 
362.19351.  Anal. calcd. for C24H27NS·¼H2O: C, 78.75; H, 7.57; N, 3.83.  Found: C, 
78.63; H, 7.42; N, 3.59.  
5.2.5.69. 2-(((3-Propylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (109).  
  
The title compound was prepared following general procedure (iii) with 49 (302 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10 mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 109 as a pale clear yellow oil (227 mg, 63%).  
1
H NMR (MeOD, 500 
MHz) δ = 0.87 (t, J = 7.4 Hz, 3H, CH3), 1.56 (p, J = 7.4 Hz, 2H, CH2), 2.33-2.36 (m, 2H, 
CH2), 2.41-2.44 (m, 2H, CH2), 2.51 (t, J = 7.5 Hz, 2H, CH2), 7.03-7.05 (m, 1H), 7.16-7.24 
(m, 9H), 7.40-7.42 (m, 4H).  
13C NMR (MeOD, 125 MHz) δ 13.96, 25.69, 36.00, 39.04, 
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41.55, 67.83, 127.75, 127.94, 128.16, 128.78, 128.85, 130.77, 131.06, 143.06, 146.17, 
146.42.  HRMS (ESI+) calcd. for C24H28NS [M+H]
+
: 362.19370; found: 362.19293.  Anal. 
calcd. for C24H27NS·¼H2O: C, 78.75; H, 7.57; N, 3.83.  Found: C, 78.64; H, 7.31; N, 3.95.   
5.2.5.70. 2-((Diphenyl(3-(trifluoromethyl)phenyl)methyl)sulfanyl)ethanamine (110).  
 
The title compound was prepared following general procedure (iii) with 35 (298 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  The reaction time was 2 h, basification of the crude 
residue (circa pH 9) was performed with aqueous NaOH (1.0 M) and EtOAc was used for 
extraction (3 x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the amine 110 as a colorless oil (125 mg, 32%).  
1
H 
NMR (500 MHz, DMSO-d6) δ = 2.16 (t, J = 7.0 Hz, 2H, CH2), 2.44 (t, J = 7.0 Hz, 2H, 
CH2), 7.26-7.29 (m, 2H), 7.32-7.38 (m, 8H), 7.57-7.66 (m, 4H).  
13
C NMR (125 MHz, 
DMSO-d6) δ = 35.61, 40.77, 65.46, 123.63 (q, JCF = 3.7 Hz, CH), 124.08 (q, JCF = 271.8 
Hz), 125.06 (q, JCF = 3.6 Hz, CH), 127.00, 128.24, 128.68 (q, JCF = 31.2 Hz), 128.95, 
129.26, 133.43, 143.91, 146.12.  
19
F NMR (376.5 MHz, DMSO-d6) δ = -61.18.  HRMS 
(ESI+) calcd. for C22H21NF3S [M+H]
+
: 388.13413; found: 388.13388.  Anal. calcd. for  
C22H20F3NS: C, 68.20; H, 5.20; N, 3.61.  Found: C, 67.97; H, 5.41; N, 2.87.   
5.2.5.71. 2-(((3-Methoxyphenyl)(diphenyl)methyl)sulfanyl)ethanamine (111).   
 
The title compound was prepared following general procedure (iii) with 44 (290 mg, 1 
mmol and cysteamine hydrochloride (114 mg, 1 mmol) in trifluoroacetic acid (1 mL) with 
the following modifications.  The reaction time was 2.5 h, basification of the crude residue 
(circa pH 9) was performed with aqueous NaOH (1.0 M) and EtOAc was used for 
extraction (3 x 10mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
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CH2Cl2 with 1% NH4OH] afforded the thioether 111 as a pale brown oil (282 mg, 81%).
 
 
1
H NMR (500 MHz, DMSO-d6) δ = 2.18 (t, J = 7.0 Hz, 2H, CH2), 2.45 (t, J = 7.1 Hz, 2H, 
CH2), 6.81-6.90 (m, 3H), 7.22-7.35 (m, 11H). 
13
C NMR (125 MHz, DMSO-d6) δ = 35.47, 
40.74, 54.96, 65.70, 111.23, 115.66, 121.62, 126.66, 127.92, 129.02, 129.10, 144.53, 
146.23, 158.73.  HRMS (ESI+) calcd. for C22H24NOS [M+H]
+
: 350.15731; found: 
350.15817.  Anal. calcd. for  C22H23NOS·¼H2O: C, 74.65; H, 6.71; N, 3.94.  Found: C, 
74.69; H, 6.69; N, 3.96. 
5.2.5.72. 2-(((3-(Methylsulfanyl)phenyl)diphenylmethyl)sulfanyl)ethanamine (112). 
 
The title compound was prepared following general procedure (iii) with 52 (306 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  The reaction time was 2 h, basification of the crude 
residue (circa pH 9) was performed with aqueous NaOH (1.0 M) and EtOAc was used for 
extraction (3 x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the thioether 112 as a clear pale yellow oil (280 mg, 
77%).  
1H NMR (500 MHz, MeOD) δ = 2.33-2.37 (m, 5H), 2.43-2.46 (m, 2H, CH2), 7.11-
7.13 (m, 1H), 7.15-7.18 (m, 1H), 7.20-7.24 (m, 3H), 7.27-7.32 (m, 5H), 7.39-7.42 (m, 4H).  
13
C NMR (125 MHz, MeOD) δ = 15.67, 36.11, 41.57, 67.69, 125.80, 127.58, 127.92, 
128.80, 128.96, 129.39, 130.74, 139.83, 146.04, 147.08.  HRMS (ESI+) calcd. for 
C22H24NS2 [M+H]
+
: 366.13447; found: 366.13452.  Anal. calcd. for  C22H23NS2: C, 72.78; 
H, 6.34; N, 3.83.  Found: C, 72.28; H, 6.29; N, 3.44.   
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5.2.5.73. 2-((Diphenyl(3-(trifluoromethoxy)phenyl)methyl)sulfanyl)ethanamine (113).  
 
The title compound was prepared following general procedure (iii) with 51 (344 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0M) and EtOAc was used for extraction (3 x 10 mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 113 as a pale clear yellow oil (313 mg, 78%).  
1
H NMR (500 MHz, 
DMSO-d6) δ = 2.17 (t, J = 7.0 Hz, 2H, CH2), 2.43 (t, J = 7.0 Hz, 2H, CH2), 7.24-7.29 (m, 
4H), 7.31-7.39 (m, 9H), 7.48 (t, J = 8.0 Hz, 1H).  
13
C NMR (125 MHz, DMSO-d6) δ = 
35.61, 40.77, 65.32, 119.12, 120.03 (q, JCF = 257.7 Hz), 121.45, 126.95, 128.17, 128.32, 
128.92, 129.96, 143.96, 147.44, 147.92.
 
 
19
F NMR (376.5 MHz, DMSO-d6) δ = -56.87.   
HRMS (ESI+) calcd. for C22H21F3NS [M+H]
+
: 404.12905; found: 404.12881.  Anal. calcd. 
for C22H20F3NOS·½H2O: C, 64.06; H, 5.13; N, 3.40.  Found: C, 64.61; H, 4.91; N, 2.90.   
5.2.5.74. (R)-3-(((3-Acetylphenyl)diphenylmethyl)sulfanyl)-2-aminopropanoic acid 
(114). 
 
A solution of 50 (346 mg, 1.0 mmol) and L-cysteine (133 mg, 1.1 mmol) in (1 mL) was 
stirred at room temperature for 4.5 h.  The volatiles were removed in vacuo, and the 
residue suspended in aqueous HCl (0.5 M, 2.5 mL) and stirred at room temperature for 2.5 
h, during which time a colourless gum precipitated.  The aqueous layer was poured off, and 
the gum washed with H2O (10 mL).  The combined aqueous layers were extracted with 
CH2Cl2 (3 x 10 mL), the gum dissolved in CH2Cl2 (5 mL), and the combined organic 
extracts concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-20% MeOH 
in CH2Cl2] afforded the thioether 114 as a white solid (290 mg, 72%).  Mpt. 109.5-112 °C.  
1H NMR (400 MHz, MeOD) δ = 2.54 (s, 3H, CH3), 2.68 (dd, J = 9.1, 13.3 Hz, 1H, CH2), 
2.80 (dd, J = 4.2, 13.2 Hz, 1H, CH2), 3.09 (dd, J = 4.2, 9.0 Hz, 1H, CH), 7.24-7.29 (m, 
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2H), 7.31-7.37 (m, 4H), 7.43-7.50 (m, 5H), 7.70-7.73 (m, 1H), 7.89-7.92 (m, 1H), 8.08-
8.09 (m, 1H).  
13
C NMR (125 MHz, MeOD) δ = 26.76, 34.09, 54.96, 67.95, 128.32, 
129.38, 129.69, 130.11, 130.65, 135.54, 138.19, 145.09, 145.19, 146.54, 172.06, 200.11.  
HRMS (ESI+) Calcd. for C24H24NO3S [M+H]
+
: 406.1471; found: 406.1466.  Anal. calcd. 
for C24H23NO3S∙H2O: C, 68.06; H, 5.95; N, 3.32.  Found: C, 68.32; H, 5.55; N, 3.02.   
5.2.5.75. 1-(3-(((2-Aminoethyl)thio)diphenylmethyl)phenyl)ethanone hydrochloride 
(115). 
 
A solution of the tertiary alcohol 50  (346 mg, 1.0 mmol) with cysteamine hydrochloride 
(125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) was stirred for 3 h at room temperature.  
The volatiles were removed in vacuo, and the crude basified (circa. pH 10) with saturated 
aqueous sodium carbonate solution.  The aqueous mixture was extracted with CH2Cl2 (3 x 
10 mL) and the organic layer dried (MgSO4) and concentrated in vacuo.  The crude residue 
was suspended in aqueous HCl (1.0 M, 30 mL), stirred at room temperature for 62 h, 
basified (circa. pH 10) with saturated aqueous sodium carbonate solution and extracted 
with CH2Cl2 (3 x 50 mL).  The organic extracts were dried (MgSO4) and concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with 1% 
NH4OH] yielded a white solid, which to generate the hydrochloride salt, was suspended in 
aqueous HCl (1.0 M, 10 mL) and stirred at room temperature for 65 h.  A white precipitate 
formed, which was filtered and washed successively with aqueous HCl (1.0 M), petroleum 
ether (60/80) and Et2O, and dried in vacuo to yield the hydrochloride salt 25 as a white 
solid (122 mg, 31%).  Mpt. 96-98 °C.  
1
H NMR (400 MHz, DMSO-d6) δ = 2.40-2.44 (m, 
2H, CH2), 2.51-2.58 (m, 5H), 7.28-7.41 (m, 10H), 7.52-7.60 (m, 2H), 7.80 (br s, 3H, 
NH3
+
), 7.92-7.95 (m, 2H).  
13
C NMR (125 MHz, DMSO-d6) δ = 26.76, 28.39, 37.63, 
66.26, 127.14, 127.55, 127.73, 128.37, 128.79, 128.97, 133.83, 136.56, 143.55, 144.69, 
197.60.  HRMS (ESI+) Calcd. for C23H24NOS [M+H]
+
: 362.1573; found: 362.1572.  Anal. 
calcd. for C23H23NOS∙1.5 HCl: C, 66.38; H, 5.93; N, 3.37. Found: C, 66.31; H, 5.90; N, 
3.24. 
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5.2.5.76. 2-(((4-Methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (116). 
 
The title compound was prepared following general procedure (iii) with 53 (274 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-12% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 116 as a white solid (229 mg, 69%).  Mpt. 72-74 °C.  
1
H NMR (400 
MHz, MeOD) δ = 2.28-2.36 (m, 5H), 2.40-2.45 (m, 2H, CH2), 7.07-7.11 (m, 2H), 7.17-
7.22 (m, 2H), 7.23-7.29 (m, 6H), 7.37-7.42 (m, 4H).  
13C NMR (100 MHz, MeOD) δ = 
20.93, 36.13, 41.57, 67.54, 127.70, 128.84, 129.48, 130.73, 137.59, 143.31, 146.52.  
HRMS (ESI+) calcd. for C22H24NS [M+H]
+
: 334.1624; found: 334.1624.  Anal. calcd. for 
C22H23NS: C, 79.23; H, 6.95; N, 4.13.  Found: C, 78.84; H, 7.03; N, 4.13. 
5.2.5.77. 2-(((4-Methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (117). 
 
The title compound was prepared following general procedure (iii) with 36 (288 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-12% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 117 as a colourless oil (296 mg, 85%).  1H NMR (500 MHz, MeOD) 
δ = 1.22 (t, J = 7.6 Hz, 3H, CH3), 2.32-2.36 (m, 2H, CH2), 2.41-2.46 (m, 2H, CH2), 2.62 (q, 
J = 7.6 Hz, 2H, CH2), 7.10-7.14 (m, 2H), 7.18-7.22 (m, 2H), 7.25-7.32 (m, 6H), 7.39-7.43 
(m, 4H).  13C NMR (125 MHz, MeOD) δ = 16.02, 29.29, 36.12, 41.58, 67.57, 127.71, 
128.30, 128.84, 130.75, 130.79, 143.58, 144.06, 146.54.  HRMS (ESI+) calcd. for 
C23H26NS [M+H]
+
: 348.1780; found: 348.1775.  Anal. calcd. for C23H25NS·⅓H2O: C, 
78.16; H, 7.32; N, 3.96.  Found: C, 78.11; H, 7.03; N, 3.66. 
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5.2.5.78. 2-(((4-Methoxyphenyl)(diphenyl)methyl)sulfanyl)ethanamine (118). 
 
The title compound was prepared following general procedure (iii) with (4-
methoxyphenyl)(diphenyl)methanol (291 mg, 1.0 mmol) and cysteamine hydrochloride 
(125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  Purification by flash chromatography 
[SiO2; 0-15% MeOH in CH2Cl2] afforded the thioether 118 as a colourless oil (63 mg, 
18%).  
1
H NMR (500 MHz, MeOD) δ = 2.32-2.36 (m, 2H, CH2), 2.41-2.45 (m, 2H, CH2), 
3.77 (s, 3H, CH3), 6.81-6.84 (m, 2H), 7.17-7.21 (m, 2H), 7.24-7.31 (m, 6H), 7.38-7.42 (m, 
4H).  
13C NMR (125 MHz, MeOD) δ = 36.14, 41.60, 55.72, 67.33, 114.13, 127.70, 128.86, 
130.67, 131.99, 138.21, 146.70, 159.78.  HRMS (ESI+) calcd. for C22H24NOS [M+H]
+
: 
350.1573; found: 350.1565.  Anal. calcd. for C22H23NOS: C, 75.61; H, 6.63; N, 4.01.  
Found: C, 74.77; H, 6.22; N, 3.19. 
5.2.5.79. 2-(((4-Ethoxyphenyl)(diphenyl)methyl)sulfanyl)ethanamine (119). 
 
The title compound was prepared following general procedure (iii) with 55 (305 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with NH4OH] 
afforded the thioether 119 as a clear pale brown oil (209 mg, 58%).  
1
H NMR (500 MHz, 
MeOD) δ = 1.37 (t, 3H, J = 7.0 Hz, CH3), 2.32-2.37 (m, 2H, CH2), 2.41-2.45 (m, 2H, 
CH2), 4.01 (q, 2H, J = 7.0 Hz, CH2), 6.79-6.84 (m, 2H), 7.17-7.22 (m, 2H), 7.24-7.30 (m, 
6H), 7.38-7.42 (m, 4H).  
13C NMR (125 MHz, MeOD) δ = 15.15, 36.13, 41.60, 64.50, 
67.34, 114.67, 127.69, 128.85, 130.67, 131.98, 138.09, 146.72, 159.07.  HRMS (ESI+) 
calcd. for C23H26NOS [M+H]
+
: 364.1730; found: 364.1727.  Anal. calcd. for 
C23H26NOS·½H2O: C, 74.56; H, 6.53; N, 3.78.  Found: C, 74.48; H, 6.93; N, 4.18. 
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5.2.5.80. 2-((Diphenyl(4-(trifluoromethoxy)phenyl)methyl)sulfanyl)ethanamine (120). 
 
The title compound was prepared following general procedure (iii) with 56 (344 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with NH4OH] 
afforded the thioether 120 as a colourless oil (145 mg, 36%).  
1
H NMR (400 MHz, MeOD) 
δ = 2.34 (t, 2H, J = 6.9 Hz), 2.46 (t, 2H, J = 6.9 Hz), 7.17-7.34 (m, 8H), 7.35-7.44 (m, 4H), 
7.50-7.54 (m, 2H).  
19
F NMR (376.5 MHz, MeOD) δ = -59.42.  
13
C NMR (100 MHz, 
MeOD) δ = 36.01, 41.48, 67.17, 121.25, 121.92 (q, JCF = 255.4 Hz), 123.18, 128.05, 
129.11, 130.66, 132.44, 145.60, 145.85, 149.04.  HRMS (ESI+) calcd. for C22H21F3NOS 
[M+H]
+
: 404.1290; found: 404.1291.  Anal. calcd. for C22H20F3NOS: C, 65.49; H, 5.00; N, 
3.47.  Found: C, 65.44; H, 5.04; N, 3.95.   
5.2.5.81. (R)-3-(((4-Acetylphenyl)diphenylmethyl)sulfanyl)2-aminopropanoic acid 
(121). 
 
A solution of 54 (346 mg, 1.0 mmol) and L-cysteine (133 mg, 1.1 mmol) in trifluoroacetic 
acid (1 mL) was stirred at room temperature for 4 h.  The volatiles were removed in vacuo, 
and the residue suspended in aqueous HCl (0.5 M, 2.5 mL) and stirred at room temperature 
for 30 min, during which time a white gum precipitated.  The aqueous layer was separated, 
and extracted with CH2Cl2 (3 x 5 mL).  The precipitated gum was washed with H2O (5 
mL), dissolved in CH2Cl2 (5 mL), and combined with the combined organic extracts 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-25% MeOH in 
CH2Cl2] afforded the thioether 121 as a white solid (221 mg, 55%).  Mpt. 116-119 °C.  
1
H 
NMR (500 MHz, MeOD) δ = 2.58 (s, 3H, CH3), 2.66-2.72 (m, 1H, CH2), 2.80 (dd, J = 3.6, 
13.3 Hz, 1H, CH2) 3.13 (dd, J = 3.6, 13.3 Hz, 1H, CH), 7.24-7.29 (m, 2H), 7.30-7.36 (m, 
4H), 7.42-7.47 (m, 4H), 7.58-7.62 (m, 2H), 7.92-7.96 (m, 2H).  
13
C NMR (125 MHz, 
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MeOD) δ = 26.73, 34.06, 54.87, 68.01, 128.34, 129.32, 129.36, 130.62, 130.66, 130.99, 
136.86, 144.91, 145.03, 151.06, 171.97.  HRMS (ESI+) Calcd. for C24H24NO3S [M+H]
+
: 
406.1471; found: 406.1468.  Anal. calcd. for C24H23NO3S∙⅓CH2Cl2: C, 67.41; H, 5.50; N, 
3.23.  Found: 67.84; H, 5.73; N, 3.20.   
5.2.5.82. 1-(4-(((2-Aminoethyl)thio)diphenylmethyl)phenyl)ethanone hydrochloride 
(122). 
 
A solution of tertiary alcohol 54 (346 mg, 1.0 mmol) with cysteamine hydrochloride (125 
mg, 1.1 mmol) in trifluoroacetic acid (1 mL) was stirred for 3 h at room temperature.  The 
volatiles were removed in vacuo, and the residue suspended in aqueous HCl (1.0 M, 10 
mL) and stirred at room temperature for 18 h, during which time a white precipitate 
formed.  The mixture was filtered, and the precipitate washed successively with HCl (1.0 
M, 10 mL), petroleum ether (60/80) and Et2O, and dried in vacuo to yield the 
hydrochloride salt 122 as a white solid (378 mg, 95%).  Mpt. 186-188 °C.  
1
H NMR (500 
MHz, DMSO-d6) δ = 2.40-2.43 (m, 2H, CH2), 2.52-2.56 (m, 5H), 7.28-7.31 (m, 2H), 7.33-
7.40 (m, 10H), 7.47-7.49 (m, 2H), 7.77 (br s, 3H, NH3
+
), 7.93-7.96 (m, 2H).  
13
C NMR 
(125 MHz, DMSO-d6) δ = 27.61, 28.36, 37.58, 66.29, 127.16, 128.17, 128.36, 128.96, 
129.31, 135.21, 143.40, 149.04, 197.30.  HRMS (ESI+) Calcd. for C23H24NOS [M+H]
+
: 
362.1573; found: 362.1571.  Anal. calcd. for C23H23NOS∙1.75HCl: C, 64.95; H, 5.87; N, 
3.29.  Found: C, 65.08; H, 5.80; N, 3.13.   
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5.2.5.83. (2R)-2-Amino-3-(((2-hydroxyphenyl)(diphenyl)methyl)sulfanyl)propanoic acid 
(123).   
 
The title compound was then prepared by an adaptation of the procedure reported by 
DeBonis et al.
130
  A solution of phenol 42 (532 mg, 1.93 mmol) and L-cysteine (212 mg, 
1.75 mmol) in AcOH (1.75 mL) was treated with BF3∙Et2O (376 μL, 2.99 mmol) at 0 °C.  
After stirring for 2 h at room temperature the reaction was quenched with aqueous NaOAc 
(10% w/v, 5.3 mL), diluted with H2O (5.3 mL) and the resulting white precipitate collected 
by filtration. The crude precipitate was dissolved in hot MeOH, filtered whilst hot and then 
concentrated in vacuo.  The crude product was purified by flash chromatography [SiO2; 
10-20% MeOH in CH2Cl2 with 1% NH4OH] to afford thioether 123 as a white solid (35 
mg, 5%).  Mpt. 156-159 °C.  
1
H NMR (400 MHz, DMSO-d6) δ = 2.20-2.25 (m, 1H), 2.40-
2.44 (m, 1H), 2.81-2.84 (m, 1H), 6.71-6.73 (m, 1H), 6.85-6.88 (m, 1H), 7.12-7.36 (m, 
11H), 7.73-7.75 (m, 1H).  
13
C NMR (100 MHz, DMSO-d6) δ = 35.32, 53.79, 65.12, 
116.40, 118.49, 125.85, 126.99, 128.52, 128.99, 129.89, 142.92, 143.17, 155.09, 171.89.  
HRMS (ESI+) calcd. for C22H22NO3S [M+H]
+
: 380.13149; found: 380.13141.  Anal. calcd. 
for C22H21NO3S·½CH2Cl2: C, 64.05; H, 5.26; N, 3.32.  Found: C, 63.64; H, 5.53; N, 4.09. 
5.2.5.84. (2R)-2-Amino-3-(((3-hydroxyphenyl)(diphenyl)methyl)sulfanyl)propanoic 
acid (124).   
 
The title compound was prepared by an adaptation of the procedure for 101 using 43 (304 
mg, 1.1 mmol) and L-cysteine (121 mg, 1 mmol) in AcOH (1 mL) followed by BF3∙Et2O 
solution (214 μL, 1.70 mmol), with a reaction time of 2 h.  Purification by flash 
chromatography [SiO2; 0-20% MeOH in CH2Cl2 with 1% NH4OH] afforded the thioether 
124 as a white solid (161 mg, 62%).  Mpt. 178-180 °C.  
1
H NMR (500 MHz, DMSO-d6) δ 
= 1.88 (s, 1H, OH), 2.40 (dd, J = 9.0, 12.4 Hz, 1H, CH2), 2.58 (dd, J = 4.4, 12.4 Hz, 1H, 
CH2), 2.99 (dd, J = 4.4, 9.0 Hz, 1H, CH), 6.64 (dd, J = 1.8, 8.0 Hz, 1H), 6.70 (d, J = 7.9 
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Hz, 1H), 6.78 (br s, 1H). 7.09 (t, J = 7.9 Hz, 1H), 7.22-7.26 (m, 2H), 7.30-7.34 (m, 8H).  
13
C NMR (125 MHz, DMSO-d6) δ = 34.02, 53.57, 65.94, 113.78, 116.39, 119.75, 126.64, 
127.92, 128.80, 129.21, 144.30, 144.35, 145.83, 157.08, 169.26.  HRMS (ESI+) calcd. for 
C22H22NO3NaS [M+Na]
+
: 402.1134; found: 402.11453.  Anal. calcd. for 
C22H21NO3S∙⅓CH2Cl2: C, 65.82; H, 5.36; N, 3.44.  Found: C, 65.83; H, 5.36; N, 3.43. 
5.2.5.85. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)phenol (125).  
 
The title compound was prepared following general procedure (iii) with 43 (276 mg, 1 
mmol) and cysteamine hydrochloride (114 mg, 1 mmol) in trifluoroacetic acid (1 mL) with 
the following modifications.  Basification of the crude residue (circa pH 9) was performed 
with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  Purification 
by flash chromatography [SiO2; 0-16% MeOH in CH2Cl2 with 1% NH4OH] afforded the 
thioether 125 as a white solid (259 mg, 77%).  Mpt. 143 °C.  
1
H NMR (400 MHz, DMSO-
d6) δ = 2.16 (t, J = 7.0 Hz, 2H, CH2), 2.44 (t, J = 7.1 Hz, 2H, CH2), 6.62 (ddd, J = 0.7, 2.4, 
8.0 Hz, 1H), 6.71-6.73 (m, 1H), 6.78-6.79 (m, 1H), 7.10 (t, J = 8.0 Hz, 1H), 7.21-7.26 (m, 
2H), 7.30-7.34 (m, 8H).  
13
C NMR (100 MHz, DMSO-d6) δ = 35.58, 40.81, 65.75, 113.64, 
116.34, 119.88, 126.60, 127.90, 128.83, 129.18, 144.72, 146.20, 156.89.  HRMS (ESI+) 
calcd. for C21H22NOS [M+H]
+
: 336.14166; found: 336.14172.  Anal. calcd. for  
C21H21NOS·⅕H2O: C, 74.39; H, 6.36; N 4.13.  Found: C, 74.33; H, 6.33; N, 4.07.   
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5.2.5.86. 2-(((3-(Aminomethyl)phenyl)(diphenyl)methyl)sulfanyl)ethanamine (127). 
 
The title compound was prepared following general procedure (iii) with 95 (250 mg, 0.86 
mmol) and cysteamine hydrochloride (108 mg, 0.95 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 127 as a clear yellow oil (250 mg, 72%).  
1
H NMR (500 MHz, 
DMSO-d6) δ = 2.15 (t, J = 7.1 Hz, 2H, CH2), 2.42 (t, J = 7.0 Hz, 2H, CH2), 3.67 (s, 2H, 
CH2), 7.10-7.12 (m, 1H), 7.20-7.26 (m, 4H), 7.30-7.34 (m, 8H), 7.36-7.38 (m, 1H).  
13
C 
NMR (125 MHz, DMSO-d6) δ = 35.70, 40.85, 45.64, 65.87, 125.35, 126.54, 127.11, 
127.62, 127.88, 129.16, 143.80, 144.52, 144.78.  HRMS (ESI+) calcd. for C22H25N2S 
[M+H]
+
: 349.1733; found: 349.1731.  Anal. calcd. for C22H24N2S·½H2O: C, 73.91; H, 
7.05; N, 7.84.  Found: C, 73.93; H, 6.97; N, 8.39.   
5.2.5.87. N-(3-(((2-aminoethyl)sulfanyl)(diphenyl)methyl)benzyl)acetamide (128).   
 
The title compound was then prepared following general procedure (iii) with 97 (166 mg, 
0.50 mmol) and cysteamine hydrochloride (63 mg, 0.55 mmol) in trifluoroacetic acid (0.5 
mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the amine 128 as a colourless oil (169 mg, 82%).  
1
H NMR (500 MHz, 
DMSO-d6) δ = 1.81 (s, 3H, CH3), 2.16 (d, J = 7.0 Hz, 2H, CH2), 2.42 (d, J = 7.0 Hz, 2H, 
CH2), 4.19 (d, J = 6.0 Hz, m, NHCH2), 7.10-7.15 (m, 2H), 7.22-7.35 (m, 12H), 8.32 (t, J = 
6.0 Hz, 1H, NH).  
13
C NMR (125 MHz, DMSO-d6) δ = 22.45, 35.48, 40.75, 42.08, 65.77, 
125.33, 126.61, 127.68, 127.74, 127.83, 127.91, 129.12, 139.37, 144.16, 169.05.  HRMS 
(ESI+) calcd. for C24H27N2OS [M+H]
+
: 391.1839; found: 391.1836.  Anal. calcd. for 
C24H26N2OS·H2O: C, 70.56; H, 6.91; N, 6.86.  Found: C, 70.87; H, 6.97; N, 6.84.   
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5.2.5.88. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzoic acid hydrochloride 
(129). 
   
A solution of the tertiary alcohol 88 (346 mg, 1.0 mmol) with cysteamine hydrochloride 
(125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) was stirred for 3.5 h at room 
temperature.  The volatiles were removed in vacuo, and the residue suspended in aqueous 
HCl (1.0 M, 10 mL) and stirred at room temperature for 18 h, during which time a white 
precipitate formed.  The mixture was filtered, and the precipitate washed successively with 
HCl (1.0 M, 10 mL), petroleum ether (60/80) and Et2O, and dried in vacuo to yield 
thioether 129 as a white solid (145 mg, 36%).  Mpt. 218-220 °C.  
1
H NMR (500 MHz, 
DMSO-d6) δ = 2.43 (m, 2H, CH2), 2.50-2.55 (m, 2H, CH2), 7.28-7.31 (m, 2H), 7.33-7.40 
(m, 8H), 7.50 (t, J = 7.8 Hz, 1H), 7.58 (ddd, J = 1.2, 2.0, 7.9 Hz, 1H), 7.85-7.87 (m, 1H), 
7.88-8.05 (m, 4H), 13.06 (br s, 1H, COOH).  
13
C NMR (125 MHz, DMSO-d6) δ = 28.42, 
37.65, 66.23, 127.15, 127.96, 128.39, 128.63, 128.96, 129.73, 130.67, 133.48, 143.59, 
144.62, 167.01.  HRMS (ESI+) calcd. for C22H22NO2S [M+H]
+
: 364.1366; found: 
364.1363.  Anal. calcd. for C21H21NO2S∙1.1HCl: C, 64.42; H, 5.69; N, 3.58.  Found: C, 
64.12; H, 5.57; N, 3.37. 
5.2.5.89. (R)-2-Amino-3-(((3-carbamoylphenyl)diphenylmethyl)sulfanyl)propanoic 
acid (130). 
 
The title compound was prepared following general procedure (iii) with 85 (303 mg, 1.0 
mmol) and L-cysteine (133 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  Purification by 
flash chromatography [SiO2; 0-35% MeOH in CH2Cl2] afforded the title compound 130 as 
a white solid (139 mg, 34%).  Mpt. 154-157 °C.  
1H NMR (500 MHz, MeOD) δ = 2.69 
(dd, J = 8.5, 13.2 Hz, 1H, CH2), 2.77 (dd, J = 4.3, 13.2 Hz, 1H, CH2), 3.09 (dd, J = 4.3, 8.5 
Hz, 1H, CH), 7.22-7.27 (m, 2H), 7.30-7.35 (m, 4H), 7.40 (t, J = 7.8 Hz, 1H), 7.43-7.56 (m, 
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4H), 7.54-7.59 (m, 1H), 7.74-7.76 (m, 1H), 8.11-8.13 (m, 1H).  
13
C NMR (125 MHz, 
MeOD) δ = 34.16, 55.01, 67.95, 127.24, 128.22, 129.33, 129.75, 130.53, 130.71, 134.42, 
135.09, 145.24, 145.49, 146.22, 172.24, 172.31.  HRMS (ESI-) calcd. for C23H21NO3S [M-
H]
-
: 405.1278; found: 405.1280.  Anal. calcd. for C23H22N2O3S∙⅓CH2Cl2: C, 64.49; H, 
5.26; N, 6.45.  Found: C, 64.73; H, 5.20; N, 6.48.   
5.2.5.90. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzamide hydrochloride 
(131).  
 
A solution of the tertiary alcohol 85 (131 mg, 0.43 mmol) with cysteamine hydrochloride 
(54 mg, 0.48 mmol) in trifluoroacetic acid (0.86 mL) was stirred for 2.5 h at room 
temperature.  The volatiles were removed in vacuo, and the crude basified (circa. pH 10) 
with aqueous NaOH (1.0 M).  The aqueous mixture was extracted with CH2Cl2 (3 x 10 
mL) and the organic layer dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] yielded a white solid, 
which was suspended in aqueous HCl (1.0 M, 10 mL) and stirred at room temperature for 
18 h, during which time a white precipitate formed.  The mixture was filtered, and the 
precipitate washed successively with HCl, petroleum ether (60/80) and Et2O, and dried in 
vacuo to afford the hydrochloride salt 131 as a white solid (48 mg, 28%).  Mpt. 202-205 
°C.  
1
H NMR (500 MHz, DMSO-d6) δ = 2.43-2.47 (m, 2H, CH2), 7.26-7.31 (m, 2H), 7.33-
7.49 (m, 11H), 7.78-7.81 (m, 1H), 7.91-7.98 (m, 4H), 7.99-8.03 (br s, 1H, CONH2).  
13
C 
NMR (125 MHz, DMSO-d6) δ = 28.38, 37.65, 66.36, 125.73, 127.03, 128.08, 128.29, 
128.39, 129.02, 131.76, 134.17, 143.73, 144.40, 167.57.  HRMS (ESI+) calcd. for 
C22H23N2OS [M+H]
+
: 363.1526; found: 363.1522.  Anal. calcd. for C22H22N2OS∙1.75HCl: 
C, 61.99; H, 5.62; N, 6.57.  Found: C, 62.39; H, 5.39; N, 6.38.   
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5.2.5.91. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)-N-methylbenzamide 
hydrochloride (132). 
  
A solution of the tertiary alcohol 91 (220 mg, 0.69 mmol) with cysteamine hydrochloride 
(87 mg, 0.76 mmol) in trifluoroacetic acid (692 µL) was stirred for 3 h at room 
temperature.  The volatiles were removed in vacuo and the crude basified (circa. pH 10) 
with saturated aqueous sodium carbonate solution.  The aqueous mixture was extracted 
with CH2Cl2 (3 x 10 mL), and the organic layer dried (MgSO4) and concentrated in vacuo.  
After purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with 1% 
NH4OH], the crude product was suspended in aqueous HCl (1.0 M, 10 mL) and stirred at 
room temperature for 18 h, during which time a white precipitate formed.  The mixture 
was filtered, the precipitate washed successively with CH2Cl2 and H2O, and dried in vacuo 
to yield the hydrochloride salt 132 as a white solid (69 mg, 24%).  Mpt. 197-200 °C.  
1
H 
NMR (500 MHz, DMSO-d6) δ = 2.43-2.48 (m, 2H, CH2), 2.74 (d, J = 4.5 Hz, 3H, CH3), 
7.26-7.47 (m, 12H), 7.74-7.77 (m, 2H), 7.88-7.99 (m, 4H), 8.51 (d, J = 4.5 Hz, 3H, NH3).   
13
C NMR (125 MHz, DMSO-d6) δ = 26.23, 28.38, 37.64, 66.35, 125.31, 127.03, 128.02, 
128.14, 128.29, 129.01, 131.59, 134.40, 143.74, 144.40, 166.24.  HRMS (ESI+) calcd. for 
C23H25N2OS [M+H]
+
: 377.1682; found: 377.1679.  Anal. calcd. for C23H24N2OS∙2.5HCl: 
C, 59.07; H, 5.71; N, 5.99.  Found: C, 58.67; H, 5.42; N, 5.90. 
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5.2.5.92. 3-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzamide (133). 
 
The title compound was prepared following general procedure (iii) with 92 (199 mg, 0.6 
mmol) and cysteamine hydrochloride (75 mg, 0.66 mmol) in trifluoroacetic acid (0.6 mL).  
Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 133 as a colourless oil (201 mg, 86%).  
1
H NMR (500 MHz, MeOD) 
δ = 2.33-2.38 (m, 2H, CH2), 2.43-2.48 (m, 2H, CH2), 2.89-2.93 (m, 3H, CH3), 3.03-3.07 
(m, 3H, CH3), 7.21-7.34 (m, 7H), 7.38-7.46 (m, 6H), 7.55-7.59 (m, 1H).  
13
C NMR (100 
MHz, MeOD) δ = 35.64, 35.92, 40.03, 41.51, 67.56, 126.51, 128.06, 129.11, 129.30, 
129.37, 130.72, 132.17, 136.86, 145.80, 147.03, 173.51.  HRMS (ESI+) calcd. for 
C24H27N2OS [M+H]
+
: 391.1839; found: 391.1836.  Anal. calcd. for C24H26N2OS∙⅓CH2Cl2: 
C, 70.73; H, 6.49; N, 6.80.  Found: C, 70.87; H, 6.44; N, 6.69.   
5.2.5.93. 2-(((3-(Methylsulfonyl)phenyl)(diphenyl)methyl)sulfanyl)ethanamine (134). 
 
The title compound was prepared following general procedure (iii) with 99 (169 mg, 0.5 
mmol) and cysteamine hydrochloride (63 mg, 0.55 mmol) in trifluoroacetic acid (0.6 mL).  
Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether 134 as a colourless oil (163 mg, 82%).  
1
H NMR (500 MHz, DMSO-d6)) 
δ = 2.17 (t, J  = 7.0 Hz, 3H, CH3), 2.43 (t, J  = 7.0 Hz, 3H, CH3), 3.19 (s, 3H, CH3), 7.26-
7.30 (m, 2H), 7.33-7.40 (m, 8H), 7.62-7.64 (m, 2H), 7.84-7.88 (m, 1H), 7.92-7.93 (m, 1H).  
13
C NMR (125 MHz, DMSO-d6) δ = 35.33, 40.73, 43.56, 65.53, 125.55, 126.73, 126.99, 
128.26, 128.95, 129.35, 134.40, 140.59, 143.86, 146.23.  HRMS (ESI+) calcd. for 
C22H24NO2S2 [M+H]
+
: 398.1243; found: 398.1241.  Anal. calcd. for 
C22H23NO2S2∙⅕CH2Cl2: C, 64.32; H, 5.69; N, 3.38.  Found: C, 64.42; H, 5.67; N, 3.32.   
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5.2.5.94. 4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzonitrile (135). 
 
The title compound was prepared following general procedure (iii) with 64 (285 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 135 as a yellow oil (253 mg, 68%).  
1
H NMR (500 MHz, DMSO-d6) 
δ = 2.15 (t, J = 7.1 Hz, 2H, CH2), 2.44 (t, J = 7.1 Hz, 2H, CH2), 7.24-7.30 (m, 2H), 7.31-
7.39 (m, 8H), 7.49-7.53 (m, 2H), 7.80-7.84 (m, 2H).  
13
C NMR (125 MHz, DMSO-d6) δ = 
35.38, 40.66, 54.88, 65.60, 109.46, 118.58, 127.01, 128.25, 130.08, 131.98, 143.65, 
150.12.  HRMS (ESI+) Calcd. for C22H21N2S [M+H]
+
: 345.1420; found: 345.1418.  Anal. 
calcd. for C22H20N2S∙⅓CH2Cl2: C, 71.96; H, 5.59; N, 7.51.  Found: C, 71.95; H, 5.54; N, 
7.39.   
5.2.5.95.  (4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)phenyl)methanol (136).  
 
The title compound was prepared following general procedure (iii) with 90 (154 mg, 0.53 
mmol) and cysteamine hydrochloride (66 mg, 0.58 mmol) in trifluoroacetic acid (0.53 
mL).  Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the thioether 136 as a yellow oil (54 mg, 29%).  
1
H NMR (500 MHz, 
MeOD) δ = 2.35 (t, J = 6.7 Hz, 2H, CH2), 2.43 (t, J = 6.7 Hz, 2H, CH2), 4.58 (s, 2H, CH2), 
7.18-7.31 (m, 8H), 7.36-7.44 (m, 6H).  
13C NMR (125 MHz, MeOD) δ = 35.94, 41.50, 
64.75, 67.61, 127.55, 127.80, 128.90, 130.74, 141.31, 145.33, 146.33.  HRMS (ESI+) 
calcd. for C22H24NOS [M+H]
+
: 350.1573; found: 350.1571.  Anal. calcd. for 
C22H23NOS·¼CH2Cl2: C, 72.09; H, 6.39; N, 3.78.  Found: C, 72.36; H, 6.19; N, 3.50.   
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5.2.5.96. 2-(((4-(Aminomethyl)phenyl)(diphenyl)methyl)sulfanyl)ethanamine (137). 
 
The title compound was prepared following general procedure (iii) using 96 (145 mg, 0.5 
mmol) and cysteamine hydrochloride (63 mg, 0.55 mmol) in trifluoroacetic acid (0.5 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 137 as an off-white solid (250 mg, 72%).  Mpt. 70-72 °C.  
1
H NMR 
(500 MHz, DMSO-d6) δ = 2.15 (t, J = 7.1 Hz, 2H, CH2), 2.43 (t, J = 7.1 Hz, 2H, CH2), 
3.69 (s, 2H, CH2), 7.21-7.34 (m, 14H).  
13
C NMR (100 MHz, DMSO-d6) δ = 35.67, 40.86, 
45.16, 65.58, 126.55, 127.90, 128.82, 129.09, 142.52, 142.60, 144.85.  HRMS (ESI+) 
calcd. for C22H25N2S [M+H]
+
: 349.1733; found: 349.1731.  Anal. calcd. for 
C22H24N2S∙½H2O: C, 73.91; H, 7.05; N, 7.84.  Found: C, 73.91; H, 6.76; N, 7.57.   
5.2.5.97. N-(4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzyl)acetamide (138).   
 
The title compound was then prepared following general procedure (iii) using 98 (166 mg, 
0.50 mmol) and cysteamine hydrochloride (63 mg, 0.55 mmol) in trifluoroacetic acid (0.5 
mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% 
NH4OH] afforded thioether 138 as a pale yellow solid (143 mg, 73%).  Mpt. 74-77 °C.  
1
H 
NMR (400 MHz, MeOD) δ = 1.97 (s, 3H, CH3), 2.31-2.35 (m, 2H, CH2), 2.40-2.45 (m, 
2H, CH2), 4.33 (s, NHCH2), 7.18-7.31 (m, 8H), 7.36-7.43 (m, 6H).  
13
C NMR (100 MHz, 
MeOD) δ = 22.52, 35.92, 41.50, 43.77, 67.54, 127.82, 128.15, 128.91, 130.74, 130.91, 
138.51, 145.37, 146.26, 173.13.  HRMS (ESI+) calcd. for C24H27NO2S [M+H]
+ 
: 391.1839; 
found: 391.1835.  Anal. calcd. for C24H26N2OS∙¼CH2Cl2: C, 70.73; H, 6.49; N, 6.80.  
Found: C, 70.47; H, 6.35; N, 6.64.   
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5.2.5.98. 4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)benzamide (139). 
 
A solution of the tertiary alcohol 86 (303.4 mg, 1.0 mmol) with cysteamine hydrochloride 
(125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) was stirred for 2 h at room temperature.  
The volatiles were removed in vacuo and the residue suspended in aqueous HCl (1.0 M, 10 
mL) and stirred at room temperature for 18.5 h, during which time a precipitate formed.  
The mixture was filtered, and the precipitate washed successively with HCl (1.0 M, 10 
mL), petroleum ether (60/80) and Et2O, and dried in vacuo to yield the crude hydrochloride 
salt as an off-white solid.  This was basified (circa. pH 10) with saturated sodium 
carbonate solution, extracted with CH2Cl2 (3 x 10 mL) and the organic layer dried 
(MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-15% 
MeOH in CH2Cl2 with 1% NH4OH] afforded the title compound 139 as a white solid (252 
mg, 70%).  Mpt. 62-65 °C.  
1
H NMR (500 MHz, MeOD) δ = 2.32-2.37 (m, 2H, CH2), 
2.42-2.47 (m, 2H, CH2), 7.21-7.26 (m, 2H), 7.26-7.33 (m, 4H), 7.40-7.44 (m, 4H), 7.50-
7.54 (m, 2H), 7.79-7.82 (m, 2H).  
13C NMR (125 MHz, MeOD) δ = 36.04, 41.51, 67.55, 
128.04, 128.29, 129.08, 130.71, 130.84, 133.31, 145.76, 150.38, 171.86.  HRMS (ESI+) 
calcd. for C22H23N2OS [M+H]
+
: 363.1526; found: 363.1523.  Anal. calcd. for 
C22H22N2OS·½H2O: C, 71.13; H, 6.24; N, 7.54.  Found: C, 70.73; H, 5.96; N, 7.33.   
5.2.5.99. 4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)-N-methylbenzamide (140). 
 
The title compound was prepared following general procedure (iii) using 93 (150 mg, 0.47 
mmol) with cysteamine hydrochloride (59 mg, 0.52 mmol) in trifluoroacetic acid (0.5 mL) 
and CH2Cl2 (2 mL).  Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 
with 1% NH4OH] afforded thioether 140 as a white solid (122 mg, 69%).  Mpt. 62-64 °C.  
1H NMR (400 MHz, MeOD) δ = 2.32-2.36 (m, 2H, CH2), 2.41-2.46 (m, 2H, CH2), 2.91 (s, 
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3H, CH3), 7.21-7.26 (m, 2H), 7.27-7.33 (m, 4H), 7.39-7.44 (m, 4H), 7.49-7.54 (m, 2H), 
7.71-7.76 (m, 2H).  
13C NMR (100 MHz, MeOD) δ = 26.89, 35.99, 41.49, 67.54, 127.80, 
128.03, 129.07, 130.71, 130.86, 133.92, 145.77, 150.01, 170.22.  HRMS (ESI+) calcd. for 
C23H25N2OS [M+H]
+
: 377.1682; found: 377.1679.  Anal. calcd. for C23H24N2OS·½H2O: C, 
71.66; H, 6.54; N, 7.27.  Found: C, 71.50; H, 6.19; N, 7.12.   
5.2.5.100. 4-(((2-Aminoethyl)sulfanyl)(diphenyl)methyl)-N,N-dimethylbenzamide 
(141). 
 
The title compound was then prepared following general procedure (iii) using 94 (125 mg, 
0.37 mmol) with cysteamine hydrochloride (51 mg, 0.42 mmol) in trifluoroacetic acid (0.5 
mL) and CH2Cl2 (2 mL).  Purification by flash chromatography [SiO2; 0-15% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the thioether 141 as a clear yellow crystalline solid 
(129 mg, 88%).  Mpt. 60-62 °C.  
1H NMR (400 MHz, MeOD) δ = 2.32-2.38 (m, 2H, CH2), 
2.42-2.48 (m, 2H, CH2), 3.01 (s, 3H, CH3), 3.09 (s, 3H, CH3), 7.21-7.26 (m, 2H), 7.27-7.33 
(m, 4H), 7.35-7.45 (m, 6H), 7.50-7.55 (m, 2H).  
13C NMR (100 MHz, MeOD) δ = 35.65, 
36.01, 40.07, 41.52, 67.56, 127.73, 128.02, 129.06, 130.74, 130.87, 135.66, 145.82, 
148.40, 173.41.  HRMS (ESI+) calcd. for C24H27N2OS [M+H]
+
: 391.1839; found: 
391.1835.  Anal. calcd. for C24H26N2OS∙⅓CH2Cl2: C, 69.82; H, 6.42; N, 6.69.  Found: C, 
69.78; H, 6.10; N, 6.56.   
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5.2.5.101. 2-(((4-(Methylsulfonyl)phenyl)(diphenyl)methyl)sulfanyl)ethanamine (142). 
 
The title compound was then prepared following general procedure (iii) using 100 (197 
mg, 0.58 mmol) and cysteamine hydrochloride (73 mg, 0.64 mmol) in trifluoroacetic acid 
(1 mL).  Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2 with 1% 
NH4OH] afforded the thioether 142 as a colourless oil (143 mg, 62%).  
1
H NMR (400 
MHz, MeOD) δ = 2.32-2.37 (m, 2H, CH2), 2.43-2.48 (m, 2H, CH2), 3.12 (s, 3H, CH3), 
7.23-7.28 (m, 2H), 7.30-7.36 (m, 4H), 7.41-7.45 (m, 4H), 7.70-7.74 (m, 2H), 7.87-7.91 (m, 
2H).  
13
C NMR (125 MHz, DMSO-d6) δ = 35.50, 40.71, 43.45, 65.54, 126.79, 126.97, 
128.23, 129.02, 129.95, 138.97, 143.97, 150.38.  HRMS (ESI+) calcd. for C22H24NO2S2 
[M+H]
+
: 398.1243; found: 398.1239.  Anal. calcd. for C22H23NO2S2∙⅕CH2Cl2: C, 64.32; 
H, 5.69; N, 3.38.  Found: C, 64.98; H, 5.55; N, 2.90. 
5.2.5.102. 2-((Diphenyl(pyridin-3-yl)methyl)sulfanyl)ethanamine (143). 
 
The title compound was prepared following general procedure (iii) with 69 (274 mg, 1.05 
mmol) and cysteamine hydrochloride (131 mg, 1.15 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the 
thioether 143 as a yellow oil (187 mg, 59%).  
1H NMR (400 MHz, MeOD) δ = 2.35-2.40 
(m, 2H, CH2), 2.45-2.50 (m, 2H, CH2), 7.25-7.30 (m, 2H), 7.32-7.37 (m, 4H), 7.38-7.44 
(m, 5H), 7.92 (ddd, J = 1.6, 2.5, 8.2 Hz, 1H), 8.40-8.42 (m, 1H), 8.56 (dd, J = 0.7, 2.5 Hz, 
1H).  
13C NMR (400 MHz, MeOD) δ = 35.36, 41.31, 65.73, 124.58, 128.39, 129.38, 
130.52, 139.18, 143.04, 145.05, 148.15, 151.05.  HRMS (ESI+) calcd. for C20H21N2S 
[M+H]
+
: 321.1431; found: 321.1424.  Anal. calcd. for C20H20N2S∙⅓CH2Cl2: C, 70.07; H, 
5.98; N, 8.04.  Found: C, 70.14; H, 5.88; N, 7.75. 
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5.2.5.103. 2-((Diphenyl(1,3-thiazol-2-yl)methyl)sulfanyl)ethanamine (144). 
 
The title compound was prepared following general procedure (iii) with 70 (267 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the 
thioether 144 as a brown solid (98 mg, 30%).  Mpt 59-61 °C.  
1
H NMR (400 MHz, MeOD) 
δ = 2.62-2.66 (m, 2H, CH2), 2.73-2.77 (m, 2H, CH2), 7.31-7.40 (m, 6H), 7.39-7.43 (m, 
4H), 7.54 (d, J = 3.4 Hz, 1H), 7.83 (d, J = 3.4 Hz, 1H).  
13
C NMR (400 MHz, MeOD) δ = 
33.99, 40.87, 65.08, 122.16, 128.98, 129.25, 130.46, 143.81, 144.82, 178.61.  HRMS 
(ESI+) calcd. for C18H19N2S2 [M+H]
+
: 327.0984; found: 327.0981.  Anal. calcd. for 
C18H18N2S2∙½CH2Cl2: C, 60.23; H, 5.19; N, 7.59.  Found: C, 60.70; H, 4.75; N, 7.63. 
5.2.5.104. 2-((1,3-Oxazol-2-yl(diphenyl)methyl)sulfanyl)ethanamine (145). 
 
The title compound was prepared following general procedure (iii) with 71 (201 mg, 0.8 
mmol) and cysteamine hydrochloride (100 mg, 0.88 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the 
thioether 145 as an orange solid (55 mg, 27%).  Mpt. 59-61 °C.  
1
H NMR (400 MHz, 
MeOD) δ = 2.62-2.70 (m, 4H, 2 x CH2), 7.21 (d, J = 0.7 Hz, 1H), 7.91 (d, J = 0.7 Hz, 1H), 
7.28-7.37 (m, 10H).  
13C NMR (400 MHz, MeOD) δ = 34.40, 40.95, 62.24, 127.76, 
129.00, 129.34, 130.05, 141.38, 142.55, 167.68.  HRMS (ESI+) calcd. for C18H19N2OS 
[M+H]
+
: 311.1213; found: 311.1210.  Anal. calcd. for C18H18N2OS∙½CH2Cl2: C, 62.97; H, 
5.43; N, 7.94.  Found: C, 62.65; H, 4.79; N, 8.04. 
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5.2.5.105. 2-((Bis-(4-methylphenyl)(phenyl)methyl)sulfanyl)ethanamine (146).   
 
The title compound was prepared using general procedure (iii) with bis 37 (289 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction of the aqueous 
mixture (3 x 10 mL).  Purification by flash chromatography [SiO2; 0-18% MeOH in 
CH2Cl2 with 1% NH4OH] afforded the thioether 146 as a yellow solid (271 mg, 79%).  
Mpt. 64-67 °C.  
1
H NMR (MeOD, 500 MHz) δ 2.30 (s, 6H, 2 x CH3), 2.32-2.35 (m, 2H, 
CH2), 2.41-2.44 (m, 2H, CH2), 7.07-7.09 (m, 4H), 7.17-7.20 (m, 1H), 7.24-7.27 (m, 5H), 
7.38-7.40 (m, 2H).  
13C NMR (MeOD, 125 MHz) δ 19.30, 20.05, 36.08, 41.56, 67.55, 
127.66, 128.21, 128.79, 130.00, 130.76, 131.94, 136.13, 136.97, 143.71, 146.56.  HRMS 
(ESI+) calcd. for C23H26NS [M+H]
+
: 348.17805; found: 348.17805.  Anal. calcd. for 
C23H25NS·¼H2O: C, 78.48; H, 7.30; N, 3.98.  Found: C, 78.41; H, 7.49; N, 3.65.   
5.2.5.106. 3-(((2-Aminoethyl)thio)(3-chlorophenyl)phenylmethyl)phenol (rac-147).   
 
The title compound was prepared following general procedure (iii) with rac-66 (311 mg, 
1.0 mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 
mL) with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-16% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether rac-147 as a pale yellow solid (253 mg, 68%).  Mpt. 74 °C.  
1
H NMR 
(500 MHz, MeOD) δ = 2.36 (t, J = 6.9 Hz, 2H, CH2), 2.48 (t, J = 6.9 Hz, 2H, CH2), 6.67 
(ddd, J = 0.7, 2.4, 8.1 Hz, 1H), 6.82-6.84 (m, 1H), 6.87-6.88 (m, 1H), 7.12 (t, J = 8.0 Hz, 
1H), 7.22-7.33 (m, 5H), 7.34-7.36 (m, 1H), 7.39-7.41 (m, 3H).  
13
C NMR (125 MHz, 
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MeOD) δ = 36.00, 41.48, 67.29, 115.02, 117.08, 121.93, 127.85, 128.05, 129.04, 129.21, 
130.00, 130.36, 130.64, 130.70, 134.85, 145.67, 147.04, 148.88, 158.35.  HRMS (ESI-) 
calcd. for C21H19Cl2NOS [M-H]
-
: 368.08814; found: 368.08881.  Anal. calcd. for  
C21H20ClNOS: C, 68.19; H, 5.45; N, 3.79.  Found: C, 68.83; H, 5.45; N, 3.40.   
5.2.5.107. 3-(((2-Aminoethyl)sulfanyl)(3-ethylphenyl)phenylmethyl)phenol (rac-148).  
 
The title compound was prepared following general procedure (iii) with rac-67 (305 mg, 
1.0 mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 
mL) with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether rac-148 as an off-white solid (186 mg, 51%).  Mpt. 50-52 °C.  
1
H NMR 
(500 MHz, MeOD) δ = 1.16 (t, J = 7.6 Hz, 3H, CH3), 2.35-2.38 (m, 2H, CH2), 2.43-2.46 
(m, 2H, CH2), 2.57 (q, J = 7.6 Hz, 2H, CH2), 6.65 (ddd, J = 0.8, 2.4, 8.1 Hz, 1H), 6.84-6.86 
(m, 1H), 6.90-6.91 (m, 1H), 7.05-7.07 (m, 1H), 7.09 (t, J = 8.0 Hz, 1H), 7.16-7.21 (m, 3H), 
7.26-7.29 (m, 3H), 7.41-7.43 (m, 2H).  
13C NMR (125 MHz, MeOD) δ = 16.15, 29.93, 
36.09, 41.56, 67.80, 118.04, 122.13, 127.21, 127.69, 128.22, 128.78, 129.71, 130.39, 
130.82, 144.99, 146.33, 146.47, 147.89, 158.12.  HRMS (ESI-) calcd. for C23H24NOS  [M-
H]
-
: 362.15841; found: 362.15860 m/z.  Anal. calcd. for  C23H25NOS·¼H2O: C, 75.06; H, 
6.98; N, 3.81. Found: C, 75.04; H, 6.90; N, 3.88.   
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5.2.5.108. 3-(((2-Aminoethyl)sulfanyl)(4-methylphenyl)phenyl methyl)phenol (rac-
149).   
 
The title compound was prepared following general procedure (iii) with rac-68 (290 mg, 1 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether rac-149 as an off-white solid (291 mg, 83%).  Mpt. 68 °C.  
1
H NMR 
(500 MHz, MeOD) δ = 2.30 (CH3), 2.34-2.37 (m, 2H, CH2), 2.44-2.47 (m, 2H, CH2), 6.63-
6.65 (m, 1H), 6.83-6.85 (m, 1H), 6.88-6.89 (m, 1H), 7.06-7.10 (m, 3H), 7.18-7.21 (m, 1H), 
7.25-7.29 (m, 4H), 7.39-7.42 (m, 2H).
 
 
13C NMR (125 MHz, MeOD) δ = 20.93, 36.00, 
41.52, 67.51, 114.60, 117.98, 122.09, 127.67, 128.78, 129.41, 129.71, 130.76, 137.55, 
143.34, 146.56, 147.99, 158.10.  HRMS (ESI+) calcd. for C22H24NOS [M+H]
+
: 348.14276; 
found: 348.14307.  Anal. calcd. for C22H23NOS·¼H2O: C, 74.65; H, 6.69; N, 3.96.  Found: 
C, 74.73; H, 6.96; N, 3.73.   
5.2.5.109. 3-(((2-Aminoethyl)sulfanyl)(4-methylphenyl)phenylmethyl)benzonitrile (rac-
150). 
 
The title compound was prepared following general procedure (iii) with rac-65 (299 mg, 
1.0 mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 
mL).  Purification by flash chromatography [SiO2; 0-17% MeOH in CH2Cl2] afforded 
thioether rac-150 as an off-white solid (254 mg, 71%).  Mpt. 46-48 °C.  
1
H NMR (500 
MHz, MeOD) δ = 2.33 (s, 3H, CH3), 2.48-2.52 (m, 2H, CH2), 2.54-2.58 (m, 2H, CH2), 
7.16-7.19 (m, 2H), 7.26-7.30 (m, 3H), 7.33-7.37 (m, 2H), 7.40-7.43 (m, 2H), 7.48-7.52 (m, 
1H), 7.61-7.64 (m, 1H), 7.74-7.79 (m, 2H).  
13C NMR (125 MHz, MeOD) δ = 20.93, 
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31.44, 39.98, 67.46, 113.30, 119.50, 128.52, 129.45, 130.07, 130.39, 130.52, 131.83, 
133.64, 135.36, 138.64, 141.68, 144.89, 147.98.  HRMS (ESI+) calcd. for C23H23N2S2 
[M+H]
+
: 359.1587; found: 359.1574.  Anal. calcd. for C23H22N2S∙CH2Cl2: C, 65.01; H, 
5.46; N, 6.32.  Found: C, 64.57; H, 5.06; N, 5.99.   
5.2.5.110. 3-(((Aminomethyl)sulfanyl)(4-methylphenyl)phenylmethyl)benzamide (rac-
151). 
 
The title compound was prepared following general procedure (iii) with rac-87 (224 mg, 
0.71 mmol) and cysteamine hydrochloride (88 mg, 0.77 mmol) in trifluoroacetic acid (1 
mL).  Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded 
thioether rac-151 as a white solid (254 mg, 71%).  Mpt. 95-97 °C.  
1
H NMR (400 MHz, 
MeOD) δ = 2.32 (s, 3H, CH3), 2.47-2.55 (m, 4H, 2 x CH2), 7.12-7.17 (m, 2H), 7.22-7.35 
(m, 5H), 7.37-7.45 (m, 3H), 7.55-7.58 (m, 1H), 7.72-7.76 (m, 1H), 8.07-8.10 (m, 1H).  
13
C 
NMR (400 MHz, MeOD) δ = 20.94, 31.97, 40.19, 67.85, 126.86, 128.16, 129.22, 129.25, 
129.85, 130.62, 134.26, 134.87, 138.17, 142.43, 145.63, 146.84, 172.14.  HRMS (ESI+) 
calcd. for C23H25N2OS2 [M+H]
+
: 377.1682; found: 377.1678.  Anal. calcd. for 
C23H24N2OS∙CH2Cl2: C, 62.47; H, 5.68; N, 6.07.  Found: C, 61.92; H, 5.01; N, 5.40.  LC-
MS tR = 11.43 min (m/z = 350.2, [M+H]
+
; purity = 97.6%).   
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5.2.5.111. 2-((2-Fluoro-3-methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (152). 
 
The title compound was prepared following general procedure (iii) with 58 (292 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded thioether 
152 as a white solid (226 mg, 64%).  Mpt. 165-168 °C.  
1H NMR (400 MHz, MeOD) δ = 
2.14-2.17 (m, 3H, CH3), 2.35-2.40 (m, 4H, 2 x CH2), 7.14-7.19 (m, 1H), 7.23-7.35 (m, 
7H), 7.46-7.49 (m, 1H), 7.71-7.76 (m, 1H).  
19
F NMR (376.5 MHz, CDCl3) δ = -105.84.  
13
C NMR (400 MHz, MeOD) δ = 14.48 (d, JCF = 5.8 Hz), 31.27, 39.81, 66.39, 124.74 (d, 
JCF = 4.2 Hz), 127.26 (d, JCF = 19.2 Hz), 128.16, 128.92, 129.13 (d, JCF = 3.6 Hz), 130.27, 
131.72 (d, JCF = 10.8 Hz), 132.67 (d, JCF = 5.3 Hz), 143.95, 160.09 (d, JCF = 250.3 Hz).  
HRMS (ESI+) calcd. for C22H23FNS [M+H]
+
: 352.1541; found: 352.1528.  Anal. calcd. for 
C22H22FNS∙CH2Cl2: C, 63.30; H, 5.54; N, 3.21.  Found: C, 62.61; H, 5.11; N, 3.05. 
5.2.5.112. 2-((2-Fluoro-4-methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (153). 
 
The title compound was prepared following general procedure (iii) with 59 (292 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2] afforded the 
thioether 153 as a white solid (170 mg, 48%).  Mpt. 74-76 °C.  
1
H NMR (400 MHz, 
CDCl3) δ = 2.23-2.28 (m, 2H, CH2), 2.32-2.38 (m, 5H), 6.78-6.83 (m, 1H), 7.03-7.06 (m, 
1H), 7.17-7.30 (m, 6H), 7.38-7.44 (m, 4H), 7.69-7.74 (m, 1H).  
19
F NMR (376.5 MHz, 
CDCl3) δ = -102.04.  
13
C NMR (100 MHz, CDCl3) δ = 20.73, 36.05, 41.38, 65.54 (d, JCF = 
2.6 Hz), 117.98 (d, JCF = 23.0 Hz), 125.61 (d, JCF = 2.74 Hz), 127.81, 128.70, 129.60 (d, 
JCF = 10.6 Hz), 130.25, 131.63 (d, JCF = 3.3 Hz), 141.71 (d, JCF = 8.0 Hz), 144.60, 161.68 
(d, JCF = 250.2 Hz).  HRMS (ESI+) calcd. for C44H45F2N2S2 [2M+H]
+
: 703.2987; found: 
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703.2991.  Anal. calcd. for C22H22FNS·¼H2O: C, 74.23; H, 6.37; N, 3.93.  Found: C, 
74.27; H, 6.23; N, 3.58. 
5.2.5.113. (2R)-2-Amino-3-(((2-fluoro-4-
methoxyphenyl)(diphenyl)methyl)sulfanyl)propanoic acid (154).   
 
The title compound was prepared following general procedure (iii) with 60 (308 mg, 1.0 
mmol) and L-cysteine (133 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  Purification by 
flash chromatography [SiO2; 0-25% MeOH in CH2Cl2 with 1% NH4OH] afforded the 
thioether 154 as a white solid (204 mg, 50%).  Mpt. 152-154.5 °C.  
1
H NMR (400 MHz, 
MeOD) δ = 2.68 (dd, 1H, J = 8.9, 13.1 Hz), 2.81 (dd, 1H, J = 4.3, 13.1 Hz), 3.17 (dd, 1H, 
J = 4.2, 8.9 Hz), 3.87 (s, 3H, CH3), 7.00-7.06 (m, 1H), 7.12-7.20 (m, 2H), 7.23-7.30 (m, 
2H), 7.30-7.36 (m, 4H), 7.41-7.46 (m, 4H).  
19
F NMR (376.5 MHz, MeOD) δ = -136.39.  
13C NMR (100 MHz, MeOD) δ = 34.75, 55.17, 56.70, 67.31, 114.20 (d, JCF = 1.4 Hz), 
118.42 (d, JCF = 20.1 Hz), 126.69 (d, JCF = 3.2 Hz), 128.15, 129.22, 130.54, 138.63 (d, JCF 
= 4.9 Hz), 145.54, 145.57, 147.91 (d, JCF = 11.0 Hz), 152.96 (d, JCF = 244.6 Hz), 173.11.  
HRMS (ESI+) calcd. for C23H23NO3FS [M+H]
+
: 412.1377; found: 412.1377.  Anal. calcd. 
for C23H22NO3FS·H2O: C, 64.32; H, 5.63; N, 3.26.  Found: C, 64.03; H, 5.59; N, 3.26. 
5.2.5.114. 2-(((2-Fluoro-4-methoxyphenyl)(diphenyl)methyl)sulfanyl)ethanamine 
(155). 
 
The title compound was prepared following general procedure (iii) with 60 (308 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2] afforded the 
thioether 155 as a brown solid (280 mg, 76%).  Mpt. 68-70 °C.  
1
H NMR (400 MHz, 
MeOD) δ = 2.32-2.37 (m, 2H, CH2), 2.43-2.48 (m, 2H, CH2), 3.85 (s, 3H, CH3), 6.96-7.02 
(m, 1H), 7.08-7.15 (m, 2H), 7.19-7.25 (m, 2H), 7.26-7.33 (m, 4H), 7.37-7.42 (m, 4H).  
19
F 
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NMR (376.5 MHz, MeOD) δ = -136.78.  
13C NMR (100 MHz, MeOD) δ = 36.08, 41.55, 
56.74, 67.01, 113.79, 118.43 (d, JCF = 20.2 Hz), 126.69 (d, JCF = 2.8 Hz), 127.94, 129.00, 
130.61, 139.38 (d, JCF = 5.5 Hz), 146.12, 147.73 (d, JCF = 10.8 Hz), 152.86 (d, JCF = 244.5 
Hz).  HRMS (ESI+) calcd. for C22H23FNOS [M+H]
+
: 368.1479; found: 368.1475.  Anal. 
calcd. for C22H22FNOS·½H2O: C, 70.19; H, 6.16; N, 3.72.  Found: C, 70.37; H, 5.80; N, 
3.40. 
5.2.5.115. 2-(((3-Fluoro-4-methoxyphenyl)(diphenyl)methyl)sulfanyl)ethanamine 
(156). 
 
The title compound was prepared following general procedure (iii) with 61 (308 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  
Purification by flash chromatography [SiO2; 0-14% MeOH in CH2Cl2 with NH4OH] 
afforded thioether 156 as a pale yellow oil (247 mg, 67%).  
1H NMR (400 MHz, MeOD) δ 
= 2.24-2.29 (m, 2H, CH2), 2.35-2.40 (m, 2H, CH2), 3.79 (s, 3H, CH3), 6.58 (dd, J = 2.6, 
13.3 Hz, 1H), 6.78 (dd, J = 2.6, 8.7 Hz, 1H), 7.17-7.29 (m, 6H), 7.39-7.44 (m, 4H), 7.68-
7.74 (m, 1H).  
19
F NMR (376.5 MHz, MeOD) δ = -99.28.  
13C NMR (100 MHz, MeOD) δ 
= 36.10, 41.43, 56.14, 65.33 (d, JCF = 2.6 Hz), 103.75 (d, JCF = 27.1 Hz), 110.06 (d, JCF = 
2.5 Hz), 124.68 (d, JCF = 11.2 Hz), 127.77 128.70 130.21, 132.42 (d, JCF = 4.1 Hz), 
144.83, 162.35 (d, JCF = 250.2 Hz), 162.36 (d, JCF = 11.0 Hz).  HRMS (ESI+) calcd. for 
C22H23FNOS [M+H]
+
: 368.1479; found: 368.1474.  Anal. calcd. for C22H22FNOS: C, 
71.90; H, 6.03; N, 3.81.  Found: C, 72.04; H, 6.05; N, 3.84. 
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5.2.5.116. 2-(((3,4-Dichlorophenyl)(diphenyl)methyl)sulfanyl)ethanamine (157).   
 
The title compound was prepared following general procedure (iii) with (3,4-
dichlorophenyl)(diphenyl)methanol (165 mg, 0.5 mmol) and cysteamine hydrochloride (57 
mg, 0.5 mmol) in trifluoroacetic acid (0.5 mL) with the following modifications.  
Basification of the crude residue (circa pH 9) was performed with aqueous NaOH (1.0 M) 
and EtOAc was used for extraction (3 x 6 mL).  Purification by flash chromatography 
[SiO2; 0-18% MeOH in CH2Cl2 with NH4OH] afforded thioether 157 as white solid (91 
mg, 47%).  Mpt. 99-102 °C.  
1
H NMR (400 MHz, DMSO-d6) δ = 2.16 (t, J = 7.0 Hz, 2H, 
CH2), 2.45 (t, J = 7.1 Hz, 2H, CH2), 7.25-7.37 (m, 11H), 7.46 (m, 1H), 7.61-7.63 (m, 1H).  
13
C NMR (100 MHz, DMSO-d6) δ = 35.60, 40.78, 64.96, 127.09, 128.23, 128.93 129.49, 
129.73, 130.27, 130.64, 130.74, 143.74, 145.90.  HRMS (ESI+) calcd. for C21H120Cl2NS  
[M+H]
+
: 388.0688; found: 388.0683.  Anal. calcd. for C21H19Cl2NS·⅓H2O: C, 63.97; H, 
5.03; N 3.55.  Found: C, 63.99; H, 5.01; N, 3.61.   
5.2.5.117. (2R)-2-Amino-3-(((3-,4-dimethylphenyl)(diphenyl)methyl)sulfanyl)propanoic 
acid (158). 
 
The title compound was prepared following general procedure (iii) with 37 (500 mg, 1.73 
mmol) and L-cysteine (231 mg, 1.1 mmol) in trifluoroacetic acid (1.7 mL).  Purification by 
flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the thioether 158 as a 
white solid (464 mg, 68%).  Mpt. 148-150 °C.  
1H NMR (400 MHz, MeOD) δ = 2.19 (s, 
3H, CH3), 2.23 (s, 3H, CH3), 2.68 (dd, 1H, J = 9.2, 13.3 Hz), 2.81 (dd, 1H, J = 4.1, 13.3 
Hz), 3.05 (dd, 1H, J = 4.1, 9.2 Hz), 7.06 (d, 1H, J = 8.0 Hz), 7.12 (dd, 1H, J = 2.0, 8.0 Hz), 
7.17-7.24 (m, 3H), 7.26-7.32 (m, 4H), 7.41-7.46 (m, 4H).  
13C NMR (125 MHz, MeOD) δ 
= 19.30, 20.02, 34.41, 55.12, 67.93, 127.90, 128.17, 129.04, 130.23, 130.69, 130.72, 
131.86, 136.45, 137.29, 143.09, 145.92, 145.96, 172.62.  HRMS (ESI+) calcd. for 
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C48H51O4N2S2 [2M+H]
+
: 783.3286; found: 783.3295.  Anal. calcd. for C24H25NO2S·H2O: 
C, 70.39; H, 6.65; N, 3.42.  Found: C, 70.31; H, 6.25; N, 3.25. 
5.2.5.118. 2-(((3,4-Dimethylphenyl)(diphenyl)methyl) sulfanyl)ethanamine (159).   
 
The title compound was prepared following general procedure (iii) with 37 (289 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the thioether 159 a pale yellow oil (273 mg, 79%).  
1
H NMR (MeOD, 500 MHz) 
δ 2.17 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.32-2.35 (m, 2H, CH2), 2.41-2.44 (m, 2H, CH2), 
7.02 (d, J = 8.0 Hz, 1H), 7.09 (dd, J = 2.0, 8.0 Hz, 1H), 7.16-7.21 (m, 3H), 7.24-7.27 (m, 
4H), 7.38-7.41 (m, 4H).  
13C NMR (MeOD, 125 MHz) δ 19.30, 20.05, 36.08, 41.56, 67.55, 
127.66, 128.21, 128.79, 130.00, 130.76, 131.94, 136.13, 136.97, 143.71, 146.56.  HRMS 
(ESI+) calcd. for C23H26NS [M+H]
+
: 348.17805; found: 348.17886.  Anal. calcd. for 
C23H25NS·¼H2O: C, 78.48; H, 7.30; N, 3.98.  Found: C, 78.47; H, 7.38; N, 3.82.   
5.2.5.119. (2R)-2-Amino-3-(((3-ethyl-4-
methylphenyl)(diphenyl)methyl)sulfanyl)propanoic acid (160). 
 
The title compound was prepared following general procedure (iii) with 62 (254 mg, 0.84 
mmol) and L-cysteine (112 mg, 0.93 mmol) in trifluoroacetic acid (1 mL).  Purification by 
flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded thioether 160 as a white 
solid (242 mg, 71%).  Mpt. 149-152 °C.  
1H NMR (500 MHz, MeOD) δ = 1.10 (t, 3H, J = 
7.6 Hz), 2.27 (s, 3H), 2.56 (q, 2H, J  = 7.6 Hz), 2.69 (dd, 1H, J = 9.2, 13.4 Hz), 2.82 (dd, 
1H, J = 4.2, 13.4 Hz), 3.05 (dd, 1H, J = 4.2, 9.2 Hz), 7.06 (d, 1H, J  = 8.0 Hz), 7.14 (dd, 
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1H, J = 2.1, 8.0 Hz), 7.18-7.24 (m, 3H), 7.27-7.32 (m, 4H), 7.42-7.46 (m, 4H).  
13
C NMR 
(125 MHz, MeOD) δ = 14.94, 18.73, 27.28, 34.36, 55.13, 68.05, 127.92, 128.07, 129.04, 
130.47, 130.70, 130.74, 135.60, 143.16, 143.29, 145.91, 145.95, 172.53.  HRMS (ESI+) 
calcd. for C25H28NO2S [M+H]
+
: 406.1835; found 406.1843.  Anal. calcd. for 
C25H27NO2S·½H2O: C, 72.43; H, 6.81; N, 3.38.  Found: C, 72.18; H, 6.37; N, 3.14. 
5.2.5.120. 2-(((3-Ethyl-4-methylphenyl)(diphenyl)methyl)sulfanyl)ethanamine (161).   
 
The title compound was prepared following general procedure (iii) with 62 (302 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-16% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether 161 as a colourless oil (260 mg, 72%).  
1H NMR (MeOD, 500 MHz) δ 
2.17 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.32-2.35 (m, 2H, CH2), 2.41-2.44 (m, 2H, CH2), 
7.02 (d, J = 8.0 Hz, 1H), 7.09 (dd, J = 2.0, 8.0 Hz, 1H), 7.16-7.21 (m, 3H), 7.24-7.27 (m, 
4H), 7.38-7.41 (m, 4H).  
13C NMR (MeOD, 125 MHz) δ 19.30, 20.05, 36.08, 41.56, 67.55, 
127.66, 128.21, 128.79, 130.00, 130.76, 131.94, 136.13, 136.97, 143.71, 146.56.  HRMS 
(ESI+) calcd. for C24H28NS [M+H]
+
: 362.19370; found: 362.19257.  Anal. calcd. for 
C24H27NS·⅕CH2Cl2: C, 76.79; H, 7.30; N, 3.70.  Found: C, 77.05; H, 7.58; N, 2.93.   
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5.2.5.121. (2R)-2-Amino-3-(((5,6,7,8-tetrahydronaphthalen-2-
yl)(diphenyl)methyl)sulfanyl)propanoic acid (162). 
 
The title compound was prepared following general procedure (iii) with 46 (314 mg, 1.0 
mmol) and L-cysteine (133 mg, 1.1 mmol) in trifluoroacetic acid (1 mL).  Purification by 
flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the thioether 162 as a 
white solid (123 mg, 29%).  Mpt. 145-148 °C.  
1H NMR (400 MHz, MeOD) δ = 1.75-1.80 
(m, 4H), 2.64-2.75 (m, 5H), 2.82 (dd, 1H J = 4.1, 13.4 Hz), 3.02 (dd, 1H J = 4.1, 9.2 Hz), 
6.98 (d, J = 8.2 Hz, 1H), 7.08-7.13 (m, 2H), 7.19-7.24 (m, 2H), 7.26-7.32 (m, 4H), 7.42-
7.46 (m, 4H).  
13C NMR (100 MHz, MeOD) δ = 24.37, 29.93, 30.53, 34.32, 55.07, 67.94, 
127.90, 128.00, 129.05, 129.76, 130.68, 130.72, 131.17, 136.99, 137.79, 142.67, 145.88, 
145.93, 172.55.  HRMS (ESI-) calcd. for C26H26NO2S [M-H]
-
: 416.1690; found 416.1692.  
Anal. calcd. for C26H27NO2S·⅔H2O: C, 72.72; H, 6.65; N 3.26.  Found: C, 72.46; H, 6.27; 
N, 3.15. 
5.2.5.122. 2-((Diphenyl(5,6,7,8-tetrahydronaphthalen-2-yl)methyl)sulfanyl)ethanamine 
(163).   
 
The title compound was prepared following general procedure (iii) with 46 (314 mg, 1.0 
mmol) and cysteamine hydrochloride (125 mg, 1.1 mmol) in trifluoroacetic acid (1 mL) 
with the following modifications.  Basification of the crude residue (circa pH 9) was 
performed with aqueous NaOH (1.0 M) and EtOAc was used for extraction (3 x 10mL).  
Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2 with 1% NH4OH] 
afforded thioether 163 as a colourless oil (262 mg, 70%).  
1H NMR (MeOD, 500 MHz) δ 
1.76-1.79 (m, 4H, 2 x CH2), 2.33-2.35 (m, 2H, CH2), 2.42-2.45 (m, 2H, CH2), 2.64-2.66 
(m, 2H, CH2), 2.71-2.73 (m, 2H, CH2), 6.94-6.95 (m, 1H), 7.06-7.08 (m, 2H), 7.17-7.21 
(m, 2H), 7.25-7.28 (m, 4H), 7.39-7.41 (m, 4H).  
13C NMR (MeOD, 125 MHz) δ 24.40, 
29.92, 30.58, 36.02, 41.56, 67.61, 127.66, 128.07, 128.79, 129.51, 130.78, 131.23, 136.72, 
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137.49, 143.32, 146.57.  HRMS (ESI+) calcd. for C25H28NOS [M+H]
+
: 374.19370; found: 
374.19400.  Anal. calcd. for C25H27NS·¾CH2Cl2: C, 70.73; H, 6.57; N, 3.20.  Found: C, 
71.00; H, 6.48; N, 3.35.   
5.2.5.123. 4-(1,1-Diphenylbut-3-en-1-yl)-1,2-dimethylbenzene (171). 
 
The title compound was prepared using an adaptation of the method reported by Kabalka et 
al.
192
  n-Butyllithium (2.5 M in hexane, 6.12 mL, 15.3 mmol) was added cautiously by 
dropwise addition to a cooled (0 °C) solution of 37 (4.00 g, 13.9 mmol) in anhydrous 
CH2Cl2 (85 mL), the reaction mixture allowed to warm to room temperature and stirred for 
30 min.  Allyltrimethylsilane (6.02 mL, 36.9 mmol) and iron trichloride (5.19 g, 32.0 
mmol) were then added and the reaction stirred at room temperature for 6 h.  The reaction 
was quenched with H2O (100mL) extracted with CH2Cl2 (3 x 100 mL).  The combined 
organic layers were washed successively with saturated aqueous NaHCO3 solution (150 
mL) and brine (200 mL), dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-10% EtOAc in hexane] afforded alkene 171 as a brown oil 
[3.119 g, 91% (based on 79% conversion)] and recovered starting material 37 (834 mg).  
1
H NMR (400 MHz, CDCl3) δ = 2.22 (s, 3H, CH3), 2.26 (s, 3H, CH3), 3.43-3.46 (m, 2H), 
4.97 (ddd, J = 1.4, 3.4, 10.3 Hz, 1H), 5.06 (ddd, J = 1.5, 3.5, 17.0 Hz, 1H), 5.70 (ddd, J = 
6.6, 10.4, 17.1 Hz, 1H), 6.94-6.98 (m, 1H), 7.03-7.08 (m, 2H), 7.19-7.34 (m, 10H).  
13
C 
NMR (100 MHz, CDCl3) δ = 19.40, 20.24, 45.67, 56.01, 117.18, 125.97, 126.97, 127.79, 
129.14, 129.58, 130.62, 134.23, 135.87, 136.35, 144.92, 147.65.  GC-MS (CI, methane) tR 
= 16.44 min (m/z = 311.2, [M-H]
+
).  Anal. calcd. for C24H24: C, 92.26; H, 7.74.  Found: C, 
91.51; H, 7.28. 
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5.2.5.124. 4-(3,4-Dimethylphenyl)-4,4-diphenylbutan-1-ol (172). 
 
A solution of BH3THF (1.0 M in THF, 20.0 mL, 20.0 mmol) was added to a cooled (0 °C) 
solution of alkene 171 (3.11 g, 10.0 mmol) in THF (20 mL), and stirred at room 
temperature for 19 h.  The reaction was cooled to 0 °C and quenched cautiously with H2O 
(5 mL) and aqueous NaOH (3.0 M, 6.8 mL, 20.4 mmol), followed by slow dropwise 
addition of hydrogen peroxide (30% in H2O, 5.1 mL, 50.0 mmol) over 5 min.  The mixture 
was maintained at 0 °C for 30 min, and then allowed to warm to room temperature and 
stirred for a further 3.5 h, diluted with H2O (50 mL) and extracted with Et2O (3 x 50 mL).  
The combined organic extracts were washed successively with saturated aqueous NaHCO3 
solution (200 mL) and brine (200 mL), dried (MgSO4) and concentrated in vacuo.  
Purification by flash chromatography [SiO2; 0-22% EtOAc in hexane] afforded the 
primary alcohol 172 as a colourless oil (1.90 g, 58%).  
1
H NMR (400 MHz, CDCl3) δ = 
1.31-1.40 (m, 2H, CH2), 2.19 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.59-2.66 (m, 2H, CH2), 
3.62 (t, J = 6.4 Hz, 2H, CH2), 6.97-7.03 (m, 2H), 7.04-7.09 (m, 1H), 7.14-7.19 (m, 2H), 
7.22-7.31 (m, 8H).  
13
C NMR (100 MHz, CDCl3) δ = 19.36, 20.25, 29.36, 36.61, 56.06, 
63.54, 125.85, 126.75, 127.89, 129.19, 129.36, 130.44, 134.11, 135.90, 144.94, 147.67.  
GC-MS (CI, methane) tR = 17.91 min (m/z = 371.1, [M+C3H5]
+
).  Anal. calcd. for 
C24H26O·¼EtOAc: C, 85.19; H, 8.01.  Found: C, 85.11; H, 7.81. 
5.2.5.125. 4-(3,4-Dimethylphenyl)-4,4-diphenylbutanal (173). 
 
The title compound was prepared using an adaptation of the method developed by Dess et 
al. and the procedure reported by Wang et al.
138, 194
  Dess-Martin periodinane (3.069 g, 
7.24 mmol) was added to a solution of alcohol 172 (1.993 g, 6.03 mmol) in anhydrous 
CH2Cl2 (24 mL).  The reaction was stirred at room temperature for 4 h, and then quenched 
cautiously with sodium thiosulfate solution (0.26 M in saturated aqueous NaHCO3 
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solution, 100 mL) and extracted with CH2Cl2 (3 x 50 mL).  The combined organic extracts 
were washed successively with saturated aqueous NaHCO3 solution, H2O, and brine (150 
mL each), dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-16% EtOAc in hexane] afforded aldehyde 173 as a colourless oil 
(830 mg, 42%).  
1
H (400 MHz, CDCl3) δ = 2.20 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.29-2.35 
(m, 2H, CH2), 2.88-2.94 (m, 2H, CH2), 6.97-7.06 (m, 3H), 7.15-7.22 (m, 2H), 7.24-7.30 
(m, 8H).  
13
C NMR (100 MHz, CDCl3) δ = 19.36, 20.24, 31.99, 41.30, 55.63, 126.17, 
126.60, 128.13, 129.18, 129.40, 130.26, 134.48, 136.21, 144.11, 146.96, 202.01.  GC-MS 
(CI, methane) tR = 17.57 min (m/z = 329.2 [M+H]
+
).   
5.2.5.126. 2-(Benzylamino)-5-(3,4-dimethylphenyl)-5,5-diphenylpentanenitrile (rac-
174). 
 
The title compound was prepared by an adaptation of the method reported by Yadav et 
al.
196
  Mont. KSF clay (4.5 g) and 1-phenylmethanamine (549 µL, 5.02 mmol) was added 
to a solution of aldehyde 173 (300 mg, 1.0 mmol) in anhydrous CH2Cl2 (45 mL) at room 
temperature.  Trimethylsilyl cyanide (686 µL, 5.48 mmol) was then added, and the reaction 
mixture was stirred at room temperature for 2.5 h, filtered and the clay rinsed with CH2Cl2.  
The filtrate was concentrated in vacuo and purification of the residue by flash 
chromatography [SiO2; 0-16% EtOAc in hexane] afforded the α-aminonitrile rac-174 as a 
pale yellow oil [931 mg, 68% (based on 79% conversion)] and unreacted 4-(3,4-
dimethylphenyl)-4,4-diphenylbutanal 173 (485 mg).  
1
H (500 MHz, CDCl3) δ = 1.56-1.62 
(m, 2H, CH2), 2.20 (s, 3H, CH3), 2.23 (s, 3H, CH3), 2.71-2.81 (m, 2H, CH2), 3.36-3.40 (m, 
1H, CH), 3.78 (d, J = 12.8 Hz, 1H, CHaHbPh), 4.02 (d, J = 12.8 Hz, 1H, CHaHbPh), 6.98-
7.06 (m, 3H), 7.17-7.21 (m, 2H), 7.25-7.31 (m, 9H), 7.33-7.36 (m, 4H).  
13
C NMR (100 
MHz, CDCl3) δ = 19.34, 20.22, 30.12, 36.31, 50.17, 51.78, 55.95, 120.33, 126.14, 126.64, 
127.72, 128.10, 128.49, 128.74, 129.18, 129.39, 130.22, 134.43, 136.17, 138.42, 144.13, 
147.03, 147.06.  HRMS (ESI+) calcd. for C32H33N2 [M+H]
+
: 445.2638; found 445.2640. 
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5.2.5.127. 2-(Benzylamino)-5-(3,4-dimethylphenyl)-5,5-diphenylpentanoic acid (rac-175). 
 
The title compound was prepared using an adaptation of the procedure reported by Wang 
et al.
138
  Conc. HCl (12 M, 25 mL) was added to a solution of the nitrile rac-174 (900 mg, 
2.02 mmol) in dioxane (25 mL) and the mixture heated at reflux for 48 h.  After cooling, 
the mixture was concentrated in vacuo.  The crude residue was basified (circa. pH 9.5) 
with saturated aqueous sodium carbonate solution and extracted with CH2Cl2 (3 x 100 mL).  
The combined organic extracts were dried (MgSO4) and concentrated in vacuo.  
Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2 with 1% NH4OH] 
afforded the protected amino acid rac-175 as a white solid (538 mg, 57%).  Mpt. 176-178 
°C.  
1H (400 MHz, MeOD) δ = 1.51-1.70 (m, 2H, CH2), 2.16 (s, 3H, CH3), 2.19 (s, 3H, 
CH3), 2.64-2.86 (m, 2H, CH2), 2.64-2.85 (m, 2H, CH2), 3.40-3.44 (m, 1H, CH), 3.92 (d, J 
= 12.8 Hz, 1H, CHaHbBn), 4.02 (d, J = 12.8 Hz, 1H, CHaHbBn), 6.95-7.05 (m, 2H), 7.11-
7.17 (m, 2H), 7.20-7.31 (m, 8H), 7.34-7.40 (m, 5H).  
13C NMR (100 MHz, MeOD) δ = 
19.23, 20.09, 27.89, 36.66, 51.22, 57.06, 63.35, 126.93, 127.81, 128.87, 130.09, 130.30, 
130.41, 131.08, 131.50, 132.78, 135.20, 136.91, 145.69, 148.55, 173.40.  HRMS (ESI+) 
calcd. for C32H34NO2 [M+H]
+
: 464.2584; found 464.2585.   
5.2.5.128. 2-Amino-5-(3,4-dimethylphenyl)-5,5-diphenylpentanoic acid (rac-176). 
 
The title compound was prepared using an adaptation of the method reported by Ram et 
al.
197
  A solution of benzyl amine rac-175 (520 mg, 1.12 mmol), 10% Pd/C (250 mg) and 
ammonium formate (354 mg, 5.61 mmol) in anhydrous MeOH (7.5 mL) was heated at 60 
°C for 2 h.  After cooling to room temperature, the mixture was filtered through a thick pad 
of Celite
®
, the residue washed with MeOH (25 mL), and the filtrate concentrated in vacuo.  
Purification by flash chromatography [SiO2; 0-25% MeOH in CH2Cl2] afforded the 
racemic amino acid rac-176 as a white solid (346 mg, 83%).  Mpt. 258-259 °C.  
1
H (500 
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MHz, MeOD) δ = 1.57-1.65 (m, 2H, CH2), 2.17 (s, 3H, CH3), 2.20 (s, 3H, CH3), 2.65-2.86 
(m, 2H, CH2), 3.53 (t, 1H, J = 6.0 Hz, CH), 6.97-7.05 (m, 2H), 7.13-7.17 (m, 2H), 7.22-
7.31 (m, 8H).  
13C NMR (125 MHz, MeOD) δ = 19.22, 20.08, 28.93, 36.75, 56.33, 57.04, 
126.92, 127.80, 128.85, 130.06, 130.33, 131.52, 135.18, 136.89, 145.72, 148.55, 148.59, 
166.57.  HRMS (ESI+) calcd. for C25H28NO2 [M+H]
+
: 374.2122; found: 374.2115.  Anal. 
calcd. for C25H27NO2·H2O: C, 76.70; H, 7.47; N, 3.58.  Found: C, 76.74; H, 7.27; N, 3.45.   
5.2.5.129. 1-(1,1-Diphenylbut-3-en-1-yl)-4-methoxybenzene (187). 
 
The title compound was prepared using an adaptation of the method reported by Kabalka et 
al.
192
  n-Butyllithium (2.5 M in hexane, 20 mL, 50.0 mmol) was added by cautiously by 
slow dropwise addition over 15 min to a cooled (0 °C) solution of (4-
methoxyphenyl)(diphenyl)methanol (10.00 g, 34.4 mmol) in anhydrous CH2Cl2 (40 mL), 
the reaction mixture allowed to warm to room temperature and stirred for 18 h.  
Allyltrimethylsilane (6.02 mL, 36.9 mmol) and iron trichloride (5.19 g, 32.0 mmol) were 
then added and the reaction stirred at room temperature for 24 h.  The reaction was 
quenched with H2O (25 mL), then aqueous HCl solution (0.25 M, 75 mL), and extracted 
with CH2Cl2 (3 x 75 mL).  The combined organic layers were washed successively with 
aqueous HCl solution (0.25 M, 150 mL), H2O (200 mL) and brine (200 mL), dried 
(MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-6% 
EtOAc in hexane] afforded alkene 187 as a pale brown solid (6.44 g, 60%).  Mpt. 71-72.5 
°C.  
1
H NMR (400 MHz, CDCl3) δ = 3.42-3.45 (m, 2H, CH2), 3.81 (s, 3H, CH3), 4.95-4.98 
(m, 1H), 5.03-5.08 (m, 1H), 5.65-5.73 (m, 1H), 6.81-6.84 (m, 2H), 7.13-7.17 (m, 2H), 
7.19-7.26 (m, 6H), 7.26-7.30 (m, 4H).  
13
C NMR (100 MHz, CDCl3) δ = 45.84, 55.30, 
55.77, 113.16, 117.30, 126.04, 127.86, 127.90, 129.48, 130.58, 136.25, 139.56, 147.76, 
157.73.  GC-MS (CI, methane) tR = 17.12 min (m/z = 315.1, [M+H]
+
).  Anal. calcd. for 
C23H22O: C, 87.86; H, 7.05.  Found: C, 86.38; H, 6.70. 
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5.2.5.130. 4-(4-Methoxyphenyl)-4,4-diphenylbutan-1-ol (188). 
 
The title compound was prepared using an adaptation of the procedure reported by 
Starnes.
266 
 A solution of concentrated sulphuric acid (200 µL, 3.76 mmol) in anhydrous 
Et2O (5.0 mL) was added slowly by dropwise addition to a solution of sodium borohydride 
(284 mg, 7.51 mmol) and alkene 187 (6.16 g, 19.6 mmol) in anhydrous diglyme (10 mL), 
and the reaction mixture stirred for 18 h at room temperature, then heated at 75 °C for a 
further 1 h.  The reaction was cooled (0 °C) and treated successively with water (540 µL), 
aqueous NaOH (3.0 M, 2.49 mL) and hydrogen peroxide (30% in H2O, 2.46 mL).  The 
mixture was allowed to warm to room temperature and stirred for 5.5 h, then extracted 
with Et2O (3 x 50 mL).  The combined organics were washed with H2O (75 mL), dried 
(MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-35% 
EtOAc in hexane] afforded the primary alcohol 188 as a white solid (3.25 g, 50%).  Mpt. 
50-52 °C.  
1
H NMR (500 MHz, CDCl3) δ = 1.35-1.41 (m, 2H, CH2), 2.61-2.66 (m, 2H, 
CH2), 3.65 (t, 2H, J = 6.5 Hz, CH2), 3.79 (s, 3H, CH3), 6.79-6.83 (m, 2H), 7.16-7.22 (m, 
4H), 7.24-7.30 (m, 8H).    
13
C NMR (125 MHz, CDCl3) δ = 29.34, 36.78, 55.31, 55.77, 
63.50, 113.27, 125.92, 127.95, 129.20, 129.26, 130.36, 139.55, 147.77, 157.64.  GC-MS 
(CI, methane) tR = 18.34 min (m/z = 361.1, [M+C2H5]
+
).  Anal. calcd. for C23H24O2·H2O: 
C, 78.83; H, 7.48.  Found: C, 79.16; H, 7.23. 
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5.2.5.131. 4-(4-Methoxyphenyl)-4,4-diphenylbutanal (189). 
 
The title compound was prepared using an adaptation of the method developed by Dess et 
al. and the procedure reported by Wang et al.
138, 194
  Dess-Martin periodinane (2.30 g, 5.42 
mmol) was added to a solution of alcohol 188 (1.50 g, 4.51 mmol) in anhydrous CH2Cl2 
(20 mL).  The reaction was stirred at room temperature for 4.5 h, and then quenched 
cautiously with sodium thiosulfate solution (0.26 M in saturated aqueous NaHCO3 
solution, 100 mL) and extracted with CH2Cl2 (3 x 50 mL).  The combined organic extracts 
were washed successively with saturated aqueous NaHCO3 solution (100 mL), H2O (150 
mL) and brine (150 mL), dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-35% EtOAc in hexane] yielded aldehyde 189 as a white solid 
(1.238 g, 83%).  Mpt. 112-113 °C.  
1
H NMR (400 MHz, CDCl3): 2.31-2.35 (m, 2H, CH2), 
2.89-2.93 (m, 2H, CH2), 3.79 (s, 3H, CH3), 6.80-6.84 (m, 2H), 7.16-7.21 (m, 4H), 7.26-
7.29 (m, 8H), 9.63 (s, 1H, CHO).  
13
C NMR (100 MHz, CDCl3): 32.12, 41.27, 55.33, 
113.49, 126.22, 128.18, 129.08, 130.21, 138.73, 147.01, 157.84, 201.91.  HRMS (ESI+) 
calcd. for C23H23O2 [M+H]
+
: 331.1693; found: 331.1690.  Anal. calcd. for C23H22O2: C, 
83.60; H, 6.71.  Found: C, 83.22; H, 6.49. 
5.2.5.132. 2-Fluoro-4-(4-methoxyphenyl)-4,4-diphenylbutan-1-ol (rac-192). 
 
The title compound was prepared by adaptation of the method reported by Beeson et al.
202
  
THF (12.06 mL) and i-PrOH (1.34 mL) was added to a flask containing L-proline (62 mg, 
0.54 mmol) and N-fluorobenzenesulfonimide (2.119 g, 6.72 mmol) and stirred until 
homogeneous.  The mixture was cooled to -10 °C, aldehyde 189 (889 mg, 2.69 mmol) 
added and stirred for 2 h at ≤ -7.5 °C, before allowing the reaction to warm to room 
temperature and stirring for a further 21 h.  The reaction mixture was cooled to -78 °C, 
diluted with Et2O (15 mL) and filtered through a thin pad of silica, eluting with Et2O.  
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Me2S (2.5 mL, 34.00 mmol) was added to the filtrate, resulting in formation of a white 
precipitate.  This suspension was washed successively with saturated aqueous NaHCO3 
solution (3 x 50 mL) and brine (50 mL), dried (MgSO4), and concentrated in vacuo.  The 
residual oil was dissolved in CH2Cl2 (15 mL) and EtOH (10 mL), cooled (0 °C), and 
sodium borohydride added (255 mg, 6.73 mmol).  The reaction mixture was then allowed 
to warm to room temperature and stirred for 4 h.  After cooling (0 °C), the reaction mixture 
was quenched cautiously with saturated aqueous NH4Cl solution (100 mL), stirred for 10 
min, then extracted with CH2Cl2 (3 x 50 mL).  The organic extracts were washed 
successively with saturated aqueous NaHCO3 solution (2 x 150 mL) and brine (150 mL), 
dried (MgSO4) and concentrated in vacuo.  Purification of the crude residue by flash 
chromatography [SiO2; 0-35% EtOAc in hexane] afforded the -fluorinated alcohol rac-
192 as a colourless oil (638 mg, 68%).  The ,-difluorinated alcohol 193 was also 
obtained as the minor product (165 mg, 17%; vide infra).  
1
H NMR (400 MHz, CDCl3) δ = 
1.62-1.66 (m, 1H), 2.55-2.66 (m, 1H), 3.02-3.34 (m, 3H), 3.78 (s, 3H, CH3), 4.39-4.57 (m, 
1H), 6.78-6.83 (m, 2H), 7.16-7.32 (m, 12H).  
19
F NMR (376.5 MHz, CDCl3) δ = -180.84.  
13
C NMR (100 MHz, CDCl3) δ = 41.96 (d, JCF = 21.4 Hz), 55.11 (d, JCF = 3.5 Hz), 55.32, 
65.54 (d, JCF = 22.4 Hz), 93.06 (d, JCF = 167.4 Hz), 113.48, 126.35, 128.20, 129.06 (d, JCF 
= 2.2 Hz), 130.24, 138.59, 146.97, 157.90.  GC-MS (CI, methane) tR = 20.20 min (m/z = 
379.1, [M+C2H5]
+
).  Anal. calcd. for C23H23FO2: C, 78.83; H, 6.62.  Found: C, 78.15; H, 
6.18.   
5.2.5.133. 2,2-Difluoro-4-(4-methoxyphenyl)-4,4-diphenylbutan-1-ol (193). 
 
The title compound 193 was obtained as the minor product in the synthesis of rac-192 as a 
colourless oil (165 mg, 17%).  
1
H NMR (400 MHz, CDCl3) δ = 1.76 (t, J = 7.0 Hz, 1H), 
2.98-3.07 (m, 2H), 3.41 (t, J = 16.1 Hz, 2H, CH2), 3.78 (s, 3H, CH3), 6.78-6.83 (m, 2H), 
7.16-7.21 (m, 2H), 7.24-7.30 (m, 6H), 7.35-7.39 (m, 4H).  
19
F NMR (376.5 MHz, CDCl3) δ 
= -98.71.  
13
C NMR (100 MHz, CDCl3) δ = 42.49 (t, JCF = 22.9 Hz), 54.13, 55.30, 65.03 (t, 
JCF = 32.0 Hz), 113.16, 122.90 (t, JCF = 246.3 Hz), 126.26, 127.91, 129.16, 130.46, 138.48, 
146.88, 157.85.  GC-MS (CI, methane) tR = 20.00 min (m/z = 397.1, [M+C2H5]
+
).  Anal. 
calcd. for C23H22F2O2: C, 74.98; H, 6.02.  Found: C, 74.37; H, 6.65. 
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5.2.5.134. 2-Fluoro-4-(4-methoxyphenyl)-4,4-diphenylbutyl-4-methylbenzenesulfonate 
(rac-194). 
 
 
The title compound was prepared by an adaptation of the procedure reported by Moussa et 
al.
267
  Tosyl chloride (220 mg, 1.73 mmol) and anhydrous pyridine (93 µL, 1.73 mmol) 
were added to a cooled (0 °C) solution of -fluorinated rac-192 in CH2Cl2 (4.6 mL) and 
stirred at room temperature for 3 h.   The reaction was quenched with H2O (5 mL) and 
saturated aqueous NH4Cl solution (2.5 mL) and extracted with CH2Cl2 (3 x 20 mL).  The 
combined organic extracts were dried (MgSO4) and concentrated in vacuo.  Purification of 
the crude residue by flash chromatography [SiO2; 0-30% EtOAc in hexane] afforded the 
toyslate 194 as a colourless opaque oil [307 mg, 93% (based on 57% conversion)] and 
unreacted β-fluorinated alcohol rac-192 (175 mg, 43%).  1H NMR (400 MHz, CDCl3) δ = 
2.45 (s, 3H, CH3), 2.49-2.61 (m, 1H), 3.22-3.36 (m, 1H), 3.42-3.59 (m, 2H), 3.78 (s, 3H, 
CH3), 4.41-4.59 (m, 1H), 6.76-6.82 (m, 2H), 7.10-7.34 (m, 14H), 7.66-7.72 (m, 2H).  
19
F 
NMR (376.5 MHz, CDCl3) δ = -177.46.  
13
C NMR (100 MHz, CDCl3) δ = 21.80, 41.80 (d, 
JCF = 21.7 Hz), 54.97 (d, JCF = 3.7 Hz), 55.33, 71.14 (d, JCF = 23.0 Hz), 88.92 (d, JCF = 
175.2 Hz), 113.61, 126.48, 128.08, 128.30, 128.88 (d, JCF = 3.7 Hz), 129.94, 130.08, 
132.76, 138.03, 145.04, 146.47, 158.00.  GC-MS (CI, methane) tR = 26.95 min (m/z = 
503.8, [M-H]
-
).   
5.2.5.135. 1-(4-Azido-3-fluoro-1,1-diphenylbutyl)-4-methoxybenzene (rac-195). 
 
The title compound was prepared by an adaptation of the procedure reported by Jiang et 
al.
268
  A solution of the tosylate rac-194 (280 mg, 0.56 mmol) and sodium azide (91 mg, 
1.40 mmol) in anhydrous DMSO (2.5 mL) was stirred at 40 °C for 18 h.   The reaction 
mixture was diluted with brine (5 mL), extracted with Et2O (3 x 10 mL), dried (MgSO4) 
and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-15% EtOAc in 
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hexane] afforded the azide rac-195 as a colourless oil, which was used directly in the next 
step (146 mg, 70%).  
1
H NMR (400 MHz, CDCl3) δ = 2.53-2.82 (m, 3H), 3.34-3.47 (m, 
1H), 3.79 (s, 3H, CH3), 4.46-4.64 (m, 1H), 6.80-6.85 (m, 2H), 7.16-7.24 (m, 4H), 7.25-
7.33 (m, 8H).   
19
F NMR (376.5 MHz, CDCl3) δ = -174.12.  
13
C NMR (100 MHz, CDCl3) δ 
= 42.98 (d, JCF = 21.7 Hz), 54.96 (d, JCF = 21.7 Hz), 55.04, 55.35, 91.46 (d, JCF = 172.2 
Hz), 113.62, 126.51 (d, JCF = 2.5 Hz), 128.34 (d, JCF = 4.5 Hz), 128.95, 130.15, 138.23, 
146.64, 158.01.  
5.2.5.136. 2-Fluoro-4-(4-methoxyphenyl)-4,4-diphenylbutan-1-amine (rac-182). 
 
The title compound was prepared using an adaptation of the method reported by Ram et 
al.
197
  A suspension of azide rac-195 (130 mg, 0.35 mmol), 10% Pd/C (142 mg) and 
ammonium formate (110 mg, 1.74 mmol) in anhydrous MeOH (3.5 mL) was heated at 60 
°C for 2 h.  After cooling to room temperature, the mixture was filtered through a thick pad 
of Celite
®
, the residue washed with EtOAc (3 x 20 mL), and the filtrate concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-20% MeOH in CH2Cl2] afforded the 
α-trifluoroamine rac-182 as a colourless oil (79 mg, 65%).  1H (400 MHz, CDCl3) δ = 
2.09-2.19 (m, 1H), 2.46-2.62 (m, 2H), 3.32-3.35 (m, 1H), 3.76 (s, 3H, CH3), 4.27-4.42 (m, 
1H), 6.80-6.84 (m, 2H), 7.14-7.33 (m, 12H).  
19
F NMR (376.5 MHz, CDCl3) δ = -180.78.  
13
C NMR (125 MHz, CDCl3) δ = 43.24 (d, JCF = 21.7 Hz), 45.98 (d, JCF = 22.2 Hz), 54.26, 
55.00 (d, JCF = 3.2 Hz), 92.99 (d, JCF = 167.7 Hz), 112.88, 125.75, 127.57, 128.80, 130.00, 
138.60, 147.07, 147.19, 157.98.  HRMS (ESI+) calcd. for C23H25NOF [M+H]
+
: 350.1915; 
found 350.1914.  LC-MS tR = 12.92 min (m/z = 350.2, [M+H]
+
; purity = 100%).   
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5.2.5.137. 1,1,1-Trifluoro-4-phenylbutan-2-ol (rac-200). 
 
The title compound was prepared by an adaptation of the procedure reported by Crich et 
al.
269
  TBAF (1.0 M in THF, 100 μL, 0.10 mmol) was added to a cooled (0 °C) solution of 
3-phenylpropionaldehyde (263 μL, 2.00 mmol) and trimethyl(trifluoromethyl)silane 
solution (2.0 M in THF, 2.00 mL, 4.00 mmol) in THF (10 mL), and the reaction mixture 
stirred at room temperature for 21 h.  TBAF (1.0 M in THF, 2.00 mL, 2.00 mmol) was then 
added, and the reaction stirred for a further 1.5 h at room temperature.  The reaction was 
quenched with saturated aqueous NH4Cl solution (10 mL) and extracted with EtOAc (3 x 
10 mL).  The combined organic extracts were then washed with brine (30 mL), dried 
(MgSO4) and concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-15% 
EtOAc in hexane] afforded the α-trifluoromethylalcohol rac-200 as a yellow oil (249 mg, 
61%).  
1
H NMR (400 MHz, CDCl3) δ = 1.89-2.08 (m, 2H), 2.19 (d, J = 6.0 Hz, 1H), 2.71-
2.80 (m, 1H), 2.89-2.98 (m, 1H), 3.85-3.95 (m, 1H), 7.20-7.27 (m, 3H), 7.29-7.35 (m, 2H).  
19
F NMR (376.5 MHz, CDCl3) δ = -79.91.  
13
C NMR (100 MHz, CDCl3) δ = 30.95, 31.13, 
69.71 (q, JCF = 31.3 Hz), 123.93, 125.73 (q, JCF = 280.0 Hz), 126.50, 128.61, 128.78, 
140.53.  GC-MS (EI, methane) tR = 10.053 min (m/z = 205.1, [M+H]
+
). 
5.2.5.138. 1,1,1-Trifluoro-5-(4-methoxyphenyl)-5,5-diphenylpentan-2-ol (rac-202). 
 
The title compound was prepared by an adaptation of the procedure reported by Crich et 
al.
269
  TBAF (1.0 M in THF, 0.74 mL, 0.74 mmol) was added to a cooled (0 °C) solution 
of aldehyde 189 (2.46 g, 7.45 mmol) and trimethyl(trifluoromethyl)silane solution (2.0 M 
in THF, 7.40 mL, 14.80 mmol) in THF (30 mL), and the reaction mixture stirred at room 
temperature for 18 h.  TBAF (1.0 M in THF, 2.00 mL, 2.00 mmol) was then added, and the 
reaction stirred for a further 4.5 h at room temperature.  The reaction was quenched with 
saturated aqueous NH4Cl solution (30 mL) and extracted with EtOAc (3 x 30 mL).  The 
combined organic extracts were then washed with brine (80 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-15% EtOAc in 
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hexane] afforded rac-202 as a colourless oil (2.29 g, 77%).  
1
H NMR (400 MHz, CDCl3) δ 
= 1.46-1.53 (m, 2H, CH2), 2.19-2.24 (m, 1H), 2.50-2.59 (m, 1H), 2.97-3.05 (m, 1H), 3.77-
3.85 (m, 4H), 6.80-6.84 (m, 2H), 7.16-7.22 (m, 4H), 7.25-7.31 (m, 8H).  
19
F NMR (376.5 
MHz, CDCl3) δ = -79.75.  
13
C NMR (100 MHz, CDCl3) δ = 26.23, 35.76, 55.32, 55.72, 
71.13 (q, JCF = 30.8 Hz), 113.44, 125.15 (q, JCF = 281.5 Hz), 126.14, 128.11, 129.14, 
130.27, 138.97, 147.22, 147.26, 157.78.  GC-MS (CI, methane) tR = 17.62 min (m/z = 
429.2, [M+C2H5]
+
).  Anal. calcd. for C24H23F3O2: C, 71.99; H, 5.79.  Found: C, 72.39; H, 
5.57. 
5.2.5.139. 1,1,1-Trifluoro-5-(4-methoxyphenyl)-5,5-diphenylpentan-2-yl 
trifluoromethanesulfonate (rac-203). 
 
The title compound was prepared by an adaptation of the procedure reported by Jiang et 
al.
268
  Trimethylsulphonic anhydride (1.0 M in CH2Cl2, 2.43 mL, 2.43 mmol) was added 
by slow dropwise addition over 15 min to a cooled (-50 °C) solution of alcohol rac-202 
(810 mg, 2.02 mmol) and anhydrous pyridine (327 µL, 4.05 mmol) in CH2Cl2.  The 
reaction was stirred for 1 h at -50 °C and 1.5 h at ≤ -35 °C before allowing to warm to 
room temperature and quenching with with brine (15 mL).  The aqueous layers were 
extracted with CH2Cl2 (2 x 10 mL), and the combined organic layers dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-20% EtOAc in 
hexane] afforded triflate rac-203 as a colourless oil (834 mg, 78%).  
1
H NMR (400 MHz, 
CDCl3) δ = 1.70-1.89 (m, 2H, m, CH2), 2.59-2.68 (m, 1H), 2.84-2.93 (m, 1H), 3.80 (s, 3H, 
CH3), 4.88-4.97 (m, 1H, CH), 6.82-6.86 (m, 2H), 7.14-7.33 (m, 12H).  
19
F NMR (376.5 
MHz, CDCl3) δ = -74.03 (q, J = 3.1 Hz), -76.20 (q, J = 3.1 Hz).  
13
C NMR (100 MHz, 
CDCl3) δ = 25.40, 34.59, 55.36, 55.50, 82.46 (q, JCF = 34.3 Hz), 113.69, 118.49 (q, JCF = 
318.4 Hz), 122.07 (q, JCF = 281.4 Hz), 126.48, 128.37, 128.44, 128.87, 130.03, 138.10, 
146.40, 146.43, 158.02.  GC-MS (CI, methane) tR = 16.96 min (m/z = 561.2, [M+C2H5]
+
).  
Anal. calcd. for C25H22F6O4S: C, 56.39; H, 4.16.  Found: C, 56.30; H, 3.97. 
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5.2.5.140. 1,1,1-Trifluoro-5-(4-methoxyphenyl)-5,5-diphenylpentan-2-yl azide (rac-
204). 
 
The title compound was prepared by an adaptation of the procedure reported by Jiang et 
al.
268
  A solution of triflate rac-203 (239 mg, 0.45 mmol) and sodium azide (80 mg, 1.23 
mmol) in anhydrous DMSO (1.8 mL) was stirred at 40 °C for 18 h.   The reaction mixture 
was diluted with brine (5 mL), extracted with Et2O (3 x 10 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by flash chromatography [SiO2; 0-20% EtOAc in 
hexane] afforded azide rac-204 as a colourless oil (144 mg, 75%), which was used directly 
in the next step.  
1
H NMR (400 MHz, CDCl3) δ = 1.47-1.55 (m, 2H), 2.49-2.58 (m, 1H), 
2.94-3.03 (m, 1H), 3.42-3.51 (m, 1H), 3.81 (s, 3H, CH3), 6.82-6.87 (m, 2H), 7.17-7.24 (m, 
4H), 7.27-7.32 (m, 8H).  
19
F NMR (376.5 MHz, CDCl3) δ = -74.96.  
13
C NMR (100 MHz, 
CDCl3) δ = 24.32, 36.19, 55.35, 55.74, 62.82 (q, JCF = 29.8 Hz), 113.56, 124.94 (d, JCF = 
282.3 Hz), 126.31, 128.24, 129.05, 130.18, 138.60, 146.90, 146.95, 157.91.   
5.2.5.141. 1,1,1-Trifluoro-5-(4-methoxyphenyl)-5,5-diphenylpentan-2-amine (rac-184). 
 
The title compound was prepared using an adaptation of the method reported by Ram et 
al.
197
  A suspension of azide rac-204 (142 mg, 0.33 mmol), 10% Pd/C (142 mg) and 
ammonium formate (105 mg, 1.67 mmol) in anhydrous MeOH (3.5 mL) was heated at 60 
°C for 2 h.  After cooling to room temperature, the mixture was filtered through a thick pad 
of Celite
®
, the residue washed with EtOAc (3 x 10 mL), and the filtrate concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-40% EtOAc in hexane] afforded 
rac-184 as a colourless oil (121 mg, 91%).  
1
H NMR (500 MHz, CDCl3) δ = 1.14-1.24 (m, 
1H), 1.29-1.37 (br s, 2H, NH2), 1.47-1.55 (m, 1H), 2.51-2.59 (m, 1H), 2.95-3.04 (m, 2H), 
3.79 (s, 3H, CH3), 6.79-6.83 (m, 2H), 7.16-7.21 (m, 4H), 7.24-7.30 (m, 8H).  
19
F NMR 
(376.5 MHz, CDCl3) δ = -78.87.  
13
C NMR (125 MHz, CDCl3) δ = 26.30, 36.81, 54.66 (d, 
JCF = 29.3 Hz) 55.33, 55.85, 113.39, 126.09, 126.78 (q, JCF = 282.3 Hz), 128.07, 129.17, 
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130.30, 139.11, 147.36, 147.39, 157.75.  GC-MS (CI, methane) tR = 17.55 min (m/z = 
400.2, [M+H]
+
).  Anal. calcd. for C24H24F3NO: C, 72.16; H, 6.06; N, 3.51.  Found: C, 
72.75; H, 6.28; N, 3.10. 
5.2.5.142. 3-(Tritylsulfanyl)propanoic acid (209). 
 
A solution of 3-mercaptopropionic acid (1.31 mL, 15.0 mmol) and triphenylmethanol (4.56 
g, 17.5 mmol) in trifluoroacetic acid (15 mL) and CH2Cl2 (10 mL) was stirred for 2 h at 
room temperature.  The volatiles were removed in vacuo and the crude suspended in H2O 
(50 mL).  The mixture was filtered, and the white precipitate washed successively with 
H2O (100 mL), petroleum ether [(60/80), 50 mL], and Et2O (50 mL).  Purification by flash 
chromatography [SiO2; 50-100% EtOAc in hexane] afforded acid 209 as a white solid 
(3.34 g, 55%).  Mpt. 207-210 °C (lit.
270
 203-204 °C).  
1
H NMR (125 MHz, DMSO-d6) δ = 
2.17 (t, J = 7.2 Hz, 2H, CH2), 2.29 (t, J = 7.2 Hz, 2H, CH2), 7.23-7.27 (m, 3H), 7.31-7.36 
(m, 12H).  
13
C NMR (125 MHz, DMSO-d6) δ = 26.67, 32.88, 66.16, 126.72, 128.03, 
129.08, 144.35, 172.67.  HRMS (ESI-) calcd. for C22H19O2S [M-H]
-
: 347.1111; found: 
347.1120.  Anal. calcd. for C22H20O2S: C, 75.83; H, 5.79.  Found: C, 75.55; H, 5.52. 
5.2.5.143. 3-(Tritylsulfanyl)propanamide (210). 
 
The title compound was prepared by an adaptation of the procedure reported by Dale et 
al.
271
  Oxalyl chloride (100 μL, 1.17 mmol) and a catalytic amount of DMF (1 drop) was 
added to a solution of 3-(tritylsulfanyl)propanoic acid 209 (349 mg, 1.00 mmol) in 
anhydrous CH2Cl2 (3 ml) and stirred for 1.5 h at room temperature.  Ammonia (0.5 M in 
dioxane, 7.4 mL, 3.70 mmol) was then added and the reaction stirred for 18 h at room 
temperature.  The volatiles were removed in vacuo, and the residue partitioned between 
CH2Cl2 (10 mL) and saturated aqueous sodium carbonate solution (10 mL).  The aqueous 
layer was extracted with CH2Cl2 (2 x 10 mL), and the combined organic layers washed 
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successively with H2O (2 x 30 mL) and brine (30 mL), dried (MgSO4) and concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-15% MeOH in CH2Cl2 with 1% 
NH4OH] afforded amide 210 as a white solid (195 mg, 56%).  Mpt. 175-177 °C.  
1
H NMR 
(400 MHz, DMSO-d6) δ = 2.12 (t, J = 7.3 Hz, 2H, CH2), 2.23 (t, J = 7.4 Hz, 2H, CH2), 
6.80 (s, 1H, NH2), 7.23-7.27 (m, 3H), 7.29-7.37 (m, 13H).  
13
C NMR (100 MHz, DMSO-
d6) δ = 27.32, 33.71, 65.95, 126.69, 128.00, 129.08, 144.47, 172.10.  HRMS (ESI+) calcd. 
for C21H21NOSNa [M+Na]
+
: 370.1236; found: 370.1236.  Anal. calcd. for C22H21NOS: C, 
76.04; H, 6.09; N, 4.03.  Found: C, 75.53; H, 5.31; N, 3.83. 
5.2.5.144. (2R)-2-Amino-3-(tritylsulfanyl)-N-methylpropanamide (216). 
 
Methanamine hydrochloride (405 mg, 6.0 mmol), followed by triethylamine (2.51 mL, 
18.0 mmol) and T3P
®
 (50% in DMF, 1.52 mL, 2.60 mmol) were added to a cooled (0 °C) 
solution of N-(tert-butoxycarbonyl)-S-trityl-L-cysteine (927 mg, 2.0 mmol) in anhydrous 
THF (4 mL), and stirred at room temperature for 24 h.  The reaction was quenched with 
H2O (10 mL) and the volatiles were removed in vacuo and the crude residue extracted with 
CH2Cl2 (3 x 10 mL).  The organic extracts were washed successively with aqueous HCl 
(0.125 M), H2O, and brine (30 mL each), dried (MgSO4), then concentrated in vacuo.  
Purification by flash chromatography [SiO2; 0-10% MeOH in CH2Cl2] afforded (R)-tert-
butyl (1-(methylamino)-1-oxo-3-(tritylthio)propan-2-yl)carbamate (212) as an off-white 
solid (669 mg, 70%), which was taken directly to the next step.   A solution of 212 (669 
mg, 1.40 mmol) was stirred in trifluoroacetic acid (2 mL) for 4 h at room temperature.  The 
volatiles were removed in vacuo, and the crude basified (circa. pH 10) with saturated 
aqueous sodium carbonate solution and extracted with CH2Cl2 (3 x 10 mL).  The combined 
organic extracts were dried (MgSO4) and concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-20% MeOH in CH2Cl2] afforded the crude product, which was 
dissolved in CH2Cl2 (20 mL) and washed with aqueous LiCl solution (5% w/v, 2 x 20 mL), 
brine (20 mL), dried (MgSO4) and concentrated in vacuo to afford 216 as light brown oil 
(53 mg,  11%).  
1
H NMR (500 MHz, MeOD) δ = 2.35-2.39 (m, 1H), 2.52-2.56 (m, 1H), 
2.71 (s, 3H, CH3), 3.09-3.12 (m, 1H), 7.20-7.24 (m, 3H), 7.27-7.32 (m, 6H), 7.36-7.43 (m, 
6H).  
13C NMR (100 MHz, MeOD) δ = 26.22, 38.23, 55.33, 67.85, 127.89, 128.97, 130.75, 
146.08, 176.08.  HRMS (ESI+) calcd. for C23H25N2OS [M+H]
+
: 377.1682; found: 
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307.1672.  Anal. calcd. for C23H24N2OS·½H2O: C, 71.66; H, 6.54; N, 7.27.  Found: C, 
72.01; H, 6.27; N, 7.05. 
5.2.5.145. (2R)-2-Amino-3-(tritylsulfanyl)-N,N-dimethylpropanamide (217). 
 
Dimethylamine hydrochloride (489 mg, 6.0 mmol), followed by triethylamine (2.51 mL, 
18.0 mmol) and T3P
®
 (50% in DMF, 1.52 mL, 2.60 mmol) were added to a cooled (0 °C) 
solution of N-(tert-butoxycarbonyl)-S-trityl-L-cysteine (927 mg, 2.0 mmol) in anhydrous 
THF (4 mL), and stirred at room temperature for 26 h.  The reaction was quenched with 
H2O (10 mL) and the volatiles were removed in vacuo and the crude residue extracted with 
CH2Cl2 (3 x 10 mL).  The combined organic extracts were washed successively with 
aqueous HCl (0.125 M), H2O, and brine (30 mL each), dried (MgSO4), then concentrated 
in vacuo.  Purification by flash chromatography [SiO2; 0-10% MeOH in CH2Cl2] afforded 
the tertiary amide (R)-tert-butyl (1-(dimethylamino)-1-oxo-3-(tritylthio)propan-2-
yl)carbamate (213) as an off-white solid (641 mg, 65%), which was taken directly to the 
next step.  A solution of 213 (641 mg, 1.31 mmol) was stirred in trifluoroacetic acid (2 
mL) for 2.5 h at room temperature.  The volatiles were removed in vacuo, and the crude 
basified (circa. pH 10) with saturated aqueous sodium carbonate solution.  The aqueous 
mixture was extracted with CH2Cl2 (3 x 10 mL) and the combined organic layers washed 
successively with H2O (2 x 30 mL), brine (30 mL), dried (MgSO4) and concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-18% MeOH in CH2Cl2] afforded 
217 as a pale brown oil (343 mg, 67%).  
1H NMR (400 MHz, MeOD) δ = 2.35-2.40 (m, 
1H), 2.57-2.62 (m, 1H), 2.78 (s, 3H, CH3), 2.87 (s, 3H, CH3), 3.37-3.41 (m, 1H), 7.20-7.32 
(m, 9H), 7.37-7.43 (m, 6H).  
13C NMR (100 MHz, MeOD) δ = 36.10, 37.59, 37.95, 51.21, 
68.17, 127.95, 129.02, 130.80, 146.09, 174.94.  HRMS (ESI+) calcd. for C24H27N2OS 
[M+H]
+
: 391.1839; found: 391.1827.  Anal. calcd. for C24H26N2OS·¼H2O: C, 72.97; H, 
6.76; N, 7.09.  Found: C, 72.39; H, 6.14; N, 6.76. 
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5.2.5.146. ((2R)-3-(Tritylsulfanyl)-1-(methoxy(methyl)amino)-1-oxopropan-2-
yl)carbamate (214). 
 
N,O-Dimethylhydroxylamine hydrochloride (878 mg, 9.0 mmol), followed by 
triethylamine (3.76 mL, 27.0 mmol) and T3P
®
 (50% in DMF, 2.630  mL, 4.50 mmol) were 
added to a cooled (0 °C) solution of N-(tert-butoxycarbonyl)-S-trityl-L-cysteine (1.39 g, 
3.0 mmol) in anhydrous THF (6 mL) and stirred at room temperature for 48 h.  The 
reaction was quenched with saturated aqueous NaHCO3 (15 mL), the volatiles removed in 
vacuo, and the mixture extracted with CH2Cl2 (3 x 15 mL).  The organic extracts were 
washed successively with aqueous CuSO4 solution (10% w/v, 50 mL), H2O (2 x 50 mL) 
and brine (75 mL), dried (MgSO4), then concentrated in vacuo.  Purification by flash 
chromatography [SiO2; 0-40% EtOAc in hexane] afforded 214 as a white solid (645 mg, 
64%).  Mpt. 98-100 °C.  
1
H NMR (500 MHz, CDCl3) δ = 1.43 (s, 9H, 3 x CH3), 2.35-2.41 
(m, 1H, CH2), 2.53-2.57 (m, 1H, CH2), 3.14 (s, 3H, CH3), 3.64 (m, 3H, CH3), 4.75 (br s, 
1H, NH), 5.09-5.13 (m, 1H, CH), 7.18-7.23 (m, 3H), 7.25-7.30 (m, 6H), 7.38-7.42 (m, 
6H).  
13
C NMR (125 MHz, CDCl3) δ = 28.49, 32.30, 34.29, 49.89, 61.69, 66.83, 126.87, 
128.06, 129.73, 144.65, 155.32, 171.27.  HRMS (ESI+) calcd. for C29H35N2O4S [M+H]
+
: 
507.2312; found: 507.2299.  Anal. calcd. for C29H34N2O4S·¼H2O: C, 68.14; H, 6.80; N, 
5.48.  Found: C, 68.29; H, 6.69; N, 5.34. 
5.2.5.147. (2R)-2-Amino-3-(tritylsulfanyl)-N-methoxy-N-methylpropanamide (218). 
 
A solution of 214 (125 mg, 0.246 mmol) was stirred in trifluoroacetic acid (1 mL) for 1.5 h 
at room temperature.  The volatiles were removed in vacuo, and the crude basified (circa. 
pH 10) with saturated aqueous sodium carbonate solution.  The aqueous mixture was 
extracted with CH2Cl2 (3 x 10 mL) and the combined organics layers concentrated in 
vacuo.  Purification by flash chromatography [SiO2; 0-12% MeOH in CH2Cl2] afforded 
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218 as a colourless oil (44 mg, 43%).  
1H NMR (500 MHz, MeOD) δ = 2.30-2.36 (m, 1H, 
CH2), 2.57-2.62 (m, 1H, CH2), 3.14 (s, 3H, CH3), 3.58-3.68 (m, 4H), 7.20-7.25 (m, 3H), 
7.27-7.32 (m, 6H), 7.37-7.44 (m, 6H).  
13C NMR (125 MHz, MeOD) δ = 32.52, 37.34, 
51.27, 62.24, 67.96, 127.90, 128.98, 130.77, 146.08, 173.27.  HRMS (ESI+) calcd. for 
C24H27N2O2S [M+H]
+
: 407.1788; found: 407.1785.  Anal. calcd. for 
C24H26N2O2S·
 
  
CH2Cl2: C, 69.74; H, 6.36; N, 6.75.  Found: C, 69.59; H, 5.62; N, 6.61 
5.2.5.148. Methyl (2R)-2-amino-3-(tritylsulfanyl)propanoate hydrochloride (219). 
 
The title compound was prepared by an adaptation of the procedure reported by Rudolph et 
al.
272
  Thionyl chloride (1.91 mL, 26.3 mmol) was added to a cooled (0 °C) suspension of 
S-trityl L-cysteine (1.27 g, 3.5 mmol) in anhydrous MeOH (25 mL).  The reaction mixture 
was allowed to warm to room temperature, then refluxed for 6 h.  After cooling to room 
temperature, the volatiles were removed in vacuo, to afford the crude methyl ester 219 as 
an off-white solid, which was used without further purification (1.43 g, 98%).  Mpt. 79-81 
°C (lit.
272
 78 °C).  
1H NMR (125 MHz, MeOD) δ = 2.75-2.85 (m, 2H, CH2), 3.32-3.36 (m, 
1H, CH), 3.76 (s, 3H, CH3), 7.25-7.37 (m, 9H), 7.41-7.47 (m, 6H).  
13
C NMR (125 MHz, 
MeOD) δ = 32.89, 53.07, 53.87, 68.77, 128.34, 129.31, 130.61, 145.16, 169.23.  HRMS 
(ESI+) calcd. for C23H24NO2S [M+H]
+
: 278.1522; found: 378.1523.   
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5.2.5.149. (2R)-2-Amino-N-hydroxy-3-(tritylsulfanyl)propanamide (220). 
 
The title compound was prepared by an adaptation of the procedure reported by Tegoni et 
al.
212
  Conc. aqueous NH4OH (1 mL) was added to chloroform (4 mL) and stirred for 15 
minutes at room temperature.  The organic layer was separated, dried (MgSO4) and the 
hydrochloride salt 219 (414 mg, 1.00 mmol) added.  After the solution was stirred for 1 h 
at room temperature, the precipitate was filtered, and the filtrate concentrated in vacuo to 
give the methyl ester as a light brown oil.  Separately, a solution of potassium hydroxide 
(336 mg, 5.98 mmol) in methanol (3.56 mL) was added to a solution of hydroxylamine 
hydrochloride (418 mg, 6.01 mmol) in methanol (3.05 mL) at 0 °C and stirred for 20 min.  
The precipitate was filtered and washed with methanol (1 mL), and approximately half of 
the methanolic hydroxylamine filtrate added to the crude methyl ester.  The reaction 
mixture was stirred at room temperature for 24 h, then a further 24 h at 5 °C.  The solution 
was filtered, washing with chloroform (5 mL).  The filtrate was concentrated in vacuo, and 
the crude recrystallised from hot methanol and kept at 5 °C for 24 h, during which time a 
precipitate formed.  After filtration, the pale orange precipitate was recrystallised from hot 
methanol and kept at 5 °C for 48 h.  The solution was filtered again, and the precipitate 
collected, dissolved in CH2Cl2 and the solvent removed under reduced pressure to afford 
the hydroxamic acid 220 as a pale orange solid (90 mg, 24%).  Mpt. 96-99 °C.  
1
H NMR 
(400 MHz, DMSO-d6) δ = 2.08-2.15 (m, 1H), 2.27-2.34 (m, 1H), 3.05-3.10 (m, 1H), 7.20-
7.38 (m, 15H), 8.86 (br s, 1H), 10.79 (br s, 1H).  
13
C NMR (100 MHz, DMSO-d6) δ = 
36.81, 51.92, 65.74, 126.99, 127.99, 129.07, 144.42, 169.38.  HRMS (ESI-) calcd. for 
C22H21N2O2S [M-H]
-
: 377.1329; found: 377.1335.  Anal. calcd. for 
C22H22N2O2S·⅓CH2Cl2: C, 65.98; H, 5.62; N, 6.89.  Found: C, 66.49; H, 5.06; N, 7.13. 
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5.3. Molecular modeling 
5.3.1. Calculation of ligand efficiencies 
The equation for calculating ligand efficiencies is: LE = -ΔG/HAC ≈ -RT.ln(Ki
app
)/HAC,  
where ΔG is the change in Gibbs free energy, T is the absolute temperature, R represents 
the gas constant and HAC is the heavy atom count for non-hydrogen atoms.
216
  Ligand 
efficiencies were calculated in Pipeline Pilot 7.4 for Windows (Accelerys Software, San 
Diego, USA).   
5.3.2. Calculation of physicochemical properties 
Physicochemical properties were calculated in Pipeline Pilot 7.4 for Windows (Accelerys 
Software, San Diego, USA).  The calculated ALog P and cLog D7.4 values are based on the 
atom based method of Ghose and Cribben.
273
   The cLog S values were calculated by the 
method of Tetko et al.
274
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Appendix 
The calculated physicochemical properties for all tested inhibitor are provided in Table 24.   
 242 
Table 24 – Calculated physicochemical properties for all tested inhibitors. 
Cmpd Molecular Formula MWt. ALog P cLog D7.4 cLog S Polar Surface Area H-bond acceptors H-bond donors 
6 C22H21NO2S 363.473 1.739 1.739 -7.315 88.62 4 2 
10 C23H23NO3S 393.499 1.723 1.723 -7.411 97.85 5 2 
16 C21H21NS 319.463 4.601 3.64 -7.566 51.32 2 1 
101 C22H20ClNO2S 397.918 2.404 2.404 -8.086 88.62 4 2 
102 C21H20FNS 337.454 4.807 3.845 -7.579 51.32 2 1 
103 C22H20ClNO2S 397.918 2.404 2.404 -8.089 88.62 4 2 
104  C21H20ClNS 353.908 5.266 4.304 -8.336 51.32 2 1 
105 C21H20BrNS 398.359 5.35 4.388 -8.838 51.32 2 1 
106 C22H23NS 333.49 5.087 4.126 -8.118 51.32 2 1 
107 C23H25NS 347.516 5.544 4.582 -8.600 51.32 2 1 
108 C24H27NS 361.543 5.795 4.834 -8.898 51.32 2 1 
109 C24H27NS 361.543 6 5.038 -9.113 51.32 2 1 
110 C22H20F3NS 387.461 5.543 4.582 -8.464 51.32 2 1 
111 C22H23NOS 349.489 4.585 3.623 -7.636 60.54 3 1 
112 C22H23NS2 365.555 5.143 4.182 -8.566 76.62 3 1 
113 C22H20F3NOS 403.461 6.721 5.76 -8.622 60.54 3 1 
114 C24H23NO3S 405.509 1.479 1.479 -7.674 105.68 5 2 
115 C23H23NOS 361.5 4.341 3.38 -7.915 68.39 3 1 
116 C22H23NS 333.49 5.087 4.582 -8.116 51.32 2 1 
117 C23H25NS 347.516 5.544 5.038 -8.602 51.32 2 1 
118 C22H23NOS 349.489 4.585 4.079 -7.672 60.54 3 1 
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Table 24 (continued) – Calculated physicochemical properties for all tested inhibitors. 
Cmpd Molecular Formula MWt. ALog P cLog D7.4 cLog S Polar Surface Area H-bond acceptors H-bond donors 
119 C23H25NOS 363.516 4.933 4.428 -8.041 60.54 3 1 
120 C22H20F3NOS 403.461 6.721 6.215 -8.776 60.54 3 1 
121 C24H23NO3S 405.509 1.479 1.479 -7.732 105.68 5 2 
122 C23H23NOS 361.5 4.341 3.38 -7.915 68.39 3 1 
123 C22H21NO3S 379.472 1.497 1.497 -6.546 108.85 5 3 
124 C22H21NO3S 379.472 1.497 1.497 -6.671 108.85 5 3 
125 C21H21NOS 335.463 4.359 3.329 -6.903 71.54 3 2 
126 C22H20N2S 344.473 4.48 3.519 -7.856 75.1 3 1 
127 C22H24N2S 348.504 3.707 1.774 -7.692 77.34 3 2 
128 C24H26N2OS 390.541 3.728 2.767 -8.202 80.42 3 2 
129 C22H21NO2S 363.473 1.752 1.791 -7.245 88.62 4 2 
130 C23H22N2O3S 406.497 0.741 0.742 -7.191 131.71 5 3 
131 C22H22N2OS 362.488 3.603 2.642 -7.402 94.4 3 2 
132 C23H24N2OS 376.514 3.809 2.848 -7.711 80.42 3 2 
133 C24H26N2OS 390.541 4.015 3.054 -7.596 71.62 3 1 
134 C22H23NO2S2 397.554 4.127 3.166 -7.619 93.84 4 1 
135 C22H20N2S 344.473 4.48 3.974 -7.908 75.1 3 1 
136 C22H23NOS 349.489 3.997 3.491 -7.363 71.54 3 2 
137 C22H24N2S 348.504 3.707 2.202 -7.722 77.34 3 2 
138 C24H26N2OS 390.541 3.728 3.223 -8.249 80.42 3 2 
139 C22H22N2OS 362.488 3.603 3.098 -7.49 94.4 3 2 
140 C23H24N2OS 376.514 3.809 3.303 -7.784 80.42 3 2 
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Table 24 (continued) – Calculated physicochemical properties for all tested inhibitors. 
Cmpd Molecular Formula MWt. ALog P cLog D7.4 cLog S Polar Surface Area H-bond acceptors H-bond donors 
141 C24H26N2OS 390.541 4.015 3.509 -7.668 71.62 3 1 
142 C22H23NO2S2 397.554 4.127 3.621 -7.728 93.84 4 1 
143 C20H20N2S 320.451 3.451 2.847 -6.983 64.21 3 1 
144 C18H18N2S2 326.479 3.463 2.46 -6.971 92.45 3 1 
145 C18H18N2OS 310.413 2.905 1.9 -6.136 77.35 3 1 
146 C23H25NS 347.516 5.574 5.068 -8.667 51.32 2 1 
rac-147 C21H20ClNOS 369.908 5.023 4.451 -7.664 71.54 3 2 
rac-148 C23H25NOS 363.516 5.301 4.729 -7.902 71.54 3 2 
rac-149 C22H23NOS 349.489 4.845 4.273 -7.439 71.54 3 2 
rac-150 C23H22N2S 358.499 4.966 4.46 -8.395 75.1 3 1 
rac-151 C23H24N2OS 376.514 4.09 3.584 -7.934 94.4 3 2 
152 C22H22FNS 351.48 5.293 4.787 -7.896 51.32 2 1 
153 C22H22FNS 351.48 5.293 4.787 -7.932 51.32 2 1 
154 C23H22FNO3S 411.489 1.928 1.929 -7.3 97.85 5 2 
155 C22H22FNOS 367.48 4.79 4.284 -7.512 60.54 3 1 
156 C22H22FNOS 367.48 4.79 4.284 -7.624 60.54 3 1 
157 C21H19Cl2NS 388.353 5.93 5.424 -9.1 51.32 2 1 
158 C24H25NO2S 391.526 2.712 2.712 -8.373 88.62 4 2 
159 C23H25NS 347.516 5.574 5.068 -8.677 51.32 2 1 
160 C25H27NO2S 405.552 3.168 3.168 -8.824 88.62 4 2 
161 C24H27NS 361.543 6.03 5.524 -9.163 51.32 2 1 
162 C26H27NO2S 417.563 3.252 3.253 -9.169 88.62 4 2 
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Table 24 (continued) – Calculated physicochemical properties for all tested inhibitors. 
Cmpd Molecular Formula MWt. ALog P cLog D7.4 cLog S Polar Surface Area H-bond acceptors H-bond donors 
163 C25H27NS 373.554 6.114 5.609 -9.563 51.32 2 1 
rac-176 C25H27NO2 373.487 2.802 2.895 -8.339 63.32 3 2 
181 C23H25NO 331.451 4.675 3.855 -7.683 35.25 2 1 
rac-182 C23H24FNO 349.441 4.648 4.639 -7.497 35.25 2 1 
183 C23H23F2NO 367.432 4.452 4.452 -7.289 35.25 2 1 
rac-184 C24H24F3NO 399.449 5.711 5.711 -8.739 35.25 2 1 
210 C21H19NOS 333.447 4.284 4.284 -7.151 68.39 2 1 
215 C22H22N2OS 362.488 3.59 2.669 -7.412 94.4 3 2 
216 C23H24N2OS 376.514 3.796 3.65 -7.673 80.42 3 2 
217 C24H26N2OS 390.541 4.002 3.857 -7.558 71.62 3 1 
218 C24H26N2O2S 406.54 3.848 3.607 -7.526 80.85 4 1 
220 C22H22N2O2S 378.487 3.603 2.663 -7.265 100.65 4 3 
rac-221 C23H23NO2 345.434 1.83 1.923 -7.280 63.32 3 2 
222 C22H23N 301.425 4.691 3.872 -7.581 26.01 1 1 
223 C22H22ClN 335.87 5.356 4.536 -8.347 26.01 1 1 
rac-224 C24H25NO2 359.461 2.316 2.409 -7.803 63.32 3 2 
225 C23H25N 315.451 5.178 4.358 -8.133 26.01 1 1 
226 C24H27N 329.478 5.634 4.814 -8.615 26.01 1 1 
227 C25H29N 343.504 5.886 5.066 -8.910 26.01 1 1 
rac-228 C24H25NO2 359.461 2.316 2.409 -7.807 63.32 3 2 
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Table 24 (continued) – Calculated physicochemical properties for all tested inhibitors. 
Cmpd Molecular Formula MWt. ALog P cLog D7.4 cLog S Polar Surface Area H-bond acceptors H-bond donors 
229 C23H25N 315.451 5.178 4.358 -8.131 26.01 1 1 
230 C24H27N 329.478 5.634 4.814 -8.618 26.01 1 1 
rac-231 C24H25NO3 375.46 1.813 1.906 -7.372 72.55 4 2 
232 C23H24FNO 349.441 4.881 4.061 -7.508 35.25 2 1 
rac-233 C23H25NO 331.451 4.936 4.116 -7.446 46.25 2 2 
rac-234 C24H27NO2 361.477 4.164 3.805 -7.285 55.48 3 2 
rac-235 C24H25N5O 399.488 4.131 3.189 -7.403 89.71 5 2 
Mean n/a 363.742 4.048 3.533 -7.873 67.32 2.89 1.50 
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